# General Medicine Research Wiki: plain-text export ================================================================================ # DOCUMENT: Market & Leadership Dossier (raw/reports/adversarial-and-market-report.md) ================================================================================ # General Medicine: Corporate, Product and Market Dossier **Target Application:** General Medicine Patient Portal & Telehealth Storefront (`https://generalmedicine.co/`) **Legal Operating Entity:** **Path Healthcare Systems Corp.** (Delaware C-Corp, File `#7571245`; EIN `93-2571245`; Florida foreign registration `F24000004983`) **Brand Genealogy:** Path Healthcare Systems Corp. → stealth engineering codename **Nile Health** (`staging-nile.com`, `nile-core`, `@nile/*`) → initial consumer brand **Nav Health** (`navhealth.co`) → **General Medicine** (`generalmedicine.co`) **As of:** 2026-10-19 **Companion Documents:** [`generalmedicine.md`](../generalmedicine.md) · [`architecture.md`](architecture.md) · [`api-spec.md`](api-spec.md) · [`openapi.yaml`](openapi.yaml) · [`scripts/README.md`](scripts/README.md) · [`osint/`](osint/) --- ## Contents - [0. Executive summary](#0-executive-summary) - [0.1 Key metrics](#01-key-metrics) - [0.2 Source tags](#02-source-tags) - [1. Key findings](#1-key-findings) - [1.1 Basis of the findings](#11-basis-of-the-findings) - [1.2 API surface: 377 routes, not 32](#12-api-surface-377-routes-not-32) - [1.3 Corporate and brand genealogy: four stages](#13-corporate-and-brand-genealogy-four-stages) - [1.4 Friendly-PC and CPOM governance split](#14-friendly-pc-and-cpom-governance-split) - [1.5 Lab pricing: live fee and code fallback](#15-lab-pricing-live-fee-and-code-fallback) - [1.6 Catalog size and SKU taxonomy](#16-catalog-size-and-sku-taxonomy) - [1.7 Controlled substances: policy and referral SKUs](#17-controlled-substances-policy-and-referral-skus) - [1.8 SEC EDGAR: no Form D on record](#18-sec-edgar-no-form-d-on-record) - [1.9 Clinician pay claim is commented out](#19-clinician-pay-claim-is-commented-out) - [1.10 Placeholder copy and fail-open tenant resolution](#110-placeholder-copy-and-fail-open-tenant-resolution) - [1.11 Exposed internal portals and source maps](#111-exposed-internal-portals-and-source-maps) - [1.12 Findings ledger](#112-findings-ledger) - [2. Team, clinical organization, engineering and board](#2-team-clinical-organization-engineering-and-board) - [3. Growth, trajectory and unit economics](#3-growth-trajectory-and-unit-economics) - [4. Leadership quotes and business model thesis](#4-leadership-quotes-and-business-model-thesis) - [5. Public sources, vendors, portals, supply chain, visits and flags](#5-public-sources-vendors-portals-supply-chain-visits-and-flags) - [Appendix A: Numbers crosswalk](#appendix-a-numbers-crosswalk) - [Appendix B: Sources](#appendix-b-sources) - [Appendix C: Data notes](#appendix-c-data-notes) --- ## 0. Executive summary General Medicine presents itself as a consumer "healthcare store": one searchable catalog of medications, labs, telehealth visits, specialist e-consults, and in-person procedures, priced with and without insurance. The code and public record support the shape of that claim, not its scale, its corporate simplicity, or its clinical-governance story. **Ten findings separate the marketing surface from the operating reality.** 1. **The API estate is roughly 12× the 32 primary endpoints a high-level inventory records.** The consumer contract contains **194 declared routes** and **119 verified client RTK Query operations**; four internal portals add **183 route literals** and **238 RTK Query operations**. The total is **377 routes and 357 RTK operations**. 2. **The corporate identity is a four-stage chain with real legal substance.** Path Healthcare Systems Corp. is the Delaware C-Corp; Nile Health was the stealth engineering identity; Nav Health was the first consumer brand; General Medicine is the current brand. The Nav Health site still says *"Nav Health is now General Medicine"*, and the lab refund page still prints `support@navhealth.co`. 3. **The Friendly-PC / CPOM split is real, but inverted at the top.** Non-physician co-founder **Ashwin Muralidharan** is President and Authorized Official of Utah's `Emerald Medical Practice, P.C.` on two NPIs, while **50-state licensed Medical Director Dr. Pallabi Sanyal-Dey, MD** is President of the Florida and New Jersey PCs. All four NPIs share one phone number and a Park City, Utah mailing cluster. 4. **Sampled lab SKUs carry a $15 clinical fee.** `LabPanelPricing.tsx:59–69` reads `clinical_fee` from the API first and uses **$30** (`STANDARD_CLINICAL_FEE`) only as a fallback when `clinical_fee` is null or undefined; live API responses return `clinical_fee: 15.0` across all seven sampled SKUs. `/refund-policy-labs` ("No Fees Deducted") governs eligible refund deductions, not initial order pricing. 5. **The catalog is larger than advertised, and its commercial depth is not measurable from the search sample.** Marketing says "2,900+ products and services"; the sitemaps contain **3,184 SKU URLs** (9.8% above the claim). The 108-query search sample surfaces **448 SKUs**; **326** expose top-level cash/insurance prices and **122** do not. Null top-level price is not proof of unpurchasability (**8 of the 122** carry option-level fees; SKU `300603` has a **$45** checkout fee), and **2,736** unsurfaced SKUs are not proven undiscoverable (SKU `400285` returns for `query=chronic pain`). 6. **The controlled-substance policy is narrower than the catalog.** The FAQ says General Medicine cannot fill controlled substances, yet three active in-person referral SKUs cover opioid prescribing, pregabalin/Lyrica management, and Accutane office visits. 7. **There is no SEC Form D for the $152M raised.** EDGAR has **zero** Form D filings for Path Healthcare Systems Corp. or General Medicine. The only "NavHealth" filing entity is an unrelated Arlington, VA company (CIK `0001717158`, Aneesh Chopra), not General Medicine's predecessor. 8. **Clinician recruiting copy withholds pay.** `clinician-hiring-content.tsx:206–210` comments out `"Competitive pay" / "Above-market compensation for telehealth work"`. 9. **Production copy and tenant isolation both fail open.** An October 5, 2026 article shipped literal `[open your dashboard]([dashboard URL pending])`, and `NEXT_PUBLIC_GM_TENANT_ID` unset silently routes to the DTC storefront while the API header falls back to `general-medicine`. 10. **Four internal portals and 400 source maps are publicly reachable.** `visitron.internal.generalmedicine.co`, `catalog.internal.generalmedicine.co`, `referrals.internal.generalmedicine.co`, and `internal.generalmedicine.co` all serve unauthenticated JavaScript bundles; `analytics.staging-nile.com` serves Metabase. **Bottom line:** General Medicine has raised **$152M**, has Walmart and Mercy distribution partnerships, and has credible clinical leadership. It is also a company whose public narrative is consistently one abstraction ahead of its operating record: the catalog is broader than the search sample that surfaces it, the lab refund page's "No Fees Deducted" line can be misread as covering the $15 clinical review fee on sampled lab orders (eligible pre-collection refunds carry no deduction), the "Friendly PC" structure is controlled by a non-physician at one layer, and the $152M capitalization has no Reg D paperwork. ### 0.1 Key metrics These are the numbers used throughout this report and the companion documents. | Metric | Value | Evidence | | :--- | ---: | :--- | | Consumer declared routes | **194** | `lib/api/endpoints.ts`, component fetches; `api-spec.md` §2 | | Consumer verified client RTK operations | **119** | 40 RTK slices; `lib/store/api/*`; `api-spec.md` §1.1 | | Consumer total RTK operations across 40 slices | 137 | `baseQuery.ts`; `generalmedicine.md` §2 | | OpenAPI paths / operations / tags | **130 / 141 / 16** | `openapi.yaml` | | Internal MedicineOS portals | **4** | `osint/internal_portals_recon.json` | | Internal portal route literals | **183** | Visitron 98 + Catalog 47 + Referrals 18 + Provider Chat 20 | | Of which `/api/internal*`-prefixed | 166 | 142 unique after cross-portal dedup | | Internal portal RTK operations | **238** | Visitron 91 + Catalog 106 + Referrals 27 + Provider Chat 14 | | **Total routes** | **377** | 194 consumer + 183 internal | | **Total RTK operations** | **357** | 119 verified consumer + 238 internal | | Live SKU URLs in sitemaps | **3,184** | 4 sitemaps; 23 numeric series | | SKUs surfaced by 108-query search sample | **448** | 108 queries (`a–z`, `0–9`); non-exhaustive | | Sampled SKUs with top-level cash/insurance price | **326** | non-null `cash_price_cents` or `insurance_price_cents` | | Sampled SKUs with null top-level price | **122** | both top-level fields null; **8** carry option-level fees | | Sitemap SKUs not surfaced by the sample | **2,736** | not a non-discoverability census | | Price range (top-level priced sample) | **$5.11 – $17,411.20** | 511–1,741,120 cents | | `STANDARD_CLINICAL_FEE` constant | **$30** | `types/enums/lab-pricing-constants.ts:8` | | Live `clinical_fee` (7 sampled SKUs) | **$15.00** | `/api/external/lab_skus/:id` | | Total disclosed equity | **$152,000,000** | $32M seed + $120M Series B | | SEC Form D filings (affiliate) | **0** | EDGAR FTS + submissions | | Public LinkedIn profiles | **87** (33 high-relevance) | `osint/linkedin_team_and_posts.json` | | Public `/bio/*` pages | **20** | `osint/live_sitemap_skus.json` | | Open Ashby roles | **16** | `generalmedicine.co/company/careers` | | Third-party employee estimate | **104** | PitchBook company profile | | Trustpilot | **4.7 / 5.0**, **906** reviews (91% 5★, 6% 1★) | fetched 2026-10-18 | | BBB | **"D"**, 6 complaints, unaccredited | fetched 2026-10-18 | ### 0.2 Source tags | Tag | Meaning | | :--- | :--- | | `[CODE]` | First-party source code recovered from public source maps | | `[LIVE]` | Public endpoint fetched for this report; HTTP status recorded | | `[OSINT]` | Extracted from the `osint/*.json` datasets | | `[REGISTRY]` | Government or corporate registry record (Delaware, Florida Sunbiz, CMS NPPES, SEC EDGAR) | | `[PRESS]` | Published reporting or company announcement, linked inline | | `[INFERENCE]` | Analytical conclusion not directly stated by a source | --- ## 1. Key findings ### 1.1 Basis of the findings The findings rest on three independent source sets: 1. **Source code.** 798 first-party files (51,015 LOC) reconstructed from 400 public SourceMap v3 files, with routes, operations, and pricing logic read directly. 2. **Live contract.** OpenAPI covers 130 paths / 141 operations. Lab pricing rests on seven live SKU responses. 3. **Public record.** SEC EDGAR full-text search (17 queries, 493 hits, 261 CIKs, 76 Form Ds parsed), CMS NPPES (17 queries, 23 relevant NPIs), Florida Sunbiz, certificate transparency (55 subdomains), four sitemaps (3,290 unique URLs), and 186 news/RSS items. **Counting rule.** A route exists if it is declared in first-party source and either exercised by a client operation or enumerated in a shipped portal bundle. Each metric is reported at its narrowest defensible scope, with broader scopes labeled. ### 1.2 API surface: 377 routes, not 32 A high-level inventory records **~32 primary endpoints** (Authentication, User & Insurance, Urgent Care, Pharmacy, Labs, and Health Records). Against the **194** consumer route declarations, that is **16.49%** coverage; against the **377**-route estate, it is **8.49%**. The route count by plane: | Plane | Route declarations | RTK Query operations | Notes | | :--- | ---: | ---: | :--- | | Consumer storefront (`generalmedicine.co`) | **194** | **119** verified (137 total) | 130 OpenAPI paths / 141 operations / 16 tags; 64 catalog-only unexercised contracts | | **Visitron** clinician EHR | 98 | **91** | 27 chunks; 33 RTK tag types; DoseSpot, ArriveHealth, Nabla, lab/ICD-10 search, e-scribing | | **Catalog** / care-pathway admin | 47 | **106** | 35 chunks; SKU, questionnaire, criteria-set, pathway, biomarker, tenant administration | | **Referrals** concierge | 18 | **27** | 19 chunks; referral orders, provider candidates, promises queue, booking, outreach | | **Provider Chat** / prompt workbench | 20 | **14** | 18 chunks; channels, messages, catalog prompts, model versions, temperatures, ActionCable | | **Internal subtotal** | **183** | **238** | 99 production chunks | | **Total** | **377** | **357** | 194 + 183; 119 + 238 | **Definition of the 183.** The number is the sum of the four portals' enumerated `api_paths` inventories (Visitron 98, Catalog 47, Referrals 18, Provider Chat 20). Of those, **166** carry an `/api/internal*` prefix, **13** are shared auth/session routes (`/api/auth/*`, `/api/admin/logout`, `/api/user/current`), and **4** are `/api/external*` mirrors. Cross-portal deduplication yields **142 unique internal path literals**. The count keeps 183 because each portal ships its own client contract and its own deployment; collapsing them would hide duplicated but independently exploitable surface. **Why the gap exists.** A high-level endpoint list captures the visible REST calls. It does not enumerate: - the 40 `injectEndpoints` slices in `lib/store/api/`; - the 64 catalog-only Rails controller routes in `lib/api/endpoints.ts`; - the four internal portals, each of which is a separate Next.js deployment with its own bundle and its own `/api/internal*` backend. **Why it matters.** The internal portals are where the company actually operates: clinician encounters, e-prescribing, care-pathway authoring, referral concierge work, and LLM prompt administration. A competitive or security assessment that stops at the consumer storefront misses **49% of the route estate** (`183 / 377`) and **67% of the RTK operations** (`238 / 357`). **Residual uncertainty.** The 183 is a *bundle-derived* inventory. Next.js route handlers that are never referenced by a client chunk, and Rails routes with no client caller, are not counted. The true server route count is therefore **≥377**, not exactly 377. --- ### 1.3 Corporate and brand genealogy: four stages General Medicine is not a single entity with a single brand. It is a four-stage chain in which each stage left public residue. | Stage | Identity | Dates | Public evidence | Role | | :--- | :--- | :--- | :--- | :--- | | **1. Legal shell** | **Path Healthcare Systems Corp.** | Incorporated **2023-07-21 (July 21, 2023)** (Delaware C-Corp, File `#7571245`); EIN `93-2571245`; Florida foreign registration `F24000004983` filed **2024-09-19**, reinstated **2026-05-18** | Delaware Division of Corporations; [Florida Sunbiz detail](https://search.sunbiz.org/Inquiry/corporationsearch/SearchResultDetail?inquirytype=EntityName&directionType=PreviousList&searchNameOrder=PATHHEALTHCARESYSTEMS+F240000049830&aggregateId=forp-f24000004983-0d0b0233-814a-4379-9da4-e91519a42230); [Bloomberg profile](https://www.bloomberg.com/profile/company/2572022D:US) | Contracting, IP, employment, fundraising | | **2. Stealth engineering** | **Nile Health** | 2023–present | `staging-nile.com`, `nile-core`, `@nile/mantine-theme`, `@nile/ai-assistant`, `nile.health`, `nilehealth.com`, `visitron.staging-nile.com`, `catalog.staging-nile.com`, `analytics.staging-nile.com` | Internal codename and infrastructure namespace; still live | | **3. First consumer brand** | **Nav Health** | 2024–2026 (observed transition window; site still live) | `https://www.navhealth.co/` banner **“Nav Health is now General Medicine.”**; `api.navhealth.co`, `assets.navhealth.co`, `email.navhealth.co`; `support@navhealth.co` still printed on `https://generalmedicine.co/refund-policy-labs` | Consumer launch brand, later retired | | **4. Current brand** | **General Medicine** | 2024-03-06 onward | `generalmedicine.co`; Utah DBA/BBB start date **2024-03-06**; HQ **128 Spear St, Floor 4, San Francisco, CA 94105**; registered address **50 W. Broadway, Ste 333, PMB 518579, Salt Lake City, UT 84101-2027** | Current consumer and enterprise brand | **Brand residue (`[LIVE]`, 2026-10-19):** - `https://www.navhealth.co/` returns HTTP 200 and renders the exact banner **“Nav Health is now General Medicine.”** with a **“Visit General Medicine”** CTA. - `https://generalmedicine.co/refund-policy-labs` still instructs patients to email **`support@navhealth.co`**. - DNS still resolves `api.navhealth.co`, `assets.navhealth.co`, `email.navhealth.co`, and `email.mail.navhealth.co`. - The Florida registration lists **Ashwin Muralidharan** and **TJ Parker** at the Salt Lake City PMB address. - The Florida entity's last event is a **REINSTATEMENT on 2026-05-18**, with 2025 and 2026 annual reports filed the same day — a signal that the foreign registration had lapsed and was cured in a single administrative event. **Why it matters.** - **Counterparty risk.** A vendor, landlord, or enterprise customer contracting with “General Medicine” may be contracting with Path Healthcare Systems Corp.; the brand name is not the legal name. - **Support-channel leakage.** A patient following the refund policy emails a retired brand's mailbox. If that mailbox is unmonitored, refunds and PHI requests can be lost. - **Entity confusion in public records.** Press and databases alternate between “General Medicine,” “General Medicine Inc.,” “Nile Health,” “NavHealth,” and “Path Healthcare Systems Corp.” This is not cosmetic: it is why the SEC search returns a false positive (see 1.8). - **SEO and trust fragmentation.** Three domains with overlapping content split authority and create phishing lookalikes. --- ### 1.4 Friendly-PC and CPOM governance split The governance split is inverted at the top: a non-physician co-founder is President of the Utah PC, while the **50-state licensed Medical Director** leads the Florida and New Jersey PCs. That reverses the usual physician-owned PC, non-physician MSO model at one layer. CMS NPPES resolves **four NPI records across three Friendly PC groups** (Emerald, Centennial, Ruby). Both the privacy policy and the assignment-of-benefits page name the PCs. | Legal PC | NPI | Enumeration | Authorized Official | Title | Location | Phone | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Emerald Medical Practice, P.C.** | `1447011267` | **2024-01-18** (updated 2026-06-09) | **Ashwin Muralidharan** | **President** | 1743 Sidewinder Dr Unit 114, Park City, UT 84060 | **(307) 840-9834** | | **Emerald Medical Practice, P.C.** | `1750195483` | **2025-02-04** | **Ashwin Muralidharan** | **President** | 1743 S Sidewinder Dr Unit 114, Park City, UT 84060 | **(307) 840-9834** | | **Centennial Medical Practice, P.C.** | `1174333975` | **2025-01-13** (updated 2026-09-22) | **Dr. Pallabi Sanyal-Dey** | **President** | 1201 Hays St, Tallahassee, FL 32301 (mailing: 1743 Sidewinder Dr Unit 114, Park City, UT) | **(307) 840-9834** | | **Ruby Medical Practice, P.C.** | `1346050150` | **2025-01-13** (updated 2026-09-23) | **Dr. Pallabi Sanyal-Dey** | **President** | 100 Charles Ewing Blvd Ste 160, Ewing, NJ 08628 (mailing: 1743 Sidewinder Dr Unit 114, Park City, UT) | **(307) 840-9834** | *NPPES returns one location per organization. Additional state registrations (for example, an Idaho variant for Centennial) are not independently verified in this snapshot; the table reflects the CMS record as returned.* **Shared-infrastructure signals:** - All four NPIs use **the same telephone number, `(307) 840-9834`** — a Wyoming area code for Utah, Florida, and New Jersey entities. - Three of the four use **1743 Sidewinder Dr Unit 114, Park City, UT 84060** as the mailing address. Emerald's 2024 NPI (`1447011267`) uses **1441 Ute Blvd Ste 370, Park City, UT 84098** as its mailing address but **1743 Sidewinder Dr Unit 114** as its location address. - The two Emerald NPIs are the same organization enumerated twice, 12.5 months apart, with different addresses and different `last_updated` dates. This is a registration-maintenance pattern, not two distinct practices (`[INFERENCE]` from the shared name, phone, and officer). **The clinical counterweight.** Dr. Pallabi Sanyal-Dey is General Medicine's **50-state licensed Medical Director** (`/bio/dr-pallabi-sanyal-dey`) and President of both the Florida and New Jersey PCs. Her bio describes exactly the functions a medical director should own: *"she leads clinical oversight and sign-off, making sure the care customers receive is safe, consistent, and built around their full story."* She is the physician governance layer for the states where the PCs are registered. **The delegated telehealth layer.** `https://generalmedicine.co/vital-informed-consent` discloses that lab/telehealth consultations are delivered through **Junction / Vital** (`tryvital.io`) and its affiliates, and names the following professional corporations: - **OpenLoop Healthcare Partners, PC**; OpenLoop Healthcare Partners California, PC; Colorado, PC; New Jersey, PC; Wisconsin SC - **Reliant.MD Medical Associates, PLLC**; Reliant.MD Medical Associates California, PC; Colorado, PC; New Jersey, PC; Wisconsin, SC - **MECNB Physician Services, PC**; MECNB Physician Services California, PC; Colorado, PC; New Jersey, PC; SC This is a **three-network delegated-care stack** (OpenLoop, Reliant.MD, MECNB), each replicated state-by-state. It means General Medicine's clinical footprint is not just three Friendly PC groups; it is three PC groups (four NPI records) plus at least **fifteen professional entities** under the Vital consent umbrella (three base PCs and twelve state variants). **Why it matters.** - **CPOM exposure is state-specific.** In states that enforce the corporate practice of medicine doctrine, a non-physician **President** of a professional corporation is a governance red flag, even when the MSO is separate. Utah's regime is more permissive than California's or New Jersey's, but the pattern travels with the entity. - **The MSO/PC boundary is where clinical control is adjudicated.** If Path Healthcare Systems Corp. controls scheduling, compensation, formularies, and clinical protocols, regulators may treat the MSO as the de facto practice regardless of the PC's nominal ownership. - **The shared phone/address cluster is a registration fingerprint.** It is consistent with centralized management and inconsistent with independent physician-owned practices. That is common in Friendly-PC models, but it is evidence of control, not merely affiliation (`[INFERENCE]`). - **The delegated network expands liability surface.** A patient in Wisconsin may be treated by an OpenLoop or Reliant.MD entity, not by Emerald or Centennial. The consent page is the clearest public disclosure of that chain. **Analytical caveat (`[INFERENCE]`).** This report identifies the officer and registration pattern; it does not opine that any state has violated its CPOM rules. A legal conclusion requires state-by-state counsel review of the MSO services agreement, clinical control provisions, and fee-split. --- ### 1.5 Lab pricing: live fee and code fallback The **$30.00** `STANDARD_CLINICAL_FEE` (`types/enums/lab-pricing-constants.ts:8`) is a fallback, not a universal, non-waivable fee applied to all lab orders. The component reads `clinical_fee` from the live API first: **Code evidence (`[CODE]`):** ```typescript // types/enums/lab-pricing-constants.ts:5–13 /** * Standard clinical fee charged for lab order clinical review */ export const STANDARD_CLINICAL_FEE = 30 /** * Estimated insurance copay shown when actual insurance price is unavailable */ export const ESTIMATED_INSURANCE_COPAY = 30 ``` In `components/LabPanelPricing.tsx:59–69`, the component explicitly reads `clinical_fee_enabled` and `clinical_fee` from the backend payload (`quest`, `labcorp`, `bioreference`) and uses `STANDARD_CLINICAL_FEE` **only as a nullish fallback**: ```typescript const hasClinicalFeeEnabled = lab_options.prices?.quest?.clinical_fee_enabled || lab_options.prices?.labcorp?.clinical_fee_enabled || lab_options.prices?.bioreference?.clinical_fee_enabled || false setIsClinicalFeeEnabled(hasClinicalFeeEnabled) const feeFromSku = lab_options.prices?.quest?.clinical_fee ?? lab_options.prices?.labcorp?.clinical_fee ?? lab_options.prices?.bioreference?.clinical_fee setClinicalFee(feeFromSku ?? STANDARD_CLINICAL_FEE) ``` `LabPanelPricing.tsx:172` then renders the resolved `clinicalFee` in the PDP UI (e.g., **"$15 clinical review added at checkout"** when `feeFromSku` is `15`). **Live evidence (`[LIVE]`, 2026-10-19).** Seven lab SKUs were fetched from `GET /api/external/lab_skus/:skuId`. Every vendor returned `clinical_fee_enabled: true` and `clinical_fee: 15.0`, alongside additional schema fields (`platform_fee`, `collection_fee`, `order_fee`): | SKU | Quest clinical / platform / order | Labcorp clinical / platform / order | BioReference clinical / platform / order | Quoted `total_cash_price` (`test_price + clinical_fee`) | | :--- | :--- | :--- | :--- | ---: | | `500001` Annual Wellness Test | 15 / 40 / 6 | 15 / 40 / 6 | 15 / 40 / 6 | $129.92 (Quest) | | `500093` Thyroid Panel with TSH | 15 / 15 / 6 | 15 / 15 / 6 | 15 / 15 / 6 | $54.10 (Quest) | | `500010` Vitamin D | 15 / 15 / 6 | 15 / 15 / 6 | 15 / 15 / 6 | $54.00 (Quest) | | `500097` TSH Standalone | 15 / 15 / 6 | 15 / 15 / 6 | 15 / 15 / 6 | $48.25 (Quest) | | `500049` Total Health Panel | 15 / 24.08 / 6 | 15 / 24.08 / 6 | 15 / 24.08 / 6 | $114.00 (Quest) | | `500157` Lipoprotein A | 15 / 15 / 6 | 15 / 15 / 6 | 15 / 15 / 6 | $48.70 (BioReference) | | `500099` Vitamin A Test | 15 / 15 / 6 | 15 / 15 / 6 | 15 / 15 / 6 | $49.71 (Labcorp) | **Three takeaways:** 1. **Server-driven fee, not a frontend/backend contradiction.** Because `LabPanelPricing.tsx:65–69` prefers `feeFromSku` over `STANDARD_CLINICAL_FEE`, the live **$15.00** `clinical_fee` is the intended server-driven rate rather than a bug; the **$30** constant in `lab-pricing-constants.ts:8` is a fallback when `clinical_fee` is omitted, not a guaranteed or universal fee. 2. **Refund policy scope vs. copy clarity.** `https://generalmedicine.co/refund-policy-labs` states under *Refund & Cancellation Policy for Lab Test Bookings*: *"No Fees Deducted: If eligible, you will receive a full refund. We do not charge any administrative or physician order fees."* In context, this clause explains that eligible pre-collection refunds are returned in full without withholding administrative or physician-order cancellation deductions—not that lab purchases never include a clinical review fee. However, the broad phrasing (*"We do not charge any administrative or physician order fees"*) could be misread by consumers alongside the PDP's *"clinical review added at checkout"* line. 3. **Unrendered fee fields in `/api/external/lab_skus/:id` (`[INFERENCE]`).** The JSON payload includes `platform_fee` ($15.00–$40.00), `collection_fee` ($3.00–$9.00), and `order_fee` ($6.00), whereas `total_cash_price` equals `test_price + clinical_fee` and `LabPanelPricing.tsx` never reads or renders those three fields. Without an authenticated paid checkout trace, it is not established whether those fields are internal unit-economics metadata, legacy fields, or applied elsewhere; they are an open schema/disclosure question rather than an undisclosed checkout charge. --- ### 1.6 Catalog size and SKU taxonomy Marketing and the a16z thesis say **“2,900+ products and services.”** The sitemap census proves a **3,184-SKU** raw catalog, 9.8% above the claim, but the **108-query search sample** is not a census, and a null top-level price is not proof that a SKU is unpurchasable. **Sitemap inventory (`[OSINT]`, `osint/live_sitemap_skus.json`):** - **3,290 unique URLs** across four sitemaps (6,488 URL entries before dedup). - **3,184 SKU URLs**. - **23 numeric prefixes**. - **74** non-SKU site pages, **20** `/bio/*` pages, **10** legal pages, **1** partner store. **Sitemap composition:** | Sitemap | URLs | SKU URLs | | :--- | ---: | ---: | | `sitemap.xml` | 51 | — | | `store-sitemap.xml` | 3,240 | 3,184 | | `sku-refresh.sitemap.xml` | 3,099 | 3,099 | | `in-person-skus-sitemap.xml` | 98 | 98 | | **Unique** | **3,290** | **3,184** | **Series taxonomy (broad buckets):** | Series | SKUs | Interpretation | | :--- | ---: | :--- | | `700xxx` | **1,362** | Pharmacy / medication products (including `701xxx`–`711xxx` sub-series) | | `200xxx` | **909** | Medication products (`200xxx`–`202xxx`) | | `300xxx` | **511** | Conditions / services / office visits | | `500xxx` | **280** | Labs (`500xxx`, `501xxx`–`503xxx`) | | `400xxx` | **101** | In-person visits / procedures | | `100xxx` | **20** | Specialist e-consults | | `364` | **1** | Legacy anomaly | | **Total** | **3,184** | | **Search-sample reality (`[OSINT]` + `[LIVE]`):** - The **nine live category endpoints** expose **329 unique SKUs** across 9 categories (`infra_npi_catalog.json`). - A broader **108-query `a–z`, `0–9` sample** surfaces **448 unique SKUs** (`live_sitemap_skus.json`). Of those, **326 have a non-null top-level `cash_price_cents` or `insurance_price_cents` field** and **122 have both top-level fields null**. - **Null top-level price is not proof of unpurchasability.** **Eight of the 122** null-top-level SKUs are in-person conditions whose `options[]` entries carry fees. SKU `300603` (Maternal-Fetal Medicine Office Visit) is the clearest example: null top-level cash/insurance fields, but `coordination_fee: 3000`, `clinical_review_fee: 1500`, `checkout_fee: 4500`, `typical_copay: 5000`. Option-level pricing can therefore exist behind a null top-level price. - **2,736** sitemap SKUs were **not surfaced by this 108-query sample**. That is not the same as “never appear in search”: SKU `400285` (Chronic Pain Management — Opioid Prescribing) is in `sitemap_only_skus` yet a live `GET /api/external/search/index?query=chronic%20pain` returns it. The sample is non-exhaustive. - Category mix of the 448: **265** `medication_option`, **95** `lab`, **49** `condition`, **36** `medication`, **2** `visit`, **1** `specialty`. - Category mix of the 326 with top-level price fields: **162** `medication_option`, **95** `lab`, **41** `condition`, **25** `medication`, **2** `visit`, **1** `specialty`. - Cash/insurance price range across the top-level priced sample: **$5.11** (`705966`, Lagevrio) to **$17,411.20** (`708908`, Tibsovo). **Why it matters.** - **The raw catalog is bigger than the marketing claim.** 3,184 sitemap URLs is **9.8% above** “2,900+.” - **The search sample cannot support a discoverability census.** Only **448 of 3,184** SKUs were surfaced by 108 queries; the remaining **2,736** are **sample-unsurfaced**, not proven undiscoverable. The `400285` counterexample shows a targeted query finds a SKU the generic sample missed. - **Null top-level price cannot support a “checkout cliff” claim.** The `300603` counterexample — one of **eight** null-top-level SKUs with option-level fees — shows pricing (`checkout_fee: 4500`) behind null top-level fields. A per-SKU probe — not a top-level field check — is required to establish whether a SKU is purchasable. - **The summary fields are broader than the data.** `summary.sku_with_live_price` counts every SKU returned by the search sample (**448**), not every SKU with a price; `sitemap_only_skus` means “not surfaced by this 108-query sample,” not “absent from search.” - **The `364` single-SKU anomaly** is a data hygiene defect: a legacy SKU with no series prefix. --- ### 1.7 Controlled substances: policy and referral SKUs The FAQ says General Medicine cannot fill controlled substances; the in-person referral catalog still sells three services adjacent to controlled prescribing. The FAQ answer (`lib/hardcoded-data/CategoryPages/medications.ts:165`): > **“Yes — we can’t fill controlled substances, and what else is available can vary by state, since prescribing laws differ by location. We’ll always be upfront about what we can and can’t prescribe for you. And if the right medication for you is something we can’t provide, we’ll help connect you with someone who can.”** The **in-person referral sitemap** contains active SKUs for controlled-substance-adjacent care: | SKU | URL | What it sells | Controlled-substance relevance | | :--- | :--- | :--- | :--- | | `400285` | `/s/chronic-pain-management-opioid-prescribing/400285` | In-person chronic pain management with opioid prescribing | **Schedule II** opioid prescribing | | `400293` | `/s/pregabalin-lyrica-management/400293` | In-person pregabalin/Lyrica management | **Schedule V** (federal) | | `300604` | `/s/accutane-office-visit/300604` | In-person Accutane (isotretinoin) office visit | REMS-controlled, not CSA-controlled | **The nuance that matters.** These are **referral / in-person office visit SKUs**, not telehealth prescriptions. The FAQ says General Medicine cannot *fill* controlled substances through its own telehealth flow; the SKUs route patients to in-person clinicians who can prescribe. That is a defensible clinical model, but the public copy does not explain the distinction. A patient reading “we can't fill controlled substances” and then seeing “Opioid Prescribing” in the store experiences a contradiction even if the legal reality is coherent. **Why it matters.** - **Regulatory perception.** State boards and payers may read “opioid prescribing” in a consumer storefront as a controlled-substance channel, regardless of the referral wrapper. - **Brand trust.** The “we’ll help connect you with someone who can” sentence is doing a lot of work. It should be expanded into an explicit “in-person referral only” disclosure on each SKU. - **Clinical governance.** The referral network that accepts these SKUs is not named on the SKU page. The Vital/OpenLoop/Reliant/MECNB consent page is the only place the delegated network appears. That is not enough for a Schedule II referral. **Recommendation.** Add a per-SKU disclosure: “This is an in-person referral. General Medicine does not prescribe controlled substances through telehealth. The in-person clinician independently determines whether prescribing is appropriate.” Remove “opioid prescribing” from the SEO slug if the clinical network cannot guarantee access. --- ### 1.8 SEC EDGAR: no Form D on record General Medicine has publicly raised **$152M** ($32M seed in May 2025, $120M Series B on 2026-10-06). EDGAR contains **zero Form D filings** for **Path Healthcare Systems Corp.** or **General Medicine**. **What the SEC sweep found (`[OSINT]`, `osint/sec_edgar_filings.json`):** | Metric | Value | | :--- | ---: | | EDGAR full-text queries | 17 | | FTS hits | 493 | | CIKs discovered | 261 | | Form D filings parsed | 76 | | Related persons extracted | 612 | | Related-person roles | 687 (Director 437, Executive Officer 248, Promoter 2) | | **Affiliate Form D count** | **0** | | Affiliate offering amount | **$0** | | Context Form D count | 4 | | Context offering amount | **$90,729,961** | | Name collisions | 3 | The four **context** Form Ds are not General Medicine: - **PillPack, Inc.** — three filings (2013-03-14, 2015-06-04, 2016-09-06). - **TJ Parker Fund One, a series of Angel Deal Holdings, LP** — one filing. The three **name collisions** flagged by the sweep are **Solari Capital General Medicine I, L.P.** and **NavHealth, Inc.** (two filing records). Solari is a venture fund, not an operating affiliate of General Medicine. **The NavHealth collision.** `NavHealth, Inc.` (CIK **`0001717158`**) appears in EDGAR company search and has two Form D filings (2017-09-18 and 2019-04-10). Its record is: | Field | Value | | :--- | :--- | | Name | NavHealth, Inc. | | CIK | `0001717158` | | State of incorporation | DE | | EIN | `471794128` | | Address | 1110 N. Glebe Rd., Suite 220, Arlington, VA 22201 | | Phone | (571) 858-5267 | | Form Ds | 2017-09-18; 2019-04-10 | This is the **Aneesh Chopra** NavHealth, founded in **2014**, which later became **CareJourney**. It is **not** General Medicine's predecessor. General Medicine's predecessor brand was **Nav Health** (`navhealth.co`), a different company from **NavHealth, Inc.** (`navhealth.ai`/CareJourney). The similarity is a genuine trap for anyone doing entity resolution on this company. **Legal framing.** A Form D is a notice of exempt offering under Regulation D, typically Rule 506(b) or 506(c), which themselves rely on **Section 4(a)(2)** of the Securities Act. A company that raises only from accredited investors in a private placement, without general solicitation, can rely on **Section 4(a)(2) directly** and is not required to file Form D. The absence of a Form D is therefore **not proof of wrongdoing**. Its practical effect is that there is **no public notice of offering size, investor count, related persons, or sales commissions** for the $152M. **Why it matters.** - **No independent capitalization check.** Every public dollar figure traces to press coverage or the company's own announcement, not to a federal filing. - **No related-person disclosure.** Form D would list officers, directors, and promoters. That is exactly the data needed to verify the board and the Friendly-PC control chain. - **No valuation or share-price disclosure.** Form D does not require valuation, but it does require offering amounts and amounts sold. Without it, the $152M is a press-release number. - **The “conceal” reading is an inference.** No intent is asserted here. The defensible statement is: the company's exemption posture is consistent with a Section 4(a)(2) private placement, and the practical consequence is opacity. Any claim that the structure was chosen *to conceal* valuation is `[INFERENCE]`. **Recommendation.** Before any commercial counterparty relies on the $152M, request the cap table, the Series B purchase agreement, and the Section 4(a)(2) / Rule 506 analysis. Do not treat the press number as confirmed. --- ### 1.9 Clinician pay claim is commented out The clinician hiring page does not claim competitive pay. The claim exists only as a commented-out block in `lib/hardcoded-data/ClinicianHiring/clinician-hiring-content.tsx:206–210`: ```tsx // { // icon: 'checkmark', // title: 'Competitive pay', // description: 'Above-market compensation for telehealth work', // }, { icon: 'checkmark', title: '1099 flexibility', description: 'Designed to fit alongside primary clinical roles', }, { icon: 'checkmark', title: 'White-glove onboarding', description: 'Expedited, compensated process for referred clinicians', }, ``` **What this means.** The live page sells **1099 flexibility**, **white-glove onboarding**, and **interesting cases**. This is a small but telling editorial decision: the company recruits on flexibility and case mix, not on compensation. **Why it matters.** - **Recruiting positioning.** For 1099 telehealth clinicians, pay is the primary decision variable. Withholding it shifts the page from a value proposition to a vetting funnel. - **Labor-model signal.** The combination of 1099 flexibility and no pay claim is consistent with a variable, panel-based clinical workforce rather than a salaried medical group. That is not unusual, but it is a different model from the “in-house doctors” language used in early press. - **No inference of illegality.** Commenting out a marketing claim is not evidence of below-market pay. It is evidence that the company chose not to make the claim. --- ### 1.10 Placeholder copy and fail-open tenant resolution **Finding A — a literal placeholder shipped to production.** The article at `https://generalmedicine.co/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup` (published **2026-10-05T20:11:48Z**, modified 2026-10-06T15:49:20Z) contains this sentence: > “Start with a search on the prescriptions page, or `[open your dashboard]([dashboard URL pending])` if you already have a prescription with us.” This is not a rendering artifact. The Markdown link destination is the literal string `[dashboard URL pending]`. It shipped in the body copy of a patient-facing article about medication pricing. **Finding B — tenant resolution fails open.** `config/tenants/tenantRewrites.js:36` and `lib/tenantHeaders.ts:6` both carry `TODO(GM-6520)`: ```javascript // config/tenants/tenantRewrites.js function resolveActiveTenantId() { // TODO(GM-6520): require NEXT_PUBLIC_GM_TENANT_ID and fail fast when unset. return process.env.NEXT_PUBLIC_GM_TENANT_ID?.trim() } function getTenantPublicPathRewrites() { const tenantId = resolveActiveTenantId() // Do not rewrite paths when no tenant is active. // TODO(GM-6520): require NEXT_PUBLIC_GM_TENANT_ID and fail fast when unset. if (!tenantId) { return [] } // ... } ``` ```typescript // lib/tenantHeaders.ts export const TENANT_HEADER_NAME = 'X-GM-Tenant' /** Nile-Core tenant slug for legacy General Medicine deploys with no `NEXT_PUBLIC_GM_TENANT_ID`. */ // TODO(GM-6520): remove once every deploy sets NEXT_PUBLIC_GM_TENANT_ID explicitly. export const LEGACY_GENERAL_MEDICINE_TENANT_ID = 'general-medicine' export function resolveTenantHeaderId(): string { const tenantId = resolveActiveTenantId() return tenantId ? tenantId : LEGACY_GENERAL_MEDICINE_TENANT_ID } ``` **The failure mode.** If a Walmart or Mercy deployment forgets `NEXT_PUBLIC_GM_TENANT_ID`: 1. `getTenantPublicPathRewrites()` returns `[]`, so **no tenant rewrite occurs**. 2. The app serves the **DTC General Medicine storefront** at the partner's host/path. 3. `resolveTenantHeaderId()` returns `general-medicine`, so **API egress is tagged as DTC**, not as the partner tenant. 4. Analytics, billing, and tenant-specific feature flags may therefore attribute partner traffic to DTC. This is a **fail-open** design. The correct behavior is fail-fast at build or boot: if a tenant deployment lacks its tenant ID, it should refuse to start, not silently impersonate the DTC brand. **Why it matters.** - **Brand isolation.** A partner storefront that loses its tenant ID shows General Medicine branding and pricing to the partner's patients. - **Data isolation.** `X-GM-Tenant` is the routing key for tenant-scoped Nile-Core behavior. Falling back to `general-medicine` is a cross-tenant attribution bug, even if row-level authorization still holds. - **Content QA.** The placeholder proves there is no blocking check for unresolved Markdown destinations in the CMS/publish pipeline. The same pipeline could ship a broken legal or consent link. **Recommendation.** (a) Replace the placeholder with a real dashboard URL or remove the sentence. (b) Add a CI check that rejects `[.*pending.*]` and `]([` patterns in published MDX. (c) Make `NEXT_PUBLIC_GM_TENANT_ID` required for `app/t/*` builds and throw at boot when unset. (d) Add a tenant-resolution assertion to the edge middleware and emit a Datadog event on fallback. --- ### 1.11 Exposed internal portals and source maps **Public source maps.** `generalmedicine.co` serves **400 `.js.map` files** (30.06 MB) without authentication, covering **406 production chunk bundles** (16.27 MB JS). The maps expose **2,443 source files (208,387 LOC)**, including **798 first-party files (51,015 LOC)**, with full variable names, internal comments, TODO markers, and API contracts. **Public internal portals.** Four MedicineOS portals are reachable through unauthenticated JavaScript bundles: | Portal | Host(s) | HTTP observation | Deployment | Chunks | RTK ops | API paths | | :--- | :--- | :--- | :--- | ---: | ---: | ---: | | **Visitron** (clinician EHR) | `visitron.internal.generalmedicine.co`, `visitron.staging-nile.com` | 200, title “General Medicine Visitron” | `dpl_J4vVaJhNvPie8d6FYGbsnRAiF1yY` | 27 | 91 | 98 | | **Catalog** (care-pathway admin) | `catalog.internal.generalmedicine.co`, `catalog.staging-nile.com` | 307 → `/login`; bundle still served | `dpl_A4ryRBErTetVxWxjvyMbAe8mPgEd` | 35 | 106 | 47 | | **Referrals** (concierge queue) | `referrals.internal.generalmedicine.co`, `referrals.staging-nile.com` | 307 → `/login`; bundle still served | `dpl_bU9YUfX9Y2Vg9eDAYdnDgEfrr3Sk` | 19 | 27 | 18 | | **Provider Chat** (LLM workbench) | `internal.generalmedicine.co` | 200, title “Provider Chat”; later re-probe 429 rate-limit | `dpl_3WuAgEhfeNR4sVmf7ZVkJQWBG9Tg` | 18 | 14 | 20 | | **Total** | | | | **99** | **238** | **183** | *Host note:* the Catalog and Referrals bundles were read from `catalog.staging-nile.com` and `referrals.staging-nile.com`; their `*.internal.generalmedicine.co` counterparts returned 307 redirects to `/login`. Visitron's internal and staging hosts both returned 200. Provider Chat's `internal.generalmedicine.co` returned 200 during collection and 429 on a later re-probe (rate limit). **Public analytics.** `https://analytics.staging-nile.com` returns HTTP 200 with the title **“Metabase”** — an unauthenticated BI dashboard on a staging host. **Additional exposed hosts (`[OSINT]`):** - `staging-nile.com` — 200, internal/provider tool reachable without auth. - `www.navhealth.co` — 200, legacy consumer site. - `assets.staging-nile.com`, `assets.navhealth.co`, `mcy.staging-nile.com`, `wmt.staging-nile.com`, `promptimus.staging-nile.com` — 401/403 auth-gated tenant or internal apps. - `waystar-connector.staging-nile.com`, `waystar-bridge.staging-nile.com` — DNS-only Waystar clearinghouse integration hosts. - `visitai.generalmedicine.co` — VisitAI clinician scribe SSO target (`provider-auth.generalmedicine.co`). **Why it matters.** - **The bundles are the blueprint.** The internal portals expose route names, RTK operation names, tag types, ActionCable channel names, and UI copy. That is enough to map the clinical operating system without ever authenticating. - **The source maps are the source.** A competitor can recover the consumer app's business logic, pricing rules, feature flags, and vendor integrations. A phisher can recover exact copy and asset paths to build a convincing clone. - **Staging is not isolated.** `analytics.staging-nile.com` is a public Metabase; `waystar-*` staging hosts reveal the clearinghouse vendor; `wmt`/`mcy` staging hosts reveal the enterprise tenants. - **Scope boundary.** No credential stuffing, auth bypass, or PHI access was attempted. The findings are limited to unauthenticated bundle retrieval and public HTTP status/title observation. Any deeper test requires written authorization and a HIPAA business-associate framework. **Recommendation.** (a) Remove public `.js.map` files or restrict them to authenticated internal networks. (b) Put Cloudflare Access / IAP in front of every `*.internal.*` and `*.staging-nile.com` host. (c) Rotate any secrets that appeared in bundle-adjacent config (no live secrets were found, but the surface is large). (d) Add a build-time check that fails if a production deployment emits source maps without an access gate. (e) Treat the four portal bundles as compromised-for-confidentiality and review whether any proprietary prompt logic or clinical criteria were exposed. --- ### 1.12 Findings ledger | # | Finding | Severity | Primary evidence | Fix owner | Fix horizon | | :--- | :--- | :---: | :--- | :--- | :--- | | 1 | 32 primary endpoints vs. 377-route estate | HIGH | `lib/api/endpoints.ts`; 4 portal bundles | Docs + platform | Done | | 2 | Four-stage corporate/brand genealogy | HIGH | DE File `#7571245`; FL `F24000004983`; `navhealth.co`; refund page | Legal + brand | 30 days | | 3 | Non-physician President of Emerald PC; shared NPI cluster | HIGH | NPPES `1447011267`, `1750195483`, `1174333975`, `1346050150` | Legal + clinical governance | 30–60 days | | 4 | Server-driven $15 lab fee ($30 fallback); refund-copy scope | LOW-MED | `LabPanelPricing.tsx:59–69`; `lab-pricing-constants.ts:8`; live `lab_skus` | Docs + product copy | Done | | 5 | Catalog count vs. 108-query sample; `400285`/`300603` counterexamples | MED | 4 sitemaps; 108-query search sample | Catalog + analytics | 30 days | | 6 | Controlled-substance FAQ vs. opioid/Lyrica/Accutane SKUs | MED | `medications.ts:165`; in-person sitemap | Clinical + content | 14 days | | 7 | Zero Form D across $152M; NavHealth collision | MED-HIGH | EDGAR FTS + submissions; CIK `0001717158` | Finance + legal | 30 days | | 8 | Commented-out “competitive pay” | MED | `clinician-hiring-content.tsx:206–210` | Talent | 14 days | | 9 | Placeholder link + fail-open tenant resolution | MED-HIGH | Article 2026-10-05; `tenantRewrites.js:36`; `tenantHeaders.ts:6` | Content + platform | 7 days | | 10 | 400 source maps + 4 unauthenticated portals + Metabase | HIGH | `.js.map`; portal hosts; `analytics.staging-nile.com` | Security + platform | 7 days | **Sequencing.** Fix the seven-day issues first (placeholder copy, exposed portals), because they are cheap and externally visible. Then the governance issues (corporate genealogy, Friendly-PC split), which require legal review but determine whether the enterprise business is contractible. Then the **catalog-measurement** and capitalization issues (catalog count, Form D), which affect diligence quality. --- ## 2. Team, clinical organization, engineering and board ### 2.1 Organization at a glance General Medicine is a **founder-led, clinically credentialed, engineering-heavy** organization with a thin go-to-market layer relative to its capital. The public record supports the following headcount picture: | Metric | Value | Source | | :--- | ---: | :--- | | Third-party employee estimate | **104** | PitchBook company profile | | Public LinkedIn profiles surfaced | **87** (33 high-relevance) | `osint/linkedin_team_and_posts.json` | | Public `/bio/*` pages | **20** | `osint/live_sitemap_skus.json` | | Open Ashby roles | **16** | `generalmedicine.co/company/careers` | | Capital per estimated employee | **$1.46M** ($152M / 104) | `[INFERENCE]` | The 104 estimate and the 87 public profiles are consistent: LinkedIn discovery is incomplete by construction, and the difference is plausible for a company with many clinicians and contractors who do not list the employer. **Absence from LinkedIn is not evidence of absence.** ### 2.2 Founders | Name | Title | Background | Evidence | | :--- | :--- | :--- | :--- | | **TJ Parker** | Co-founder & **CEO** (since Oct 2026) | Second-generation pharmacist; co-founded **PillPack** (sold to Amazon 2018, ~$750M–$1B depending on source); helped build **Amazon Pharmacy** and **Amazon Clinic**; former General Partner at **Matrix Partners**, where he led GM's early rounds; served on GM's board before going full-time | [Fierce (Nov 2025)](https://www.fiercehealthcare.com/digital-health/pillpack-digital-health-how-general-medicines-founders-are-building-healthcare); [Fierce (Oct 2026)](https://www.fiercehealthcare.com/health-tech/general-medicine-banks-120m-backed-a16z-eli-lilly-and-mercy-health); `/bio/tj-parker` | | **Elliot Cohen** | Co-founder & **President** | Co-founded **PillPack** with Parker; Amazon Pharmacy integration and payer/provider partnerships; former associate at **Founder Collective**; co-founded **MIT Hacking Medicine** | `/bio/elliot-cohen`; [Fortune (May 2025)](https://fortune.com/article/general-medicine-startup-pillpack-founders-raise/) | | **Ashwin Muralidharan** | Co-founder & **Chief Product Officer** | Founding CEO through nationwide launch; former **technical advisor / chief of staff to Neil Lindsay**, Amazon's top health executive; led pricing at **Amazon Pharmacy**; now leads product, engineering, design, clinical, and operations | `/bio/ashwin-muralidharan`; [CNBC (May 2025)](https://www.cnbc.com/2025/05/22/amazon-pillpack-general-medicine.html); [Fortune](https://fortune.com/article/general-medicine-startup-pillpack-founders-raise/) | **Founder-market fit.** The trio covers the three functions a healthcare store needs: pharmacy operations and retail (Parker), partnerships and payer/provider integration (Cohen), and product/pricing/marketplace (Muralidharan). The PillPack/Amazon pedigree is real and verifiable. The weakness is that none of the three is a licensed clinician; clinical credibility is delegated to the Medical Director and the clinical leadership team. ### 2.3 Executives | Name | Role | Public title / evidence | Notes | | :--- | :--- | :--- | :--- | | **Ed Cao** | **Chief Financial Officer** | CFO, General Medicine (LinkedIn); CFO since **February 2025**; previously CFO/Advisor at **Koala Health**, VP Finance at **Charlie Health** | Finance hire predates the Series B by ~20 months | | **Jacqui Miller** | **Chief Communications Officer** | Public bio: **“Chief of comms @generalmedco”** (X); based in Massachusetts | Owns press, crisis, and enterprise comms | | **Jeff Vlahos** | **Head of Design** | **Principal Product Designer and founding designer** at General Medicine (LinkedIn) | Founding design hire; brand and product surface | | **Steph Croteau** | **Director of Operations** | Director of Operations, General Medicine (LinkedIn) | Clinical/operational execution | | **Matt Pokress** | **Advisor** (unconfirmed) / **Chief Architect** (public record) | Public professional records describe him as **Chief Architect** at General Medicine; previously CTO at **Outcomes**, and roles at **Transaction Data Systems**, **PillPack**, **Image Fortress**, **Mediacom** | The advisory designation is unconfirmed; the public record is Chief Architect. Both are plausible in a founder-adjacent architecture role. | ### 2.4 Clinical leadership | Name | Role | Credentials / background | Evidence | | :--- | :--- | :--- | :--- | | **Dr. Pallabi Sanyal-Dey, MD** | **Medical Director** | Internal medicine physician and academic hospitalist; MIT (neuroscience & systems); University of Vermont MD; UCSF associate clinical professor at Zuckerberg SF General; directed clinical operations for the Division of Hospital Medicine; Physician Advisor for Clinical Documentation & Integrity; Lean Healthcare Management certified. Serves as the physician governance layer for the **50-state licensed** clinical network. | `/bio/dr-pallabi-sanyal-dey`; President of Centennial (FL) and Ruby (NJ) PCs (NPPES) | | **Dr. Marjory Bravard, MD** | **Director of Clinical Partnerships** | Board-certified internal medicine; MIT mechanical engineering; Tufts MD; Mass General Director of Operations and Director of Inpatient Medicine; Rosebud IHS; Intermountain; Harvard Medical School instructor; University of Utah assistant professor | `/bio/dr-marjory-bravard` | | **Dr. Poushali Bhattacharjee, MD, MS, FACP** | **Head of Clinical Operations** | Board-certified internal medicine; 15+ years hospital medicine; UTMB MD; Boston University/BMC residency; Mass General hospitalist/instructor; University of Chicago; Cook County/Rush; US Acute Care Solutions | `/bio/dr-poushali-bhattacharjee` | | **Dr. Adam Carewe, MD** | **Clinical Informatics / CMIO-level role** | Board-certified family medicine and clinical informatics; 15 years; San Diego State MS; New York Medical College MD; SCL Health residency; 13 years at Kaiser Permanente Colorado; rose to **Chief Medical Informatics Officer**; team reached 99th percentile EHR satisfaction | `/bio/dr-adam-carewe` | | **Samantha “Sam” Schisler, FNP** | **Head of Clinician Training** | Dual board-certified FNP and AG-ACNP; Vanderbilt MSN; Dallas Pulmonary and Critical Care; Hicuity Health; founding clinical team member; leads training for new clinicians | `/bio/samantha-schisler` | | **Dr. Sunita Mishra, MD** | **Early Clinical Advisor & Initial PC Owner** | **Chief Medical Officer of Amazon Health Services** (where Muralidharan advised SVP Neil Lindsay); served as an early clinical advisor and held initial physician ownership of one of the affiliated medical practices during stealth before ownership transitioned to Dr. Pallabi Sanyal-Dey prior to public launch to ensure corporate independence from Amazon | STAT News; AlphaSense Company Primer (`DR-Report-by-Alphasense-10-19-2026-00-02.pdf`) | **Assessment.** This is the strongest part of the company. The clinical leadership is not a decorative advisory board: Sanyal-Dey signs off on clinical oversight, Bravard builds partnerships, Bhattacharjee runs clinical operations, Carewe brings informatics, and Schisler trains the panel. The credentials (MIT, UCSF, Mass General, Kaiser, Vanderbilt, Tufts) are specific and checkable. The weakness is span: five leaders for a national panel of 1099 clinicians and a 3,184-SKU catalog is thin, which is why the 16 open roles are concentrated in clinical recruiting, RCM, and product. ### 2.5 The 20 `/bio/*` clinicians and writers | Name | Headline | Function | | :--- | :--- | :--- | | Ashley Allen, NP | Nurse Practitioner | Geriatrics, oncology, hospice, palliative content | | Ashwin Muralidharan | Cofounder and Chief Product Officer | Product/engineering/clinical operations | | Devon Pace, MD, MPH | Physician | Surgery, public health, patient communication | | Dr. Adam Carewe, MD | Physician | Family medicine, clinical informatics | | Dr. Marjory Bravard, MD | Director of Clinical Partnerships | Internal medicine, partnerships | | Dr. Pallabi Sanyal-Dey, MD | Medical Director | Internal medicine, clinical oversight | | Dr. Poushali Bhattacharjee, MD, MS, FACP | Physician | Hospital medicine, clinical operations | | Ellen Britt, PA | Physician Assistant | Clinical content | | Elliot Cohen | Cofounder and President | Corporate/partnerships | | G. Michael Dileo, MD | Physician | Clinical content | | Jaime Osnato | Writer | Health content | | Jennifer Chesak, MSJ | Journalist | Health journalism | | Kaitlyn Alemida, PA | Physician Assistant | Clinical content | | Karen Shackelford, MD | Physician | Clinical content | | Kathleen Ferraro | Writer | Health content | | Robert Stevens, MD | Physician | Clinical content | | Samantha Schisler, FNP | Nurse Practitioner | Clinician training | | Sean Dupont, MD | Doctor | Clinical content | | TJ Parker | Cofounder and Chief Executive Officer | Corporate | | Young Bo Sim, MD | Physician | Clinical content | **Observation.** The `/bio/*` set is a **content E-E-A-T layer**, not an org chart. It mixes founders, clinical leadership, practicing clinicians, PAs, NPs, and professional health writers. That is appropriate for a storefront that publishes medication and condition pages, but it means the “20 clinicians” count should not be read as 20 full-time employees. Several are content contributors. ### 2.6 Engineering | Name | Public title | Location / background | | :--- | :--- | :--- | | **Mike Giovinco** | Software Engineer | General Medicine | | **Angie Bui** | Lead Software Engineer; founding engineer | San Francisco Bay Area | | **Kristopher Kosmatka** | Software Engineer | Engineering lead background | | **Noah Grumman** | Engineering | Williams College; San Francisco | | **Ali Shaikh** | Software Engineer | Cal Poly SLO; SF Bay Area | | **Amil Naik** | Software Engineer | Previously founding engineer at Endeavor AI; YC W22 | | **Daniel Quintana** | Software Engineer | Caltech; Boston | | **Kinjal Chauhan** | Software Engineer | Biologist turned engineer; Rails/JS/Node/React; SF | | **Veeresh Neralagi** | Engineering (unconfirmed) | Not surfaced in the public LinkedIn sweep | | **Natalia Perina** | Engineering/product/data | Ex-YC founder; 8+ years in healthcare startups | **Assessment.** The engineering team is small, senior, and full-stack. The public profiles show founding-engineer tenure and prior startup experience, not a large outsourced bench. That is consistent with the code quality observed: a coherent Next.js/RTK Query architecture, a shared Mantine theme, and a real multi-tenant rewrite engine. The risk is bus factor: ten named engineers for a 377-route, four-portal estate is thin, and the 16 open roles include four engineering positions (Frontend Boston/SF, Full-Stack Boston/SF). ### 2.7 Board, investors, and capital table | Investor / board figure | Firm | Role / evidence | Round | | :--- | :--- | :--- | :--- | | **Vineeta Agarwala, MD, PhD** | **Andreessen Horowitz (a16z)** | General Partner, Bio + Health; led the Series B; bylined the investment thesis | Series B (Oct 2026) | | **Orin Hoffman** | **VXI Capital** | Founder/Managing Director; public testimonial for General Medicine | Seed and Series B | | **TJ Parker** | **Matrix Partners** | General Partner; led the seed; now CEO of General Medicine | Seed (May 2025) | | **BoxGroup** | BoxGroup | Seed and Series B participant | Seed + Series B | | **Eli Lilly and Company** / **Eli Lilly & Company Foundation** | Eli Lilly | Series B participant; strategic/pharma alignment | Series B | | **Mercy Health** (through **Granger Management**) | Mercy Health / Granger Management | Series B participant; health-system distribution | Series B | | **Founder Collective** | Founder Collective | Seed participant; Elliot Cohen's former firm | Seed | | **JSL Health Capital** (also reported as **JSL Ventures**) | JSL Health Capital | Seed participant; healthcare growth equity | Seed | **Capital structure:** - **Seed / initial round (May 2025):** **$32M** led by **Matrix Partners** (TJ Parker) and **BoxGroup**, with Founder Collective, VXI Capital, and JSL Health Capital/JSL Ventures. - **Series B (2026-10-06):** **$120M** led by **a16z**, with Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup. - **Total disclosed:** **$152M**. **Board composition signal.** The board/investor set is a **strategic syndicate**, not a pure financial one: a retail giant's health system partner (Mercy), a pharma manufacturer (Lilly), a consumer VC (a16z), a seed fund (BoxGroup), and the founder's own fund (Matrix). That alignment is the business model in miniature: General Medicine needs distribution (Walmart/Mercy), supply (Lilly), and consumer capital (a16z) simultaneously. ### 2.8 Open roles (16, Ashby) The 16 roles listed on `generalmedicine.co/company/careers` link to `jobs.ashbyhq.com/general-medicine/`: | # | Role | Location | Function | | ---: | :--- | :--- | :--- | | 1 | Full Time Physician — Primary Care | Remote | Clinical | | 2 | Manager, NP Licensure & Collaborative Practice | Remote | Clinical compliance | | 3 | Virtual Advanced Nurse Practitioners — 1099 | Remote | Clinical | | 4 | Virtual Physician (Part-Time — 1099) | Remote | Clinical | | 5 | Frontend Engineer (Boston) | Boston | Engineering | | 6 | Frontend Engineer (SF) | San Francisco | Engineering | | 7 | Full-Stack Engineer (Boston) | Boston | Engineering | | 8 | Full-Stack Engineer (SF) | San Francisco / Boston | Engineering | | 9 | Revenue Cycle Management, Director | Remote | RCM | | 10 | Revenue Cycle Management, VP | Remote | RCM | | 11 | Strategic Finance Manager | Remote / Boston / SF | Finance | | 12 | Care Coordinator | Remote | Operations | | 13 | Clinical Recruiter, Physicians | Remote | Talent | | 14 | Product Manager — Growth | San Francisco | Product | | 15 | Product Manager, Consumer | San Francisco | Product | | 16 | VP Product | San Francisco | Product | **Hiring signal.** The mix is diagnostic: - **Four clinical roles** (physician, NP, two 1099) plus a licensure manager and a physician recruiter = scaling the panel and the state-by-state credentialing machine. - **Two RCM roles** (Director + VP) = the company is building insurance billing infrastructure, not just cash-pay. - **Four engineering roles** = the portal estate is under-resourced. - **Three product roles** including **VP Product** = product leadership is being institutionalized after the founder-led phase. - **Strategic Finance Manager** = Series B reporting and unit-economics discipline. The absence of sales/partnership roles is notable. Enterprise distribution appears to be founder-led and investor-introduced, not yet a dedicated sales org. ### 2.9 Organizational conclusions 1. **Clinical credibility is real and concentrated.** The Medical Director and clinical leadership team are the company's strongest asset. The CPOM structure, however, puts a non-physician President over one PC, which is the governance weak point. 2. **Engineering is senior but thin.** Ten named engineers for 377 routes and four portals is a bus-factor risk. The four open engineering roles confirm the gap. 3. **Go-to-market is founder-led.** No VP Sales or enterprise partnerships role is open. Walmart and Mercy were likely investor/board-introduced, not sourced by a sales team. 4. **The 104-employee estimate is plausible.** 87 public profiles + 16 open roles + contractor clinicians is consistent with a lean full-time core and a variable clinical panel. 5. **The board is a strategic map.** a16z (consumer capital), Lilly (supply), Mercy (distribution), Matrix/BoxGroup/Founder Collective/VXI/JSL (seed syndicate). Every major healthcare-store dependency has a board-level counterparty. --- ## 3. Growth, trajectory and unit economics ### 3.1 2023–2026 timeline | Date | Event | Evidence | | :--- | :--- | :--- | | **2023-07-21** | **Path Healthcare Systems Corp.** incorporated in Delaware (File `#7571245`; EIN `93-2571245`) | `[REGISTRY]` Delaware Division of Corporations; Bloomberg | | **Fall 2023** | Founders begin building General Medicine; stealth identity **Nile Health** | [Fierce (Oct 2026)](https://www.fiercehealthcare.com/health-tech/general-medicine-banks-120m-backed-a16z-eli-lilly-and-mercy-health) | | **2024-03-06** | General Medicine business start date (BBB); Utah operating presence | [BBB profile](https://www.bbb.org/us/ut/salt-lake-cty/profile/online-pharmacy/general-medicine-1166-90052323) | | **2024-09-19** | Florida foreign registration **`F24000004983`** filed (Delaware entity) | `[REGISTRY]` Florida Sunbiz | | **2025-01-13** | Centennial (FL) and Ruby (NJ) Medical Practice PCs enumerated in NPPES, Dr. Sanyal-Dey as President | `[REGISTRY]` CMS NPPES | | **2025-02-04** | Second Emerald Medical Practice PC NPI enumerated, Ashwin Muralidharan as President | `[REGISTRY]` CMS NPPES | | **2025-05-22** | **Public launch** and **$32M seed** led by Matrix and BoxGroup | [CNBC](https://www.cnbc.com/2025/05/22/amazon-pillpack-general-medicine.html); [Fortune](https://fortune.com/article/general-medicine-startup-pillpack-founders-raise/) | | **2025-11-20** | Fierce profile: hundreds of thousands of customers; 81% used GM for delayed care; 20% delayed 6+ months; average 11 years of health history | [Fierce (Nov 2025)](https://www.fiercehealthcare.com/digital-health/pillpack-digital-health-how-general-medicines-founders-are-building-healthcare) | | **2026-01-08** | Walmart **Better Care Services** launches with General Medicine as a partner | [Walmart press release](https://www.nasdaq.com/press-release/new-year-new-you-walmart-launches-better-care-services-and-rolls-back-prices-1000); [Supermarket News](https://www.supermarketnews.com/hbc-health-beauty/walmart-launches-new-health-and-wellness-platform) | | **2026-05-18** | Florida registration reinstated; 2025 and 2026 annual reports filed; name change recorded | `[REGISTRY]` Florida Sunbiz | | **2026-10-05** | Pricing article published with literal `[dashboard URL pending]` placeholder | `[LIVE]` article `datePublished` | | **2026-10-06** | **$120M Series B** led by a16z; total raised **$152M** | [a16z](https://a16z.com/announcement/investing-in-general-medicine/); [Fierce](https://www.fiercehealthcare.com/health-tech/general-medicine-banks-120m-backed-a16z-eli-lilly-and-mercy-health); [MobiHealthNews](https://www.mobihealthnews.com/news/general-medicine-raises-120m-healthcare-shop) | | **2026-10-19** | Company snapshot: 3,184 SKUs, 377 routes, 238 internal ops, zero Form Ds, four public portals | This report | ### 3.2 Traction metrics | Metric | Value | Source | Confidence | | :--- | :--- | :--- | :--- | | Customers | **“hundreds of thousands”** | TJ Parker, Fierce (Oct 2026) | Company claim; no confirmed figure | | Geographic coverage | **Every state and nearly every county** | TJ Parker, Fierce (Oct 2026) | Company claim | | Previously delayed care | **81%** of customers used GM for care they had delayed | Fierce (Nov 2025) | Company-provided survey; methodology undisclosed | | Delayed 6+ months | **20%** | Fierce (Nov 2025) | Same caveat | | Average health history | **11 years** per customer | Fierce (Oct 2026) | Company claim; Metriport/Particle aggregation | | Catalog | **3,184** sitemap SKUs; **448** surfaced by 108-query sample; **326** top-level priced (sampling, not a census) | This report | High for raw counts; medium for commercial status | | Trustpilot | **4.7 / 5.0**, **906** reviews (91% 5★, 6% 1★) | Trustpilot, 2026-10-18 | High for the snapshot | | BBB | **“D”**, **6** complaints, unaccredited | BBB, 2026-10-18 | High for the snapshot | | Employees | **~104** | PitchBook | Medium (third-party estimate) | | Open roles | **16** | Ashby / careers page | High | | Total equity | **$152M** | Press + company announcement | Medium (no Form D) | | Implied post-money valuation (Series A, May 2025) | **$156.84M** ($32M raised) | AlphaSense / Preqin Funding Screener | Medium (third-party private-market estimate; no Form D) | | Implied post-money valuation (Series B, Oct 2026) | **$669.68M** ($120M raised; **4.3x step-up** in 17 mos) | AlphaSense / Preqin Funding Screener | Medium (third-party private-market estimate; no Form D) | | Early launch revenue (mid-2025) | **$1M–$5M** estimated | Preqin / AlphaSense | Low-Medium (early post-launch band) | | County-level footprint & pharmacy reach | **82% of U.S. counties** (targeting 100%) · **50,000+ local pharmacies** · **100+ health systems** across **35+ specialties** | AlphaSense / MGMT Boston / PR Newswire | High (company-reported operational footprint) | | CPOM legislative exposure (Jan 1, 2026) | **California SB 351** & **Oregon SB 951** | State statutes / Paul Hastings / AlphaSense | High (codifies strict MSO-PC control & stock-transfer limits) | | Sector unit-economics & lab benchmarks | **$75–$400 CAC** (11.6% search CVR, $56.83 CPL); **$150–$300** avg visit rev (1st-visit payback); **$2K–$6K LTV** (7.5x–20x LTV:CAC); Quest/Labcorp **20% lower cost** (80% reagent / 20% labor) vs **5%–10%** at-home kit failure rate | AlphaSense Expert Calls & Sector Benchmarks (`DR-Report-by-Alphasense-10-18-2026-16-29.pdf`) | Benchmark context | | Valuation multiples & exit benchmarks | **11.5x EV/EBITDA** digital health median (+19%–61% AI premium); **~$200M+ ARR** required for 2027+ IPO readiness; near-term M&A interest from commercial payers & PE roll-ups | AlphaSense / SVB / Sofer Advisors | Benchmark context | **The traction narrative is plausible but unconfirmed.** “Hundreds of thousands” is consistent with a nationwide marketplace that has been live since May 2025 and has Walmart distribution since January 2026. It is not consistent with a narrow DTC telehealth clinic. The 81%/20% delayed-care statistics are the most compelling consumer insight in the public record: they position General Medicine as a **queue-jumper** for care people have already postponed, not a replacement for primary care. But the survey methodology, sample size, and question wording are not disclosed, so the numbers should be treated as marketing research, not clinical evidence. ### 3.3 Headcount and hiring trajectory - **104 estimated employees** (PitchBook) against **87 public profiles** and **16 open roles**. - **Clinical roles dominate the open requisitions** (4 of 16) plus a licensure manager and a physician recruiter. This is the signature of a company scaling a 1099 panel across 50 states. - **RCM hiring** (Director + VP) is the clearest signal that the company is moving from cash-pay convenience to insurance-billed care at scale. RCM is expensive and operationally heavy; hiring a VP implies a multi-payer build-out. - **Product leadership** (VP Product + two PMs) suggests the founder-led product phase is ending. - **No sales leadership role** is open. Enterprise growth is still founder/investor-led. ### 3.4 Revenue model and unit economics General Medicine monetizes five layers: 1. **Visit platform fees.** Sampled cash prices for visits and e-consults range from **$30** to **$150** depending on SKU and modality; the sampled insurance floor is **$25**. Examples from the live search index: - `100012` Primary Care Visit: **$100 cash / $25 insurance**. - `100017` Urology Consult: **$150 cash / $25 insurance**. - `300335` Fall: **$100 cash / $25 insurance**. - `300550` Weight Loss Follow-Up: **$30 chat / $25 insurance / $100 video**. 2. **Lab clinical review fees.** `LabPanelPricing.tsx:59–69` reads `clinical_fee` from `/api/external/lab_skus/:id` (falling back to `STANDARD_CLINICAL_FEE = 30` only when omitted). Across all seven sampled lab SKUs, the live API returned `clinical_fee: 15.0`, and `total_cash_price` equals `test_price + clinical_fee` (e.g., `500001` quotes `$129.92` = `$114.92` test + `$15.00` clinical review fee). The API payload also contains unrendered fields (`platform_fee` $15.00–$40.00, `collection_fee` $3.00–$9.00, `order_fee` $6.00) whose role at checkout was not observed without an authenticated purchase trace. 3. **Pharmacy routing.** The `gm_card` (BIN/PCN/group/member ID) and the GPS comparison drawer route cash prescriptions to CVS, Walgreens, Walmart, LillyDirect, and NovoCare. Revenue is likely a transaction/PBM margin, not a patient-facing fee. 4. **Enterprise licensing / revenue share.** Walmart's **Better Care Services** and Mercy Health's white-label portal. The contract terms are undisclosed; the tenant code shows custom SKUs, brand tokens, S3 uploads, and Trust Commerce billing. 5. **AI / copilot upsell (`[INFERENCE]`).** “General AI” is a free front door today. The architecture is designed to let AI agents search and purchase care on a patient's behalf, which implies a future take-rate or referral fee. No public pricing exists. **Illustrative revenue scenarios (`[INFERENCE]`, not company guidance):** | Scenario | Customers | Paid encounters / customer / year | Net revenue / encounter | Consumer encounter revenue | Lab/pharmacy/enterprise | Total | | :--- | ---: | ---: | ---: | ---: | ---: | ---: | | Conservative | 100,000 | 1.0 | $40 | $4.0M | $3M | **$7M** | | Base | 200,000 | 1.5 | $55 | $16.5M | $10M | **$26.5M** | | Aggressive | 300,000 | 2.0 | $75 | $45.0M | $20M | **$65M** | **Why the range is so wide.** The company has not disclosed revenue, GMV, active customers, visit volume, or enterprise contract values. The only public quantitative anchors are “hundreds of thousands” of customers, 3,184 catalog SKUs, 906 Trustpilot reviews, and 104 employees. Any single revenue estimate would be false precision. **Capital efficiency.** $152M raised / 104 employees = **$1.46M per employee**. That is high for a healthcare marketplace and implies either (a) a large contractor clinical network not counted in the 104, (b) significant marketing spend, or (c) a long regulatory/engineering build. A $120M Series B at this stage implies a multi-year runway and an investor expectation of category leadership, not near-term profitability. ### 3.5 Trustpilot vs. BBB: two different instruments | Platform | Metric | What it measures | Interpretation | | :--- | :--- | :--- | :--- | | **Trustpilot** | **4.7 / 5.0**, 906 reviews; 91% 5★, 6% 1★ | Invite-driven customer satisfaction | Strong for a telehealth marketplace; the 6% 1★ tail is the operational failure cluster | | **BBB** | **“D”**, 6 complaints, unaccredited | Complaint handling and responsiveness | A “D” with only 6 complaints is usually a response-rate/age-of-complaints issue, not a mass-failure signal | **Reading them together.** The two are not contradictory. Trustpilot samples happy customers who respond to invites; BBB samples aggrieved customers who escalate. A 4.7/5 with 906 reviews and a D with 6 complaints describes a company that usually delivers but handles a small tail of failures poorly. The specific BBB complaint in the record — pre-authorizing a card and demanding ID before service — is a **trust friction** issue, not a clinical quality issue. The Trustpilot 1★ complaint — prescription never arriving at the pharmacy — is a **fulfillment handoff** issue. **What would change the picture.** A response rate above 90% on BBB, a reduction in the 1★ tail below 4%, and a public SLA for pharmacy transmission would all be stronger signals than the star average. --- ### 3.6 Customer feedback: best and worst General Medicine is a web SPA; no Apple App Store or Google Play listing was found as of 2026-10-18. The review proxies are Trustpilot (invite-driven) and BBB (complaint-driven). **Positive — individually attributed:** > **“They were really on my side when I was in a tight spot. My prescription for diabetes medication had run out during a transition between insurers, and I needed a bridge refill fast. The General Medicine doctor made it happen that very afternoon.”** > — **Cassie**, **5★**, 2026-10-15, [Trustpilot `generalmedicine.co`](https://www.trustpilot.com/review/generalmedicine.co) **Positive — Trustpilot consensus summary:** > **“Customers consistently praise the service for its efficiency and promptness, often highlighting how quickly they can get appointments and prescriptions filled... People appreciate the exceptional customer service and the convenience of virtual consultations.”** > — Trustpilot review summary, [listing](https://www.trustpilot.com/review/generalmedicine.co), [page 4](https://www.trustpilot.com/review/generalmedicine.co?page=4), [page 5](https://www.trustpilot.com/review/generalmedicine.co?page=5) **Critical — individually attributed:** > **“Asking for credit card information driver license picture or passport and pre-authorizing charges before service is unacceptable.”** > — **Vitaloy S.**, **1★**, 2026-05-19, [BBB customer reviews](https://www.bbb.org/us/ut/salt-lake-cty/profile/online-pharmacy/general-medicine-1166-90052323/customer-reviews) > **“I had an online appointment, paid for it, and was told a prescription was sent to my local pharmacy. I visited the pharmacy 3 times, with no prescription in my name.”** > — **Verified Patient**, **1★**, [Trustpilot UK, page 4](https://uk.trustpilot.com/review/generalmedicine.co?page=4) **Pattern.** The positive tail is about **speed and advocacy** (“made it happen that very afternoon”). The negative tail is about **pre-payment friction** and **fulfillment handoff** (“no prescription in my name”). Neither tail is about clinical misdiagnosis. That is consistent with a marketplace whose core risk is operational coordination, not medical judgment. --- ## 4. Leadership quotes and business model thesis **Quote types.** Labels distinguish **direct interview quotes**, **first-party biographies (third person)**, **social posts**, and **reported speech**. ### 4.1 TJ Parker — Co-founder & CEO > **“Consumers need a healthcare store.”** > — TJ Parker, [Fierce Healthcare, 2026-10-07](https://www.fiercehealthcare.com/health-tech/general-medicine-banks-120m-backed-a16z-eli-lilly-and-mercy-health) · **direct interview quote** > **“hundreds of thousands”** of customers across **“every state and nearly every county,”** spanning commercial insurance, Medicare, and Medicaid. > — TJ Parker, [Fierce Healthcare, 2026-10-07](https://www.fiercehealthcare.com/health-tech/general-medicine-banks-120m-backed-a16z-eli-lilly-and-mercy-health) · **direct interview quote (fragments)** > **“Given our ambition is to create this continuity to traditional offline care, we felt super aligned that they would be a really interesting partner to try to figure out exactly how that works and what that looks like for customers to go seamlessly from a digital storefront all the way through to an offline procedure or visit.”** > — TJ Parker on Mercy Health's participation, [Fierce Healthcare, 2026-10-07](https://www.fiercehealthcare.com/health-tech/general-medicine-banks-120m-backed-a16z-eli-lilly-and-mercy-health) · **direct interview quote** **Thesis signal.** Parker's language is retail, not clinical: “store,” “shop,” “selection,” “continuity.” The Mercy quote is the most important strategic statement in the record: the goal is not telehealth; it is a **digital-to-offline continuity layer** that ends in a procedure or in-person visit. ### 4.2 Elliot Cohen — Co-founder & President > There are **“a bevy of companies and startups in the space tackling different aspects of what General Medicine is offering, but few to none in his experience that bring all patient needs together in one experience and who aren't beholden to insurance companies.”** > — Elliot Cohen, [Fortune, May 2025](https://fortune.com/article/general-medicine-startup-pillpack-founders-raise/) · **reported speech, not a direct quotation** **Thesis signal.** Cohen's differentiation claim is **independence from insurers**, not clinical superiority. That is consistent with the dual cash/insurance pricing engine and the “see the price before you decide” product surface. It is also the claim most exposed by the insurance-billing build-out (RCM VP/Director hires): the more the company bills insurance, the less “not beholden” it becomes. ### 4.3 Ashwin Muralidharan — Co-founder & Chief Product Officer > **“They shop by need.”** > — Ashwin Muralidharan, [MobiHealthNews, October 2026](https://www.mobihealthnews.com/news/general-medicine-raises-120m-healthcare-shop) · **direct quote (fragment)** > **“The U.S. already has world-class medicine.”** > — Ashwin Muralidharan, [Fierce Healthcare, 2025-11-20](https://www.fiercehealthcare.com/digital-health/pillpack-digital-health-how-general-medicines-founders-are-building-healthcare) · **direct interview quote** **Thesis signal.** The two fragments are the product thesis in miniature: the supply of medicine is already good; the failure is **navigation and access**. General Medicine is a discovery and fulfillment layer, not a new standard of care. That is why the catalog, search, and pricing surfaces matter more than the clinical protocol. ### 4.4 Vineeta Agarwala, MD, PhD — General Partner, a16z > **“When we shop for almost anything, we expect three things: (1) to understand our options, (2) to see what they cost, and (3) to get what we need quickly.”** > — Vineeta Agarwala, Jorge Conde, Daisy Wolf, and Eva Steinman, [a16z, 2026-10-06](https://a16z.com/announcement/investing-in-general-medicine/) · **first-party investor memo (bylined)** > **“We couldn't be more excited to lead General Medicine's $120M Series B as they build the general store for healthcare.”** > — Same memo · **first-party investor memo** **Thesis signal.** a16z's thesis is explicit: healthcare is the last industry that has not been rebuilt around **consumer shopping primitives** — options, prices, speed. The memo's “general store” metaphor is the same one Parker uses. This is a **consumer-internet thesis applied to healthcare supply**, not a clinical-outcomes thesis. ### 4.5 Dr. Pallabi Sanyal-Dey, MD — Medical Director > **“As Medical Director at General Medicine, she leads clinical oversight and sign-off, making sure the care customers receive is safe, consistent, and built around their full story.”** > — [First-party biography](https://generalmedicine.co/bio/dr-pallabi-sanyal-dey) · **third-person company biography, not a spoken quote** > **“In addition to her role as Medical Director, Dr. Sanyal-Dey remains committed to patient safety, quality improvement, and physician well-being, the work that makes care more reliable for the people receiving it and more sustainable for the clinicians delivering it.”** > — Same biography · **third-person company biography** **Thesis signal.** The clinical promise is **oversight and sign-off**, not direct care for every patient. That is the correct model for a marketplace, but it means the quality of the delegated network (OpenLoop, Reliant.MD, MECNB, the Friendly PCs) determines the actual patient experience. The Medical Director is the governance node, not the care delivery node. ### 4.6 Dr. Adam Carewe, MD — Clinical Informatics > **“Today, Dr. Carewe applies that background to General Medicine, where he sees customers and works to make sure the technology behind their care helps clinicians do their jobs rather than get in the way.”** > — [First-party biography](https://generalmedicine.co/bio/dr-adam-carewe) · **third-person company biography, not a spoken quote** **Thesis signal.** This is the **clinician-experience** thesis: technology should reduce friction for clinicians, not add documentation burden. It is consistent with the Visitron portal's investment in DoseSpot e-prescribing, ArriveHealth real-time benefit checks, and Nabla scribe status — all tools that remove clicks from the encounter. ### 4.7 Kevin Host, PharmD — Walmart > **“Walmart's Better Care Services is about more than access; it's about building a more connected healthcare experience over time.”** > — Kevin Host, Walmart, [LinkedIn post](https://www.linkedin.com/posts/kevin-host-pharmd-1412453_teladoc-health-expands-access-to-care-through-activity-7465861001964449792-bgOG) · **social post (public snippet)** **Thesis signal.** Walmart's language is **longitudinal connection**, not episodic telehealth. That is the enterprise demand signal General Medicine is selling: a storefront that keeps the customer's history and routes them across pharmacy, telehealth, and in-person care. It is also why the Walmart tenant disables the consumer AI copilot and real-time chat (`generalAi: false`, `textCareTeam: false`) — enterprise compliance trumps DTC growth features. ### 4.8 Orin Hoffman — VXI Capital (investor testimonial) > **“Every engagement is seamless, timely, and gets me answers or referrals in minutes that would have previously taken months.”** > — Orin Hoffman, Managing Director, VXI Capital, [LinkedIn public testimonial](https://www.linkedin.com/in/orin-hoffman-a7489230/) · **social post (public snippet)** **Thesis signal.** The value proposition in one sentence: **time compression**. Not better medicine; faster answers and referrals. This is the same “delayed care” insight behind the 81%/20% traction statistics. ### 4.9 Business model thesis synthesis The public record supports a single coherent thesis: > **General Medicine is a consumer healthcare storefront that aggregates existing clinical supply, normalizes it into SKUs, exposes cash and insurance prices, and monetizes the transaction layer — visits, labs, pharmacy routing, and enterprise distribution — while keeping clinical governance in Friendly PCs and delegated professional networks.** Five implications follow: 1. **The catalog is the moat, not the clinic.** The sitemap census contains **3,184** SKUs; the 108-query sample surfaces **448**. The clinical network is replaceable; the taxonomy, pricing, and checkout are not. 2. **The pricing engine is the trust engine.** Cash vs. insurance, primary vs. cheaper, fee disclosure, and lab add-ons are the moments where the brand either earns or loses trust. The lab-fee disclosure gap (1.5), where the refund page says "No Fees Deducted" and checkout adds a $15 clinical review fee, is therefore a checkout trust risk. 3. **Enterprise distribution is the growth engine.** Walmart and Mercy are not side deals; they are likely central to the a16z/Lilly investment case (`[INFERENCE]`). The tenant code is the most commercially sensitive part of the codebase. 4. **AI is the front door, not the doctor.** “General AI” triages and recommends; clinicians and partner networks deliver. The architecture is explicitly designed for AI agents to search and purchase care on a patient's behalf. 5. **The regulatory model is layered but clinically staffed.** Path (MSO) → Friendly PCs (Utah, Florida, New Jersey) → delegated networks (OpenLoop, Reliant.MD, MECNB). The clinical leadership is credible; the corporate layering is what makes the model scalable and what makes diligence hard. --- ## 5. Public sources, vendors, portals, supply chain, visits and flags ### 5.1 Public-record collection suite Public records cover the company, team, infrastructure, NPIs, and catalog. Technical references: [`scripts/`](scripts/README.md) (including collector commands), [`osint/`](osint/), [`architecture.md`](architecture.md), and [`api-spec.md`](api-spec.md). | Script | What it collects | Output | 2026-10-19 run | | :--- | :--- | :--- | :--- | | **`osint_common.py`** | Shared HTTP session, SEC User-Agent, atomic JSON writer, HTML/Markdown cleaners, sentence extractor, path constants | — | Shared module | | **`sec_edgar_search.py`** | 17 EDGAR full-text queries; follows every CIK through `data.sec.gov/submissions`; downloads and parses Form D (`primary_doc.xml`) for issuer identity, former names, jurisdiction, address, related persons, offering amounts, investor count, commissions | `sec_edgar_filings.json` | **17 queries, 493 FTS hits, 261 CIKs, 76 Form Ds parsed, 612 related persons, 687 roles, 0 affiliate filings** | | **`apify_exa_x_linkedin_news.py`** | 10-query X sweep, 13-query LinkedIn sweep, 15-query news/press sweep across search and news APIs plus Google News RSS; scrapes articles to Markdown and extracts quoted sentences | `x_posts.json`, `linkedin_team_and_posts.json`, `news_and_quotes.json`, `apify_runs.json` | **51 X posts / 12 profiles; 87 LinkedIn people / 10 companies / 31 posts; 186 news items / 20 full articles / 148 quotes; 71 SERP results** | | **`infra_npi_and_catalog_probe.py`** | Certificate-transparency + DNS discovery across six domains (four fallbacks each), HTTP fingerprints of 38 hosts, CMS NPPES queries for the MSO/PCs/founders/clinicians, live catalog API probes | `infra_npi_catalog.json` | **55 subdomains, 38 HTTP fingerprints, 23 relevant NPIs, 329 live SKUs across 9 categories** | | **`sitemap_catalog_scraper.py`** | All four sitemaps; every `/s//` URL; series grouping; live search-index price harvest for `a–z, 0–9`; all 20 `/bio/*` pages; five policy pages | `live_sitemap_skus.json` | **3,290 unique URLs, 3,184 SKUs across 23 series, 448 sample-surfaced / 326 top-level priced (122 null top-level; 2,736 sample-unsurfaced), 20 bios, 5 policies** | | **`internal_portals_recon.py`** | Reconstructs the four MedicineOS portals from unauthenticated Next.js chunks: chunk counts, RTK tag types, RTK operations, `/api/*` paths, ActionCable channels | `internal_portals_recon.json` | **4 portals, 99 chunks, 238 RTK ops, 183 API paths** | **Coverage limits.** Coverage is incomplete for social profiles, search results and certificate records as of 2026-10-19. ### 5.2 SKU and vendor landscape **Catalog structure.** The 3,184 SKU URLs split into seven broad series and 23 numeric prefixes. The `700xxx` pharmacy family alone is **1,362** SKUs (42.8% of the catalog); the `200xxx` medication family is **909** (28.6%). Together, medications and pharmacy products are **71.4%** of the catalog. Labs are **8.8%** (280), conditions/services **16.1%** (511), in-person visits **3.2%** (101), specialist e-consults **0.6%** (20). **The SKU URL contract.** Every product page follows `/s//`. The slug is SEO copy; the SKU ID is the commercial key. SKU IDs are not stable across series: the same clinical concept can appear as a `300xxx` condition, a `400xxx` in-person visit, and a `500xxx` lab panel. This is why the catalog needs a normalization layer — and why the company describes its core IP as a “standardized catalog that translates how patients, clinicians, insurers and providers describe the same healthcare service.” **Vendor matrix:** | Domain | Vendor(s) | Integration evidence | Commercial role | | :--- | :--- | :--- | :--- | | **Labs** | **Quest Diagnostics**, **Labcorp**, **BioReference** | `LabPanelPricing.tsx`; `/api/external/lab_skus/:id` returns per-vendor `test_price`, `insurance_price`, `clinical_fee`, `platform_fee`, `collection_fee`, `order_fee` | Multi-lab wholesale arbitrage; lowest cash price displayed | | **Urgent care** | **Solv Health** | `urgentCareApi.ts`; `POST /api/external/urgent_care/orders`; `locations`, `offers`, `checkout`, `reschedule` | Real-time clinic search, wait times, slot booking | | **Pharmacy** | **CVS**, **Walgreens**, **Walmart**, **LillyDirect**, **NovoCare** | `ComparePharmaciesDrawer.tsx`; `pharmacy_comparisons`; `gm_card`; `searchPharmaciesUtils.ts` | GPS price comparison; branded GLP-1 direct routing | | **Pharmacy pricing** | **GoodRx**, **NCPDP** | `gm_card` (BIN/PCN/group/member ID); NCPDP directory | Cash discount card; retail claim routing | | **EHR / HIE** | **Metriport**, **Particle Health** | `/api/external/health_history/latest_metriport`; `HealthHistoryContext.tsx` | FHIR history sync; 11-year average history claim | | **Identity** | **Persona**, **Nile Verified** | Persona Web SDK; `POST /api/external/verified` (DOB + SSN) | Government ID/biometric KYC; 1-click identity | | **Payments** | **Stripe**, **Trust Commerce** | Stripe SetupIntents/Elements; `/api/external/patient/mercy_billing` | Consumer cards; Mercy hospital billing | | **Communications** | **Twilio** | Message Center WebSocket token; `/api/external/conversations` | Patient chat | | **E-prescribing** | **DoseSpot** | Visitron tag types `DoseSpotIdpStatus`, `DoseSpotRtpbInquiry`, `DoseSpotRtpbPatientContext`; operations `getDoseSpotIdpStatus` | Clinician e-Rx and real-time benefit check | | **Benefits / RTPB** | **ArriveHealth** | Visitron tag types `ArriveHealthInquiry`, `ArriveHealthPatientContext`; ops `launchInsurancePrice`, `getInsurancePriceStatus` | Real-time pharmacy benefit and price transparency | | **Clinical scribe** | **Nabla** | Visitron op `getNablaStatus` | Ambient documentation | | **Lab biomarkers** | **Junction** (`tryvital.io`) | Catalog ops `getJunctionBiomarker`, `getJunctionBiomarkers`, `getJunctionBiomarkerFilterOptions`; `/vital-informed-consent` | Biomarker catalog and lab ordering | | **Delegated telehealth** | **OpenLoop**, **Reliant.MD**, **MECNB** | `/vital-informed-consent` | State-by-state professional corporations | | **Clearinghouse** | **Waystar** | DNS: `waystar-connector.staging-nile.com`, `waystar-bridge.staging-nile.com` | Claims/eligibility bridge (`[INFERENCE]` from host names) | | **Feature flags** | **LaunchDarkly** | `LaunchDarklyContext.tsx`, `launchDarklyFlagEvaluator.ts` | A/B tests, tenant features, AI prewarm | | **Telemetry** | **Datadog RUM**, **Segment** | `reportErrorToDD`, `@nile/mantine-theme/analytics` | Error tracing, product analytics | **Vendor concentration risk.** Labs and pharmacy are multi-sourced (good). E-prescribing, identity, and payments are single-sourced (DoseSpot, Persona, Stripe) with a secondary billing gateway for Mercy (Trust Commerce). The most fragile dependency is **DoseSpot**: if the e-prescribing integration fails, Visitron cannot prescribe, and the entire visit-to-pharmacy funnel stops. The second most fragile is **Solv** for urgent care, because the in-person booking flow depends on live clinic availability. ### 5.3 Internal admin portals Four internal portals sit behind the storefront. #### Visitron — clinician EHR (91 RTK ops, 98 API paths, 27 chunks) **Hosts:** `visitron.internal.generalmedicine.co`, `visitron.staging-nile.com` **Deployment:** `dpl_J4vVaJhNvPie8d6FYGbsnRAiF1yY` **Tag types (33):** `AdHocEncounterInfo`, `AppointmentInfo`, `ArriveHealthInquiry`, `ArriveHealthPatientContext`, `AsyncClinicalReview`, `CareJourneys`, `CarePathways`, `Channel`, `ChatShiftExtensionStatus`, `ClinicianReview`, `ClinicianReviews`, `DiagnosisSearch`, `DoseSpotIdpStatus`, `DoseSpotRtpbInquiry`, `DoseSpotRtpbPatientContext`, `DraftEncounter`, `DrugSearch`, `EscribingDraftPrescription`, `EscribingInboundRequest`, `History`, `NextStepReview`, `Orders`, `PatientAppointments`, `PatientChartContext`, `PatientSearch`, `PendingShiftCheckouts`, `PharmacyInsurancePrice`, `PharmacySearch`, `ProviderAppointments`, `ProviderNotifications`, `ShiftCheckoutStatus`, `User`, `VisitronPrompt`. **Capabilities visible in operation names:** - **Encounter management:** `getAdHocEncounterInfo`, `getAppointmentDraftEncounter`, `getAppointmentInfo`, `getPastVisits`, `getPatientChartContext`. - **Async clinical review:** `getAsyncClinicalReview`, `getAsyncClinicalReviewFileUploadPreview`, `applyReview`, `getPendingReview`, `generateNextStepReview`, `createNextStepReview`. - **Care journeys/pathways:** `getCareJourney`, `getCareJourneys`, `createCareJourney`, `changePathway`, `changePhase`, `confirmCarePlan`, `getPublishedPathways`. - **E-prescribing:** `createDraftPrescription`, `finalizeDraftPrescription`, `cancelDraftPrescription`, `cancelPrescriptionOrder`, `approveInboundRequest`, `denyInboundRequest`, `getDoseSpotIdpStatus`; `EscribingInboundRequest` tag type. - **Benefits/pricing:** `launchInsurancePrice`, `getInsurancePriceStatus`, `PharmacyInsurancePrice` tag, `PharmacySearch`. - **Clinical search:** `getIcd10Codes`, `getLabCodes`, `getQuestionnaireCodes`, `getSkus`, `getProviders`, `getStateOptions`. - **Chat shift management:** `createChannel`, `getChannel`, `getChatHistory`, `extendChatShift`, `getChatShiftExtensionStatus`, `createShiftCheckout`, `getPendingShiftCheckouts`, `getShiftCheckoutStatus`. - **AI assistance:** `getNablaStatus`, `getVisitronPrompts`. **Assessment.** Visitron is a real clinician workspace, not a read-only dashboard. It covers the full encounter: appointment → chart context → async review → care pathway → prescription → pharmacy price → shift checkout. The DoseSpot and ArriveHealth integrations are the commercial core: they let a clinician prescribe and see the patient's benefit price in the same session. #### Catalog — care-pathway and SKU admin (106 RTK ops, 47 API paths, 35 chunks) **Hosts:** `catalog.internal.generalmedicine.co`, `catalog.staging-nile.com` **Deployment:** `dpl_A4ryRBErTetVxWxjvyMbAe8mPgEd` **Tag types:** `User` only (the catalog uses ad-hoc invalidation or a single broad tag). **Capabilities:** - **SKU CRUD:** `createSku`, `getSku`, `getSkus`, `getSkuCategories`, `getSkuPhaseTypes`, `getSkuPhases`, `createSkuPhase`, `deleteSkuPhase`, `getSkuStates`, `getSkuQuestionnairesJson`, `getSkuQuestionnairesPdf`, `downloadBulkSkuQuestionnairesPdf`, `generateSkuImage`, `getSkuImageGeneration`. - **Care pathways:** `createCarePathway`, `getCarePathway`, `getCarePathways`, `updateCarePathway`, `archiveCarePathway`, `publishCarePathway`, `returnCarePathwayToDraft`, `createCarePathwayPhase`, `updateCarePathwayPhase`, `deleteCarePathwayPhase`, `reorderCarePathwayPhases`, `updateCarePathwayLinkedSkus`, `getCarePathwayPhaseKinds`. - **Clinical criteria:** `createCriteriaSet`, `getCriteriaSet`, `getCriteriaSets`, `updateCriteriaSet`, `cloneCriteriaSet`, `getCriteriaSetReferences`, `createRequirement`, `getRequirements`, `deleteRequirement`. - **Condition taxonomy:** `createConditionCategory`, `getConditionCategory`, `getConditionCategories`, `updateConditionCategory`, `deleteConditionCategory`, `replaceConditionCategoryCatalogConditions`, `getCatalogCondition`, `getCatalogConditions`. - **Questionnaires:** `createQuestionnaire`, `getQuestionnaire`, `getQuestionnaires`, `deleteQuestionnaire`, `applyQuestionnaireEdit`, `discardQuestionnaireEdit`, `requestQuestionnaireEdits`, `getQuestionnaireEdits`, `getQuestionnaireEditPdf`, `getQuestionnaireUsage`, `createEmptyQuestionnaires`. - **Lab/procedure mapping:** `getLabPanels`, `saveLabPanel`, `removeLabPanel`, `getLabSkuDetail`, `updateLabSkuDetail`, `generateLabSkuDetail`, `getAvailableLabPanelBiomarkers`, `createProcedureCodeMapping`, `getProcedureCodeMapping`, `getProcedureCodeMappings`, `getProcedureCodeMappingProcedureTypes`, `getProcedureCodeMappingServiceTypes`, `searchIcd10Codes`. - **Prompts/tenants:** `createPrompt`, `getPrompt`, `getPromptSummaries`, `updatePrompt`, `getTenants`, `getProviderRoles`. - **Junction biomarkers:** `getJunctionBiomarker`, `getJunctionBiomarkers`, `getJunctionBiomarkerFilterOptions`, `updateJunctionBiomarker`. **Assessment.** Catalog is the **product definition engine**. It is where a clinical concept becomes a SKU, a questionnaire, a care pathway, a lab panel, and a price. The presence of prompt authoring and tenant management in the same portal is notable: catalog admins can shape both the clinical product and the AI behavior. #### Referrals — concierge and promises queue (27 RTK ops, 18 API paths, 19 chunks) **Hosts:** `referrals.internal.generalmedicine.co`, `referrals.staging-nile.com` **Deployment:** `dpl_bU9YUfX9Y2Vg9eDAYdnDgEfrr3Sk` **Tag types:** `Booking`, `Candidates`, `OrderPreference`, `Patient`, `QueueEnabled`, `ReferralDetail`, `Referrals`, `User`. **Capabilities:** - **Referral orders:** `getReferral`, `getReferrals`, `getOrder`, `listAllOrders`, `listUserOrders`, `cancelOrder`, `logOutcome`. - **Provider candidates:** `getCandidates`, `addCandidate`, `removeCandidate`, `updateCandidate`, `searchProviders`. - **Promises queue:** `claimPromise`, `dropOrSnoozeOrder`, `getQueueEnabled`, `getPreference`, `recordOutreach`. - **Booking:** `getBooking`, `createBookingEvent`, `updateBooking`, `endShift`. - **Patient:** `getPatient`, `getPreference`. **API paths include** `/api/internal_oauth/referral/orders`, `/api/internal_oauth/referral/orders/all`, `/api/internal_oauth/promises/queue/claim`, `/api/internal_oauth/promises/queue/drop`, `/api/internal_oauth/promises/queue/enabled`, `/api/internal/ops/referrals`, `/api/internal/ops/referral_provider_candidates/`. **Assessment.** This is a **human concierge layer** for in-person referrals. The “promises queue” is the operational heart: staff claim a patient promise (e.g., “find a cardiologist who takes this plan”), work candidates, record outreach, and log the outcome. This is not automated; it is a high-touch service that makes the storefront feel seamless. It is also the labor cost center behind the “in-person visits” catalog. #### Provider Chat — LLM prompt workbench (14 RTK ops, 20 API paths, 18 chunks) **Host:** `internal.generalmedicine.co` **Deployment:** `dpl_3WuAgEhfeNR4sVmf7ZVkJQWBG9Tg` **Tag types:** `Channel`, `History`, `Prompt`, `User`. **ActionCable channels:** `ExternalCable::CopilotChannel`, `InternalCable::CopilotChannel`. **Capabilities:** `createChannel`, `getChannel`, `getChatHistory`, `sendMessage`, `createCatalogPrompt`, `getCatalogPrompt`, `getCatalogPrompts`, `updateCatalogPrompt`, `getModelVersions`, `getTemperatures`. **API paths include** `/api/internal_oauth/copilot_channels`, `/api/internal_oauth/copilot_channels/`, `/api/internal_oauth/messages`, `/api/internal_oauth/prompts`, `/api/internal_oauth/prompts/`, `/api/internal_oauth/prompts/model_versions`, `/api/internal_oauth/prompts/temperatures?model_version=`, and both `/api/external/cable` and `/api/internal/cable`. **Assessment.** This is an **internal LLM operations console**, not a patient chat tool. It lets staff create copilot channels, inspect history, send messages, and manage prompt templates with model-version and temperature controls. The dual `ExternalCable::CopilotChannel` / `InternalCable::CopilotChannel` channels suggest the same copilot infrastructure serves both patient-facing and internal use cases. Exposing this bundle publicly reveals the prompt-management model and the model-version surface, even without credentials. ### 5.4 Supply chain and clinical governance **The legal/clinical chain:** ``` Path Healthcare Systems Corp. (Delaware C-Corp; MSO, brand, IP, employment, fundraising) │ ├── Emerald Medical Practice, P.C. (Utah; NPI 1447011267, 1750195483) │ President / Authorized Official: Ashwin Muralidharan (non-physician) │ ├── Centennial Medical Practice, P.C. (Florida; NPI 1174333975) │ President / Authorized Official: Dr. Pallabi Sanyal-Dey, MD │ ├── Ruby Medical Practice, P.C. (New Jersey; NPI 1346050150) │ President / Authorized Official: Dr. Pallabi Sanyal-Dey, MD │ └── Delegated telehealth networks (via Vital consent) ├── OpenLoop Healthcare Partners, PC + CA/CO/NJ/WI entities ├── Reliant.MD Medical Associates, PLLC + CA/CO/NJ/WI entities └── MECNB Physician Services, PC + CA/CO/NJ entities ``` **The care supply chain:** ``` Patient │ ├── Consumer storefront (Next.js / Vercel Edge) │ ├── Universal search → SKU PDP → checkout │ ├── Visit cart → telehealth (video/chat/ACR) │ └── Lab order → Quest / Labcorp / BioReference │ ├── Visitron (clinician EHR) │ ├── DoseSpot e-Rx │ ├── ArriveHealth RTPB │ ├── Nabla scribe │ └── Quest/Labcorp lab codes │ ├── Referrals (concierge queue) │ ├── Provider candidates search │ ├── Booking events │ └── Promises queue (claim/drop/snooze) │ ├── Pharmacy routing │ ├── CVS / Walgreens / Walmart │ ├── LillyDirect / NovoCare │ └── GoodRx / NCPDP `gm_card` │ └── Enterprise tenants ├── Walmart “Better Care Services” (S3 uploads, custom SKUs 1400015/17/18) └── Mercy Health (Trust Commerce billing, 1020px layout) ``` **Supply-chain observations:** 1. **Clinical supply is aggregated, not owned.** The company owns the storefront, the catalog, and the MSO. It does not own the labs, pharmacies, urgent care clinics, or most of the clinicians. That is capital-light and scalable; it also means quality depends on vendor SLAs. 2. **The lab chain uses 3-network wholesale pricing plus a server-driven clinical review fee.** Quest/Labcorp/BioReference responses return `test_price` and `clinical_fee` (`$15.00` live across seven sampled SKUs, with `$30` as the client fallback in `lab-pricing-constants.ts:8`), which sum to `total_cash_price`. The payload also carries unrendered `platform_fee`, `collection_fee`, and `order_fee` fields (`[INFERENCE]`: likely internal cost/margin metadata or unused schema fields, as `LabPanelPricing.tsx` does not display them). 3. **The pharmacy chain is the most brand-sensitive.** LillyDirect and NovoCare are featured first in the pharmacy tab (`searchPharmaciesUtils.ts`). That is a strategic alignment with the Series B investors (Eli Lilly) and a potential conflict-of-interest disclosure issue. 4. **The referral chain is the most labor-intensive.** The referrals portal is a human queue, not an automated marketplace. That is why the company is hiring a Care Coordinator and a Clinical Recruiter. 5. **The enterprise chain is the most contract-sensitive.** Walmart and Mercy each have custom SKUs, branding, upload paths, and billing. The tenant rewrite engine is the technical expression of those contracts. ### 5.5 Online visits **Modalities:** - **Synchronous video** via Zoom (patient-facing `/using-zoom` guide; visit links via SMS/email). - **Chat** visits (e.g., `300550` Weight Loss Follow-Up at $30 cash). - **Asynchronous Clinical Review (ACR)** (`300591` ACR Follow-Up). - **Specialist e-consults** (`100xxx`; e.g., `100017` Urology at $150 cash / $25 insurance). - **In-person referrals** (`400xxx`; e.g., `400285` opioid prescribing, `400293` pregabalin, `300604` Accutane). - **Urgent care** via Solv (`400002`, `400336`, Walmart `1400015`). **Visit SKUs (consumer):** - `400013` General Video Visit. - `100012` Primary Care Visit ($100 cash / $25 insurance). - `400015` Follow-Up Video Visit. - `300591` ACR Follow-Up. - `200007` General Rx Renewal; `400020` Renewal for Existing Patients. - `400002` Urgent Care In-Person Reservation; `400336` In-Person Urgent Care Booking Fallback. - `400001` Doctor's Note Consultation. - `300001` UTI Evaluation; `300007` Migraine Clinical Protocol. **Clinical workflow (Visitron):** 1. Appointment appears in `ProviderAppointments` / `PatientAppointments`. 2. Clinician opens `PatientChartContext` (Metriport/Particle history + GM encounters). 3. Encounter draft is created (`DraftEncounter`). 4. Clinician reviews async materials (`AsyncClinicalReview`) or conducts video/chat. 5. Care pathway/phase is selected (`CarePathways`, `changePathway`). 6. Orders are placed (`Orders`; labs via `getLabCodes`; diagnoses via `getIcd10Codes`). 7. Prescription is drafted and finalized (`DraftEncounter` → `createDraftPrescription` → `finalizeDraftPrescription`, with DoseSpot). 8. Pharmacy price/benefit is checked (`PharmacyInsurancePrice`, `launchInsurancePrice`). 9. Next-step review is generated (`NextStepReview`). 10. Shift checkout records the encounter (`ShiftCheckoutStatus`). **State licensure.** `getStateOptions` and the Friendly-PC/delegated-network map imply state-by-state routing. The consumer storefront does not expose a clear “which clinician will I see in my state” disclosure; the Vital consent page is the only place the delegated entities are named. That is a transparency gap for a 50-state service. **Quality signal.** The clinical leadership bios are strong, and the Visitron workflow is coherent. The weak link is the **handoff**: the Trustpilot 1★ complaint about a prescription never reaching the pharmacy is a handoff failure between Visitron/e-Rx and the retail pharmacy, not a clinical judgment failure. The fix is operational (e-Rx confirmation, pharmacy status tracking), not architectural. ### 5.6 Feature flags and experiment surface **LaunchDarkly is the control plane.** `LaunchDarklyContext.tsx` wraps the app in `LDProvider`; `launchDarklyFlagEvaluator.ts` exposes `useLaunchDarklyFlag(flagName, options)`. The context key is persisted in the `launchdarkly_context_key` cookie and re-identified when the patient ID changes (`UserContext.tsx:117`, `:225`). **Named flags and flag-gated surfaces:** - **`gen-ai-prewarm-copilot`** — gates prewarming the General AI copilot (`useGeneralAiStatus.tsx:58`). - **SKU refresh flags** — `SkuBodyRenderer.tsx` takes a `refreshFlagKey` and reports the evaluation to Datadog RUM (`window.DD_RUM?.addFeatureFlagEvaluation`). - **FAQ flags** — `FrequentlyAskedQuestions.tsx` calls `useFlags()`; the flag object is available for variant copy or visibility. - **Phone input flags** — `PhoneInput.tsx` calls `useFlags()` and identifies the LaunchDarkly client on mount. - **Tenant feature flags** — `config/tenants/walmartPublic.ts` sets `generalAi: false`, `directToS3FileUpload: true`, `multiFulfillmentOwner: true`, `textCareTeam: false`. **Experiment/telemetry coupling.** Flag evaluations are mirrored to Datadog RUM, so an experiment can be analyzed against error rates, dwell time, and latency. That is a mature setup for a company at this stage. The risk is **flag debt**: with 40 RTK slices, four portals, and tenant-specific behavior, the number of flag combinations can exceed the test matrix. The `GM-6520` TODO is the clearest example: a tenant fallback that should be a hard requirement is still a soft default. **Flag governance recommendation.** (a) Require every flag to have an owner, an expiry date, and a cleanup ticket. (b) Treat tenant identity as configuration, not a flag; make it fail-fast. (c) Add a synthetic test that boots each tenant with a missing env var and asserts a hard failure. (d) Log flag evaluations with the tenant ID so cross-tenant leakage is detectable. ### 5.7 Figure register | Figure | Source | Output | | :--- | :--- | :--- | | 377 routes / 357 RTK ops | `./internal_portals_recon.py` + `api-spec.md` §2 | `internal_portals_recon.json` | | 3,184 SKUs / 448 sample-surfaced / 326 top-level priced | `./sitemap_catalog_scraper.py` | `live_sitemap_skus.json` | | 329 live category SKUs | `./infra_npi_and_catalog_probe.py` | `infra_npi_catalog.json` | | 23 relevant NPIs / Friendly PCs | `./infra_npi_and_catalog_probe.py` | `infra_npi_catalog.json` | | 0 affiliate Form Ds | `./sec_edgar_search.py` | `sec_edgar_filings.json` | | 87 LinkedIn profiles / 20 bios | `./apify_exa_x_linkedin_news.py` / `./sitemap_catalog_scraper.py` | `linkedin_team_and_posts.json` / `live_sitemap_skus.json` | | 16 open roles | `curl https://generalmedicine.co/company/careers` | 16 Ashby links | | Lab fee $15 live / $30 constant | `curl https://generalmedicine.co/api/external/lab_skus/500001` + `lab-pricing-constants.ts:8` | Live JSON + code | | 400 source maps | `curl` any `/_next/static/chunks/*.js.map` | HTTP 200 | ### 5.8 Limitations and confidence | Domain | Confidence | Caveat | | :--- | :---: | :--- | | Consumer route count (194) | High | Declared routes; some may be dead | | Verified client ops (119) | High | Line-by-line RTK verification | | Internal route count (183) | High for bundle-derived, medium for server truth | Does not include unreferenced Rails routes | | Internal RTK ops (238) | High | Extracted from shipped chunks | | SKU count (3,184) | High | Sitemap snapshot 2026-10-19 | | Top-level price-field count (326) | High for field presence | Not proof of unpurchasability; option-level fees can exist behind null top-level fields (e.g., `300603`) | | NPI officer data | High | CMS NPPES snapshot; self-reported by organizations | | Form D absence | High for EDGAR; medium for legal conclusion | Section 4(a)(2) can be used without Form D | | Revenue estimates | Low | No company disclosure; illustrative only | | Board/investor roles | Medium | Press, LinkedIn, PitchBook; no Form D related-person data | | Headcount (104) | Medium | Third-party estimate | | Clinical quality | Medium | Bios and workflow evidence, not outcomes data | **What this report does not cover.** - PHI, patient records, or authenticated portals. - Credential stuffing, auth bypass, or exploitation. - Revenue, GMV, or valuation against company financials. - Independent verification of the 81%/20% delayed-care survey. - Clinical accuracy of any SKU or protocol. --- ## Appendix A: Numbers crosswalk | Number | Meaning | Where it appears | | ---: | :--- | :--- | | **32** | Primary endpoints in a high-level inventory | 1.2 | | **194** | Consumer declared routes | 1.2; `generalmedicine.md` §6 | | **119** | Verified consumer RTK ops | 1.2; `generalmedicine.md` §2/§6 | | **137** | Total consumer RTK ops (incl. catalog-only) | `generalmedicine.md` §2 | | **130 / 141 / 16** | OpenAPI paths / operations / tags | 1.2; `openapi.yaml` | | **183** | Internal portal route literals | 1.2; 1.11; `scripts/README.md` | | **238** | Internal portal RTK ops | 1.2; 1.11; `scripts/README.md` | | **377** | Total routes (194 + 183) | 1.2; `generalmedicine.md`; `scripts/README.md` | | **357** | Total RTK ops (119 + 238) | 1.2; `generalmedicine.md`; `scripts/README.md` | | **3,184** | Sitemap SKU URLs | 1.6; `scripts/README.md` | | **448** | Search-sample SKUs (108 queries) | 1.6; `scripts/README.md` | | **326** | Sampled SKUs with top-level price fields | 1.6; `scripts/README.md` | | **122** | Sampled SKUs with null top-level price (**8** with option-level fees) | 1.6 | | **2,736** | Sitemap SKUs not surfaced by the sample | 1.6; `scripts/README.md` | | **$5.11–$17,411.20** | Price range | 1.6 | | **$30 / $15** | Code clinical fee / live clinical fee | 1.5 | | **0** | Affiliate Form Ds | 1.8; `scripts/README.md` | | **4** | Internal portals | 1.11; `scripts/README.md` | | **99** | Internal portal chunks | 1.11 | | **20** | `/bio/*` pages | Section 2; `scripts/README.md` | | **87 / 33** | LinkedIn profiles / high-relevance | Section 2; `scripts/README.md` | | **16** | Open Ashby roles | Section 2 | | **104** | Estimated employees | Section 2/3 | | **$152M** | Total disclosed equity | Section 3 | | **4.7 / 906** | Trustpilot score / reviews | Section 3 | | **D / 6** | BBB rating / complaints | Section 3 | --- ## Appendix B: Sources **Primary registries and live endpoints:** - Delaware Division of Corporations entity search — https://icis.corp.delaware.gov/ecorp/entitysearch/NameSearch.aspx - Florida Sunbiz detail for Path Healthcare Systems Corp. — https://search.sunbiz.org/Inquiry/corporationsearch/SearchResultDetail?inquirytype=EntityName&directionType=PreviousList&searchNameOrder=PATHHEALTHCARESYSTEMS+F240000049830&aggregateId=forp-f24000004983-0d0b0233-814a-4379-9da4-e91519a42230 - CMS NPPES Registry — https://npiregistry.cms.hhs.gov/ - SEC EDGAR full-text search — https://efts.sec.gov/LATEST/search-index - SEC submissions API — https://data.sec.gov/submissions/CIK{cik}.json - General Medicine careers — https://generalmedicine.co/company/careers - Ashby job board — https://jobs.ashbyhq.com/general-medicine - Trustpilot — https://www.trustpilot.com/review/generalmedicine.co - BBB — https://www.bbb.org/us/ut/salt-lake-cty/profile/online-pharmacy/general-medicine-1166-90052323 **Company and press:** - a16z, “Investing in General Medicine” (2026-10-06) — https://a16z.com/announcement/investing-in-general-medicine/ - Fortune, “PillPack's founders and an Amazon colleague launch General Medicine” (May 2025) — https://fortune.com/article/general-medicine-startup-pillpack-founders-raise/ - CNBC, “Founders of Amazon's PillPack launch health-care marketplace startup” (2025-05-22) — https://www.cnbc.com/2025/05/22/amazon-pillpack-general-medicine.html - Fierce Healthcare, “General Medicine banks $120M…” (2026-10-07) — https://www.fiercehealthcare.com/health-tech/general-medicine-banks-120m-backed-a16z-eli-lilly-and-mercy-health - Fierce Healthcare, “From PillPack to digital health…” (2025-11-20) — https://www.fiercehealthcare.com/digital-health/pillpack-digital-health-how-general-medicines-founders-are-building-healthcare - MobiHealthNews, “General Medicine raises $120M for healthcare shop” (2026-10) — https://www.mobihealthnews.com/news/general-medicine-raises-120m-healthcare-shop - AlleyWatch, weekly funding report (2026-10-12) — https://alleywatch.com/2026/10/the-weekly-notable-startup-funding-report-10-12-26/ - FinSMEs, “General Medicine raises $120M” — https://www.finsmes.com/2026/10/general-medicine-raises-120m-in-series-b-funding.html - Walmart, Better Care Services launch — https://www.nasdaq.com/press-release/new-year-new-you-walmart-launches-better-care-services-and-rolls-back-prices-1000 - Supermarket News, Walmart health platform — https://www.supermarketnews.com/hbc-health-beauty/walmart-launches-new-health-and-wellness-platform **Live company pages:** - https://generalmedicine.co/ - https://generalmedicine.co/refund-policy-labs - https://generalmedicine.co/vital-informed-consent - https://generalmedicine.co/assignment-of-benefits - https://generalmedicine.co/company/careers - https://www.navhealth.co/ **People and firm profiles:** - PitchBook, General Medicine company profile — https://pitchbook.com/profiles/company/773942-86 - TheOrg, Ed Cao (CFO) — https://theorg.com/org/general-medicine/org-chart/ed-cao - Jacqui Miller (chief of comms) — https://x.com/jacquimiller - Orin Hoffman, VXI Capital — https://www.linkedin.com/in/orin-hoffman-a7489230/ - Kevin Host, Walmart (LinkedIn post) — https://www.linkedin.com/posts/kevin-host-pharmd-1412453_teladoc-health-expands-access-to-care-through-activity-7465861001964449792-bgOG - JSL Health Capital — https://www.crunchbase.com/organization/jsl-health-capital **Internal datasets:** - `osint/sec_edgar_filings.json` - `osint/x_posts.json` - `osint/linkedin_team_and_posts.json` - `osint/news_and_quotes.json` - `osint/apify_runs.json` - `osint/infra_npi_catalog.json` - `osint/live_sitemap_skus.json` - `osint/internal_portals_recon.json` --- ## Appendix C: Data notes | Item | Current position | Basis | | :--- | :--- | :--- | | Endpoint count | **194 consumer routes + 183 internal routes = 377** | 1.2 | | Legal entity | **Path Healthcare Systems Corp.**; Nile Health is an operating/engineering identity | 1.3 | | Nav Health vs. NavHealth, Inc. | **Nav Health** (`navhealth.co`) was the prior consumer brand; **NavHealth, Inc.** (CIK `0001717158`) is an unrelated Arlington, VA company | 1.3, 1.8 | | Lab clinical fee | Server-driven `clinical_fee` (**$15.00 live** across seven sampled SKUs); `STANDARD_CLINICAL_FEE = 30` is a nullish fallback in `LabPanelPricing.tsx:65–69` | 1.5 | | Catalog size | **3,184 sitemap SKUs**; **448** surfaced by the 108-query sample; **326** with top-level price fields; **2,736** not surfaced by that sample | 1.6 | | Sample vs. census | The **2,736** are sample-unsurfaced, not absent from search: `400285` is in `sitemap_only_skus` but returns for `query=chronic pain`; **8 of the 122** null-top-level SKUs carry option-level fees (e.g., `300603` `checkout_fee: 4500`) | 1.6 | | Refund policy scope | Applies to eligible pre-collection **refund deductions** ("No Fees Deducted: If eligible, you will receive a full refund"), not a claim that orders never carry a clinical review fee | 1.5 | | Controlled substances | No telehealth fills; three active **in-person referral** SKUs cover opioid, pregabalin, and Accutane care | 1.7 | | Capitalization | **$152M** raised, press-sourced; **zero Form D filings** on EDGAR | 1.8 | | Clinician compensation | “Above-market compensation” is commented out in `clinician-hiring-content.tsx:206–210` | 1.9 | | Enterprise tenants | Code confirms Walmart and Mercy; OSINT adds `wmt.staging-nile.com` and `mcy.staging-nile.com` as auth-gated hosts | 1.11, `infra_npi_catalog.json` | | Platform | Web only as of 2026-10-18; no iOS or Android listing found | Trustpilot/BBB/store checks | | Review signals | **4.7/5 across 906 reviews** coexists with **BBB “D” / 6 complaints**; different instruments | Section 3.5 | --- *End of report. Live observations are dated 2026-10-19 unless otherwise stated. Code citations refer to the recovered General Medicine first-party source; OSINT citations refer to the `osint/` datasets.* ================================================================================ # DOCUMENT: GLP-1 Journey: Search to Week 4 on Tirzepatide (raw/reports/glp1-tirzepatide-journey.md) ================================================================================ # General Medicine: organic click to four weeks on tirzepatide End-to-end journey for a new patient who finds General Medicine through an organic Google result, starts tirzepatide, and reaches the week-4 dose decision. The journey is mapped at the level needed to build a technology plan and an operating plan. Terms: GM is General Medicine; PC is the state professional corporation that furnishes care; PA is prior authorization; RTPB is real-time benefit check; NCPDP is the pharmacy provider identifier; PBM is pharmacy benefit manager; HIE is health information exchange; SKU is a sellable catalog item. Evidence and gap legend. **Observed** means a specific source artifact or public response was inspected; it does not mean the full patient workflow was executed. **Published** means a company or vendor representation, not a measured SLA. **Inferred** means a plausible connection between observations. **Proposed** means a recommended future contract or control. **Recovery gap** means implementation was not available in the inspected material. **Mapping gap** means this document omits a required step. "No field in the inspected interface" does not mean "no capability anywhere at GM." No authenticated GLP-1 encounter, prescription, claim, checkout, fulfillment, or check-in was exercised. Evidence tags: `A:A1` means step A1 in `evidence-A.md`; that row carries the exact code path, URL, or dataset key. `[INFERENCE]` marks reasoning not directly observed. --- ## 0. Summary General Medicine sells a visit, not a drug. A patient who clicks the organic GLP-1 evaluation result lands on a page that advertises a $25 estimated copay or a $100 cash video visit, creates a phone-only account with SMS OTP, autofills identity through Verified or falls back to manual entry, optionally checks insurance, answers a server-driven screening questionnaire, and books a video visit whose availability promise is today. The clinician writes a prescription, and that prescription becomes a separate pharmacy order the patient must route and pay for. The medication price is not part of the visit purchase: LillyDirect and Amazon quote $299 for the 2.5 mg KwikPen, retail quotes $496.12 to $508.09, and the public catalog does not quote this patient's insured drug cost. Four weeks of 2.5 mg are followed by a clinician review, a new prescription for 5 mg, a new order, and a new payment. The inspected client surfaces cover clinical workflow well. No pharmacy fulfillment event contract, dose-administration event, or dedicated prior-authorization case contract was recovered in those surfaces; production capability and staff workflows outside them are not established. The money is visit fees plus a $15 lab clinical fee; the drug price is a manufacturer pass-through with no observed General Medicine margin. ### Key numbers | Measure | Value | Basis | |---|---|---| | Time to first dose, cash retail pickup | 1 to 2 days, illustrative | `[D:D17]` `[INFERENCE]`: same-day video promise plus retail fill; no measured click-to-fill data | | Time to first dose, cash LillyDirect or Amazon | No measured click-to-first-dose bound | LillyDirect publishes 3 to 5 business days after eRx receipt for verification and patient contact, then 1 to 4 days to process and ship after purchase. Transit, patient response, PA, stock and upstream care add time. Amazon timing is unverified. `[PUBLIC https://www.lilly.com/lillydirect/faq]` | | Time to first dose, insured retail with PA | 5 to 13+ days | `[LIVE GLP-1 guide, 2026-10-19]`: PA takes several business days; `[INFERENCE]` on the rest | | Initial visit plus first 28-day supply, cash KwikPen | **$399.00** | $100 visit + $299 2.5 mg KwikPen. `[LIVE /api/external/sku_options/300543]` `[LIVE /api/external/medication_option_skus/710641/cash_price]` | | Initial visit, first supply and Quest panel | **$485.58** | Above plus $86.58 panel. `[LIVE /api/external/lab_skus/503263]` | | Through purchase of the second fill | **$984.58** | Above plus $100 week-4 visit and $399 5 mg KwikPen. Two 28-day drug purchases, not one month of medicine | | Same two-fill scenario without panel | **$898.00** | `[E:E4.5]` illustrative total | | Same two-fill scenario with chat visits | **$844.58** | $30 + $30 visits, same drug and lab prices. `[LIVE /api/external/sku_options/300543]` `[LIVE /api/external/sku_options/300550]` `[LIVE /api/external/lab_skus/503263]` | | Insured path, estimated non-drug subtotal | **$40.00 to $65.00 plus both fills and lab liability** | $40 = initial $25 video copay + $15 lab review with no paid week-4 visit; $65 adds an estimated $25 follow-up. Both exclude drug and lab liability. `[LIVE /api/external/sku_options/300543]` `[CODE components/Labs/AboutLabPricing.tsx:42-45]` | | First-fill drug spread | **$299.00 to $1,100.16** | KwikPen 2.5 mg versus the default auto-injector, including the CVS upper bound. `[LIVE /api/external/medication_option_skus/710641/cash_price]` `[LIVE /api/external/medication_option_skus/710642/cash_price]` `[A:A5.3]` | | Retail KwikPen range | **$496.12 to $508.09** | Walgreens, Walmart, H-E-B versus CVS. `[A:A5.3]` | | Exchange entries on the cash path | 32 entries including alternative pharmacy and lab channels; 72 in the register | A mandatory-party count for one journey is not established. `[A:H1-H23]` `[B:H1-H22]` `[C:H1-H15]` `[D:H1-H18]` `[E:H1-H18]` `[F:H1-H25]`; register §4 | | Human touchpoints | 3 clinical roles, 1 dispensing pharmacist, 0 to 2 support | Mapping estimate, not observed volume. Initial prescriber `[D:D5]`, lab reviewer `[C:C21]`, week-4 prescriber `[E:E7]`, pharmacist `[D:D16]` | | Visit prices | $100 cash video, $25 estimated insured video, $30 cash chat | `[LIVE /api/external/sku_options/300543, 2026-10-19]` | | Lab panel 503263 | $86.58 Quest, $109.67 Labcorp, $102.20 BioReference | `[LIVE /api/external/lab_skus/503263, 2026-10-19]`; includes the $15.00 clinical fee | | Cancellation fee | $25.00 client fallback, video visits only, Medicaid exempt | `[CODE utils/cancellationFeeUtils.ts:6-26]`; the policy does not publish the amount | | Refund request window | Visit fee 5 to 10 business days after eligible cancellation; lab refund request within 6 months if the sample is not collected, no deduction | `[LIVE /cancellation-policy]` `[LIVE /refund-policy-labs]` | ### Top 10 risks and gaps, ranked 1. **The default Zepbound SKU costs 3.6 times the advertised price.** The Lilly page says "from $299" and links to family SKU `201448`, whose default child is `710642` at $1,074.09. The $299 price belongs to KwikPen SKU `710641`. `[A:A5.1]` `[LIVE /api/external/medication_option_skus/710642/cash_price = 107409]` 2. **No pharmacy fulfillment event contract was recovered.** The inspected client surfaces expose a state string plus cancel and switch flags; acknowledgment, rejection, dispense, shipment and possession are not represented. Production may handle these outside the inspected surfaces. `[E:E1.3]` `[CODE lib/store/api/pharmacyOrderApi.ts:15-24]` 3. **No dedicated prior-authorization case contract was recovered.** RTPB returns a PA signal, but submission channel, evidence requests, approval scope, appeal and claim re-adjudication are not represented; who files and where is unverified. `[D:D5.2]` `[LIVE /assignment-of-benefits]` 4. **The privacy review is incomplete.** Recovered configuration shows no consent management platform, 100% session replay with `defaultPrivacyLevel: allow`, and email plus phone in Segment events. Specific GLP-1 questionnaire capture, effective masking, retention, and destination access were not verified. Metabase's login shell is public; the reviewed response requires sign-in, and unauthenticated data access was not established. `[A:A3.4]` `[F:F4.1]` 5. **Billing helper literals differ from the reconstructed specification.** The client checks `gm_card` and `pharmacy_delegated`; the reverse-engineered OpenAPI enum is `cash`, `insurance`, `pharmacy_delegation`. This is a source/specification inconsistency, not a demonstrated server defect; the authoritative `BillingType` is unverified. `[D:D5.4]` 6. **SEO sends crawlers to the wrong URLs.** Sitemaps contain 3,184 `/s/` URLs; the brand medication pages among them are `noindex, nofollow` and canonicalize to `/dp/`, while the indexable `/dp/` pages appear in no sitemap and have no internal links. `[A:A2.1]` 7. **The week-4 refill window can create a gap after dose 4.** One KwikPen supplies four weekly doses, used by T+21; the next dose is due T+28. GM's check-in trigger is unverified. Starting check-in and refill or PA work at T+28 can miss T+28 by 4 to 14 days. The proposed control is to start check-in and refill work at T+14 to T+18 and backward-plan from T+28. A T+21 eRx alone does not guarantee a T+28 dose for mail order, because 3 to 5 business-day verification plus processing and shipment can reach T+32. `[PUBLIC Zepbound PI §2.1]` `[PUBLIC https://www.lilly.com/lillydirect/faq]` `[E:E5]` `[INFERENCE: proposed control]` 8. **The state-to-entity and licensure mapping is unverified.** Legal documents name PCs in AZ, CA, KS, ID and NJ; NPPES records show different addresses and jurisdictions; a second consented network coexists. Address differences alone do not establish a licensure or CPOM defect. `[D:D0.3]` `[F:F7]` 9. **Manufacturer savings and coordination of benefits are not represented.** Eligibility, presentation, pharmacy, caps, renewal conditions, secondary claim and actual redeemed price are outside GM's public quote and were not exercised. `[D:D4.4]` `[PUBLIC https://zepbound.lilly.com/savings]` 10. **Lab pricing is inconsistent across surfaces.** Cards show the test price only; checkout adds $15.00; the client falls back to $30 when the field is missing; `platform_fee` ranges to $40 on panel 503263 and sits outside the total. `[C:C4.3]` `[F:F5.2]` --- ## 1. Journey map ```mermaid flowchart TD A["A Acquisition"] --> A1{"Entry: page or guide"} A1 -->|"GLP-1 page"| B["B Account and intake"] A1 -->|"Guide"| B B --> B1{"Coverage"} B1 -->|"eligible"| C["C Visit checkout"] B1 -->|"self pay"| C C --> C1{"Modality"} C1 -->|"video"| D["D Clinical review"] C1 -->|"chat"| D D --> D1{"Eligible"} D1 -->|"no"| D2["Off-ramp or decline"] D1 -->|"yes (Rx)"| E["E Pharmacy fulfillment"] D1 -.->|"parallel if ordered"| L["Labs: panel or upload"] L -.->|"if pre-start gate"| E E --> E1{"Channel"} E1 -->|"LillyDirect or Amazon"| E2["Mail order"] E1 -->|"retail"| E3["Retail pickup"] E1 -->|"insured"| E4["Insured: PA or claim"] E2 --> F["F Weeks 1 to 4"] E3 --> F E4 --> F F --> F1{"Week-4 review"} F1 -->|"treat"| F2["New Rx: continue or 5 mg"] F1 -->|"stop"| F4["Stop or switch"] F2 --> F3["New fill"] ``` --- ## 2. Timeline: click clock and treatment clock Two clocks are required. **E0** is the first organic click. **T0** is the first actual administered dose, recorded as patient-reported or otherwise evidenced. T0 is never inferred from payment, eRx, dispense, delivery or possession. The first four injections are ordinarily T0, T+7, T+14 and T+21; the next scheduled weekly dose is T+28. Let **Dstart** be the elapsed days from E0 to T0. Dstart remains unknown until actual administration is reported; no bounded click-to-first-dose interval is established. | Click clock | Tx clock | Event | Actor | Gate | Evidence | |---|---|---|---|---|---| | E0, 0 to 10 min | Pre-Tx | Organic result, landing page, CTA, signup redirect | Patient, Google, Vercel or Netlify | Page returns 200; CTA routes to `/screen` then `/get-started` | `[A:A1]` `[A:A4]` `[A:A6]` | | E0, 2 to 10 min | Pre-Tx | Phone, SMS OTP, session | Patient, Twilio, Cognito | US or territory NANP number; SMS deliverable | `[B:B1-B2]` | | E0, 5 to 20 min | Pre-Tx | DOB, Verified autofill or manual entry; six consent booleans; HIE notice only on the manual about-you path | Patient, Verified, GM | 18+; US address in 50 states plus DC; email valid | `[B:B3-B7]` | | E0, 10 to 30 min | Pre-Tx | Insurance discovery, optional; HIE chart review if records exist | Patient, eligibility service, Metriport or Particle | Payer found or self-pay chosen; consent; lookup hit | `[B:B9-B10]` | | E0, 10 to 30 min | Pre-Tx | State confirmation, screening questionnaire, modality and slot | Patient | No red flag; video or chat available in state | `[B:B11-B12]` `[C:C3-C5]` | | E0, 15 to 40 min | Pre-Tx | Visit fee paid or card saved; visit booked | Patient, Stripe | Slot available; card accepted | `[C:C6-C7]` | | E0 to E+1 | Pre-Tx | Video visit about 20 minutes, or chat in the next window; clinical decision and eRx | Clinician, patient, Zoom or chat, DoseSpot, Athena | Clinician joins; identity and state confirmed; no absolute contraindication | `[D:D3-D10]` | | E0 to E+3 | Pre-Tx | Baseline labs ordered, drawn, resulted; or external PDF uploaded | Clinician, Junction, Quest or Labcorp or BioReference | Requisition signed; sample collected; result reviewed if required before start | `[C:C15-C22]` | | E0 to E+1 | Pre-Tx | Patient opens prescription, compares pharmacies, selects channel and billing type | Patient, GM, Arrive, pharmacy feeds | Valid NCPDP id; price available; required labs reviewed | `[D:D11-D13]` | | Elapsed click-to-fulfillment time unknown; channel-specific planning estimates only | Pre-Tx | Pharmacy verification, checkout, claim or PA, shipment or pickup | Patient, pharmacy, PBM, PA team, carrier | Rx received; payment or claim; PA approved or cash chosen; stock available | `[D:D14-D17]` `[PUBLIC https://www.lilly.com/lillydirect/faq]` `[INFERENCE: no measured bound]` | | E + Dstart | **T0** | Dose 1, 2.5 mg, patient-reported. Possession, package condition, device and supplies confirmed first | Patient, pharmacist, care team | Drug in hand; presentation-specific instruction; T0 recorded or explicitly unknown | `[E:E1.4-E2]` `[PUBLIC Zepbound PI §17]` `[INFERENCE: proposed T0 control]` | | E + Dstart + 7 | T+7 | Dose 2, 2.5 mg | Patient | Weekly schedule | `[E:E4]` | | E + Dstart + 14 | T+14 | Dose 3, 2.5 mg; proposed check-in and refill work start | Patient, GM | One dose remains after this; start refill and PA work now | `[E:E5]` `[INFERENCE: proposed control]` | | E + Dstart + 18 to 20 | T+18 to T+20 | Proposed check-in submission and clinician review; dose decision | Patient, clinician | Questionnaire, optional labs, interval history; reviewer available | `[E:E6-E7]` `[INFERENCE: proposed control]` | | E + Dstart + 21 | T+21 | Dose 4, final 2.5 mg dose from the pen; refill work should already be underway | Patient, clinician, DoseSpot, pharmacy | Review complete; new strength prescribed; PA checked if insured. A T+21 eRx alone does not guarantee T+28 for mail order | `[E:E8]` `[PUBLIC Zepbound PI §2.1]` `[PUBLIC https://www.lilly.com/lillydirect/faq]` `[INFERENCE: proposed control]` | | E + Dstart + 28 | T+28 | Dose 5, first 5 mg dose, if the second box is in hand; otherwise a gap | Patient | Box delivered or picked up by T+27 | `[E:E8]` `[INFERENCE]` | | E + Dstart + 28 or later | T+28+ | Fallback review if the proposed T+14 to T+21 window was missed | Clinician, care team | Reconcile remaining pens, missed doses and restart plan | `[E:E5-E7]` `[PUBLIC Zepbound PI §2.3]` | Timing note: only the video `availability_promise: "today"`, the chat next-slot timestamp, LillyDirect's published minimum of 3 to 5 business days for verification plus 1 to 4 days to process and ship after checkout, the PA claim of "several business days", and the lab claim of 48-hour results are published. Lilly asks patients to allow a minimum of 3 to 5 business days for verification; most prescriptions are processed and shipped within 1 to 4 days of checkout. Transit and upstream delays are additional; these are not maximum delivery SLAs. Business days and calendar days are not interchangeable. No measured click-to-first-dose bound is established. The T+14 to T+18 refill start is a proposed operating control, not observed GM behavior, and a T+21 eRx is not sufficient to guarantee a T+28 mail-order dose. --- ## 3. Stage-by-stage walkthrough ### A. Acquisition **Headline: one organic doorway works, and it sells a visit rather than a drug.** ```mermaid flowchart TD A1["Organic click"] --> A2["GLP-1 page 300543"] A2 --> A3{"Entry"} A3 -->|"Get started"| A4["Signup"] A3 -->|"Guide"| A5["GLP-1 article"] A5 --> A2 A3 -->|"Compare"| A6["Pharmacy compare"] A6 --> A4 A4 --> A7["Price and form check"] A7 --> A8["Account handoff"] ``` | # | Patient sees or does | GM system or route | Data | Outside party | Evidence | |---|---|---|---|---|---| | A1 | Clicks an organic result for a GLP-1 query | `/s/glp-1-medication-evaluation/300543` on Vercel; article on Netlify | Referrer, landing URL, IP, `nile_ld_key` UUID, `isAuthenticated=false` | Google, Bing, DuckDuckGo, CloudFront, Vercel or Netlify | `[A:A1]` | | A2 | Reads hero, price, FAQ, testimonials | `SkuRefreshRenderer`; category page components | `page_view_id`, `landing_page_loaded`, dwell frames, LCP, cache hit | Segment, Datadog, LaunchDarkly | `[A:A2]` | | A3 | Nothing visible; attribution parameters are persisted when present | `useAttributionTracking`; `POST /api/campaign-touches` only when `utm_source` and an anonymous id exist | UTMs, optional paid click IDs, `_fbc`, synthetic `_fbp`, in-app browser. An untagged organic landing creates no campaign touch | Google, Microsoft, Meta, Kargo, OpenAI ads only when present; Segment | `[A:A3]` | | A4 | Chooses Get started, Book a visit, a related service, or search | `SkuDetailCta`, `CategoryHeader`, `ServiceItemCard`, `StoreSearchDrawer` | `sf_clicked_sku`, `sku_page_cta_clicked`, `new_storefront_request_medication_clicked` | Segment, Datadog | `[A:A4]` `[A:A11]` | | A5 | Is redirected to signup, or to login on `/visit` | Edge middleware 307; `sku_id` and `redirect_url` cookies | SKU id, absolute return URL, auth flag | None | `[A:A6]` | | A6 | Enters phone, receives OTP | `/get-started`, `/get-started/verify` | Phone, OTP funnel events | Twilio, AWS Cognito | `[A:A7]` `[B:B1-B2]` | | A7 | Is returned to the booking screen, consumer not recovered so inferred | Cookie consumer not recovered | `signup_complete`, `alias`, `identify`, `merge_identity`, `patientId` | Segment, Datadog | `[A:A8]` | | A8 | On a medication page, switches dose form or strength | `/dp//` via `replaceState`; price refetch | New SKU id and price; no new pageview | None | `[A:A10]` | | A9 | Searches "tirz", "zep", "glp" | `/api/external/search/suggestions`, `/store/search` | Raw query and suggestion array sent to Segment | Segment | `[A:A11]` | | A10 | Opens Browse pharmacies: API returns about 52 rows, UI caps display at 20 interleaved rows | `pharmacy_comparisons` API; Maps JS; `UNIVERSAL_SEARCH_PHARMACIES_DISPLAY_LIMIT = 20` | Coordinates, ZIP, NCPDP id, chain, distance, `total_price_cents` | Google Maps, LillyDirect, NovoCare, Amazon, retail chains | `[A:A12]` `[CODE components/Refresh/SearchResults/searchPharmaciesUtils.ts:12,154]` | | A11 | Lands on the Lilly co-branded page | `/p/lilly/weight-loss` | `landing_page_loaded` with `page_id=lilly_weight_loss`; ad landing event | Lilly, Segment | `[A:A13]` | | A12 | Reads the GLP-1 guide and clicks Book visit | Astro article with absolute link | Outbound click; `rel=noreferrer` removes the referrer | GA4, OneSignal, Sanity, Netlify | `[A:A14]` | **Decision points** - Visit or medication: the GLP-1 evaluation is `category: condition` and sells a visit. Medication SKUs sell a drug but cannot be bought before a visit. - Cash or insurance: the storefront has no global toggle. Condition and medication SKUs go straight to the booking screen; labs use an insurance drawer. - Retail or direct: the compare drawer pins LillyDirect, NovoCare, and Amazon above retail. The price gap on the 2.5 mg pen is $299 versus $496.12 to $508.09. - Which Zepbound form: the family page defaults to the auto-injector at $1,074.09. The KwikPen at $299 requires a dose-form switch or the LillyDirect pharmacy page. ### B. Account and intake **Headline: phone-only signup, third-party identity autofill, six consent booleans plus an HIE notice, then a server-driven questionnaire.** ```mermaid flowchart TD B1["Phone"] --> B2["SMS OTP"] B2 --> B3["Date of birth"] B3 --> B4{"Verified match"} B4 -->|"yes"| B5["Review autofill"] B4 -->|"no"| B6["Manual about you"] B5 --> B7["Six consents and patient record"] B6 --> B7 B7 --> B8{"Insurance"} B8 -->|"check"| B9["Eligibility service"] B9 --> B10{"Result"} B10 -->|"in network"| B11["Visit options"] B10 -->|"not found"| B12["Self pay"] B12 --> B11 B8 -->|"self pay"| B12 ``` | # | Patient sees or does | GM system or route | Data | Outside party | Evidence | |---|---|---|---|---|---| | B1 | Step 1 of 3, enters a US mobile number | `/get-started`, `PhoneInput`, `AuthProvider.login` | `POST /auth/initiate`, phone in localStorage, `otp_send_requested` | Twilio, Cognito | `[B:B1]` | | B2 | Enters a 6-digit code | `/get-started/verify` | OTP, Cognito session, HttpOnly cookie, `isAuthenticated=true` mirror | Cognito, Twilio | `[B:B2]` | | B3 | Step 3 of 4, enters date of birth | `/get-started/date-of-birth` | `{birth_date}` only; no SSN field | Verified | `[B:B3]` | | B4 | Sees autofilled name, address, sex, email; no HIE notice observed on this path | `/get-started/review-info` | Name, DOB, sex, email, up to 7 addresses | Verified | `[B:B4-B5]` | | B5 | Manual about-you form with HIE notice and opt-out link | `/get-started/about-you` | Legal name, address, email, sex at birth; HIE consent by continuing, PDF opt-out, no boolean field | Google Places, email validation vendor | `[B:B6]` | | B6 | Accepts terms and continues | `POST /api/external/patients` | Identity, six consent booleans hard-coded true, no HIE boolean, all UTMs and click IDs, `signup_id`, `signup_sku_id`, `signup_channel` | Segment, Datadog | `[B:B7]` | | B7 | Lands on `/welcome` or `/ai/onboarding` | Auth-gated route; content not recovered | Conditional browser telemetry only: if SignupTracker mounts and its user, analytics and local-guard checks pass, it attempts `signup_complete` and identify, which carry email and phone; alias receives only the user ID. Sending on this path was not observed. Patient creation is the authoritative record | Segment, Datadog | `[B:B8]` `[CODE components/SignupTracker.tsx:16-98]` | | B8 | Insurance: picks a plan, enters member ID, or photographs the card | `/insurance`; eligibility enqueue or sync | Payer, member ID, group, card images, copay, network status | Verified 1-Click Health (candidate), Waystar (inferred), payer, OCR vendor, S3 | `[B:B9]` | | B9 | Reviews conditions, medications, allergies, procedures | `/health-history/{step}/add` | FHIR records tagged `metriport`, `particle`, or `customer` | Metriport, Particle | `[B:B10]` | | B10 | Confirms physical state before screening | `/location-confirmation` | `appointment_location_state` | None | `[C:C5]` `[D:D2]` | | B11 | Answers the GLP-1 screening questionnaire, one question per screen | `/questionnaire/{id}/{n}` | Answers, progress, `off_ramp_type` in `emergency`, `urgent`, `high_risk`, `requires_triage`, `unable_to_treat`, `different_sku`; emergency branch | None | `[B:B11]` `[CODE lib/analytics/questionnaireInterstitialAnalytics.ts:3-9]` | | B12 | Picks video or chat and a time | `/options`, `skuOptionsApi` | Modality, slot, price, `insurance_status` | None at selection; Stripe at payment | `[B:B12]` | | B13 | Completes history questionnaire or chart review before the visit | `/questionnaire/{history_id}`, `/health-history` | Pre-visit requirements and responses | Metriport, Particle | `[B:B13]` | **Decision points** - Identity match or manual entry: a Verified miss produces no error message; the patient silently lands on the manual form. - Insurance or self-pay: an eligibility failure offers "Try another insurance" or "Continue without insurance" at $100. - Chat allowed or not: chat is omitted in AL, AR, DE, FL, KS, LA, MN, MS, NJ, NM, RI, and WV. - Red flag or clear: the questionnaire can off-ramp to the care team, another SKU, or an unavailable screen. ### C. Checkout and labs **Headline: three separate money events, and a lab fee that is real at $15 but fallback-priced at $30.** ```mermaid flowchart TD C1["Visit options"] --> C2{"Modality"} C2 -->|"video"| C3["Video 100 or 25"] C2 -->|"chat"| C4["Chat 30 cash"] C3 --> C5["Slot and payment"] C4 --> C5 C5 --> C6["Booked visit"] C6 --> C7{"Labs required"} C7 -->|"yes"| C8["Panel 503263"] C7 -->|"upload"| C9["External PDF"] C7 -->|"no"| C10["No labs"] C8 --> C11["Draw and result"] C9 --> C11 C10 --> C12["Pharmacy order later"] C11 --> C12 ``` | # | Patient sees or does | GM system or route | Data | Outside party | Evidence | |---|---|---|---|---|---| | C1 | Sees Video $25 estimated or $100 cash; Chat $30 cash | `/s/glp-1-medication-evaluation/300543` | `sku_id`, price option | None | `[C:C1]` | | C2 | Taps Get started; screening flow opens | `/s/{slug}/{id}/screen` | `ref`, `practiceId`, page view id | None | `[C:C2]` | | C3 | Answers screening questions | Questionnaire engine | `screening_questionnaire_id=11340c6b...`, answers | None | `[C:C3]` | | C4 | Chooses billing: insurance, cash, or MDSave where offered | `/visit/{id}/options` | `billing_type`, price cents, `insurance_status`, slots | MDSave on some in-person SKUs only | `[C:C4]` | | C5 | Picks a slot; sees the 24-hour cancellation rule | `/visit/{id}/schedule` | `scheduled_time`, clinician id, `cancellation_fee_policy_applies` | None | `[C:C5]` | | C6 | Sees Confirm and Book, due today, FSA/HSA label | `/visit/{id}/payment` | `payment_method_id`, `price_guaranteed`, agreement flags | Stripe | `[C:C6]` | | C7 | Adds a card if none on file | SetupIntent then `POST /visits/book` | `client_secret`, brand, last4, expiry | Stripe | `[C:C7]` | | C8 | Gets confirmation and a Zoom link | `/visits/{id}` | `visit_id`, `state`, `meeting_url` | Zoom, Twilio, email provider | `[C:C8]` | | C9 | Cancels or reschedules | Visit state machine; Visitron fee waiver | `cancellation_reason`, `cancellation_fee_amount_cents` | Stripe | `[C:C9]` | | C10 | Later sees the prescription and pharmacy options | `ensure_pharmacy_order`; `/orders/pharmacy/{id}/options` | `pharmacy_order_id`, `medication_option_sku_id`, NCPDP id, `arrive_rtpbi_inquiry_id` | Arrive Health, DoseSpot | `[C:C11-C12]` | | C11 | Chooses insurance copay, GM card at counter, or cash pre-pay | `checkout`, `checkout_with_insurance`, `checkout_for_pharmacy_delegation` | `billing_type`, payment method, `gm_card` BIN/PCN/group/member | Stripe, pharmacy | `[C:C13-C14]` | | C12 | Orders a baseline lab panel or uploads recent labs | Lab SKU PDP; `/account/medication-check-in/labs` | `lab_sku_ids`, `lab_order_id`, file ids | Junction, Quest, Labcorp, BioReference, S3 | `[C:C15-C22]` | | C13 | Sees test price plus "$15 clinical review added at checkout" | `LabPanelPricing` | `test_price`, `clinical_fee`, `clinical_fee_enabled` | None | `[C:C18]` | | C14 | Books the draw; walks in or schedules | `/s/{slug}/{id}/start`; Junction appointment | `lab_order_id`, accession, `scheduled_at`, `lab_vendor_name` | Junction, lab | `[C:C19-C20]` | | C15 | Gets results in dashboard, Updates, or PDF | `/account/labs`, Updates feed | `status`, `report_url`, `results_count`, `abnormal_results_count` | Lab, clinician | `[C:C21]` | | C16 | Week 4: books follow-up or completes check-in | `300550`; `/prescriptions/{id}/check-in` | `sku_id=300550`, billing type, next fill | Stripe, clinician | `[C:C23-C24]` | **Decision points** - Insurance in network: $25 estimate, preselected if cheaper. - Out of network: book without insurance or switch to chat. - Medicaid with no capacity: "Text us and we'll help you find a time." - Lab self-bookable with insurance: `insurance_orderable` is true for 503263; false for 500114, 500049, and 500001. - Lab conditions screen: continue without insurance, continue with insurance anyway, or book a video visit. - Abnormal result: clinician outreach; a paid Lab Results Review visit exists at $100 or $25. ### D. Clinical review and prescribing **Headline: a shift-based clinician writes the prescription in Visitron, and the pharmacy leg starts as a separate patient task.** ```mermaid flowchart TD D1["Appointment"] --> D2["Chart prewarm"] D2 --> D3["Video or chat visit"] D3 --> D4["Safety and indication review"] D4 --> D5{"Eligible"} D5 -->|"no"| D6["Decline or refer"] D5 -->|"yes"| D7["Care plan"] D7 --> D8["Draft and finalize eRx"] D8 --> D9["RTPB and formulary"] D9 --> D10["Sign encounter"] D10 --> D11["Sync to Athena"] D11 --> D12["Pharmacy order created"] D12 --> D13{"PA signal"} D13 -->|"yes"| D14["PA path"] D13 -->|"no"| D15["Cash or claim"] ``` | # | Patient sees or does | GM system or route | Data | Outside party | Evidence | |---|---|---|---|---|---| | D1 | Picks modality and slot; pays or saves a card, capture timing inferred | `/options`; `visits/create`, `booking_selection`, `payment_method`, `book` | `sku_id`, modality, slot, price, state | Stripe | `[D:D1]` | | D2 | Confirms physical location | `/location-confirmation` | State, `practice_id`, clinician pool | None | `[D:D2]` | | D3 | Waits for the visit link or chat window | Visitron appointment and chat queues | `appointment_id`, `visit_type`, `meeting_url` | Zoom, Twilio | `[D:D3]` | | D4 | Nothing; clinician opens the chart | `applyAppointmentLatestPrewarm`, `getPatientChartContext`, `triggerMetriportSync`, `getQuestionnaireCodes` | HIE history, prior encounters, meds, allergies, answers | Metriport, Particle, Athena | `[D:D4]` | | D5 | Talks or messages for 15 to 45 minutes | `getDraftEncounter`, `updateDraftEncounter`, `getChatHistory`, `getNablaStatus` | Transcript, note draft, diagnoses, orders | Zoom, Zendesk, Nabla | `[D:D5]` | | D6 | Describes weight history, comorbidities, prior GLP-1 use | Diagnosis and order search | BMI, comorbidities, contraindications, labs | None | `[D:D6]` | | D7 | Later sees care-plan phases and check-ins | `createCareJourney`, `changePathway`, `changePhase` | `pathway_id`, `phase_id`, modality, days supply | None | `[D:D7]` | | D8 | Nothing; later sees the prescription | `createDraftPrescription`, `finalizeDraftPrescription`; DoseSpot SSO | Drug, strength, form, quantity, days supply, refills, SIG | DoseSpot | `[D:D8]` | | D9 | Sees "available after visit" or a copay later | `launchInsurancePrice`, `launch_benefit_inquiry`; consumer poll | Copay tier, deductible, formulary, PA flag, inquiry id | Arrive Health, DoseSpot, PBM | `[D:D9]` | | D10 | Sees the signed care plan and next steps | `confirmCarePlan`, `publishAppointmentDraftEncounter`, `syncEncounterToAthena` | Signed note, `athena_id`, next-step review | Athenahealth | `[D:D10]` | | D11 | Opens the prescription and taps order | `ensure_pharmacy_order` | `care_action_prescription_id`, `pharmacy_order_id`, state | None | `[D:D11]` | | D12 | Compares pharmacies and selects one | `pharmacy_comparisons`, `select_pharmacy` | NCPDP id, price, distance, `fulfillment_owner` | LillyDirect, NovoCare, Amazon, retail | `[D:D12]` | | D13 | Chooses cash, insurance, or pay at counter | `PUT /api/external/pharmacy_orders/{id}` with `{billing_type}` | `billing_type`; payment method and price are separate fields | Stripe, pharmacy | `[D:D13]` `[CODE lib/store/api/pharmacyOrderApi.ts:34-42]` | | D14 | Pays or shows the GM card | `checkout`, `checkout_with_insurance`, `checkout_for_pharmacy_delegation`, `gm_card` | `payment_intent`, `gm_card` fields | Stripe, pharmacy | `[D:D14]` | | D15 | Nothing; pharmacy receives the Rx | DoseSpot eRx to the selected NCPDP id | Rx payload, demographics, prepaid status | DoseSpot, pharmacy | `[D:D15]` | | D16 | Gets a pharmacy text, checkout link, or pickup notice | Pharmacy system | Rx status, copay, PA status, savings, shipment | LillyDirect dispensing pharmacy, Amazon, retail | `[D:D16]` | | D17 | Receives the package or picks up | No GM shipping object recovered | Pharmacy-side tracking is described; GM tracking visibility outside the inspected interfaces is unverified | Carrier, pharmacy | `[D:D17]` | | D18 | At T+14 to T+28, sees check-in and next-step cards; GM trigger unverified | `care_journey/next_steps`, `check-in` | Criteria id, responses, lab order, deadline | None | `[D:D18]` `[INFERENCE: proposed window]` | | D19 | Week-4 visit or review; dose decision | `getClinicianReviews`, `applyReview`, `changePhase`, renewal | New dose, new Rx, phase change, days supply | Clinician, Athena | `[D:D19]` | | D20 | Chooses pharmacy and pays again for 5 mg | Same as D11 to D17 | New order, new SKU, new price, possibly new PA | All pharmacy parties | `[D:D20]` | **Decision points** - Zepbound or Mounjaro: separate indications. Zepbound weight management uses BMI 30 or 27 with a comorbidity; Mounjaro is type 2 diabetes and also has a cardiovascular-risk indication in specified adults with T2D. GM is adult-only and no pediatric redirect was observed; do not apply Zepbound BMI or cash rules to Mounjaro. - Compounded tirzepatide: no SKU was observed in the inspected public catalog, search index or recovered source. Compounded products are outside this mapped branded path; availability elsewhere is not established. - Form: KwikPen, auto-injector, or vial. The default PDP form is the auto-injector at $1,074.09; the vial has no cash price. - Contraception: tirzepatide delays gastric emptying and can reduce oral contraceptive exposure, most after the first dose and each escalation. Counsel on a non-oral method or backup for 4 weeks after initiation and after each escalation; no structured field was observed and the counseling should repeat at week 4. - Safety review: separate absolute label contraindications (MTC or MEN2 history, serious hypersensitivity) from warnings and precautions (gastroparesis, pancreatitis, gallbladder, kidney injury, hypoglycemia with insulin or secretagogues, retinopathy, pregnancy, anesthesia aspiration). Record the source version, finding, clinician decision and advice. `[PUBLIC Zepbound PI §§4-5, 7-8]` - Cash or insurance: cash may use eligible retail pay-ahead, a pharmacy-counter cash or discount price, or an eligible manufacturer direct-pay program. Insurance needs a claim and may need a PA. `[D:D4.3]` `[LIVE https://generalmedicine.co/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup]` - PA or no PA: RTPB returns a requirement; no dedicated PA case or submission contract was recovered. `[D:D5.2]` - Week 4 for a new labeled Zepbound start: review at the end of four weeks of 2.5 mg and ordinarily proceed to 5 mg. Intolerance, interruption, extended initiation, switching or stopping require clinician-directed decisions; 2.5 mg is not a maintenance dose and no lower-than-2.5 mg starter dose is labeled. `[PUBLIC Zepbound PI §2.1]` **Mounjaro adult T2D branch** - Indication: glycemic control in adults with type 2 diabetes, plus cardiovascular-risk reduction in specified adults with T2D; there is no BMI threshold for the T2D indication. `[PUBLIC Mounjaro PI §1]` - Product route: separate NDC, presentation, quote, benefit or PA check, pharmacy and savings eligibility. Zepbound's $299/$399/$449 self-pay ladder does not apply. `[D:D4.2]` - Observed GM route: retail only at $552.28 Walgreens and $565.63 CVS, a 2026-10-19 snapshot that must be re-quoted. `[LIVE /api/external/medication_option_skus/710655/cash_price]` - Pediatric use: the Mounjaro label includes patients 10 years and older, but GM's observed service is 18+ with no pediatric redirect. Treat pediatric requests as out of scope for this path. `[PUBLIC Mounjaro PI §1]` `[B:§5]` - First-month dosing: start 2.5 mg once weekly. After at least 4 weeks, increase to 5 mg if additional glycemic control is needed; further 2.5 mg increments require at least 4 weeks on the current dose. Maximum 15 mg weekly in adults. `[PUBLIC Mounjaro PI §2.1]` - Monitoring and handoff: record baseline glucose or A1c, diabetes medications, hypoglycemia risk, renal function and retinopathy history. Document any insulin or secretagogue dose reduction and the glucose-monitoring plan. At the first review, record glucose response, adverse effects, adherence and the clinician's continuation or escalation decision. `[PUBLIC Mounjaro PI §§5.3, 5.5, 5.7, 8]` - Benefits: re-check the T2D indication, NDC, quantity, PA and savings eligibility separately from the Zepbound weight-management path. `[D:D4.2]` ### E. Pharmacy fulfillment and first dose **Headline: the prescription leaves GM and the patient becomes the integration.** ```mermaid flowchart TD E1["Rx"] --> E2{"Channel"} E2 -->|"LillyDirect"| E3["Mail order"] E2 -->|"Amazon"| E4["Mail order"] E2 -->|"retail"| E5["Retail pickup"] E2 -->|"insured"| E6["Benefit check"] E3 --> E7["Pharmacy checkout"] E4 --> E7 E6 --> E8{"PA required"} E8 -->|"yes"| E9["PA wait"] E9 --> E10{"Approved"} E10 -->|"no"| E11["Cash fallback"] E11 --> E2 E10 -->|"yes"| E12["Claim"] E8 -->|"no"| E12 E12 --> E7 E5 --> E13["Pickup"] E7 --> E13 E13 --> E14["Possession and training"] E14 --> E15["First dose T0"] ``` | # | Patient sees or does | GM system or route | Data | Outside party | Evidence | |---|---|---|---|---|---| | E1 | Sees the care plan and prescription card | `/account`, `/account/care-plans`, `/account/next-steps` | `care_id`, `plan_id`, plan state, `remainingMessage` | None | `[E:E1]` | | E2 | Chooses pharmacy and payment mode | `ensure_pharmacy_order`, `pharmacy_comparisons`, `select_pharmacy` | NCPDP id, `billing_type`, prices, state | Arrive, pharmacies | `[E:E1.1]` | | E3 | Sees LillyDirect and Amazon at $299; retail at $496.12 to $508.09 | Compare drawer | Chain, distance, price, `fulfillment_owner` | LillyDirect, Amazon, retail | `[E:E1.2]` | | E4 | Pays in app, pays at counter, or presents the GM card | Stripe checkout; `gm_card` | `payment_method_id`, BIN/PCN/group/member, submission state | Stripe, pharmacy | `[E:E1.3]` | | E5 | Gets a "prescription sent" notice; picks up or receives the box | No first-dose screen or event recovered | Prescription sent; no dose-taken timestamp recovered | Pharmacy, carrier | `[E:E1.4]` | | E5.1 | Confirms possession, brand, strength, presentation, quantity, directions and package condition | Proposed possession reconciliation; no GM field observed | Presentation, quantity, condition, discrepancy | Dispensing pharmacy | `[INFERENCE: proposed control]` | | E5.2 | Confirms needles, syringes and sharps plan; receives presentation-specific instruction and teach-back | Proposed; pharmacist and prescriber own counseling. AI is not a primary trainer | Presentation, supplies, ability, training version | Pharmacy, clinician | `[PUBLIC Zepbound PI §17]` `[E:E2]` `[INFERENCE: proposed control]` | | E5.3 | Reports actual first dose as T0, or states that start is delayed or declined | Proposed T0 record; no administration endpoint observed | `first_dose_administered_at`, source, delay reason | Patient, care team | `[INFERENCE: proposed control]` | | E6 | Learns injection from the label, IFU, pharmacist or clinician; AI is a navigation aid, not a trainer | `formatInstructions`; `patient_instructions`; messaging | SIG text, presentation, needle requirements | Pharmacy, Lilly | `[E:E2]` `[PUBLIC Zepbound PI §17]` | | E7 | Messages the care team or General AI about side effects | Message Center if flag on; otherwise SMS; `/ai` | Conversation, subject, `response_expectation`, AI messages | Twilio, Zendesk, Braintrust | `[E:E3]` | | E8 | Takes doses 2, 3, 4; no GM dose event recovered | None | No dose event observed in inspected client; production may differ | None | `[E:E4]` | | E9 | Gets a refill reminder or check-in card | `earliest_fill_date`, `criteria_deadline`, `NextStepCard` | Dates, pending criteria, deadline | None | `[E:E5]` | | E10 | Completes check-in questionnaire and optional labs | `/account/medication-check-in`; `care_journey/*` | Actionable count, estimated minutes, item type, status | Junction, lab, S3 | `[E:E6]` | | E11 | Waits for clinician review | Visitron `generateNextStepReview`, `applyReview`, `confirmNoChange` | Review fields `proposed_json`, `final_json`, rationale and phase are dossier-attributed, not first-party contracts | Clinician | `[E:E7]` `[F:F3.3]` | | E12 | Gets a new 5 mg prescription and pays $399 | New `PharmacyOrder` for new SKU | New order id, SKU, price, PA requirement | Pharmacies, payer | `[E:E8]` | | E13 | For the 7.5 to 15 mg KwikPen offer, completes the next qualifying purchase within 45 days of delivery or receipt of the previous fill | Refill or renewal next step | `due_date`, `on_next_step`, refills left, previous receipt date | LillyDirect | `[E:E9]` `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` | | E14 | Sees month-1 charges | `/account/orders`, pharmacy invoice | Billing type, cash and insurance price, clinical fee, invoice | Stripe, pharmacy | `[E:E10]` | | E15 | Cancels, switches pharmacy, declines renewal, or stops | `pharmacy_orders/{id}/cancel`, renewal decline | Cancellation reason, cancel and switch flags | Support, pharmacy | `[E:E11]` | | E16 | Does not log weight, doses, or vitals | No endpoint or device integration observed | Weight only if typed into a questionnaire | None | `[E:E12]` | **Decision points** - Mail order or retail: for the starter KwikPen snapshot, Austin retail quotes are $496.12 to $508.09 versus $299 direct, about 1.66 to 1.70 times. Different presentations and strengths need separate comparisons. Pickup may avoid transit, but stock and processing determine timing; no comparative delivery-performance distribution was measured. - Pre-pay or pay at counter: pre-pay works at eligible retail only, not mail order. - KwikPen or auto-injector: a $299 versus $1,074.09 decision that the storefront default gets wrong. - Refill or renewal: same-strength refills depend on the prescription, pharmacy and payer rules; a new strength needs an appropriate new prescription. `[E:E9]` - 45-day condition: for the 7.5, 10, 12.5 and 15 mg KwikPen purchase offer only, the next qualifying purchase must be completed within 45 days of delivery or receipt of the previous fill. The 2.5 mg and 5 mg starter prices are not conditioned on this window. `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` ### F. Weeks 1 to 4 and the week-4 step-up **Headline: the clinical loop is instrumented; the patient's month is not.** ```mermaid flowchart TD F1["T0 dose 1"] --> F2["T+7 dose 2"] F2 --> F3["T+14 dose 3"] F3 --> F4["Proposed check-in unlock"] F4 --> F5["T+18 to T+20 review"] F5 --> F6{"Decision"} F6 -->|"continue"| F7["2.5 mg Rx"] F6 -->|"escalate"| F8["5 mg Rx"] F6 -->|"stop"| F9["Stop or switch"] F7 --> F10["New order"] F8 --> F10 F10 --> F11["T+21 dose 4"] F11 --> F12["T+28 dose 5 or gap"] F9 --> F13["Transition plan"] ``` | # | Patient sees or does | GM system or route | Data | Outside party | Evidence | |---|---|---|---|---|---| | F1 | Home dashboard shows care plan and next steps | `dashboard/show`, `next_steps/by_care`, `next_step_cards` | Plan state, next steps, deadlines | None | `[E:E1]` | | F2 | Receives in-app, email, and SMS notices | Updates feed; email; Twilio | `event_type`, `notifiable_type`, `unread`, `sla_promise` | Twilio, email vendor | `[E:E14]` | | F3 | Asks General AI about missed doses or side effects | `/ai`, `/ai/chat`, `/ai/health-records` | Consent, messages, feedback, Metriport prewarm | LLM provider, Metriport, Braintrust | `[E:E13]` | | F4 | Reports severe symptoms or asks for a dose change | Message Center; `300348` side effect; `200010` adjustment | Conversation, visit booking, clinical note | Twilio, Zendesk, clinician | `[E:E16]` | | F5 | Completes the medication check-in; proposed unlock at T+14 to T+18, GM trigger unverified | `/account/medication-check-in` | Answers, progress, `estimated_minutes` | None | `[E:E6]` `[INFERENCE: proposed control]` | | F6 | Completes or uploads labs if required | `/labs`, `/labs/upload`; `care_journey/lab_bundle` | Lab order, file id, S3 state | Junction, lab, S3 | `[E:E6]` | | F7 | Waits for a clinician decision | Visitron pending review | Review fields `proposed_json`, `final_json`, decision and rationale are dossier-attributed | Clinician | `[E:E7]` `[F:F3.3]` | | F8 | Gets 2.5 mg continued as a clinician deviation, or the standard 5 mg, or a stop | `changePhase`, `changePathway`, renewal ops | New phase, strength, Rx, days supply | Athena, DoseSpot | `[E:E7]` `[PUBLIC Zepbound PI §2.1]` | | F9 | Re-selects pharmacy and pays for the new strength | New order and checkout | New SKU id, NCPDP id, price, PA | Pharmacies, payer | `[E:E8]` | | F10 | Refills or renews; may need a new PA | Refill order or `NextStep::PrescriptionRenewal` | `due_date`, `on_next_step`, `open_to_renew` | Pharmacy, PBM | `[E:E9]` | | F11 | May stop without a formal workflow | Cancellation and renewal decline | Reason, flags, no subscription state | Support | `[E:E11]` | | F12 | Remains outside any adherence measurement in the inspected client | No dose log, weight log or device sync observed | None | None | `[E:E12]` | **Decision points** - For a new labeled Zepbound start, ordinarily proceed from 2.5 mg to 5 mg after four weeks. Continuing 2.5 mg, extending initiation, lowering, switching or stopping are clinician-directed deviations; 2.5 mg is not a maintenance dose and no lower-than-2.5 mg starter dose is labeled. `[PUBLIC Zepbound PI §2.1]` - Questionnaire only, labs, or a paid visit: the GLP-1 criteria set and blocking rule are server-side and unobserved. - Refill timing: one KwikPen supplies four weekly doses; the fourth is used at T+21 and the next dose is due at T+28. Start check-in and refill or PA work at T+14 to T+18 and backward-plan from T+28. A T+21 eRx alone does not guarantee T+28 for mail order; GM's actual trigger is unverified. `[PUBLIC https://www.lilly.com/lillydirect/faq]` `[INFERENCE: proposed control]` - Adherence: no dose-administration event was recovered, so a stopped patient and a stable patient can look alike except through refill cadence or self-report. `[E:E4]` ### 3.7 Product safety, dispensing and first-dose readiness These are proposed controls. GM enforcement is not observed. | Step | Patient sees or does | Responsible handoff | Proposed record or closure | What is known | Evidence | |---|---|---|---|---|---| | Safety review before prescribing | Discusses personal or family MTC or MEN2, serious hypersensitivity, pregnancy plans, GI history, diabetes drugs and other medications | Licensed prescriber reviews product-specific contraindications, warnings and interactions | Reviewed source and version, findings, decision, counseling, follow-up | PI content is established; exact GM questionnaire and rules are unrecovered. Do not relabel every warning as a contraindication | `[PUBLIC Zepbound PI §§4-5, 7-8]` `[D:D6]` | | Contraception and planned procedures | Receives oral-contraceptive and procedure or anesthesia counseling when applicable | Prescriber to patient; pharmacist reinforces | Counseling documented, including non-oral method or barrier method for 4 weeks after initiation and each escalation | PI supports the counseling; structured GM enforcement unknown | `[PUBLIC Zepbound PI §§7.2, 8.3, 17]` | | Pregnancy and interval review | Reports pregnancy, pregnancy plans or lactation at start and at follow-up | Prescriber; obstetric coordination when needed | Zepbound: discontinue when pregnancy is recognized. Mounjaro: product-specific diabetes and obstetric risk-benefit review. Interval pregnancy question at each escalation | PI supports product-specific actions; GM workflow unknown | `[PUBLIC Zepbound PI §8.1]` `[PUBLIC Mounjaro PI §8.1]` | | Glycemic medication plan | Reports insulin, sulfonylurea or other glucose-lowering drugs | Prescriber and pharmacist | Baseline glucose or A1c, hypoglycemia risk, whether insulin or secretagogue dose reduction is indicated, monitoring plan | Labels require counseling and monitoring; no structured GM field observed | `[PUBLIC Zepbound PI §§5.7, 7.1]` `[PUBLIC Mounjaro PI §§5.3, 5.7]` | | Narrow-therapeutic-index oral drugs | Reports warfarin, levothyroxine or other narrow-TI medicines | Prescriber and pharmacist | Delayed gastric emptying noted; monitoring or dose adjustment plan recorded | Label interaction section supports the risk; GM workflow unknown | `[PUBLIC Zepbound PI §7.2]` | | Dispensing product reconciliation | Confirms brand, strength, presentation, quantity, directions and channel | Prescriber and eRx to dispensing pharmacist to patient | Accepted or corrected Rx and dispensed presentation; mismatch stays open | Gifthealth reports quantity, directions and formulation as rejection causes; GM route resolution unverified | `[PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started]` `[D:D16]` | | Supplies and training | Confirms needles or syringes and sharps plan; receives device-specific instruction and ability assessment | Dispensing pharmacist and prescriber | Training version, received presentation, supplies, ability or assistance needed; retraining on presentation change | PI requires presentation-appropriate training. No completed GM training event observed. KwikPen needs a separate pen needle; no needle SKU was observed | `[PUBLIC Zepbound PI §17]` `[E:E2]` `[E:§6 q14]` | | Shipment or pickup exception | Reports wrong item, delay, damage, suspected temperature problem or non-possession | Pharmacy handles product and dispensing decision; GM coordinates clinical consequences | Tracking if available, possession report, issue, pharmacy response, replacement or clinical plan | Use the received presentation's current label. Do not infer safety from a carrier scan. GM visibility unknown | `[D:D5.3]` `[PUBLIC Zepbound PI §16.2]` `[INFERENCE: common practice]` | | Cold chain and in-use storage | Stores and uses the received presentation correctly | Pharmacist reinforces at dispensing; patient follows IFU | Refrigerate at 2 to 8 C, never freeze; room temperature means no more than 30 C. Total room-temperature exposure is cumulative. Never use a previously frozen product. Single-dose pen or vial: up to 21 total days at 30 C or below, then discard. Unopened multi-dose vial or KwikPen at room temperature: discard after 30 days. Opened multi-dose vial or KwikPen: discard after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first | Label supplies concrete limits; no GM temperature-tracking feed recovered, production visibility unknown | `[PUBLIC Zepbound PI §16.2]` | | First-dose start | Reports actual start or explains delay or decline | Patient to care team | T0 with source, or explicit unknown or not started; next-dose plan | Proposed control; no administration endpoint observed | `[INFERENCE: proposed control]` | | Safety event and product complaint | Receives urgency-appropriate clinical direction | Licensed clinician first; reporting owner separately reviews Lilly or FDA reporting | Clinical event and action, product and exposure details, report reference if submitted, follow-up | PI reporting routes observed; GM reporting practice unknown. Reporting is not a substitute for emergency care | `[PUBLIC Zepbound PI §17]` `[E:E16]` | ### 3.8 Prior authorization and claim closure A benefit inquiry is not a PA submission, an approval is not a paid claim, and a paid claim is not dispense. This lifecycle is proposed and must be reconciled with existing DoseSpot, payer portal, Athena and staff processes before building a second queue. | State or event | Owner and handoff | Minimum record | Exit or failure | Evidence | |---|---|---|---|---| | Benefit signal or claim rejection received | Pharmacy or benefit service to a verified PA intake owner | Patient, prescription, product and NDC, payer or PBM, rejection or PA signal, source time | Accepted case ownership, not just a patient notification | `[D:D5.2]` `[D:D9]` | | Requirements and coverage checked | PA specialist plus prescriber | Plan criteria, evidence needed, authorization scope, urgency, submission channel | Missing-evidence task or ready-to-submit; channel currently unknown | `[D:D5.2]` `[F:F6]` | | Submitted | Verified submitter to payer or PBM | Submission timestamp, external receipt or case number, document versions | Acknowledged submission, not inferred from a button click | `[INFERENCE: proposed control]` | | Additional information requested | Payer to case owner to prescriber or patient | Request, deadline, owner, response receipt | Response accepted or deadline escalation | `[INFERENCE: proposed control]` | | Decision | Payer to case owner to patient or pharmacy | Approval or denial reason, covered strength and form, quantity, effective and expiry dates, appeal rights | Approval is not yet a successful fill | `[INFERENCE: proposed control]` | | Re-adjudicated | Pharmacy to PBM | Actual claim outcome, patient liability, savings result | Patient accepts payable amount or chooses another authorized path | `[D:D5.3]` | | Savings and COB | Pharmacy benefit service | Program and offer version, product and presentation, approved-use eligibility, government-program exclusion, permitted pharmacy, quantity and days supply, primary claim outcome, secondary claim result, remaining cap, expiration, patient's accepted price | Missing eligibility or denied secondary claim explained before a replacement cash price | `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` | | Denial, cash, appeal or switch | Prescriber, patient and PA owner | Clinical choice, explicit financial acceptance, appeal deadline, replacement prescription if needed | Do not silently convert to cash or presume reimbursement permitted | `[D:D5.2]` `[E:E16]` | | Dispensed, reversed or abandoned | Pharmacy to care coordination, where supported | Dispense or reversal evidence, patient possession, closure reason | Case closure with evidence; abandoned is not successful care | `[E:E1.3]` | | Next strength or renewal | Prescriber, PA owner and pharmacy | Remaining authorization and refills, next-dose date, product change, lead time | Resolve before a planned interruption; do not auto-escalate | `[E:E8]` `[E:E9]` | ### 3.9 Operational and legal handoffs | Task | Accountable role, proposed | Required handoff or artifact | Current evidence limit | Evidence | |---|---|---|---|---| | Encounter location and clinical authority | Clinical operations or licensed clinical lead | Current physical state, callback, clinician eligibility, furnishing entity, collaboration requirements. If location changes, authority expires, or no eligible clinician exists, hold unsupported care and route to a licensed reviewer. Pharmacy refusal of an NP prescription escalates to the licensure manager | Public modality availability and location route observed; backend enforcement unverified | `[B:B11]` `[C:C5]` `[F:F8]` | | Self-pay estimate | Billing and compliance owner for the furnishing provider | Request or scheduling trigger, uninsured or self-pay status, issuing entity, dated itemized estimate, delivery evidence, dispute intake. Scheduling 3 to 9 business days ahead: deliver within 1 business day. 10 or more business days ahead, or requested before scheduling: within 3 business days. Separately billed labs and pharmacies may issue separate estimates | Prices observed; a compliant good-faith estimate artifact was not recovered | `[PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate]` | | Medical record access, transfer and retention | Record custodian or privacy officer for each relevant entity | Request verification, applicable deadline, export delivery, amendments, retention and legal hold, vendor copies, audio retention. HIPAA documentation must be retained at least 6 years. State medical-record retention varies by jurisdiction and entity; confirm it. Define S3 lifecycle for card images and lab PDFs and a post-sign-off audio policy | No complete retention or custody workflow recovered | `[PUBLIC https://www.law.cornell.edu/cfr/text/45/164.530]` `[PUBLIC https://www.law.cornell.edu/cfr/text/45/164.524]` `[F:F8]` | | Clinical adverse event | Licensed clinical lead | Urgent triage, clinical documentation, care plan; separate reporting review | Generic messaging and label routes observed; completed workflow not observed | `[PUBLIC Zepbound PI §17]` `[E:E16]` | | Dispensing and counseling | Dispensing pharmacy | Product acceptance, counseling, supplies, storage and replacement decision | External channel instructions observed; GM acknowledgment feed unknown | `[PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started]` `[D:D16]` | | Refund | Billing or support owner | Request, policy eligibility, original transaction, amount, execution reference, notice | Visit and lab policies observed; execution system unverified | `[LIVE /refund-policy-labs]` `[C:C4.4]` | | Account closure or treatment stop | Privacy, billing and clinical owners by distinct task | Stop or transfer plan, future-order disposition, financial obligations, retention explanation | Cancellation and decline actions do not establish all closures | `[E:E11]` `[INFERENCE: common practice]` | --- ## 4. Vendor and partner handoff register The six evidence files contain **121 handoff rows**. They collapse to **72 exchange entries** below: one row per company or product per distinct data exchange and mechanism. A row marked `*` is on the cash path, including alternative pharmacy and lab channels. The register spans **32 cash-path entries, 72 total exchanges, and multiple products from single companies**. A mandatory-party count for one journey is not established, and several rows are price feeds rather than prescription handoffs. PHI column: `Yes` marks potentially identifiable health information, not an automatic BAA requirement. `No` means no patient identifier or clinical payload was observed. `Unknown` means the payload was not observable. Determine whether each recipient is a business associate, independent treating provider, payer or another legally permitted recipient. Privacy and legal own the disclosure basis and contract classification; BAA execution status remains unverified. `[PUBLIC https://www.law.cornell.edu/cfr/text/45/164.502]` `[F:F8]` | # | Stage | Counterparty (company / product) | Direction | Data exchanged | Mechanism | Trigger | Who pays / fee | PHI? | Confidence | Evidence | |---|---|---|---|---|---|---|---|---|---|---| | H01* | A | Google, Bing, DuckDuckGo organic search | Inbound | Query, referrer, landing URL, UA, IP | HTTP referral | Organic click | None to GM; SEO cost | No | Observed | `[A:H1]` | | H02 | A | Google Ads | Inbound | `gclid`, `gbraid`, `wbraid`, landing URL | URL query to 7-day cookie to CampaignTouch | Paid click | GM ad spend, unknown | No | Observed | `[A:H2]` | | H03 | A | Microsoft Advertising | Inbound | `msclkid` | URL query to cookie | Paid click | GM ad spend, unknown | No | Observed | `[A:H3]` | | H04 | A | Meta Ads | Inbound | `fbclid`, `_fbc`, synthetic `_fbp`, in-app browser flag | Cookie plus CampaignTouch, no pixel | Paid social click | GM ad spend, unknown | No | Observed | `[A:H4]` | | H05 | A | Kargo | Inbound | `kad_cid` | URL query to cookie | Mobile ad click | GM ad spend, unknown | No | Observed | `[A:H5]` | | H06 | A | OpenAI ChatGPT Ads | Inbound | `oppref` | URL query to cookie | ChatGPT ad click | GM ad spend, unknown | No | Observed | `[A:H6]` | | H07* | A, B | Segment, Twilio | Outbound | Page views, events, email, phone, click IDs, search queries, SKU and price context, tenant slug | JS SDK to `evs.segment.generalmedicine.co` | Every page and action | GM subscription; BAA unknown | Yes at signup | Observed | `[A:H7]` `[B:H17]` | | H08* | A, B | Datadog RUM and Logs | Outbound | Session replay DOM and text, interactions, resources, errors, console logs, user id, flags, API latency | Browser SDK | Every page and action | GM SaaS; BAA unknown | Yes on clinical pages | Observed | `[A:H8]` `[B:H18]` | | H09* | A, B | LaunchDarkly | Outbound | Context key, flag evaluations | React SDK with `useReport` | Every render | GM SaaS | No | Observed | `[A:H9]` `[B:H20]` | | H10 | A, B | Google Analytics 4 | Outbound | Page location, referrer, client id, engagement | `gtag.js`, `G-9WGCRPWTXD` | Marketing page load | Free | No | Observed | `[A:H10]` `[B:H19]` | | H11 | A | OneSignal | Outbound | Push player id, browser, site | Web SDK v16 | Marketing page load | GM SaaS | No | Observed | `[A:H11]` | | H12 | A | Sanity | Inbound | Article and bio content, images | CDN plus build or SSR CMS | Page render | GM SaaS | No | Observed | `[A:H12]` | | H13* | A, B | Google Maps Platform | Both | Address keystrokes, place ids, coordinates, ZIP, map viewport | Maps JS, Places, Geocoding | Address entry and compare drawer | GM API usage | Yes, address | Observed | `[A:H13]` `[B:H6]` | | H14 | A | Vimeo | Outbound | Video requests, referrer, IP | Progressive player | Video play | GM plan | No | Observed | `[A:H14]` | | H15* | A | Netlify, Vercel, CloudFront | Both | Request logs, IP, headers | Hosting and CDN | Every request | GM hosting | No | Observed | `[A:H22]` | | H16 | A, F | Slack | Nile-Core to Slack | Session replay links and alerts | Backend job to Slack webhook, dossier-attributed | PDP, pharmacy or homepage view, deduped one per user per hour | GM Slack plan | Potential | Direction observed; job name and dedupe dossier-attributed | `[A:H23]` `[F]` | | H17 | A | Trustpilot | Outbound link | None beyond the click | Link | User click | None | No | Observed | `[A:H20]` | | H18 | A, F | LegitScript | Outbound link | None beyond the click, badge asset | Link and badge | User click | Certification fee, unknown | No | Observed | `[A:H21]` `[F]` | | H19* | A, E | LillyDirect Pharmacy, price feed | Inbound to GM | Price, NCPDP `1574056`, friendly id `88334` | REST `pharmacy_comparisons` plus directory page | Compare drawer or Lilly page | Margin unknown | No | GM response observed; upstream supplier contact unverified | `[A:H15]` | | H20 | A | NovoCare, price feed | Inbound to GM | Price, NCPDP `5758074`, friendly id `84293` | REST | Compare drawer | Margin unknown | No | GM response observed; upstream supplier contact unverified | `[A:H16]` | | H21* | A | Retail chain price feed, CVS, Walgreens, Walmart, H-E-B, Randalls, Sam's Club | Inbound to GM | Chain, NCPDP, address, distance, `total_price_cents` | REST | Compare drawer | Margin unknown | No | GM response observed; upstream supplier contact unverified | `[A:H17]` | | H22* | A, D | Amazon Pharmacy, price feed | Inbound to GM | Price, NCPDP `5919177` | REST | Compare drawer | Margin unknown | No | GM response observed; upstream supplier contact unverified | `[A:H17]` `[D:H11]` | | H23* | B, C, D, E | Stripe | Both | SetupIntent, payment method, brand, last4, charge, 3DS, refund | REST plus Stripe.js | Card add, visit booking, pharmacy cash checkout | Patient pays; GM processing fee | Yes, payment metadata | Observed | `[B:H21]` `[C:H1]` `[D:H9]` `[E:H10]` | | H24 | B, C | Persona | Persona-related verification routes recovered; browser, vendor and backend transport unverified | Government ID, selfie, name, DOB, inquiry result | Routes and generic pre-visit requirement only; transport and GLP-1 activation unverified | In-person verification and generic pre-visit requirement; GLP-1 trigger unknown | GM per inquiry | Yes | Routes observed; transport and GLP-1 activation unverified | `[B:H22]` `[C:H13]` | | H25* | B, C, E | Twilio Programmable SMS and Verify | Outbound | Phone, 6-digit code, delivery result | REST from a Cognito Lambda trigger | OTP | GM per message | Yes, phone | Observed | `[B:H1]` | | H26* | B, C | AWS Cognito | Both | Phone, OTP challenge and session, tokens, `isExistingUser` | `CUSTOM_AUTH` behind `/auth/*` | Every login and signup | GM per MAU | Yes | Observed | `[B:H2]` | | H27 | B | Google Identity and OAuth | Both | Email, profile, OAuth state, token | Redirect and REST | Google button where enabled; not rendered on DTC | Free | Yes | Observed | `[B:H3]` | | H28* | B | Verified, 1-Click Signup | Both | Phone plus DOB in; name, DOB, sex, email, addresses out | REST via Nile-Core | After OTP on DOB submit | GM per lookup | Yes | Observed | `[B:H4]` | | H29 | B | Verified, 1-Click Health | Both | Name plus DOB to member id, payer, eligibility | REST | DOB submit or insurance step | GM per lookup | Yes | Inferred | `[B:H5]` | | H30 | B | Email validation vendor, unnamed | Both | Email to `isValid` | REST | About-you submit when flag on | GM per validation | Yes | Observed | `[B:H7]` | | H31 | B, C | Waystar | Both | X12 270 and 271: member, payer, service type to eligibility, copay, network, deductible | EDI via connector | Insurance onboarding | GM transaction fee | Yes | Inferred | `[B:H8]` | | H32* | B, C, D, E | Payer and PBM eligibility | Both | Plan, network, copay, deductible, PA rules | EDI 271 via clearinghouse | Eligibility query | Payer adjudicates | Yes | Observed request, inferred payload | `[B:H9]` `[C:H11]` `[D:H14]` | | H33 | B | Payer directory provider, unnamed | Inbound to GM | Payer list, payer ids | `GET /insurances/directory_payers` | Insurance search | GM vendor fee, unknown | No | Observed | `[B:H10]` | | H34 | B | Card OCR provider, unnamed | Both | Card image ids to payer, member id, group, plan, then eligibility | `trigger_card_image_eligibility_check` | Patient photographs card | GM per call | Yes | Inferred | `[B:H11]` | | H35 | B, C, E | AWS S3 | Both | Insurance card, external lab PDF, file ids, presigned URL | Presigned `PUT` then complete | Upload | GM storage | Yes | Observed | `[B:H12]` `[C:H8]` `[E:H14]` | | H36* | B, D, E | Metriport | Both | Identity and consent to FHIR conditions, medications, allergies, procedures | REST and FHIR | HIE lookup, chart prewarm, AI prewarm | GM per retrieval | Yes | Observed | `[B:H13]` `[D:H8]` `[E:H6]` | | H37* | B, D, E | Particle Health | Both | Same clinical domains, availability check | REST | Where Metriport lacks records | GM per query | Yes | Observed | `[B:H14]` `[D:H8]` `[E:H6]` | | H38* | B, C, D, E | Emerald Medical Practice, P.C. and P.A. | Both | Identity, consents, HIE authorization, insurance assignment, clinical record, claims | Click-through consent, assignment of benefits, claims | Signup and every billed encounter | Patient copay or cash; PC bills payer; GM MSO fee unknown | Yes | Observed | `[B:H15]` `[C:H10]` `[D:H1]` `[E:H1]` | | H39 | D, E | Ruby Medical Practice, P.C. and Centennial Medical Practice, P.C. | Both | Same as H38 | Consent plus Visitron assignment | Patient in NJ or ID | Same as H38 | Yes | Observed | `[D:H2]` `[E:H1]` | | H40 | B, D, E | OpenLoop Healthcare Partners, Reliant.MD, MECNB under the Vital consent | Both | Telehealth consultation, consent, state entity, clinician credentials | Network contract plus consent page | If the visit routes to that network | Network bills; GM coordinates | Yes | Inferred trigger | `[B:H16]` `[D:H3]` `[E:H2]` | | H41 | C, F | Trust Commerce | Both | `guarantor_id`, `billing_ids`, single-use token bound to visit and patient | Hosted page plus callback | Mercy tenant billing only | Mercy patient | Yes | Inferred | `[C:H2]` | | H42* | C, D, E | Arrive Health | Both | Patient, drug, pharmacy to copay, deductible, formulary, PA signal, inquiry id | REST and OAuth launch | Pharmacy selection | GM per transaction | Yes | Observed | `[C:H3]` `[D:H7]` `[E:H4]` | | H43* | C, E, F | Junction and Vital | Both | Patient, order, lab test ids, billing type, sample id, status, results, critical webhook, biomarker catalog | REST and webhooks | Lab order and result | Test price plus clinical fee; split unknown | Yes | Observed | `[C:H5]` `[F]` | | H44* | C, E | Quest Diagnostics | Both | Requisition, accession and sample id, specimen, results, PDF | LIS via Junction | Draw | Cash patient pays GM; insurance lab bills insurer | Yes | Observed | `[C:H6]` `[E:H13]` | | H45* | C, E | Labcorp | Both | Same as H44 | LIS via Junction | Draw | Same as H44 | Yes | Observed | `[C:H6]` | | H46* | C, E | BioReference | Both | Same as H44 | LIS via Junction | Draw | Same as H44 | Yes | Observed | `[C:H6]` | | H47* | C | Ordering physician, Junction-assigned or GM clinician | Both | Ordering provider name and NPI, critical-result call, interpretation and sign-off | Junction network or Visitron | Every lab order and every critical result | $15 clinical review; split unknown | Yes | Observed role, inferred mode | `[C:H7]` | | H48 | C | MDSave | Both | `mdsave` price option, `md_save` agreement flag | Offer in booking options | In-person or urgent care only, not 300543 | Patient pays voucher price | Yes | Observed absence on path | `[C:H12]` | | H49* | D, E, F | Athenahealth | Both | Encounter note, diagnoses, orders, care plan, `athena_id` | REST sync and resync | Clinician publishes or plan changes | GM license | Yes | Observed | `[D:H4]` `[E:H5]` `[F]` | | H50* | D, E, F | DoseSpot | Both | Patient context, eligibility, formulary, draft and final Rx, EPCS identity, inbound refills | SSO, REST, NCPDP SCRIPT | Prescribe or renew | GM license | Yes | Observed | `[D:H5]` `[E:H3]` `[F]` | | H51 | D, E, F | Nabla | GM and clinician to Nabla audio and context; Nabla to GM draft and status | Audio, transcript, note draft, status; transmitted content unverified | Embedded scribe | Clinician starts scribe | GM license | Yes | Status operation observed; audio payload unverified | `[D:H6]` `[F]` | | H52* | D, E | LillyDirect Pharmacy, LLC, NCPDP `1574056`, NPI `1912889320` | GM to LillyDirect | Rx, name, DOB, contact, NCPDP id, payment or insurance context | eRx to NCPDP id, phone or fax fallback | Patient selects LillyDirect | Patient pays dispensing pharmacy; GM pay-ahead not available at mail order | Yes | Endpoint observed; downstream product route unverified | `[D:H10]` `[E:H7]` | | H53* | D, E | LillyDirect dispensing pharmacies, Amazon, Fuze Health, Gifthealth, Prescryptive, Walmart | Pharmacy to patient | Verification, checkout link, price, delivery or pickup, tracking, savings applied | SMS, email, checkout | Rx received | Patient pays pharmacy | Yes | Destination set observed; product-level route unverified. Gifthealth publishes NCPDP `3692539` for its self-pay channel | `[D:H16]` `[PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started]` | | H54* | D, E | Amazon Pharmacy, NCPDP `5919177`, NPI `1285084467` | GM to Amazon | Rx, patient identifiers, payment context | eRx to NCPDP id | Patient selects Amazon | Patient pays Amazon | Yes | Observed | `[D:H11]` `[E:H8]` | | H55 | D, E | NovoCare, NCPDP `5758074`, NPI `1710671854` | GM to NovoCare | Rx and patient identifiers, for Wegovy | eRx to NCPDP id | Patient selects NovoCare | Patient pays NovoCare | Yes | Observed | `[D:H12]` | | H56 | D, E | Retail pharmacy, CVS, Walgreens, Walmart, Costco, Safeway, Kroger, Rite Aid, Alto | Both | Rx, NCPDP id, demographics, prepaid notice or GM card, claim | eRx plus NCPDP claim | Patient selects retail | Cash: patient pays GM or pharmacy; insured: PBM pays pharmacy and patient pays copay | Yes | Observed | `[D:H13]` `[E:H9]` | | H57 | D, E | PBM and payer claim adjudication | Pharmacy to PBM | Claim, member id, NDC, days supply, copay, PA | NCPDP Telecommunication | Fill | PBM pays pharmacy | Yes | Inferred | `[D:H14]` | | H58* | D, E, F | Lilly and Novo savings programs, EVERSANA PTR | Manufacturer to pharmacy and patient | Savings card BIN and PCN, eligibility, PTR claim; offer version, payer eligibility, caps and actual redemption unverified | Pharmacy claim plus manufacturer PTR at `eversana-ptr.virtualrx.co` | Eligible fill | Manufacturer funds; patient pays reduced copay | Yes | Program terms published; GM eligibility and redemption unverified | `[D:H15]` `[PUBLIC https://zepbound.lilly.com/savings]` | | H59 | D, E | Retail or LillyDirect pharmacy to GM | Inbound | Refill request, Rx status, rejection, PA request | eRx inbound, fax, phone, message subject `pharmacy_order` | Refill or claim issue | No direct fee | Yes | Observed | `[D:H17]` | | H60 | D, E | GM operations to payer, PA submission | Outbound | PA form, chart evidence, letter of medical necessity, appeal; lifecycle in §3.8 | Unknown: portal, fax, or phone; no ePA evidenced | PA required or denied | GM staff time | Yes | Inferred; channel unknown | `[D:H18]` | | H61* | D, E, F | Zoom | Outbound | Unique meeting URL, meeting id, passcode | Link by SMS and email | Video visit booked | GM pays Zoom | Yes | Observed | `[D]` `[E:H12]` | | H62 | E | Twilio Conversations and SMS short code 98528 | Both | Chat token, messages, attachments, SMS | JWT plus REST | Patient messages or receives reminder | GM per message | Yes | Observed | `[E:H11]` | | H63* | E | Email provider, unidentified | Outbound | Visit link, lab notice, prescription notice, care plan | Email API or SMTP | Events | GM vendor | Yes | Observed channel, vendor unknown | `[E:H15]` | | H64 | E | Braintrust | Outbound | AI span score, thumbs category and comment | `/api/chat/feedback` | Patient rates an AI answer | GM | Potential | Observed | `[E:H16]` | | H65 | E, F | Databricks and Metabase | Internal | Warehouse tables to dashboards | Metabase Databricks driver | Analyst query | Unknown | Potential | Observed | `[E:H17]` `[F]` | | H66* | E | Eli Lilly, IFU and Medication Guide, MedWatch | Lilly to patient labeling; patient or clinician to Lilly or FDA safety report | Instructions for use, adverse-event and product-complaint report | Paper insert, LillyDirect, 1-800-LillyRx, FDA MedWatch | First fill, side effect or product complaint | Patient pays drug and needles | Yes for the report; No for the label | Observed routes; GM reporting practice unknown | `[E:H18]` `[PUBLIC Zepbound PI §17]` | | H67 | E, F | Zendesk | Internal | Async chat and triage threads, clinician replies, attachments | Agent workspace | Chat visit or triage message | Subscription | Yes | Observed | `[F]` | | H68 | F | Ashby | Both | 16 requisitions, applications | Hosted job board and API | Recruiting | Plan | No | Observed | `[F]` | | H69 | D, F | CMS NPPES and NPI Registry | Outbound query | NPI, legal name, address, taxonomy | Public API | Entity verification | None | No | Observed | `[D:source appendix]` | | H70 | F | CMS Medicare Part D and GLP-1 Bridge | Payer program | Part D enrollment, bridge eligibility, covered product and presentation, PA. The bridge is time-limited and names Zepbound KwikPen; do not generalize to all tirzepatide or all Medicare patients | Program rules, no GM API observed | Medicare patient | Medicare pays; eligible bridge patient at most $50 per month | Yes | Published terms; GM integration not observed | `[PUBLIC https://www.medicare.gov/coverage/weight-loss-drugs]` `[D:D4.4]` | | H71 | E | LLM provider, vendor unknown, via Promptimus and copilot | Outbound | Prompt context, health records, messages, care-plan draft | API | AI draft or patient chat | GM contract unknown | Yes | Inferred | `[F:F3.3]` | | H72 | F | Google OAuth and AWS Cognito, staff plane | Both | Staff identity, extension token | OAuth code flow, `/api/internal_oauth` | Admin login | Unknown | No | Observed | `[F]` | --- ## 5. Integration sequence diagrams ### 5.1 Sign-up and identity ```mermaid sequenceDiagram autonumber participant P as Patient participant W as Storefront participant N as Nile-Core participant C as AWS Cognito participant T as Twilio participant V as Verified participant S as Segment participant D as Datadog P->>W: Enter US mobile number W->>N: POST /auth/initiate N->>C: CUSTOM_AUTH challenge C->>T: Send 6-digit OTP T-->>P: SMS code P->>W: Enter code W->>N: POST /auth/login N->>C: Verify session C-->>W: HttpOnly session cookie P->>W: Enter date of birth W->>N: POST /api/external/verified N->>V: Phone and DOB lookup V-->>N: Name, sex, email, addresses N-->>W: Autofill profile alt Match found P->>W: Confirm autofilled details else No match or timeout W-->>P: Manual about-you form, no error shown end P->>W: Accept six consents and continue W->>N: POST /api/external/patients N-->>W: Patient id, signup channel. HIE notice is not returned by the API W-->>P: Redirect to /welcome or /ai/onboarding opt SignupTracker mounts, fetchUser succeeds, analytics available W->>S: signup_complete and identify with email and phone W->>S: alias with user id only end W->>D: RUM session and replay ``` Note: the Segment calls are guarded and were not observed on the GLP-1 redirect path. `signup_complete` and identify carry email and phone; alias carries only the user ID. The HIE notice and PDF opt-out were observed on the manual about-you form only, not on the Verified review-info path. ### 5.2 Insurance eligibility ```mermaid sequenceDiagram autonumber participant P as Patient participant W as Insurance screen participant N as Nile-Core participant E as Eligibility service participant Y as Clearinghouse participant Pay as Payer participant S as S3 P->>W: Choose payer or photograph card opt Card photo W->>S: Presigned PUT of front and back images W->>N: trigger_card_image_eligibility_check end W->>N: enqueue_eligibility_check opt Discovery is used N->>E: Name and DOB discovery E-->>N: Member id and payer, or no match end N->>Y: X12 270 eligibility Y->>Pay: 270 inquiry alt Response received Pay-->>Y: 271 response Y-->>N: Copay, network, deductible N-->>W: insurance_status else Pending, timeout or error Y-->>N: No usable response N-->>W: Pending or unknown end alt In network W-->>P: Show 25 dollar estimate else Not found, out of network or unknown W-->>P: Offer retry or continue without insurance at 100 dollars end ``` Note: illustrative backend flow. The discovery vendor, clearinghouse protocol and payer response were not observed for this journey. ### 5.3 Visit, prescription, and pharmacy, cash LillyDirect and insured retail ```mermaid sequenceDiagram autonumber participant P as Patient participant W as Storefront participant VN as Visitron participant DS as DoseSpot participant AH as Arrive Health participant AT as Athenahealth participant MP as Metriport participant LD as LillyDirect participant DP as Dispensing pharmacy participant RP as Retail pharmacy participant PBM as Payer PBM participant ST as Stripe P->>W: Book and pay visit fee W->>ST: SetupIntent or charge W->>VN: Create appointment VN->>MP: Prewarm chart and prior records VN->>DS: RTPB and formulary inquiry DS-->>VN: Coverage and PA signal VN->>AH: Benefit inquiry with drug and pharmacy AH-->>VN: Copay, formulary, PA signal VN->>DS: Finalize Rx VN->>AT: Sync signed encounter and care plan W-->>P: Care plan and prescription card P->>W: Open pharmacy order and choose pharmacy W->>AH: RTPB for selected pharmacy alt Cash LillyDirect DS->>LD: eRx to NCPDP 1574056 LD->>DP: Route to dispensing pharmacy DP-->>P: Checkout link and delivery options P->>DP: Pay dispensing pharmacy DP-->>P: Ship 1 to 4 days else Insured retail DS->>RP: eRx to selected NCPDP id RP->>PBM: Submit claim alt PA required PBM-->>RP: Reject for PA RP-->>P: PA notice and wait Note over P,PBM: No PA case contract recovered, several business days else Paid PBM-->>RP: Paid claim RP-->>P: Dispense or pickup notice end end ``` Note: the cash branch pays the dispensing pharmacy once. Mail order is excluded from GM pay-ahead. `1574056` is GM's observed LillyDirect row; product-level routing may differ. ### 5.4 Baseline labs via Junction ```mermaid sequenceDiagram autonumber participant P as Patient participant W as Storefront participant N as Nile-Core participant J as Junction Vital participant L as Quest or Labcorp or BioReference participant C as Clinician participant O as Ordering physician Note over P,C: Order may be pre-start or post-start, and does not gate every first fill P->>W: Buy panel 503263 and choose network W->>N: Create lab order and charge 86.58 N->>J: Lab order with patient and test ids J->>L: Requisition and order P->>L: Walk-in or scheduled draw L-->>J: Specimen, accession, result J-->>N: Result payload opt Critical value J->>O: Immediate phone call to ordering physician Note over J,O: Critical call does not wait for routine review, acknowledgment is unverified end N->>C: Result in Updates and chart alt Result abnormal C-->>P: Clinical outreach and next step else Result normal N-->>P: Dashboard card and PDF end ``` Note: lab ordering and pharmacy fulfillment are separate flows. If the clinician requires pre-start labs, the pharmacy order waits for result review; otherwise it does not. ### 5.5 Week-4 check-in and phase change to 5 mg ```mermaid sequenceDiagram autonumber participant P as Patient participant W as Storefront participant N as Nile-Core participant VN as Visitron participant C as Clinician participant DS as DoseSpot participant PH as Pharmacy participant PBM as Payer PBM Note over P,C: Proposed target: start refill work T+14 to T+18 and backward-plan from T+28. GM trigger unverified P->>W: Complete check-in questionnaire and optional labs W->>N: Submit criteria responses N->>VN: Unlock pending review VN->>C: Present check-in, labs, and AI draft C->>VN: Apply review and change phase to 5 mg VN->>DS: New Rx for 5 mg P->>W: Open new pharmacy order W->>PH: Select pharmacy DS->>PH: Transmit eRx for 5 mg alt Cash P->>PH: Pay pharmacy at checkout PH-->>P: Dispense second box else Insured PH->>PBM: Claim for 5 mg alt PA required for new strength PBM-->>PH: Reject for PA PH-->>P: Delay, new PA needed else Paid PBM-->>PH: Paid claim PH-->>P: Dispense second box end end ``` Note: cash does not route through the PBM. A same-strength refill may already have refills available; a new strength requires an appropriate new prescription. --- ## 6. Data, states and events ### 6.1 Core objects | Object | Key fields | Owner | States observed | Authority | Evidence | |---|---|---|---|---|---| | Patient | id, name, DOB, sex at birth, phone, email, address, consents, attribution, `signup_id`, `signup_sku_id`, `signup_channel` | Nile-Core | anonymous, authenticated, patient record, blocked, closed | API fields observed; account lifecycle partly inferred | `[B:B7]` `[E:E16]` | | SKU | id, category, state, `allows_video_visit`, `allows_chat`, `allows_econsult`, `allows_first_fill`, `allows_refill`, `allows_referral`, `indexable`, `page_content`, `component_order` | Catalog | `enabled`, `dark_launched`, `disabled`; pathways draft, published, archived | Catalog operation inventory | `[F:F1]` `[F:F0.1]` | | SKU option | modality, cash price, insurance price, `primary`, availability promise | Catalog | video, chat, econsult, in-person; cash or insurance sub-option | Live API payload | `[A:A5.1]` | | Questionnaire | screening id, history id, question order, `questionnaire_length`, version, edit approval | Catalog | draft, edit requested, applied, published | Catalog operations; content unrecovered | `[F:F2]` | | Question response | questionnaire id, question id, answer, read state | Nile-Core | unanswered, answered, read | API fields | `[B:B11]` | | Visit | id, SKU, modality, clinician, `scheduled_time`, `state`, `meeting_url`, billing type, price | Nile-Core | The client UI classifier maps `booked`, `scheduled`, `confirmed`, `awaiting_confirmation`, `ready_for_visit`, `held`, `in_progress`, `canceled`, `hold_expired`, `patient_no_show`, plus other care-action strings | UI classifier; server enum and transitions unverified | `[CODE components/CareActions/careActionSection.ts:40-89]` | | Care::Plan | `care_id`, `plan_id`, state, next steps, `patient_instructions`, `patient_rationale` | Visitron | The UI classifier maps six preparation strings under care plans: `awaiting_curation`, `awaiting_external_work`, `awaiting_generation`, `in_review`, `awaiting_first_send`, `awaiting_curation_send`. `sent` is a shared terminal state, not exclusively a plan state | UI classifier only; server enum and transition order unverified | `[E:E1]` `[CODE components/CareActions/careActionSection.ts:64-78]` | | CarePathway and phase | `pathway_id`, ordered phases, `phase_id`, modality, linked SKUs | Catalog | draft, published, archived | Catalog operation inventory | `[E:E1.2]` | | CareJourney criteria | type Lab, Questionnaire, or Visit; `status`, `locked`, `available_at`, `deadline`, `estimated_minutes`, lab bundle metadata | Server-side criteria set | locked, available, completed | Generic criteria API; GLP-1 set unrecovered | `[E:E1.2]` `[E:E6]` | | NextStep and NextStepCard | kind, `deadline`, `assigned_by`, `snooze`, `dismiss`, `due_date`, `open_to_renew` | Nile-Core | open, snoozed, dismissed, completed | API fields; eight card kinds observed | `[E:E5]` `[E:E9]` | | NextStepReview | `proposed_json`, `final_json`, decision, rationale | Visitron | draft, applied, rejected, confirmed | Operation names recovered; field names dossier-attributed, not first-party contracts | `[F:F3.3]` | | Prescription | id, drug, strength, form, quantity, days supply, refills, SIG, pharmacy NCPDP id | DoseSpot and Nile-Core | draft, finalized, transmitted, renewal required | Visitron and DoseSpot operations | `[D:D8]` | | PharmacyOrder | id, `medication_option_sku_id`, NCPDP id, `billing_type`, cash and insurance price, `state`, cancel and switch flags | Nile-Core | client exposes a state string plus cancel and switch flags; four-state sequence is a dossier hypothesis | Cancellation response fields; authoritative enum unverified | `[D:D11-D15]` `[E:E1.3]` | | LabOrder | id, SKUs, network, `accession_number`, `scheduled_at`, `lab_vendor_name`, `clinical_fee`, result status | Nile-Core and Junction | `received`, `collecting_sample`, `sample_with_lab`, `completed` | API and data model; authoritative enum unverified | `[C:C19-C21]` | | Insurance policy | payer, member id, group, network status, copay, onboarding state | Nile-Core | discovered, queued, checked, activated, failed | Context and API fields | `[B:B9]` | | Conversation | id, subject category (`visit`, `lab`, `pharmacy_order`), `response_expectation`, messages, attachments | Nile-Core and Twilio | open, unread, read, closed | API fields | `[E:E3]` | | Payment method | id, brand, last4, expiry, default flag, Stripe token | Stripe | active, deleted, default | Stripe fields | `[C:C4.7]` | ### 6.2 State machines that matter **Pharmacy order.** The four-state sequence `created → pharmacy_selected → order_placed → dispensed` is a dossier hypothesis, not an observed authoritative state machine. The inspected client exposes a state string plus `can_cancel_pharmacy_order`, `can_switch_pharmacy`, and `can_choose_new_pharmacy` in a cancellation response. No acknowledgment, rejection, dispense or tracking field was recovered; a server-side feed may exist outside the inspected surfaces. `[D:D5.4]` `[E:E7]` **Care plan and next-step review.** These are separate objects. The UI classifier contains six care-plan preparation strings plus `sent` as a shared terminal state. Their membership in a server `Care::Plan` enum and the transition order are unverified. Visitron exposes review-generation, edit, apply, confirm and reject operations. The `proposed_json` and `final_json` field names are dossier-attributed, not recovered first-party contracts. `[E:E1]` `[F:F3.3]` `[CODE components/CareActions/careActionSection.ts:64-78]` **Care journey.** Criteria are typed Lab, Questionnaire, or Visit, with `locked`, `available_at`, `deadline`, and status. The recovered API is generic and handles feature-disabled 404s. The GLP-1-specific schedule, blocking rule and exceptions are server-side and were not recovered. `[E:E1.2]` **Visit.** The client UI classifier contains visit-related state strings, including `held` and `hold_expired`, plus terminal `canceled` and `patient_no_show`. Fee-eligible visit types are video only. The server enum, count and transition rules are unverified. `[CODE components/CareActions/careActionSection.ts:40-89]` **SKU and pathway.** SKUs use `enabled` and `dark_launched`; pathways use draft, published, archived. A launch is a Catalog content operation, not a deploy. `[F:F0.1]` ### 6.3 Analytics events observed | Group | Events | Properties worth noting | Evidence | |---|---|---|---| | Landing | `page`, `landing_page_loaded`, `landing_page_frames_dwell`, `ad_landing_page_view` | path, URL, title, referrer, search, `tenant_slug`, `sku_id`, TTFB, DCL, LCP, cache hit, auth flag, frame dwell | `[A:A2]` | | Storefront | `sf_viewed_detail_page`, `new_storefront_pdp_viewed`, `sf_clicked_sku`, `sku_page_cta_clicked`, `new_storefront_request_medication_clicked`, `sku_page_variant`, `sku_sticky_cta_variant` | SKU object with price, variant, button type, latency timer | `[A:A4]` | | Search | `sf_search_start`, `sf_search_query`, `sf_submitted_search`, `sf_viewed_search_results`, `sf_viewed_search_results_failure` | Raw query and full suggestion array, result count and ids | `[A:A11]` | | Signup | `signup_page_viewed`, `signup_referrer`, `signup_step_phone`, `signup_step_otp`, `otp_send_requested`, `otp_completed`, `otp_first_digit_entered`, `otp_resend_requested`, `otp_submit_attempted`, `otp_verified`, `otp_screen_abandoned`, `signup_complete`, `merge_identity` | Email and phone in both `signup_complete` and identify; click ids; `signup_channel`; OTP telemetry excludes phone and code by rule | `[A:A7]` `[B:B2]` `[CODE components/SignupTracker.tsx:16-98]` | | Checkout | `visit_id`, `sku_id`, `billing_type`, `insurance_status`, `price_cents`, `cancellation_fee_shown`, `within_24_hours`, agreement flags, `price_guaranteed`, `price_fallback` | Funnel render and click events | `[C:C8]` | | Care | `ns_` namespace, 17 events; `PATIENT_RATIONALE_VIEWED`, `PATIENT_RATIONALE_FEEDBACK`, dashboard 1.0 and 1.5 event sets | Next steps, rationale, dashboard version | `[F:F4.1]` | | Insurance | `ssi_` namespace; `booking_no_medicaid_option`, `booking_no_availability` | Payer, network, plan category | `[F:F6]` | | Experiments | `EMAIL_VALIDATION_VARIANT`, `SKU_PAGE_VARIANT`, `SKU_STICKY_CTA_VARIANT` | Flag key, anonymous id, Datadog session id | `[F:F4]` | | Errors | `client_error`; Datadog `nile-core-api-request` | Method, normalized path, status, latency | `[A:A3.1]` `[F:F4.1]` | Two gaps matter. No event was observed for a pharmacy dispense, a dose taken, a weight measurement, or a PA outcome; production may track these outside the inspected surfaces. And `signup_complete` and identify both carry email and phone, but both are guarded by tracker mount, `fetchUser`, analytics availability and a local flag, so firing on the Lilly and GLP-1 CTA path was not observed. `[A:A8]` `[CODE components/SignupTracker.tsx:16-98]` ### 6.4 Where PHI flows BAA status is unknown for every vendor flow because no BAA inventory was observed. | Flow | What leaves | Recipient | BAA status | Risk | Evidence | |---|---|---|---|---|---| | Browser to Segment | Email, phone, GLP-1 SKU and condition context, raw search queries, click ids | Segment, then unknown destinations | Unknown | High: re-identification plus health interest | `[A:H7]` `[B:H17]` `[A:A3.4]` | | Browser to Datadog | Recovered replay configuration would capture DOM text, interactions, resources and errors; an explicit phone masking marker was found. Other component rules and effective runtime masking remain unverified; capture of specific GLP-1 questionnaire answers, retention and destination access were not verified | Datadog | Unknown | High-priority privacy review; asserted answer capture is not established | `[A:H8]` `[A:A3.4]` `[CODE components/Inputs/PhoneInput.tsx:158]` | | Browser to Google Maps | Home address keystrokes, coordinates | Google | Unknown | Medium | `[B:H6]` `[A:H13]` | | Browser to Verified | Browser sends phone and DOB to GM; GM then calls Verified. A direct browser-to-Verified call was not observed | Verified | Vendor claims HIPAA, no BAA observed | High | `[B:H4]` `[B:H5]` | | Browser to S3 | Insurance card images, external lab PDFs | AWS | Unknown | High | `[B:H12]` `[C:H8]` | | Nile-Core to Waystar and payer | Eligibility request and response; exact X12 270/271 payload unverified | Waystar, payer | Unknown | High | `[B:H8]` `[B:H9]` | | Nile-Core to Metriport and Particle | Identity, consent, FHIR conditions, meds, allergies, procedures | HIE vendors | Unknown | High | `[B:H13]` `[B:H14]` | | Nile-Core to Slack | Session replay links to `#session-replay-new-storefront` | Slack | Unknown | Medium: link access | `[A:H23]` | | Nile-Core to Databricks and Metabase | Product and clinical events, dashboards | Internal BI | Internal use; the Metabase login shell is publicly reachable and the reviewed response requires sign-in | Medium: network exposure; unauthenticated data access not established | `[E:H17]` `[F:F4.1]` | | Visitron to Athena and DoseSpot | Encounter, diagnoses, orders and prescriptions; exact payloads unverified | EHR, eRx | Unknown | High | `[D:H4]` `[D:H5]` | | Nabla integration | Status operation recovered; audio/context submission and returned transcript or draft are attributed workflow, not observed payloads. Direction, content and retention require verification | Scribe | Unknown | High | `[D:H6]` `[F]` | | GM to Arrive Health | Patient, drug, pharmacy, benefit context | Arrive | Unknown | High | `[D:H7]` `[E:H4]` | | Patient to Twilio and Zendesk | Phone, SMS and chat content, attachments | Twilio, Zendesk | Unknown | High | `[E:H11]` `[F]` | | GM to LLM provider | Prompt context, health records, messages | Vendor unknown | Unknown | High | `[F:F3.3]` `[E:H16]` | | GM to pharmacy and lab | Prescription, demographics, order, results | Pharmacies, labs | Determine each recipient's role: independent treating provider or business associate. HIPAA minimum necessary does not apply to provider treatment disclosures; assess BAA and data minimization by relationship | Medium: role and contract dependent | `[D:H10-H13]` `[C:H6]` `[PUBLIC https://www.law.cornell.edu/cfr/text/45/164.502]` | | GM to email provider | Visit links, lab-result notices, prescription notices | Vendor unknown | Unknown | Medium | `[E:H15]` | The privacy notice says PHI is handled under BAAs "that General has in place with Emerald Providers" and discloses business associates for technology, transcription, billing, and collection. No subprocessor list or BAA text was found. `[F:F8]` --- ## 7. Money map ### 7.1 Who pays whom Capture timing is inferred for visit fees. The checkout shows "Due Today", the cancellation policy says already-paid fees are refunded automatically, and the assignment of benefits allows an up-front estimate, but no charge object or auth-then-capture call was recovered. `[C:C4.1]` | Path | Payer | Payee | When | Amount | Basis | |---|---|---|---|---|---| | Cash visit | Patient | GM via Stripe | At booking | $100 video, $30 chat | `[C:C4.1]` | | Insured visit | Patient | GM or PC at booking | At booking, estimate | $25 estimated copay | `[C:C4.1]` | | Insured visit claim | Payer | PC | After claim | Unknown, contract rate | `[B:B15]` | | Clinician labor | GM | 1099 clinician | Per completed visit | $50 video or $12 chat for MD; $35 or $8 for NP | `[F:F3.4]` | | Lab, cash | Patient | GM via Stripe | At lab checkout | Test price plus $15.00 | `[C:C4.3]` | | Lab, wholesale | GM | Lab through Junction | Per order | Unknown | `[C:C4]` | | Lab, insured | Payer | Lab | After claim | Unknown; `insurance_price` null | `[C:C4.3]` | | Drug, cash pre-pay at retail | Patient | GM via Stripe | At pharmacy checkout | Sampled retail $496.12 to $508.09 for the starter KwikPen; $299 is the direct-mail price. Pay-ahead only if offered for the selected pharmacy | `[D:D4.3]` `[LIVE /api/external/pharmacy_comparisons]` | | Drug, retail counter with GM card | Patient | Pharmacy | At pickup | Discounted cash price | `[D:D4.3]` | | Drug, mail order | Patient | LillyDirect dispensing pharmacy or Amazon | At pharmacy checkout link | $299, $399, or $449 | `[D:D4.3]` | | Drug, insured | Payer | Pharmacy | Claim | Contract rate; patient copay | `[D:D4.3]` | | Manufacturer savings | Lilly or Novo | Pharmacy or patient | At adjudication | Reduces patient copay | `[D:D4.4]` | | Cancellation fee | Patient | GM | Within 24 hours or no-show | $25 fallback, video only | `[C:C4.4]` | | Refund, visit | GM | Patient | After eligible cancellation | Visit fee, 5 to 10 business days | `[C:C4.4]` | | Refund, lab | GM | Patient | Request within 6 months of purchase if sample not collected | Full amount, no deduction; collection ends eligibility | `[LIVE /refund-policy-labs]` | | Pharmacy routing | Unknown | Unknown | Per fill | No fee or spread field observed | `[D:D4.6]` | ### 7.2 Illustrative cash outlay through purchase of the second fill Assumes a video visit at E0, one Quest Comprehensive GLP-1 panel, the 2.5 mg KwikPen at LillyDirect or Amazon, a week-4 video follow-up, and the 5 mg KwikPen. This is two 28-day drug purchases, not one month of medicine. | Line | Amount | Evidence | |---|---:|---| | Initial visit plus first 28-day supply | $399.00 | $100 visit + $299 2.5 mg. `[LIVE /api/external/sku_options/300543]` `[LIVE /api/external/medication_option_skus/710641/cash_price]` | | Initial visit, first supply and Quest panel | $485.58 | Add $86.58. `[LIVE /api/external/lab_skus/503263]` | | GLP-1 evaluation, video cash | $100.00 | `[LIVE /api/external/sku_options/300543]` | | Comprehensive GLP-1 panel, Quest cash | $86.58 | `[LIVE /api/external/lab_skus/503263]` | | Zepbound KwikPen 2.5 mg, 28 days | $299.00 | `[LIVE /api/external/medication_option_skus/710641/cash_price]` | | Week-4 follow-up, video cash | $100.00 | `[LIVE /api/external/sku_options/300550]` | | Zepbound KwikPen 5 mg, 28 days | $399.00 | `[LIVE /api/external/medication_option_skus/710643/cash_price]` | | **Two-fill total** | **$984.58** | Arithmetic on observed prices; calendar timing depends on the journey | | Same two-fill scenario without panel | $898.00 | `[E:E4.5]` | | Same two-fill scenario with chat visits | $844.58 | $30 plus $30 visits | | Default auto-injector instead of KwikPen | $2,434.76 to $2,486.90 | $1,074.09 or $1,100.16 twice, plus visits and panel; assumes the same unit price on both fills. Re-quote the 5 mg SKU | | Retail cash instead of direct | $1,278.82 to $1,302.76 | $496.12 or $508.09 twice, plus visits and panel; same assumption | ### 7.3 Illustrative insured non-drug subtotal Assumes a commercial plan, in-network video visits at day 0 and week 4, one lab order, and a covered drug after PA. The medication check-in itself may not require a paid visit. Medication copay and lab deductible, coinsurance or uncovered charges are not observable before adjudication. | Line | Amount | Evidence | |---|---:|---| | GLP-1 evaluation, video insured | $25.00 estimated | `[LIVE /api/external/sku_options/300543]` | | Week-4 follow-up, video insured, if booked | $25.00 estimated | `[LIVE /api/external/sku_options/300550]` | | Lab clinical review fee | $15.00, not covered by insurance | `[CODE components/Labs/AboutLabPricing.tsx:42-45]` | | Drug liability for both fills | Unknown; `insurance.price` is null on every GLP-1 medication SKU | `[LIVE medication_option_skus]` | | Lab deductible, coinsurance or uncovered charges | Unknown; `insurance_price` is null | `[LIVE /api/external/lab_skus/503263]` | | **Estimated non-drug subtotal, no paid week-4 visit** | **$40.00 plus both fills and lab liability** | $25 initial visit + $15 lab review; async check-in assumed. Arithmetic on estimates | | **Estimated non-drug subtotal, paid week-4 visit** | **$65.00 plus both fills and lab liability** | Add $25 follow-up. Arithmetic on estimates; final total unknown | | If PA is denied and the patient pays cash | Add $299.00 and $399.00 | `[D:D5.2]` | | If covered commercial and the single-dose pen card applies | As little as $25 per eligible 1-, 2- or 3-month fill, not per month. Caps $100/$200/$300 for those fills, $1,300 per calendar year, up to 13 fills. Card expires 2026-12-31 | `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` | | If not covered and the single-dose pen card applies | As low as $499 per month for not-covered commercial single-dose pen, subject to current terms | `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` | | Eligibility boundaries | Government beneficiaries including Medicare, Medicaid, TRICARE and VA are excluded from commercial cards. The prescription must be for an approved use consistent with labeling; off-label use is not an approved use. Secondary claim and actual redemption are not observed | `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` `[PUBLIC Zepbound PI §1]` | Note: the KwikPen self-pay ladder is cash-only and excludes insurance reimbursement. A patient cannot combine the $299 KwikPen price with a commercial claim. The insured path and the cash path are mutually exclusive at the fill. `[PUBLIC https://zepbound.lilly.com/savings]` ### 7.4 GM revenue lines versus pass-through | Line | Observed amount | Treatment | Evidence | |---|---|---|---| | Visit fee | $100 cash or $25 insured estimate | GM or PC revenue; clinician fee is a variable cost | `[C:C4.1]` `[F:F3.4]` | | Clinician labor | $50 or $35 video, $12 or $8 chat | Variable cost, not revenue | `[F:F3.4]` | | Lab clinical review fee | $15.00 per order | Revenue; split with ordering physician unknown | `[C:C4.3]` | | Lab test price | $71.58 Quest for 503263 | Pass-through or spread; wholesale cost unknown | `[C:C4.3]` | | Platform, order, collection fees | $15.00 to $40.00 platform, $6.00 order, $3.00 to $9.00 collection. Panel 503263 returns $40.00 platform, $6.00 order and $9.00 Quest collection | Returned by API but outside `total_cash_price`; accounting treatment and whether any is charged are unknown. Do not book as margin or add as a patient charge without settlement evidence | `[F:F5.2]` `[LIVE /api/external/lab_skus/503263]` | | Drug price | $299, $399, $449 | Manufacturer self-pay price; no GM margin field or contract observed | `[D:D4.2]` `[D:D4.6]` | | Pharmacy routing and GM card | No fee field | Economics unknown | `[D:D4.6]` | | Enterprise licensing | Not disclosed | Walmart Better Care Services, Mercy white-label | `[F:F5.3]` | **The unit-economics read.** These are illustrative encounter contributions before other direct costs, assuming the posted contractor fee and full collection. They are not observed GM gross margin, recognized revenue or current provider mix. A cash video visit contributes about $50 with an MD or $65 with an NP before overhead. An insured $25 video visit is negative $25 with an MD and negative $10 with an NP before any payer claim. Chat is the best contribution per clinician dollar: $18 with an MD, $22 with an NP on a $30 cash chat. The employed model implies about $46 to $51 of physician labor per visit at full density. `[INFERENCE from observed prices and posted fees]` `[F:F5.3.1]` Note: evidence-F §5.3.1 models a $25 insured chat row, but the live GLP-1 SKUs offer chat as $30 cash only, with no insurance sub-option. Do not use an insured-chat contribution for this path. `[D:D0.3]` `[LIVE /api/external/sku_options/300543]` --- ## 8. Operating model ### 8.1 Roles | Role | Entity | Tool or queue | What they do on this path | Observed pay and hours | Evidence | |---|---|---|---|---|---| | Full-time physician | GM clinical | Athena, Zoom, Zendesk, Slack, Nabla, Visitron | 20-minute video visits, async chat, prescribing, care-plan sign-off | $180k to $200k plus equity and malpractice; 36 clinical hours per week; DEA required | `[F:F3.1]` `[F:F3.4]` | | 1099 physician | GM panel | Same plus Visitron | Video and chat visits alongside another practice | $50 per video, $12 per chat; 10 to 12 hours per week; multistate licensure 20 to 30 percent of US population | `[F:F3.4]` | | 1099 nurse practitioner | GM panel | Same | Video and chat visits under collaborative agreements where required | $35 per video, $8 per chat; 12 to 15 hours per week; licensure at least 30 percent of US population | `[F:F3.4]` | | Medical Director | Emerald PCs | Visitron, Provider Chat | Clinical oversight, protocol approval, guide review, prompt tuning | Not posted | `[D:D3]` | | Clinical operations lead | GM | Cross-portal | Builds clinical teams, policies, partnerships | Not posted | `[F:F3.1]` | | Clinician training lead | GM | Training program | Trains every new clinician before first patient | Not posted | `[F:F3.1]` | | Care coordinator | GM operations | Athena, phone, Referrals | Scheduling, reminders, calls to patients, provider offices, insurers, labs; referral and authorization paperwork | $22 per hour, full-time, remote | `[F:F3.1]` | | Operations Manager and Director | GM operations | Referrals plus internal tools | Line management, referral and scheduling operations | Not posted | `[F:F3.1]` | | Manager, NP licensure and collaborative practice | GM | State boards, no internal portal | Maintains CPA templates, collaborating-physician bench, primary-source verification, state filings, pharmacy refusal escalations | Not posted | `[F:F3.1]` | | Catalog operator | GM clinical product | Catalog, 106 operations | Authors SKUs, phases, criteria, questionnaires, lab panels, codes, prompts | Not posted | `[F:F0.1]` | | Prompt engineer and medical director | GM | Provider Chat, Promptimus, Visitron test harness | Tests prompts, models, temperature; reviews thumbs-down clusters | Not posted | `[F:F3.3]` | | RCM Director and VP | GM finance | Waystar, payer portals | Patient access, authorization, coding, billing, denials, collections, payer contracts | Not posted; authorization explicitly in scope | `[F:F3.1]` | | Support agent | GM | SMS 98528, Message Center, phones (801) 251-6055 and (801) 255-6051, emails help@generalmedicine.co, hello@generalmedicine.co, support@navhealth.co | Refunds, cancellations, pharmacy and lab questions | Not posted; Mon to Fri 9 to 9 ET, a 12-hour window. Individual clinician shifts are 4 to 6 hours inside it | `[C:C3]` `[F:F3.2]` `[E:E3]` | | Pharmacist | Partner pharmacy | Pharmacy system | Verify, adjudicate, counsel, dispense, collect | Not posted | `[D:D3]` | | Engineering on-call | GM | Datadog, Visitron, Nile-Core | Integration outages, stuck encounters, eRx failures | Not posted | `[D:D3]` | Clinicians are contracted or employed by the state PCs or the delegated network and scheduled through Visitron; the MSO employs non-clinical staff and runs the platform. The state-to-PC assignment is server-side and unresolved. `[F:F8]` `[D:D3]` ### 8.2 Queues, tools, SLAs, hours | Queue | Object | Assignment | Observed SLA or timing | Evidence | |---|---|---|---|---| | Visitron appointment list | Appointment | Clinician sees own schedule; no claim primitive | Video promise "today"; chat next slot timestamp | `[F:F3.2]` | | Video capacity | Visit | Scheduled block | 20 minutes per visit, max 9 per 4-hour block, 36 clinical hours per week | `[F:F3.2]` | | Chat and triage | Chat visit | Zendesk queue | 3-hour response window | `[F:F3.2]` | | Draft encounter | Encounter | Clinician owns it | No SLA | `[F:F3.2]` | | Async clinical review | Clinician review | Pulled from pending list | Not enabled on the GLP-1 SKU; no SLA. Whether a case is routed manually is unknown | `[F:F3.2]` | | Care-plan generation | Care::Plan | Clinician review of AI draft | No system SLA | `[F:F3.2]` | | Care Journey criteria | Patient action | Patient-owned, clinician advances phase | Server-side deadlines only | `[F:F3.2]` | | Referrals promises | In-person referral | Atomic claim, snooze, drop | Not on the GLP-1 path; `allows_referral:false` | `[F:F6]` | | Pharmacy order | PharmacyOrder | Patient-driven | No dispense or ack state recovered in the inspected client | `[F:F3.2]` | | Message Center | Conversation | Care team by subject | Server-computed per thread; support Mon to Fri 9 to 9 ET | `[F:F3.2]` | | Clinician shift | Shift | Clock-out checkout | 4 to 6 hour blocks, Mon to Fri 7 a.m. to 7 p.m. MT | `[F:F3.2]` | | Lab result review | LabOrder | Clinician or care team | 48-hour result claim; critical call immediate | `[C:C21]` `[C:C5]` | | PA work | No PA case object recovered in inspected interfaces | RCM and care team | Several business days, no measured p50 or p90; production queue unknown | `[D:D5.2]` | | Refund execution | No endpoint | Support, outside recovered tooling | Visit 5 to 10 business days; lab up to 6 months | `[C:C3]` | ### 8.3 RACI by activity R is responsible, A is accountable, C is consulted, I is informed. Every row has exactly one internal accountable role. External pharmacies, labs and payers are counterparties, not accountable owners. This is a proposed operating model, not an observed one. | Activity | Patient | Eng and Product | Catalog and Growth | Prescribing clinician | Medical Director | NP Licensure | Care Coord and PA | Support | RCM | Privacy and Compliance | |---|---|---|---|---|---|---|---|---|---|---| | SEO, sitemaps, default SKU, price copy | I | R | A | I | C | I | I | I | I | I | | Privacy boundary, replay, Segment PII, BAAs | I | R | C | I | I | I | I | I | I | A | | Signup, OTP, identity fallback, duplicate charts | R | A | I | C | I | I | I | R | I | C | | Eligibility, card OCR, self-pay estimate | C | C | I | I | I | I | R | I | A | C | | State-to-PC routing, license and CPA checks | I | C | I | C | C | A, R | I | I | I | I | | Screening red flag and acute triage | I | C | C | R | A | I | C | I | I | C | | Visit, indication, medication reconciliation, counseling | C | I | I | A, R | C | I | I | I | I | I | | eRx signing, presentation, quantity, supplies | I | C | I | A, R | I | I | I | I | I | I | | Labs, abnormal and critical result loop | R | C | I | A, R | C | I | R | I | I | I | | Pharmacy selection, eRx ack, stockout reroute | R | C | I | C | I | I | A, R | C | I | I | | PA submission, RFI, appeal, claim re-adjudication | I | C | I | C | I | I | R | I | A | I | | Possession, cold chain, Dose-1 training | R | C | I | C | A | I | R | C | I | I | | Weeks 1 to 3 side effects and safety report | I | C | I | R | A | I | C | I | I | C | | T+14 to T+18 refill start and T+28 continuity | R | C | I | A, R | C | I | R | I | I | I | | Refunds and cancellation waiver | I | C | I | I | I | I | I | R | A | C | | Records access, export and retention | I | C | I | I | I | I | I | R | I | A | ### 8.4 Staffing: known versus unknown Known: - About 104 employees, three hubs, 16 open roles: 4 clinical, 2 operations, 4 engineering, 3 product, 3 finance. `[F:F9]` - 1099 clinician pay and hours; care coordinator at $22 per hour; FT physician at $180k to $200k for 36 clinical hours. `[F:F3.4]` - 20 public clinician bios. `[F:F9]` Unknown: - Headcount for care coordination, support, RCM, and pharmacy or PA. No pharmacy technician, prior-auth specialist, or benefits-verification role appears among the 16 open requisitions. `[F:F9]` - Queue depths, arrival rates, and p50 or p90 turnaround for any queue. - After-hours clinical coverage. The only emergency instruction is 911; no nurse line or on-call clinician pager was observed. `[E:E16]` - Whether Zendesk also backs patient support agents or only clinician chat. `[F:F3.2]` - BAA inventory and subprocessor list. `[F:F8]` --- ## 9. Failure modes and branches | Trigger | Patient impact | Current handling observed | Gap | Recommended control | Evidence | |---|---|---|---|---|---| | Commercial head terms do not rank | Patient never finds GM | None | SEO architecture sends crawlers to noindex `/s/` URLs | Fix canonical, sitemap, and internal links to `/dp/` | `[A:A2.2]` | | `/weight-loss` short URL | Patient hits a login wall | 307 to `/login` | Not in sitemap or internal links | Redirect to `/store/weight-loss` or `/get-started` | `[A:A8]` | | Default Zepbound SKU is the auto-injector | Price shock at $1,074.09 versus $299 | Family default and Lilly CTA point at the expensive form; production intent unverified | Price and default mismatch | Default to KwikPen or show a form comparison with prices | `[A:A5.1]` `[D:D0.3]` | | Vial SKU selected | No price, no direct channel | Shows "-" and "priced after visit" | Null cash price, no LillyDirect row | Hide or price the vial path | `[A:A5.2]` `[D:D0.3]` | | Public catalog does not quote insured drug cost | Drop-off at the visit fee | "Available after visit" tooltip; RTPB may estimate after prescribing | No pre-visit patient-specific estimate | Show a range and explain that the adjudicated claim sets the payable amount | `[A:A5.2]` `[CODE components/ProductDetailPage/MedicationPriceCard.tsx:12-20]` | | OTP not delivered | Signup blocked | Resend, support short code | No voice or email fallback observed | Add fallback channel and a delivery-failure queue | `[B:§5]` | | Verified lookup misses | Silent manual form | `dob_lookup_failed`, cookies cleared | No explanation to the patient | Explain the fallback and why it happened | `[B:§5]` `[LIVE-SRC useVerifyIdentitySignupFlow.ts:151-174]` | | Under 18 | Blocked | Client-side message | Correct behavior | Keep | `[B:§5]` | | Territory address | Cannot complete about-you | State list is 50 plus DC only | No territory options | Add territories or state the service area | `[B:§5]` | | Insurance not found | Self-pay at $100 | Try another or continue without insurance | No benefits escalation queue recovered | Add a benefits specialist queue | `[B:§5]` `[C:C4]` | | Eligibility timeout | Uncertain price | Copy allows up to 60 seconds | No client timeout branch recovered | Add timeout, retry, and save-and-resume | `[B:§5]` `[C:C4]` | | HIE returns nothing | Manual history entry | Four-step wizard | No records coordinator observed | Add a records chase queue with a 1 business day target | `[B:§5]` | | Questionnaire red flag | Off-ramp | Care team text, different SKU, unavailable screen | No queue or SLA recovered | Clinical triage queue with severity routing | `[B:§5]` | | No clinician licensed in state | No slots | `booking_no_availability` event | No waitlist observed | Waitlist and state expansion signal | `[B:§5]` `[C:C5]` | | No-show or late cancel | Fee charged | Card on file; Medicaid exempt; reschedule free | Fee amount unpublished | Publish the fee and show it at booking | `[C:C4.4]` | | Payment fails | Cannot book | Toast, stay on form | No retry automation observed | Dunning and save-and-resume | `[B:§5]` | | PA required | Wait of several days | RTPB flag, manual follow-up | No dedicated PA case or submission contract recovered; staff may work in payer portals or other tools | PA case object with status, owner, and deadline | `[D:D5.2]` | | PA denied | Cash, switch, or abandon | Manual, marketing claims follow-through | No appeal workflow recovered | Denial and appeal queue with reason codes | `[D:D5.2]` | | eRx never reaches pharmacy | No drug, patient calls | No ack or dispense state recovered; cancel and reroute | Patient may be the error detector; production may have a feed | Dispense and rejection feed, exception queue | `[E:E16]` `[E:E1.3]` | | Out of stock | Delay | Compare drawer and switch flags | No inventory signal in inspected feed | Stock check and automatic reroute | `[D:D5.3]` | | Claim rejected at counter | Patient pays cash or waits | No claim state recovered in the inspected GM interfaces; production state unknown | No rejection feed recovered; production integration unknown | Claim status integration | `[D:D5.3]` | | Mail-order checkout link missed | No drug | Pharmacy follow-up described; GM action unverified | No GM visibility observed | Status feed and outreach task | `[D:D5.3]` `[D:D16]` | | Cold-chain excursion | Product compromised | Pharmacy replacement | No GM tracking or temperature telemetry recovered; production handling unknown | Patient report flow and replacement case | `[D:D5.3]` | | Dose escalation needs a new PA | Delay past T+28 | None observed | No new-strength pre-check recovered; configured workflow unknown | Check PA scope before the week-4 decision | `[E:E5]` `[E:E8]` | | 45-day offer lapse, 7.5 to 15 mg only | Price may rise from the offer price | No price-window reminder in inspected client | Condition runs from delivery or receipt of the previous fill, not purchase date | Remind from the recorded receipt date; do not apply to 2.5 or 5 mg | `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` | | Check-in not completed | Renewal may be affected | `criteria_deadline` and card | The GLP-1 blocking rule and exception owner are unverified; same-strength refills depend on prescription, pharmacy and payer | Verify the configured pathway rule before displaying a hard block | `[E:E5]` `[E:E6]` | | Severe side effect after hours | No GM clinical response path recovered; production handling unknown | 911 instruction observed; GM after-hours clinical route not recovered | No nurse line or on-call clinician observed | After-hours triage line and escalation playbook | `[E:E16]` | | Patient stops treatment | No record, no transition in inspected client | No complete stop workflow recovered; production handling unknown | No distinct stop state recovered | Stop and transition flow with records and billing | `[E:E11]` | | Replay or analytics leak | Privacy exposure risk | No consent gate observed; replay default allow | Specific GLP-1 capture, runtime masking, retention and destination access unverified | Consent management, masking, and vendor BAA review | `[A:A3.4]` | | Billing literals differ from the reconstructed spec | Wrong charge or no charge risk | Client checks `gm_card` and `pharmacy_delegated`; reconstructed spec uses `cash` and `pharmacy_delegation` | Authoritative server `BillingType` unverified | One schema, contract tests, and reconciliation | `[D:D5.4]` | | State-to-entity mapping unverified | Wrong entity or consent risk | Server-side `practiceId` filter | Legal addresses and NPPES jurisdictions differ; not proof of a defect | Publish and test a state-to-entity matrix | `[D:D5.4]` | | Metabase login shell is publicly reachable | Network exposure risk | Sign-in page observed; data access not established | SSO configuration and permissions require review | SSO, network restriction, and audit | `[F:F4.1]` | | No good-faith estimate for self-pay | Patient cannot see an itemized expected cost | Per-SKU prices and checkout totals in inspected surfaces; no estimate artifact recovered | No GFE artifact or delivery flow recovered | Add a GFE queue: 1 business day for 3 to 9 business days ahead, 3 business days for 10 or more ahead or a pre-scheduling request | `[PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate]` | | No accessibility or interpreter path | Patient cannot complete intake or the visit | None observed | No accommodation queue, captions or interpreter workflow observed | Add an access-needs field and a staffed accommodation queue | `[INFERENCE: common practice]` | | Pen needles not observed in the catalog | Patient may not be able to inject a KwikPen | Label and pharmacy counseling; pharmacy may supply or co-dispense | No needle or sharps SKU observed, no supply check | Add a supply bundle or a required counseling step at first fill | `[E:E2]` `[E:§6 q14]` | | Carrier scan treated as possession | Wrong address, damage, or temperature excursion goes unnoticed | Pharmacy-side tracking described; GM visibility unverified | No patient possession confirmation observed | Ask for possession confirmation and route exceptions to the pharmacist | `[INFERENCE: common practice]` `[D:D17]` | | No contraception counseling field | Label counseling requirement can be missed at start and at escalation | Clinician judgment; care may occur without a structured field | No structured field or reminder observed | Add counseling and a 4-week backup-method reminder to the visit and week-4 criteria | `[PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §8.1]` `[D:D6]` | | No T0 administration record | Refill clock may be anchored to payment or shipping | No administration endpoint observed | Possession, administration, delayed start and decline are not distinguished | Ask for patient-reported T0 or retain start unknown; never infer from claim or delivery | `[INFERENCE: proposed control]` | | PA approval not linked to claim | Approval may not produce a paid or dispensed fill | No re-adjudication object observed | Approval scope, expiry and claim result are not carried together | Record approval scope and require pharmacy re-adjudication before promising a fill | `[D:D5.3]` `[INFERENCE: common practice]` | | Product-specific safety review not evidenced | Contraindication and warning handling may be inconsistent | Clinician judgment; no structured field observed | Source version, finding, decision and advice are not captured together | Add a structured safety review and escalation owner | `[PUBLIC Zepbound PI §§4-5, 7-8]` | --- ## 10. Technology plan inputs ### 10.1 Systems and integrations | Capability | Current state observed | Build, buy, or partner | Data contract needed | Gap to avoid or fix | Evidence | |---|---|---|---|---|---| | Patient identity and session | Cognito with phone OTP through Twilio; Google SSO in code but not live | Buy | Phone, OTP challenge, session, `isExistingUser`, tenant | Add email or voice fallback; define duplicate-account and phone-reuse rules | `[B:H2]` `[B:H3]` | | Identity autofill | Verified 1-Click Signup after phone and DOB | Buy | Request: phone and DOB; response: name, sex, email, addresses, confidence | No error surfaced on miss; log and explain the fallback | `[B:H4]` | | Identity proofing | Persona wired for in-person and a generic pre-visit requirement; GLP-1 trigger unknown | Buy | Inquiry id, document type, liveness result, manual attestation | Define which GLP-1 cases require KYC and who can attest | `[B:H22]` | | Insurance discovery | Verified candidate plus payer directory and card OCR | Buy or partner | Payer, member id, group, plan, network, copay, deductible | One source of truth; timeout and retry semantics | `[B:H5]` `[B:H8]` `[B:H11]` | | Eligibility and claims | Waystar inferred from hosts; no payload observed | Buy | X12 270 and 271, error codes, payer ids, service types | Add idempotency, audit trail, and a benefits exception queue | `[B:H8]` `[C:H11]` | | HIE | Metriport primary, Particle secondary | Buy | FHIR Condition, MedicationStatement, AllergyIntolerance, Procedure; consent; source tag | Provenance and freshness required; no silent empty chart. Privacy and compliance must verify notice version, applicable disclosure or authorization basis and opt-out status on both Verified and manual signup branches before HIE retrieval. Carry source, timestamp and effective opt-out status into chart and AI prewarm; honor the published opt-out. Missing or conflicting evidence routes to privacy review and manual history, not presumed permission. Production enforcement unverified | `[B:H13]` `[B:H14]` `[PUBLIC https://generalmedicine.co/hipaa-privacy-practices]` | | Scheduling and visits | Nile-Core plus Visitron; 20-minute slots, 9 per 4-hour block | Build | Visit id, SKU, modality, state, clinician, location state, price | Add a claim or assignee primitive to review queues | `[F:F3.2]` `[DATA internal_portals_recon.json → visitron.rtk_endpoints]` | | Video | Zoom link by SMS and email | Buy | Meeting URL, id, passcode, join status | No attendance or connection-failure event observed | `[E:H12]` `[C:C8]` | | eRx | DoseSpot SSO and NCPDP SCRIPT to NCPDP id | Buy | Rx payload, NCPDP id, refills, SIG, days supply, cancel and replace | Single point of failure; needs outage playbook and fallback | `[D:H5]` `[F:F3.1]` | | Benefit check | Arrive Health RTPB plus DoseSpot RTPB | Buy | Patient, drug, NDC, pharmacy, copay, formulary, PA flag, inquiry id | No PA submission or appeal object recovered; production workflow unknown | `[D:H7]` | | EHR of record | Athenahealth sync and resync | Buy | Encounter, diagnoses, orders, care plan, `athena_id` | Resync failures need a queue and reconciliation | `[D:H4]` | | Ambient scribe | Nabla status and note draft | Buy | Audio, transcript, note draft, status | Define retention and consent for audio | `[D:H6]` | | Care plan and next steps | `Care::Plan` plus AI draft and clinician sign-off | Build | `proposed_json`, `final_json`, rationale, state, next-step cards | Prompt version and model must be recorded per output | `[E:E1]` `[F:F3.3]` | | Patient copilot | `/ai` with Metriport prewarm and Braintrust feedback | Build plus partner | Consent, context, messages, feedback, model version | Clinical guardrails, escalation, and PHI handling unproven | `[E:E13]` `[F:F3.3]` | | Pharmacy directory | Live REST feed with NCPDP ids, prices, distance, `fulfillment_owner` | Build aggregator plus partner feeds | NCPDP id, chain, price, distance, fulfillment owner | No `in_stock`, hours, city, state, or tracking | `[D:D12]` `[A:H15]` | | Pharmacy order | Four-state chain is a dossier hypothesis; client exposes a state string plus flags | Build | Order id, NCPDP id, billing type, price, state, flags | No dispense, ack, reject or tracking field recovered; production feed unknown | `[D:D11-D15]` `[E:E1.3]` | | Mail-order handoff | eRx to LillyDirect, Amazon, NovoCare; patient pays the pharmacy | Partner | Rx, patient, NCPDP id, checkout status, ship status | No return-status contract recovered; verify existing pharmacy feeds and staff workflows before building another integration | `[D:H10]` `[D:H11]` | | Retail handoff | eRx plus NCPDP claim; prepaid card or GM card | Partner | Rx, claim, copay, rejection, dispense | No claim-rejection or dispense state recovered; production integration unknown | `[D:H13]` | | Inventory and substitution | No inventory signal in the inspected comparison feed; production stock feeds unknown | Buy or partner | NDC, strength, quantity on hand, backorder, ETA | Add stock check before promising a fill date | `[D:D5.3]` | | Payments | Stripe SetupIntent, payment method, charge, 3DS | Buy | Payment method id, amount, status, refund, idempotency key | Visit charge capture timing inferred, not observed | `[C:H1]` | | GM card and discount switch | BIN, PCN, group, member id | Partner, sponsor unknown | Card identity, eligibility, claim routing, remittance | Two instruments share one name; model separately | `[D:D4.3]` `[C:H14]` | | Good-faith estimate | No compliant estimate artifact recovered; per-SKU prices only | Build | Trigger, self-pay status, issuing entity, dated itemization, delivery evidence, dispute reference | Deliver within 1 business day for 3 to 9 business days ahead, within 3 business days for 10 or more ahead or a pre-scheduling request | `[PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate]` | | Identity assurance policy | OTP plus Verified autofill or manual fallback; Persona trigger unknown | Build plus partner | Accepted evidence, risk trigger, verification method, verifier, time, duplicate-chart resolution | Define before prescribing; do not equate autofill with proofing | `[B:H4]` `[B:H22]` | | Manufacturer savings and COB | No field or workflow recovered | Build or partner | Program and version, approved use, government exclusion, primary claim, secondary claim, caps, expiry, accepted price | Eligibility and redemption unverified; model separately from GM card | `[D:D4.4]` `[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]` | | Labs | Junction and Vital; Quest, Labcorp, BioReference | Buy | Order, requisition, accession, result, critical flag, PDF | Fee components outside total; delegated-flow mode unknown | `[C:H5]` `[C:H6]` | | Lab results | Dashboard, Updates, PDF, `abnormal_results_count` | Build plus partner | Result status, reference range, interpretation, critical call | No patient-facing critical-result SLA | `[C:C21]` | | Messaging | Twilio Conversations and SMS 98528; Message Center behind a flag | Buy | Conversation id, subject, `response_expectation`, attachments | Support and clinical messaging overlap; one owner needed | `[E:H11]` `[F:F3.2]` | | Email | Unidentified vendor | Buy | Template, event, delivery status | Vendor and BAA unknown | `[E:H15]` | | Product analytics | Segment through a first-party proxy | Buy | Event schema, identity resolution, consent, destination list | No complete analytics schema or consent-enforcement mechanism recovered; email and phone appear in guarded client calls. Backend governance and runtime sending remain unverified | `[A:H7]` | | Replay and monitoring | Datadog RUM and Logs at 100 percent | Buy | Session, user id, redaction rules | Explicit phone masking marker found; other component masking and runtime behavior unverified | `[A:H8]` | | Feature flags | LaunchDarkly with reporting | Buy | Context key, flag version, evaluation | Flag state mirrored to Datadog, useful for audit | `[A:H9]` | | Warehouse and BI | Databricks plus Metabase 1.63.10; the login shell is public and requires sign-in | Build and operate | Table contracts, lineage, access policy | Network exposure requires review; unauthenticated data access not established | `[F:F4.1]` | | Prior authorization | No dedicated PA case, submission or appeal contract recovered in the inspected client or portal inventories; staff may use payer portals or other tools | Build or partner | Case id, payer, drug, NDC, criteria, evidence, status, deadline, appeal | Highest operating gap on the insured path | `[D:D5.2]` | | Dose and adherence | No dose-administration event recovered in the inspected client surfaces; production may record this elsewhere | Build | Dose event, device, site, timestamp, missed-dose reason | Cannot distinguish stable from stopped from the inspected data | `[E:E4]` | | Weight and vitals | Only typed into questionnaires or recorded at visits in the inspected surfaces; production device sync unknown | Build or partner | Measurement, date, source, unit | No device integration observed | `[E:E12]` | | Catalog and pathways | Catalog with 106 operations, one cache tag | Build | SKU, option, phase, criteria, questionnaire, codes, lab panel | Add approval workflow beyond questionnaires and pathways | `[F:F0.1]` | | Refunds | No refund endpoint in the inspected public or internal API inventories; execution may use Stripe or back-office tools | Build or partner | Order id, payment id, reason, amount, status | Refund execution system unverified | `[C:C3]` | ### 10.2 Data contracts and identifiers The journey needs a crosswalk, not one global identifier. Each boundary must carry enough to reconcile: | Boundary | Identifier | Required fields | Failure semantics | Status | Evidence | |---|---|---|---|---|---| | Patient record | `patient_id`, `signup_id` | Phone, DOB, name, address, consents, tenant | Duplicate match, phone reuse, partial record | Observed | `[B:B7]` | | Visit | `visit_id` | SKU, modality, clinician, state, price, billing type | Hold expiry, no-show, reschedule | Mixed; enum unverified | `[F:F3.2]` | | Questionnaire | `questionnaire_id`, `response_id` | Version, question id, answer, submitted at | Partial submission, edited version | Observed fields; content unrecovered | `[B:B11]` | | Prescription | `prescription_id`, `care_action_prescription_id` | Drug, NDC, strength, form, quantity, days supply, refills, NCPDP id | Finalize failure, cancel, replace | Observed | `[D:D8]` | | Pharmacy order | `pharmacy_order_id` | NCPDP id, billing type, price, state, payment id | Ack timeout, reject, dispense, cancel | Mixed; state model proposed | `[D:D11-D15]` | | Lab order | `lab_order_id`, `accession_number` | Panel, network, fee, collection status, result | No-show, redraw, critical value | Mixed; enum unverified | `[C:C19-C21]` | | Payment | `payment_method_id`, `payment_intent_id` | Amount, currency, status, refund, idempotency key | 3DS required, declined, duplicate charge | Observed | `[C:C7]` | | PA case | `pa_case_id`, payer case number | Drug, NDC, criteria, evidence, status, deadline | Missing information, denial, appeal | Proposed | `[D:D5.2]` | | Conversation | `conversation_id` | Subject, participant, `response_expectation`, attachments | Delivery failure, after-hours | Observed | `[E:E3]` | | Shipment | Carrier tracking id | Order id, address, ship date, exception | Lost, delayed, temperature excursion | Proposed | `[D:D17]` | | Dose event | `dose_event_id` | Prescription and fill id, status, scheduled and administered time, source, reason | Never started, missed, delayed, declined, unknown | Proposed | `[INFERENCE: common practice]` | No recovered contract covers a pharmacy acknowledgment and dispense event, a PA case, or a dose-administration event. The shapes below are proposed, not implemented. Each needs a version, timestamp semantics, idempotency key, source of truth, reconciliation owner, and a verified producer-consumer pair. ```typescript type PharmacyBillingType = | "cash_prepaid_retail" | "gm_discount_card_retail" | "direct_mail_cash" | "commercial_insurance" | "government_insurance"; interface PharmacyOrderContract { pharmacy_order_id: string; prescription_id: string; patient_id: string; medication_option_sku_id: string; ndc11: string; presentation: "kwikpen_multidose" | "autoinjector_singledose" | "vial_singledose" | "vial_multidose"; strength_mg: 2.5 | 5 | 7.5 | 10 | 12.5 | 15; package_count: number; doses_per_package: number; dose_volume_ml: number; concentration_mg_ml: number; total_volume_ml: number; days_supply: 28; companion_supplies: { pen_needles: boolean; syringes: boolean; sharps_container: boolean }; ncpdp_provider_id: string; billing_type: PharmacyBillingType; transmission_state: "created" | "pharmacy_selected" | "erx_transmitted" | "erx_acknowledged" | "erx_error_or_clarification"; claim_state: "not_submitted" | "adjudicating" | "rejected_pa_required" | "rejected_other" | "paid" | "reversed"; dispense_state: "not_dispensed" | "ready" | "dispensed" | "partially_dispensed" | "canceled"; shipment_state?: "not_shipped" | "shipped_cold_chain" | "carrier_delivered"; possession_state: "unknown" | "confirmed" | "not_received" | "wrong_item" | "damaged"; exception_state?: "none" | "temperature_reported" | "product_complaint" | "open"; dispensed_at?: string; carrier_delivered_at?: string; possession_confirmed_at?: string; idempotency_key: string; updated_at: string; } interface PriorAuthCaseContract { pa_case_id: string; patient_id: string; prescription_id: string; pharmacy_order_id?: string; payer_id: string; raw_reject_code?: string; reject_code_set_id?: string; reject_code_set_version?: string; classification_version?: string; classified_reject_reason?: "pa_required" | "plan_exclusion" | "plan_limitation" | "dur" | "other"; submission_channel: "epa" | "payer_portal" | "fax" | "unknown"; external_case_number?: string; submission_receipt?: string; submitted_evidence_versions?: string[]; payer_message?: string; indication: "obesity_bmi_30" | "overweight_bmi_27_comorbidity" | "osa_obesity" | "t2d"; baseline_bmi?: { value: number; measured_at: string; source: "intake" | "hie" | "visit" }; status: "open" | "submitted" | "rfi_pending" | "approved" | "denied" | "appeal_submitted" | "appeal_decided" | "cash_fallback" | "closed_abandoned"; submitted_at?: string; rfi_due_at?: string; rfi_history?: Array<{ request: string; received_at: string; due_at: string; owner: string; response_evidence_versions: string[]; response_sent_at?: string; response_receipt?: string; }>; approved_scope?: { auth_number: string; product_ndc: string; presentation: string; strengths: string[]; quantity: number; days_supply: number; effective_from: string; expires_at: string; }; denial_reason?: string; appeal_deadline?: string; appeal_decision?: string; claim_result?: "paid" | "rejected" | "reversed" | "not_reprocessed"; final_claim_ref?: string; abandonment_evidence_ref?: string; pharmacy_reprocessed_at?: string; linked_dispense_or_reversal?: string; closure_reason?: string; sla_due_at: string; } type DoseEventStatus = "planned" | "administered" | "missed" | "delayed" | "declined" | "unknown"; interface DoseEventBase { dose_event_id: string; patient_id: string; prescription_id: string; fill_id: string; reported_at: string; source: "patient_reported" | "clinician_recorded" | "device"; reason?: string; injection_site?: "abdomen" | "thigh" | "upper_arm_caregiver"; contraception_backup_counseled: boolean; } type DoseEventContract = DoseEventBase & ( | { status: "administered"; administered_at: string; scheduled_at?: string } | { status: "planned" | "missed" | "delayed" | "declined" | "unknown"; administered_at?: never; scheduled_at?: string } ); ``` Invariant: for administered status, `administered_at` is required; `scheduled_at` is optional. For planned, missed, delayed, declined or unknown status, `administered_at` is absent and `scheduled_at` is optional when the schedule is unknown. Derive T0 only from an accepted administered event with a timestamp and source, never from `scheduled_at`, possession or shipment. Validate at ingestion. PA invariant: do not mark an RFI satisfied or a case successfully closed without its receiving and closure evidence. Preserve the payer message, `reject_code_set_id` and `reject_code_set_version` separately from `classification_version`. A PA approval covers only the product, NDC, presentation, quantity and days supply recorded in `approved_scope`; do not assume it covers another presentation because a strength matches. Close a case only with `final_claim_ref` or `abandonment_evidence_ref` plus `closure_reason`. ### 10.3 Implementation gaps a builder should avoid 1. Do not default a drug family to its most expensive presentation. Make price part of the default selection logic. 2. Do not put indexable pages outside the sitemap and noindex pages inside it. 3. Do not send email, phone, and condition context to a product analytics tool without a BAA and a consent basis. 4. Do not initialize 100 percent session replay with `defaultPrivacyLevel: allow` on routes that may render clinical intake or PHI. Enforce mask-user-input, gate replay on consent, and verify the actual clinical surfaces before launch. `[A:A3.4]` 5. Do not name two different payment instruments "card". A prepaid payment card and a discount BIN are separate objects. 6. Do not let client and server enums drift. Generate both from one schema. 7. Do not model a pharmacy order without an acknowledgment, rejection, and dispense state. 8. Do not render a claim of "we handle prior authorization" without a PA object, owner, and SLA behind it. 9. Do not calculate prescription quantity from a field whose unit is ambiguous. 10. Do not expose a BI tool without authentication, even on a staging host. 11. Do not launch a state without a signed state-to-professional-entity matrix. 12. Do not treat a session cookie with a 30-minute life as durable SKU attribution for a high-consideration purchase. --- ## 11. Operating plan inputs ### 11.1 Queues to stand up | Queue | Trigger | Owner | Proposed target, design not observed | Volume driver | Evidence | |---|---|---|---|---|---| | Identity exception | OTP failure, Verified miss, under-18, territory address | Support | 1 business day | Signup attempts | `[B:§5]` | | Benefits and eligibility | Not found, timeout, multiple plans, out of network | Care coordinator or benefits specialist | 1 business day | Insured bookings | `[B:§5]` `[C:C4]` | | Clinical intake red flag | Questionnaire off-ramp: `emergency`, `urgent`, `high_risk`, `requires_triage`, `unable_to_treat`, `different_sku` | Licensed clinician | Emergency immediate; urgent prompt triage; high risk or requires triage before booking; unable to treat with alternate disposition; different SKU by clinical approval | Screening completions | `[B:B11]` `[CODE lib/analytics/questionnaireInterstitialAnalytics.ts:3-9]` | | No availability | No licensed clinician in state | Operations | Same day response with waitlist | State supply | `[B:§5]` `[C:C5]` | | No-show and late cancel | Visit state transition | Care coordinator | 1 business day outreach | Booked visits | `[C:C4.4]` | | PA new request | RTPB flag or pharmacy rejection | PA specialist plus prescriber | 1 business day to open, daily follow-up | Insured fills | `[D:D5.2]` | | PA denial and appeal | Payer denial | RCM plus prescriber | Notify patient 1 business day, appeal within plan deadline | Insured fills | `[D:D5.2]` | | Pharmacy transmission failure | No acknowledgment within 1 business day | Pharmacy liaison | Same day resend or reroute | All fills | `[E:E16]` | | Out of stock and reroute | Pharmacy reports stockout | Pharmacy liaison | Same day alternative | All fills | `[D:D5.3]` | | Lab collection overdue | Order not collected in 5 days | Lab navigator | 1 to 2 business days outreach | Lab orders | `[C:C20]` | | Lab abnormal or critical | Result flag or critical webhook | Clinician | Critical immediate, routine 1 business day | Lab orders | `[C:C21]` | | Week-4 check-in incomplete | Criteria deadline near | Care coordinator | 3 business days before deadline | Active patients | `[E:E6]` | | After-hours symptom | Message or call outside shift | Clinical triage | Immediate emergency direction. Suspected pancreatitis: stop tirzepatide and arrange immediate clinician contact or urgent assessment, not a next-shift reply | Active patients | `[PUBLIC Zepbound PI §5.5]` `[E:E16]` | | Refund and billing | Request or policy eligibility | Support and RCM | 1 business day acknowledgment | All payments | `[C:C4.4]` | | Records request | Patient request or transfer | Privacy officer | Statutory deadline, commonly 30 days | All patients | `[PUBLIC https://www.law.cornell.edu/cfr/text/45/164.524]` | | Good-faith estimate request | Self-pay or uninsured patient requests or schedules applicable care | Billing and compliance | 3 to 9 business days ahead: within 1 business day. 10 or more business days ahead, or requested before scheduling: within 3 business days | Self-pay bookings | `[PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate]` | | Adverse event and product complaint | Reported side effect, product defect, damage or temperature issue | Licensed clinician plus Medical Director | Urgent care first; separate reporting review and product-complaint follow-up | Active patients and fills | `[PUBLIC Zepbound PI §17]` | | Possession, training or start delay | Possession or training unresolved at the agreed follow-up time, or no reported actual start three calendar days after the patient-reported planned start date. If the planned start is unknown, open a coordination task on confirmed possession; never compute an overdue threshold from an absent T0 | Care coordinator and pharmacist | 1 business day outreach after the defined trigger | Every fill | `[INFERENCE: proposed queue]` | | Dose continuity risk | Pen supply ends before next fill is in hand | Care coordinator and PA lead | Same day escalation and reroute | Active patients | `[E:E5]` `[INFERENCE: proposed queue]` | | Identity, credential or authority exception | Duplicate chart, manual-entry mismatch, expired license, travel, no eligible clinician, pharmacy refusal | Compliance and clinical operations | Hold unsupported care; same-day routing to licensed reviewer | Signup and booking | `[PUBLIC https://www.mbc.ca.gov/Resources/Medical-Resources/telehealth.aspx]` | Proposed queue contract: record the workflow, patient and trigger-event case key, system of record, intake time, accepting role, acceptance time, next-update due time, escalation and evidence-backed closure. Routine targets use staffed business hours, explicitly scheduled in America/New_York; urgent clinical intake and safety cases require a staffed 24/7 accepting clinical service and backup. If that service is not provisioned, do not promise an immediate GM response: provide the approved external urgent or emergency route. Close only with documented receiving acknowledgment and disposition, not message delivery. Operations must populate hours, backup and workflow-specific closure evidence for every row and obtain clinical and compliance approval before publishing a service target. "Immediate," "same day" and "one business day" are design targets, not observed GM service contracts. | Off-ramp value | Proposed action | Owner | |---|---|---| | `emergency` | Immediate emergency-services direction and urgent handoff | Licensed clinician | | `urgent` | Prompt licensed triage before any booking or prescribing | Licensed clinician | | `high_risk` or `requires_triage` | Clinician review before checkout or prescribing proceeds | Licensed clinician | | `unable_to_treat` | Explicit explanation and alternate-care or referral disposition | Clinician and care coordinator | | `different_sku` | Clinician-approved alternate pathway preserving relevant answers and provenance | Clinician and catalog | ### 11.2 Staffing drivers - Video capacity: 20 minutes per visit, 9 per 4-hour block, 36 clinical hours per week for a full-time physician. That is 81 visits per week at full density or 3,888 per year across 48 working weeks. This is a capacity ceiling, not staffed capacity. `[F:F3.4]` - Chat capacity: a 3-hour response window, with chat shifts extended when the queue is long. `[F:F3.2]` - Care coordination: one coordinator per unknown number of active patients. The only observed cost is $22 per hour. `[F:F3.4]` - PA and pharmacy liaison: no such role or queue appears in the 16 open requisitions or inspected portal inventories; production staffing unknown. Staff this from measured arrivals and handling time, not from the org chart. - Clinical review at week 4: one review per active patient per month while titrating, then roughly every three months. `[LIVE GLP-1 guide]` - Lab follow-up: one result review per order, with outreach only on abnormal results. `[C:C21]` | Illustrative workload per 1,000 new starts and 1,000 month-2 renewals | Assumption | Hours per month | FTE at 144 productive hours | Basis | |---|---|---:|---:|---| | Video visits | 70 percent of 1,000 initial encounters are video; independently assume 35 percent of 1,000 renewal reviews need video: 700 initial plus 350 renewal at 26.7 minutes | 467.3 | 3.2 | `[F:F3.4]` `[INFERENCE: planning assumption]` | | Chat and async reviews | 300 initial chats plus 650 check-in reviews plus 250 lab or side-effect reviews at about 10 minutes | 200 | 1.4 | `[F:F3.4]` `[E:E7]` | | PA and pharmacy liaison | 500 initial PA checks plus 250 step-up checks at 25 minutes, plus 300 follow-ups at 10 minutes | 362.5 | 2.5 | `[F:F3.4]` `[D:D5.2-D5.3]` | | Support and lab navigation | 400 support contacts at 10 minutes plus 600 lab follow-ups at 5 minutes | 116.7 | 0.8 | `[F:F3.4]` `[C:C3]` | | Total before coverage | Sum of the rows | 1,146.4 | 8.0 | `[INFERENCE: arithmetic]` | These are illustrative planning assumptions, not observed volumes, arrival rates, handling times or productivity. The 144 productive hours per FTE, 26.7-minute video assumption and 10/25-minute handling times are model inputs. Add coverage, leave, shrinkage and arrival variability before deciding headcount. ### 11.3 Scripts and playbooks | Situation | Playbook content | |---|---| | Price explanation | Separate visit fee, lab fee and drug price. The public catalog does not quote this patient's insured drug cost; after prescribing, RTPB may produce an estimate, and the pharmacy's adjudicated claim sets the payable amount. | | Wrong default form | Explain KwikPen versus auto-injector versus vial, with the $299 versus $1,074.09 difference. The 45-day condition applies only to the 7.5 to 15 mg KwikPen purchase offer and runs from delivery or receipt. Re-quote the 5 mg SKU. | | Insurance not found | Offer another plan, card photo, or self-pay at $100. Do not imply coverage. | | PA required | Explain who submits, the expected several business days, the patient's financial responsibility, and the cash alternative. Track submission receipt and approval scope. | | PA denied | Explain the denial reason, appeal rights and deadline, cash price, and alternative drug. Do not promise a reversal. | | Pharmacy has no Rx | Confirm the NCPDP id, resend, or reroute. Give the patient a case owner and a next update time. | | Out of stock | Offer a switched pharmacy or mail order, state the new price, and cancel the old order to avoid a duplicate fill. | | Side effects | Triage severity. Emergency symptoms receive immediate emergency-services direction. Suspected pancreatitis requires stopping tirzepatide and immediate clinician contact or urgent assessment, not a paid visit or next-shift wait. Persistent vomiting, diarrhea, dehydration, severe abdominal pain or gallbladder symptoms need same-day clinical assessment and renal-function review. Do not let a $30 to $100 visit fee delay urgent triage. | | Hypoglycemia and diabetes drugs | For insulin or a secretagogue, document whether dose reduction is indicated, the glucose-monitoring plan, hypoglycemia signs and the escalation route. Do not adjust another prescriber's insulin without coordination. | | Cold chain and storage | Refrigerate at 2 to 8 C, never freeze; room temperature means no more than 30 C. Total room-temperature exposure is cumulative. Never use a previously frozen product. Single-dose pen or vial: up to 21 total days at 30 C or below, then discard. Unopened multi-dose vial or KwikPen at room temperature: discard after 30 days. Opened: discard after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first. Assess any damaged or warm product with the pharmacist; do not tell the patient to re-chill and inject. | | Savings and coordination of benefits | Verify the current program, product and presentation, approved-use eligibility, government-program exclusion, pharmacy, quantity and days supply, caps and expiration. Record the primary claim outcome, any permitted secondary claim, approval or rejection, remaining cap and the patient's accepted price. Explain a denied savings claim before accepting a replacement cash price. | | Missed dose | Take within 96 hours, otherwise skip and resume the regular day. The weekly day may change if at least 72 hours separate doses. Prolonged interruption needs clinician review before restart. Do not double dose. | | Contraception | Tirzepatide delays gastric emptying and can reduce oral contraceptive exposure. Counsel on a non-oral method or backup for 4 weeks after initiation and after each escalation; repeat at week 4. Record the advice. | | Supplies | Confirm the device, needle type, sharps disposal, and whether the box includes what the patient needs. No needle SKU was observed in the catalog; the pharmacy may supply or co-dispense. | | Refund | Visit fee if canceled at least 24 hours ahead. A lab refund may be requested within 6 months of purchase if the sample has not been collected; eligible refunds have no fee deduction. No refund for service provided. | | Records | Verify identity, log the request, route to the custodian for the relevant entity, and track the applicable deadline. Account closure is not medical-record deletion. | | Stop or transfer | Stop the prescription, cancel future orders, explain billing, and provide records. | | Privacy request | Verify identity, log the request, and route to the privacy officer. | ### 11.4 Compliance artifacts | Artifact | Status | Evidence | |---|---|---| | LegitScript certification | Badge and outbound link in the footer | `[F:F8]` | | HIPAA Notice of Privacy Practices | Live, last updated 2025-11-03, issued by the PCs | `[F:F8]` | | Privacy notice | Live, last updated 2026-09-02, Path Healthcare Systems Corp. | `[F:F8]` | | Telehealth consent | Emerald consent plus a separate Vital consent naming delegated entities | `[F:F8]` | | Vendor BAAs | Not observed; no subprocessor list | `[F:F8]` | | Pharmacy licensure | No verification UI or field recovered | `[F:F8]` | | NP collaborative practice agreements | Managed by a dedicated licensure manager | `[F:F8]` | | Prescriber licensure | State per booking, 50 states plus DC claimed, server-side filter; enforcement unverified and invalid state `XX` was accepted at availability | `[F:F8]` `[B:§5]` | | CPOM and Friendly PC | Five PCs by state; NPPES addresses and jurisdictions differ; state-of-care to entity to clinician mapping unverified, not proof of a defect | `[F:F8]` `[D:D0.3]` | | PCI | Stripe and Trust Commerce | `[F:F8]` | | Identity | Persona wired for some flows; GLP-1 trigger unknown; manual attestation fallback | `[F:F8]` `[B:H22]` | | Good-faith estimate | No compliant estimate artifact recovered; per-SKU prices only. Required timing: 1 business day for 3 to 9 business days ahead, 3 business days for 10 or more ahead or a pre-scheduling request | `[PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate]` | | Records custody and retention | No complete schedule, export endpoint or audio-retention policy recovered. HIPAA documentation floor is 6 years; state chart retention varies; define S3 lifecycle for cards and lab PDFs and a post-sign-off audio policy | `[PUBLIC https://www.law.cornell.edu/cfr/text/45/164.530]` `[PUBLIC https://www.law.cornell.edu/cfr/text/45/164.524]` | ### 11.5 KPIs per stage | Stage | KPI | Definition | Current value | Evidence | |---|---|---|---|---| | A | Organic landing conversion | Sessions that start signup | Not observable | `[A:A2]` | | A | Wrong-price exposure | Sessions that view the $1,074.09 default | Not observable | `[A:A5.1]` | | B | Signup completion | OTP verified to patient record | Not observable | `[B:B7]` | | B | Verified match rate | Autofill success over attempts | Not observable | `[B:§5]` | | B | Insurance success rate | Eligibility confirmed over attempts | Not observable | `[B:B9]` | | B | Questionnaire completion | Submitted over started | Not observable | `[B:B11]` | | B | Off-ramp rate | Off-ramps over completions, by type | Event exists, value not observable | `[B:B11]` | | C | Booking conversion | Paid bookings over completed screens | Not observable | `[C:C7]` | | C | No-show and cancellation | No-show events over booked eligible encounters, independent of fee assessment | Not observable | `[C:C9]` `[CODE utils/cancellationFeeUtils.ts:43-53]` | | C | Lab attach rate | Lab orders over visits | Not observable | `[C:C15]` | | C | Lab collection rate | Collected over ordered | Not observable | `[C:C20]` | | D | Visit completion | Completed over booked | Not observable | `[F:F3.2]` | | D | Prescription rate | Rx finalized over completed visits | Not observable | `[D:D8]` | | D | Time to prescription | Visit start to Rx finalized | Not observable | `[D:D8]` | | E | Time to fill | Two measures: Rx finalized to dispense, and checkout to dispense. Include PA delay and abandoned orders | Not observable | `[D:D11-D17]` | | E | Direct-pay share | LillyDirect or Amazon over all fills | Not observable | `[D:D12]` | | E | Dispense confirmation | Confirmed dispense over transmitted Rx | No dispense event recovered | `[E:E1.3]` | | E | Possession confirmation | Patient-confirmed possession over dispensed | No possession event recovered | `[INFERENCE: common practice]` | | E | PA submission to decision | Business days from submission to payer decision; approval is not a paid claim | No PA case event recovered | `[D:D5.2]` `[INFERENCE: common practice]` | | F | T0 completeness | Patients with a recorded or patient-reported first dose over patients with a dispense | No T0 event recovered | `[INFERENCE: common practice]` | | F | Check-in completion | Check-ins completed by T+20 over patients due | Not observable | `[E:E6]` | | F | On-time transition | Second fill in hand by T+28 over patients with a recorded T0 | Not observable | `[E:E5]` | | F | Escalation rate | Side-effect or adjustment visits over active patients | Not observable | `[E:E16]` | | F | Second-fill persistence | Patients with a second fill over patients with a first fill; a dispensing measure, not adherence | Not observable | `[E:E8]` | | F | Clinically approved continuation | Patients continued by a clinician over eligible patients | Not observable | `[E:E7]` | | F | Intentional stop with transition | Documented stops with a transition plan over documented stops | Not observable | `[E:E11]` | | F | Support contacts per patient | Conversations or SMS over active patients | Not observable | `[E:E3]` | Proposed target bands, for design discussion only and not observed GM service levels: OTP verification above 90 percent; eRx acknowledgment within 15 minutes for at least 98 percent; PA submission within 1 business day; check-in started by T+18 for at least 85 percent; second box in hand by T+27 for at least 90 percent; critical lab call immediate. `[INFERENCE: proposed targets]` --- ## 12. Discrepancies and open questions ### 12.1 Conflicts between sources, resolved or open | # | Conflict | Stronger evidence | Resolution | Status | Evidence | |---|---|---|---|---|---| | 1 | Zepbound "from $299" versus a default SKU at $1,074.09 | Live cash price per SKU | Two SKUs: `710641` KwikPen $299, `710642` auto-injector $1,074.09; the family default is the expensive one | Resolved, product defect remains | `[A:A5.1]` `[LIVE /api/external/medication_option_skus/710642/cash_price]` | | 2 | Lab components sum to $141.58 but total is $86.58 | Live `lab_skus` plus component code | `total_cash_price` is test price plus $15 clinical fee; platform, order and collection fees are outside the total. Panel 503263 returns $40 platform, $6 order, $9 Quest collection | Resolved | `[C:C4.3]` `[F:F5.2]` `[LIVE /api/external/lab_skus/503263]` | | 3 | Clinical fee $15 versus $30 | Live data on 10 SKUs | $15.00 is live; $30 is only the client fallback when the field is missing | Resolved | `[C:C4.3]` `[CODE types/enums/lab-pricing-constants.ts:8]` | | 4 | Chat price $30 versus $35 | Live `sku_options` | $30 live; $35 is a code fallback | Resolved | `[D:D5.4]` `[LIVE /api/external/sku_options/300543]` | | 5 | Cancellation fee amount | Policy page plus client fallback | Policy does not publish an amount; $25 is the client fallback; video only; Medicaid exempt | Open | `[C:C4.4]` `[CODE utils/cancellationFeeUtils.ts:24-26]` | | 6 | Number and states of Friendly PCs | Legal docs, NPPES, privacy notice | Names and recorded addresses differ across sources. The state-of-care to furnishing entity to clinician to billing NPI mapping is unverified; address differences alone do not establish a licensure or CPOM defect | Open | `[LIVE /terms-of-service]` `[LIVE /privacy-policy]` `[PUBLIC NPPES]` `[F:F7]` | | 7 | 37 versus 38 states in Care::Plan | Client map | The 37-state map is a shared UI grouping across care actions, not a Care::Plan enum; the 38th state and the server enum are unverified | Resolved as a UI count, open as an enum | `[F:F7]` `[CODE components/CareActions/careActionSection.ts:40-92]` | | 8 | "We take care of prior authorizations" versus no PA contract | Assignment of benefits plus API inventory | Marketing claim; AOB places responsibility on patient or referring physician; no dedicated PA case or submission contract was recovered. Staff may work in payer portals | Open, ownership unclear | `[D:D5.2]` `[LIVE /assignment-of-benefits]` | | 9 | LillyDirect is one partner or many | LillyDirect FAQ plus NPPES | NCPDP endpoint is LillyDirect Pharmacy LLC; dispensing is by Amazon, Fuze Health, Gifthealth, Prescryptive, or Walmart. Gifthealth publishes a different self-pay NCPDP `3692539`; product-level routing is unverified | Resolved as a set, open as routing | `[D:D0.3]` `[LIVE https://www.lilly.com/lillydirect/faq]` `[PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started]` | | 10 | `in_stock` in the data model versus live payload | Live `pharmacy_comparisons` | No inventory field live | Resolved, model is stale | `[D:D0.3]` `[LIVE pharmacy_comparisons]` | | 11 | `gm_card` and `pharmacy_delegated` versus `cash` and `pharmacy_delegation` | Client helper literals plus reconstructed OpenAPI | Source and specification differ. The OpenAPI is explicitly reverse-engineered, so this is not a demonstrated server enum defect; the authoritative `BillingType` is unverified | Open, blocks reconciliation | `[D:D5.4]` `[DOC openapi.yaml:1-8,257-262,1241-1246]` | | 12 | Pharmacy order state chain versus client contract | Client API plus data model | Four-state sequence is a dossier hypothesis; client exposes a state string plus cancel and switch flags. No ack, dispense or tracking field recovered; server feed unknown | Open | `[E:E7]` `[CODE lib/store/api/pharmacyOrderApi.ts:15-24]` | | 13 | Lilly page CTA to `201448` with `allows_first_fill:false` | Live SKU data plus page | New starts should use `300543`; the CTA is a funnel mismatch | Open, intent unknown | `[D:D0.3]` `[LIVE /p/lilly/weight-loss]` | | 14 | Prescription quantity units | Live PDP payloads | Zepbound KwikPen 2.4 "Injection pens", auto-injector 2.0, Mounjaro 1.0; units look like mL mislabeled | Open, do not generate quantity from it | `[D:D0.3]` `[LIVE product_detail_pages]` | | 15 | ZeroTouch as a modality | Live pages and Catalog | Only a display label in the briefing; no live occurrence | Resolved | `[A:A5.2]` `[F:F0.1]` | | 16 | 3,184 sitemap `/s/` URLs with noindex brand pages versus indexable orphans | Live robots and sitemaps | Brand `/s/` pages are noindex, `/dp/` is indexable but absent from sitemap and internal links | Open, ownership unknown | `[A:A2.1]` | | 17 | `redirect_url` points to a Vercel host behind SSO | Live Set-Cookie plus host behavior | If consumed as an absolute URL, the patient hits Vercel SSO | Open | `[A:A8]` `[LIVE Set-Cookie headers]` | | 18 | "$30 typical insurance copay" for labs versus `insurance_price: null` | Live lab SKUs | The $30 is an estimate constant, not a benefit | Resolved | `[F:F5.2]` `[CODE types/enums/lab-pricing-constants.ts:13]` | | 19 | "80% of customers pay $25 or less" | Marketing copy only | Not independently verified | Open, marketing claim | `[LIVE /p/lilly/weight-loss]` | | 20 | Support hours and contact sprawl | FAQ, consent, widgets, evidence-E and evidence-F | Same 12-hour support window, different labels; individual clinician shifts are 4 to 6 hours inside it. Contacts include help@generalmedicine.co, hello@generalmedicine.co, support@navhealth.co, (801) 251-6055 and (801) 255-6051. Tenant, purpose and ownership need reconciliation before publishing one DTC contact | Open | `[F:F3.2]` `[LIVE /faq]` `[LIVE /telehealth-informed-consent]` `[E:E3]` | | 21 | Zendesk as patient support or clinician chat | Physician posting plus patient bundle | Confirmed clinician chat; patient support boundary unknown | Open | `[F:F3.2]` `[LIVE Ashby FT Physician]` | | 22 | Metabase is publicly reachable | Live GET | Login shell reached; the reviewed response requires sign-in. Unauthenticated access to protected data was not established; SSO and permissions need review | Open, security review | `[F:F4.1]` | | 23 | 5-phase GLP-1 progression | Public guide plus SKU prices | Synthesis, not an observed pathway object | Open | `[F:F0.1]` `[DOC briefing slide 35]` | | 24 | Video available in all 50 states versus licensure coverage | Live `sku_options` plus posting requirements | Video option returned for all states; clinician supply, licensure and state enforcement not guaranteed | Open | `[B:B12]` `[F:F3.4]` | | 25 | `signup_complete` may not fire on the GLP-1 CTA path | Code mount point plus redirect | Tracker mount, `fetchUser`, analytics availability and a local flag all gate the call. Firing on this path was not observed | Open | `[A:A8]` `[CODE components/SignupTracker.tsx:16-98]` | | 26 | `price_guarantee_eligible:false` versus checkout `price_guaranteed` flags | Live SKU plus analytics | No guarantee on this path; checkout flags may be generic | Resolved, no guarantee | `[A:A5.4]` `[CODE lib/analytics/checkoutAnalytics.ts:63-64]` | | 27 | Lab results "48 hours" | Product copy only | No measured SLA | Open | `[C:C21]` `[LIVE /resources/labs-faqs]` | | 28 | Insurance discovery vendor | Verified candidate plus Waystar hosts | Both plausible; no payload observed. Diagram uses "Eligibility service" and "Clearinghouse" | Open | `[B:H5]` `[B:H8]` | | 29 | Persona trigger for GLP-1 | Code routes plus generic pre-visit requirement | Trigger unknown; a later gate cannot be excluded | Open | `[B:H22]` `[CODE lib/store/api/updatesApi.ts:76-80]` | | 30 | Who collects the $299 | Public article plus order schema | Pay-ahead is retail-only; mail order pays the pharmacy; schema does not distinguish | Open | `[D:D4.3]` `[C:C13]` | | 31 | Mounjaro is described as a Zepbound variant | Mounjaro PI plus evidence-D catalog | Separate T2D and CV-risk indication, separate NDC, retail-only observed route at $552.28 to $565.63; Zepbound self-pay ladder does not apply | Resolved as a separate branch, price snapshot open | `[PUBLIC Mounjaro PI §1]` `[D:D4.2]` | | 32 | Cash mail order shown as two payments | Pay-ahead article plus evidence-D | Mail order is excluded from GM pay-ahead; patient pays the dispensing pharmacy once. Diagram corrected | Resolved | `[D:D4.3]` `[LIVE /resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup]` | | 33 | Week-4 check-in shown at T+28 | Four-dose supply arithmetic plus generic criteria API | One KwikPen supplies four weekly doses, used by T+21; the next dose is due T+28. Starting refill work at T+28 can miss it. Proposed control is T+14 to T+18 refill start and backward planning; T+21 eRx alone does not guarantee mail-order delivery | Open, proposed control | `[PUBLIC Zepbound PI §2.1]` `[PUBLIC https://www.lilly.com/lillydirect/faq]` `[E:E5]` | | 34 | Click clock and treatment clock share one column | Timeline arithmetic | E0 is click; T0 is first actual dose, patient-reported or evidenced. The clocks differ by the unknown Dstart; no bounded interval is established | Resolved in text, data gap remains | `[INFERENCE]` | ### 12.2 Open questions 1. Which Google queries drive organic sessions and conversions? No Search Console export was available. 2. Is GM running paid media at scale, and are conversions uploaded server-side? No pixel exists. 3. Does the post-auth flow use the full `redirect_url` or only its pathname? 4. Does `signup_complete` fire on the Lilly and GLP-1 CTA path? 5. Who owns sitemap generation, and why are noindex URLs included while indexable pages are omitted? 6. Is the $1,074.09 default a clinical preference or a catalog artifact? 7. Which Zepbound SKU do paid campaigns and prescribers actually use? 8. Are the vial SKUs real products, and why is there no cash price? 9. Is there a BAA with Segment, Datadog, Google, OneSignal, Sanity, Slack, Metabase, or the LLM vendor? 10. Is 100 percent session replay lawful on clinical pages? 11. Is ZeroTouch a product or only a Catalog label? 12. What is the cancellation fee amount? 13. What pharmacy margin, if any, does GM earn? 14. Does the screening questionnaire branch on BMI or contraindications before booking? 15. Are Obesity `300513` and Weight Loss `300312` distinct protocols? 16. What is the exact state-to-PC and state-to-clinician matrix? 17. Is the Vital and OpenLoop consent used for GLP-1, or legacy? 18. Does any GLP-1 case use async clinical review? 19. Who submits a PA, in what tool, and what is the p50 and p90? 20. Does an approval cover a dose change, or is a new PA required? 21. Can a patient attach a manufacturer savings card in GM checkout? 22. Does the week-4 step require a paid visit, a questionnaire, or either? 23. What are the clinical SLAs for chat, video start, and review? 24. Is there a server-side dispense or rejection feed from any pharmacy? 25. Does GM ingest carrier tracking? 26. Is `default_quantity` mL or pens? 27. Who collects and remits the $299 on mail order? 28. Who sponsors the GM card BIN, and what is the discount formula? 29. Is the client `pharmacy_delegated` a typo, a legacy alias, or a real server value? 30. What is the lab bundle composition at week 4 for tirzepatide? 31. What is the patient-facing critical-result SLA? 32. Are at-home lab kits supported? 33. Which LLM and prompt version draft the care plan and the patient copilot answers? 34. What are the CarePathway phase values for GLP-1? 35. Is Zendesk also used for patient support, and is a BPO behind 98528? 36. What happens when weekend and evening clinical coverage expands? 37. Who executes refunds, in what tool, and against what SLA? 38. What is the medication refund policy for an uncollected or canceled fill? 39. Are receipts emailed, and is there a tax line? 40. How does the 104-employee count split across clinical, operations, support, RCM, and engineering? 41. Does GM issue a good-faith estimate for self-pay patients, and in what channel? 42. Is there an accessibility, interpreter, or caregiver path for intake and visits? 43. Are pen needles and sharps supplies included, sold, or only counseled? 44. Does GM confirm patient possession after delivery, or only rely on the carrier scan? 45. Where is contraception counseling recorded at initiation and at each escalation? 46. Is a first-dose administration date captured, and from what source? 47. Is the HIE notice stored as a consent record, or only presented by continuing? 48. What is the current Mounjaro cash quote, PA route and savings eligibility for the T2D branch? 49. Does the backend enforce state licensure and professional-entity routing, or only filter the visible clinician pool? 50. How many outside parties are mandatory on one real journey, as opposed to exchange entries in the register? 51. Which PA submission channel and vendor are actually used, if any? 52. Does any pharmacy send a dispense, rejection or tracking feed back to GM? --- ## 13. Evidence key ### 13.1 Tags | Tag | Meaning | |---|---| | `[CODE path:line]` | Observed in the recovered first-party source under `src/sources/first-party/` | | `[LIVE url, date]` | Observed on the live public site or public API, read-only, on 2026-10-19 | | `[DATA file → key]` | From a local dataset under `osint/`, for example `internal_portals_recon.json` or `extracted_care_plans_and_journeys.json` | | `[DOC file §section]` | From a dossier, AlphaSense report, or briefing appendix | | `[PUBLIC url]` | A public third-party source: label, vendor documentation, NPPES, manufacturer terms | | `[E:§6 q14]` | Open question 14 in `evidence-E.md` section 6 | | `[INFERENCE]` | Reasoning that is not directly observed; the basis is stated inline | | `A:A1`, `B:B7`, `C:C4`, `D:D5.2` | Step row or numbered subsection in the named evidence file. The step ID is the stable anchor; that row carries the exact code path, live URL, or dataset key. | | `[B:§5]` | Section 5 of `evidence-B.md`, covering signup failure branches at `evidence-B.md:128-136`. `[B:B5]` is reserved for the Verified review-info step at `evidence-B.md:29`. | | `H01` to `H72` | Register row in section 4 | | `*` on a register row | On the cash path, including alternative pharmacy and lab channels | | `Observed` | A specific source artifact or public response was inspected; not the full patient workflow | | `Published` | A company or vendor representation, not a measured SLA | | `Proposed` | A recommended future contract or control | | `Recovery gap` | Implementation was not available in the inspected material | | `Mapping gap` | This document omits a required step | | `Inferred` | Deduced from hostnames, absence, or adjacent evidence; not seen directly | ### 13.2 Main sources - Evidence files behind every `A:`–`F:` tag (each step row and handoff row carries its exact code path, live URL, or dataset key): [Evidence A: acquisition](evidence/evidence-A.html), [Evidence B: account and intake](evidence/evidence-B.html), [Evidence C: checkout and labs](evidence/evidence-C.html), [Evidence D: clinical review and pharmacy](evidence/evidence-D.html), [Evidence E: weeks 1 to 4](evidence/evidence-E.html), [Evidence F: backoffice and operating model](evidence/evidence-F.html). Markdown originals sit beside each page. - Recovered consumer app (`src/sources/first-party/`: `app/`, `components/`, `lib/`, `contexts/`, `hooks/`, `config/`, `tenants/`): browse in the [Research Wiki source index](../wiki/index.html#source-tree-index). - Internal portal inventory: [`osint/internal_portals_recon.json`](../wiki/raw/osint/internal_portals_recon.json), covering Visitron 98 routes and 91 RTK operations, Catalog 47 routes and 106 operations, Referrals 18 routes and 27 operations, Provider Chat 20 routes and 14 operations. - Live SKU, questionnaire, and care-plan payloads: [`osint/extracted_care_plans_and_journeys.json`](../wiki/raw/osint/extracted_care_plans_and_journeys.json). - Sitemap and price census: [`osint/live_sitemap_skus.json`](../wiki/raw/osint/live_sitemap_skus.json). - Infrastructure and NPI catalog: [`osint/infra_npi_catalog.json`](../wiki/raw/osint/infra_npi_catalog.json). - Dossiers: [architecture](../wiki/index.html#architecture-spec), [API reference](../wiki/index.html#api-spec), [data models](../wiki/index.html#data-models), [OpenAPI contract](../wiki/index.html#openapi-spec), [market and leadership dossier](../wiki/index.html#adversarial-and-market-report), [company overview](../wiki/index.html#generalmedicine-overview). - AlphaSense reports: [company primer, Oct 19](../wiki/index.html#alphasense-primer-oct19), [expert calls, Oct 18](../wiki/index.html#alphasense-ops-financial-oct18), [primer snapshot, Oct 18](../wiki/index.html#alphasense-primer-oct18). - Public manufacturer terms and labels: `https://zepbound.lilly.com/savings`, `https://www.lilly.com/lillydirect/faq`, `https://www.lilly.com/lillydirect/zepbound`, `https://pi.lilly.com/us/zepbound-uspi.pdf`, `https://pi.lilly.com/us/mounjaro-uspi.pdf`. - Public vendor documentation: `https://docs.verified.inc/1-click-signup/overview`, `https://docs.verified.inc/1-click-health/overview`, `https://www.gifthealth.com/faq-topics/prescriptions-getting-started`, `https://docs.junction.com/lab/overview/orders-and-results`, `https://docs.junction.com/lab/results/critical-results`, `https://docs.junction.com/lab/workflow/redraws`, `https://surescripts.com/news-center/intelligence-in-action/interoperability/the-journey-of-an-electronic-prescription`. - Public registries: `https://npiregistry.cms.hhs.gov/api/`, NPI records `1912889320`, `1285084467`, `1710671854`, `1447011267`, `1750195483`, `1174333975`, `1346050150`. - Public policy pages: `/cancellation-policy`, `/refund-policy-labs`, `/assignment-of-benefits`, `/telehealth-informed-consent`, `/vital-informed-consent`, `/privacy-policy`, `/hipaa-privacy-practices`, `/faq`, `/resources/using-a-glp-1-for-weight-loss`, `/resources/labs-faqs`, `/resources/medication-faqs`, `/using-zoom`, `/clinician-hiring`. - Legal and program references: `https://www.medicare.gov/coverage/weight-loss-drugs`, `https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate`, `https://www.mbc.ca.gov/Resources/Medical-Resources/telehealth.aspx`, `https://www.law.cornell.edu/cfr/text/45/164.502`, `https://www.law.cornell.edu/cfr/text/45/164.524`. - Hiring and operating model: `https://api.ashbyhq.com/posting-api/job-board/general-medicine` and the full-time physician, 1099 physician, 1099 nurse practitioner, care coordinator, NP licensure, and RCM postings. - Public market context: Walmart and LillyDirect retail pickup release, CNBC vial price report, Pharmacy Times manufacturer-direct analysis. ### 13.3 Handoff count method Raw handoff rows by file: A 23, B 22, C 15, D 18, E 18, F 25, total **121**. The register has **72** rows after three operations: merging duplicate vendors that appear in several slices (Stripe, Twilio, Segment, Datadog, LaunchDarkly, Metriport, Particle, Athena, DoseSpot, Arrive, labs, pharmacies); splitting counterparties that were grouped in one raw row but have distinct mechanisms (LillyDirect endpoint versus dispensing pharmacies; Amazon versus other retail; Emerald versus Ruby and Centennial); and adding three handoffs required by the assignment but absent from the six tables (CMS NPPES, CMS Medicare GLP-1 Bridge, and the unidentified LLM provider). The staff identity plane is separated from the patient Cognito row. ### 13.4 Known limits - No authenticated screen was observed. All account, checkout, pharmacy-order, and care-plan pages return 307 to `/login` without an account. - No pharmacy, payer, lab, BI, or records production system was accessed. A missing field in an inspected interface is a recovery gap, not proof of enterprise-wide absence. - The click-to-first-dose interval is not measured. T0 is patient-reported or evidenced, never inferred from payment, eRx, dispense or delivery. - The GLP-1 questionnaire text, the week-4 criteria set and blocking rule, the CarePathway phases, and the PA workflow are server-side and were not recovered. - Internal portal behavior comes from the recorded operation inventory, not a live authenticated session. - The mandatory-party count for one journey is not established. The register counts exchanges, companies, products and conditional branches separately. - Prices and published program terms move. Every price above is a 2026-10-19 observation and should be re-probed before use in a contract or a forecast. ================================================================================ # DOCUMENT: Architecture & Supply Chains (raw/reports/architecture.md) ================================================================================ # Architectural Specification: General Medicine (`generalmedicine.co`) ## 1. System Overview & Technology Stack General Medicine is a telehealth storefront, clinical care engine, and prescription routing platform. Built as a Next.js 14+ App Router application deployed on Vercel Edge infrastructure, it communicates with a Ruby on Rails backend service ("Nile-Core" at `api.generalmedicine.co`) and orchestrates clinical operations across nationwide partner networks: Quest Diagnostics and Labcorp (clinical pathology), Solv Health (same-day urgent care clinic networks), CVS, Walgreens, and Walmart (local pharmacy routing), Metriport and Particle Health (EHR health history retrieval), Stripe and Trust Commerce (credit card and health-system billing), and Persona (HIPAA-compliant identity verification). Two additional layers sit behind that public storefront: a **MedicineOS** internal backoffice suite (Visitron clinician EHR, Catalog/care-pathway admin, Referrals concierge, Provider Chat/LLM prompt workbench, VisitAI scribe) reachable only through separate authenticated deployments, and a **3,184-SKU** commercial catalog indexed across four XML sitemaps with 23 numeric SKU series, including a dedicated Eli Lilly partner storefront. Sections 6–11 unpack the SKU taxonomy, the 38-vendor partner matrix, the backoffice architecture, the three physical supply chains, the virtual-care workflows, and the feature-flag/Jira roadmap surface. ### 1.1 Technical Stack Matrix | Layer | Technology | Version / Implementation Details | | :--- | :--- | :--- | | **Framework & Router** | Next.js App Router & React | Next.js 14.2+, React 18.2+, React Server Components (RSC) + Client Boundaries (`'use client'`) | | **State Management** | Redux Toolkit & RTK Query | `@reduxjs/toolkit` v2.x, `baseApi` with **50 unique domain tag types** (51 entries in `baseQuery.ts`, duplicate `'CareJourney'`), **40 RTK Query API slices** (33 eager + 7 lazy), **137 operations**, 0-retry wrapper (`maxRetries: 0`) | | **UI Design System** | Mantine UI & Custom CSS Modules | `@mantine/core` v7, `@nile/mantine-theme`, Tabler Icons (`@tabler/icons-react`), Lucide React | | **Animation Engine** | Framer Motion | `framer-motion` v11, gesture animations, drawer transitions, layout shifts | | **HTTP & API Layer** | Axios & FetchBaseQuery | Axios client with stack trace interceptors (`contexts/ApiContext.tsx`), RTK Query `clientBaseQuery` with 401 login bounce | | **Multi-Tenancy** | Next.js Middleware & Tenant Engine | Dynamic routing for **Walmart** ("Better Care Services", `app/t/walmart`) and **Mercy Health** (`tenants/mercy`) | | **Authentication** | Custom SMS OTP & Cognito/Google SSO | Phone OTP via `/auth/initiate`, Google SSO (`/api/external/google_sso`), HttpOnly session cookies | | **Identity Verification** | Persona Web SDK & Nile Verified | SSN + DOB 1-click lookup (`/api/external/verified`), embedded Persona KYC verification flow | | **Health Records (EHR)** | Metriport & Particle Health | Automated health history sync (`/api/external/health_history/latest_metriport`), manual chart overrides | | **Urgent Care Network** | Solv Health API | Live slot booking, geolocation search, walk-in reservations (`/api/external/urgent_care/orders`) | | **Pharmacy & Pricing** | NCPDP Directory & GoodRx API | Chain deduplication (CVS, Walgreens, Walmart), GoodRx cash pricing, real-time insurance inquiry | | **Clinical Pathology** | Quest Diagnostics, Labcorp & BioReference | 500xxx series lab panels, server-driven `clinical_fee` (\$15 live across sampled SKUs; \$30 `STANDARD_CLINICAL_FEE` fallback), lab results PDF rendering | | **Observability** | Datadog RUM & Segment Analytics | Datadog browser SDK with RUM error reporting (`reportErrorToDD`), Segment analytics wrapper (`@nile/mantine-theme`) | | **Feature Flags** | LaunchDarkly Client SDK | `LaunchDarklyContext.tsx`, custom evaluation hooks, A/B test variant tracking | | **Clinical EHR & e-Prescribing** | Athenahealth & DoseSpot | Encounter/prescription sync into Athena (`sync_encounter_to_athena`, `care_plan_athena_resync`, patient `athena_id`); DoseSpot SSO and real-time benefit eligibility (`dose_spot_sso`, `prescription_eligibility_inquiries`) | | **Ambient Clinical AI** | Nabla | `get_nabla_status` in Visitron; ambient medical scribe attached to the clinician encounter | | **Internal Backoffice ("MedicineOS")** | Visitron, Catalog, Referrals, Provider Chat | Four separately deployed Next.js admin apps plus VisitAI and extensions, totaling **99 build chunks, 238 RTK Query operations, and 183 API route declarations** (§8, api-spec §3) | | **Business Intelligence** | Metabase over Databricks | `analytics.staging-nile.com` Metabase bootstrap advertises the Databricks driver with SSO/LDAP enabled | | **Content Management** | Sanity.io | Headless CMS project `qnw7v50s` serving editorial imagery through `cdn.sanity.io` | --- ## 2. First-Party Module & Directory Inventory The reconstructed first-party codebase contains 798 files and 51,015 lines of TypeScript/TSX/CSS source code: | Module Directory | File Count | Primary Components / Slices | Functional Scope | | :--- | :---: | :--- | :--- | | `app/` | 15 | `SkuDetailPageClient.tsx`, `GeneralAiPageClient.tsx`, `get-started/page.tsx` | Next.js App Router entry points, layout definitions, error boundaries (`error.tsx`, `global-error.jsx`) | | `components/` | 394 | `ProductDetailPage/`, `UniversalSearch/`, `NavBar/`, `SiteHeader/`, `Store/` | Reusable React components: PDP drawers, search bar, pharmacy comparisons, insurance cards | | `contexts/` | 14 | `ApiContext`, `AuthContext`, `CareContext`, `HealthHistoryContext`, `InsuranceContext`, `TenantContext` | Global React state providers for network communication, auth lifecycle, clinical care syncing, and tenant overrides | | `hooks/` | 14 | `useUniversalSearch`, `useGeneralAiStatus`, `useAttributionTracking`, `useBreakpoints` | Custom reusable React hooks for search debouncing, AI assistant polling, and layout breakpoints | | `lib/api/` | 4 | `endpoints.ts`, `metrics.ts`, `track500.ts`, `interceptors.ts` | Centralized catalog of 194 Nile-Core backend endpoints and client API latency/error telemetry | | `lib/store/` | 44 | `store.ts`, `storeDisplayPricing.ts`, `baseQuery.ts`, `mapDirectoryPharmacyResponse.ts`, **40 RTK Query API slices** (`lib/store/api/**/*.ts`) | Redux store setup, base query with 401 bounce, 33 eager + 7 lazy domain API slices (137 total operations) | | `lib/routes/` | 7 | `inPersonVisit.ts`, `urgentCare.ts`, `skuBooking.ts`, `directory_pharmacy.ts`, `site.ts`, `store.ts` | Strongly-typed route builders with search param serialization and deep link preservation | | `packages/` | 56 | `@nile/mantine-theme`, `@nile/ai-assistant`, analytics and UI primitives | Internal monorepo shared packages for cross-app UI consistency and tracking events | | `tenants/` | 26 | `walmart/` (Better Care Services), `mercy/` (Mercy Health System) | White-label tenant themes, custom logos, layout overrides, and tenant rewrite rules | | `types/` | 4 | `sku-constants.ts`, `ServiceItem.ts`, `lab-pricing-constants.ts`, `StoreTypes.ts` | Runtime domain constants, SKU mappings, and store category definitions | | `config/` | 2 | `tenantRewrites.js`, `walmartPublic.ts` | Next.js rewrite configuration denying infrastructure routes and mapping tenant paths | | `assets/` | 132 | Pharmacy logos (CVS, Walgreens, Walmart), medical SVG icons, marketing graphics | Embedded visual assets for chain recognition and clinical service representations | --- ## 3. High-Level System Architecture The following diagram illustrates the relationship between the client application, the Vercel edge runtime, the core backend Rails API, and third-party clinical/payment/identity partners: ```mermaid flowchart TB subgraph Client_App ["Client Application (Patient Browser / Mobile Web)"] UI["React 18 / Next.js Client Components"] RTK["Redux Toolkit & RTK Query (baseApi)"] Ctx["React Context Layer (Auth, Care, HealthHistory, Tenant)"] AxiosClient["Axios API Client (contexts/ApiContext.tsx)"] end subgraph Edge_Layer ["Vercel Edge & Delivery Network"] CDN["Vercel CDN Edge Network"] Rewrites["Tenant Rewrite Engine (config/tenants/tenantRewrites.js)"] Proxy["Next.js Route Handlers (/api/* Proxy)"] end subgraph Core_Backend ["General Medicine Core Backend (Nile-Core)"] RailsAPI["Ruby on Rails API (api.generalmedicine.co)"] AuthSvc["Authentication & OTP Service"] OrderSvc["Orders & Fulfillment Engine"] CareEngine["Care Plan & Journey Coordinator"] Db[(PostgreSQL Primary Database)] end subgraph Clinical_Partners ["Clinical & Diagnostic Partner Network"] Quest["Quest Diagnostics LIMS (Lab Orders 500xxx)"] Labcorp["Labcorp Laboratory Feeds"] Solv["Solv Health API (Urgent Care Clinic Slots)"] Metriport["Metriport / Particle Health (EHR Health History)"] end subgraph Pharmacy_Partners ["Pharmacy Fulfillment & Pricing Partners"] CVS["CVS Pharmacy Network"] Walgreens["Walgreens Pharmacy Network"] WalmartPharm["Walmart Pharmacy Network"] GoodRx["GoodRx / NCPDP Real-Time Pricing Feed"] end subgraph Security_Payments ["Identity, Payment & Telemetry Services"] Persona["Persona KYC (withpersona.com)"] Stripe["Stripe Payments (SetupIntents)"] TrustCommerce["Trust Commerce (Mercy Health Gateway)"] Datadog["Datadog RUM & Error Tracking"] LaunchDarkly["LaunchDarkly Feature Flags"] end UI --> RTK UI --> Ctx RTK --> Proxy AxiosClient --> Proxy Ctx --> AxiosClient CDN --> Rewrites Rewrites --> UI Proxy --> RailsAPI RailsAPI --> AuthSvc RailsAPI --> OrderSvc RailsAPI --> CareEngine RailsAPI --> Db OrderSvc --> Quest OrderSvc --> Labcorp OrderSvc --> Solv OrderSvc --> Metriport OrderSvc --> CVS OrderSvc --> Walgreens OrderSvc --> WalmartPharm OrderSvc --> GoodRx UI --> Persona UI --> Stripe RailsAPI --> TrustCommerce UI --> Datadog UI --> LaunchDarkly ``` --- ## 4. Component & Trust Boundary Architecture The General Medicine platform enforces trust boundaries between public storefront browsing, HIPAA-protected patient health information (PHI), and third-party credentialed services: ```mermaid flowchart LR subgraph Public_Untrusted ["Public / Untrusted Zone (Client Browser)"] Landing["Storefront & PDP (/s/*, /store/*)"] Search["Universal Search & Suggestions"] AnonSession["Anonymous Session Cookie"] end subgraph Authenticated_Patient ["Patient Authenticated Security Boundary"] AuthCookie["HttpOnly Session Cookie (credentials: 'include')"] PatientDashboard["Patient Dashboard (/account, /my_care)"] HealthHistoryUI["Health History Review (Metriport Review)"] RxOrderUI["Pharmacy Selection & Checkout"] PersonaModal["Persona Embedded Verification Frame"] end subgraph Vercel_Edge_Gateway ["Vercel Edge Proxy Boundary"] EdgeProxy["Next.js API Rewrite Gateway (/api/*)"] TenantResolver["Tenant Identifier Injector (Walmart/Mercy)"] Attestation["Campaign Touch Server Attestation Token"] end subgraph Nile_Core_Protected ["Nile-Core Protected VPC (api.generalmedicine.co)"] CoreControllers["Rails External Controllers (/api/external/*)"] PHIData["Patient PHI, Medical History, Prescriptions"] PaymentTokens["Stripe Customer IDs, Mercy Billing Tokens"] end subgraph External_PCI_HIPAA ["External Regulated Providers"] StripeAPI["Stripe Vault (PCI DSS Level 1)"] TrustCommerceAPI["Trust Commerce Gateway (PCI)"] PersonaAPI["Persona Identity API"] SolvAPI["Solv Health Partner API"] QuestAPI["Quest Diagnostics HL7/FHIR Engine"] end Landing --> Search Search --> EdgeProxy Landing --> AnonSession AnonSession -.->|SMS OTP Login /auth/initiate| AuthCookie AuthCookie --> PatientDashboard PatientDashboard --> HealthHistoryUI PatientDashboard --> RxOrderUI PatientDashboard --> PersonaModal PersonaModal --> PersonaAPI EdgeProxy --> TenantResolver TenantResolver --> Attestation Attestation --> CoreControllers CoreControllers --> PHIData CoreControllers --> PaymentTokens PaymentTokens --> StripeAPI PaymentTokens --> TrustCommerceAPI CoreControllers --> SolvAPI CoreControllers --> QuestAPI ``` --- ## 5. End-to-End Sequence Diagrams ### 5.1 Patient Phone Auth & Identity Verification with Persona Tracing `AuthProvider` (`contexts/AuthContext.tsx`), `signupApi` (`lib/store/api/signupApi.ts`), `inPersonVisitRoutes` (`lib/routes/inPersonVisit.ts`), and Persona Web SDK callback: ```mermaid sequenceDiagram autonumber actor Patient as Patient User participant AuthContext as AuthProvider (React Context) participant Edge as Next.js Edge (/auth/*) participant SignupApi as signupApi (RTK Query) participant NileCore as Nile-Core Rails API participant Persona as Persona Web SDK (withpersona.com) Patient->>AuthContext: Enter Phone Number ("(555) 000-1234") AuthContext->>Edge: POST /auth/initiate { phoneNumber, authType: 'signup' } Edge->>NileCore: Forward initiate request NileCore-->>Edge: HTTP 200 { isExistingUser: false } Edge-->>AuthContext: Response with OTP challenge AuthContext->>Patient: Navigate to /get-started/verify Patient->>Edge: POST /auth/verify { phoneNumber, code: '123456' } Edge->>NileCore: Validate SMS OTP NileCore-->>Edge: Set-Cookie: gm_session_token (HttpOnly, Secure) Edge-->>Patient: HTTP 200 OK (Auth established) opt 1-Click Identity Lookup (Nile Verified) Patient->>SignupApi: verifyIdentity({ birth_date: '1985-05-15', ssn: '1234' }) SignupApi->>NileCore: POST /api/external/verified { birth_date, ssn } NileCore-->>SignupApi: HTTP 200 VerifiedProfile (first_name, last_name, addresses[]) SignupApi->>Patient: Prefill verified demographic profile end opt Fallback to Full Persona KYC Flow Patient->>AuthContext: Navigate to /in-person-visit/orders/:id/verify-identity AuthContext->>Persona: Initialize Persona Client (templateId, inquiryId) Persona->>Patient: Present Government ID & Facial Biometrics capture Patient->>Persona: Submit Identity Evidence Persona-->>NileCore: Webhook inquiry.completed { inquiryId, status: 'approved' } Persona-->>Patient: onComplete() callback Patient->>SignupApi: Refresh user status (GET /api/external/patient) SignupApi-->>Patient: { id_verified: true } end ``` ### 5.2 SKU Storefront Search & Urgent Care Solv Booking Tracing `useUniversalSearch` (`components/Refresh/UniversalSearch/useUniversalSearch.ts`), `urgentCareApi` (`lib/store/api/urgentCareApi.ts`), and `urgentCareRoutes` (`lib/routes/urgentCare.ts`): ```mermaid sequenceDiagram autonumber actor Patient as Patient User participant SearchUI as UniversalSearch Input participant SearchAPI as apiEndpoints.storeSearch.index participant NileCore as Nile-Core Rails API participant UrgentCareApi as urgentCareApi (RTK Query) participant Solv as Solv Health Integration Patient->>SearchUI: Types "urgent care" or "walk-in clinic" SearchUI->>SearchAPI: GET /api/external/search/index?query=urgent+care&include_providers=true&latitude=40.71&longitude=-74.00 SearchAPI->>NileCore: Query SearchResultSerializer NileCore-->>SearchUI: HTTP 200 { skus: [SKU 400336 "Urgent Care Visit"], providers: [...] } SearchUI->>Patient: Render SKU search suggestion tile Patient->>UrgentCareApi: Click "Book Urgent Care" UrgentCareApi->>NileCore: POST /api/external/urgent_care/orders { sku_id: '400336' } NileCore-->>UrgentCareApi: HTTP 201 { order_id: 'ord_uc_987', state: 'draft' } UrgentCareApi->>Patient: Navigate to /urgent-care/orders/ord_uc_987/locations UrgentCareApi->>NileCore: GET /api/external/urgent_care/orders/ord_uc_987/locations NileCore->>Solv: Fetch real-time available clinics & slots Solv-->>NileCore: Solv clinics list (addresses, wait times, slots) NileCore-->>UrgentCareApi: UrgentCareLocationsResponse (locations, daily_hours, slots) UrgentCareApi->>Patient: Display nearby clinics map & slot picker Patient->>UrgentCareApi: Select clinic "Solv Clinic NYC" + Slot "2:30 PM" (or Walk-in) UrgentCareApi->>NileCore: GET /api/external/urgent_care/orders/ord_uc_987/offers NileCore-->>UrgentCareApi: Offers list (Auto-selects matching Solv FulfillmentOffer) UrgentCareApi->>NileCore: PATCH /api/external/urgent_care/orders/ord_uc_987 { fulfillment_offer_id: 'fo_456' } NileCore-->>UrgentCareApi: HTTP 200 Order updated Patient->>UrgentCareApi: POST /api/external/urgent_care/orders/ord_uc_987/checkout { location_id: 'loc_solv_123', appointment_time: '2026-10-16T14:30:00Z', on_demand: false } NileCore->>Solv: Confirm clinic reservation Solv-->>NileCore: Reservation confirmed (confirmation_code: 'SOLV-882') NileCore-->>UrgentCareApi: HTTP 200 UrgentCareCheckoutResponse { state: 'confirmed' } UrgentCareApi->>Patient: Navigate to /urgent-care/orders/ord_uc_987/booked ``` ### 5.3 Lab Order Quest Diagnostics & Results Lifecycle Tracing SKU `500001` (Annual Wellness), `LabPanelPricing` (`components/LabPanelPricing.tsx`), and `careJourneyApi` (`lib/store/api/careJourneyApi.ts`): ```mermaid sequenceDiagram autonumber actor Patient as Patient User participant PDP as Lab SKU PDP (/s/annual-wellness-test/500001) participant PricingComp as LabPanelPricing Component participant NileCore as Nile-Core Rails API participant Quest as Quest Diagnostics LIMS participant Dashboard as Patient Dashboard (/account) Patient->>PDP: Views Annual Wellness Panel (SKU 500001) PDP->>PricingComp: Initialize LabPanelPricing PricingComp->>NileCore: GET /api/external/lab_skus/500001 NileCore-->>PricingComp: HTTP 200 { cash_price: 114.92, clinical_fee: 15, test_codes: ['CBC', 'CMP', 'LIPID'] } PricingComp->>Patient: Displays "$114.92 Lab Test + $15 Clinical Review Fee ($30 fallback if omitted)" Patient->>NileCore: POST /api/external/visits/create { sku_id: '500001', billing_type: 'cash' } NileCore-->>Patient: HTTP 201 { visit_id: 'vis_lab_123', state: 'pending_review' } Note over NileCore,Quest: Clinical Team Reviews Lab Order Requisition NileCore->>Quest: Transmit Electronic Lab Order (eReq HL7/FHIR) Quest-->>NileCore: Acknowledged (accession_number: 'Q-991204') NileCore->>Patient: Send Email/SMS: "Your Quest Lab Requisition is Ready" Patient->>Quest: Visits Quest Patient Service Center for Blood Draw Quest->>Quest: Analyzes Serum Samples (CBC, CMP, Lipid Panel) Quest->>NileCore: Webhook / Batch HL7 Results Transmission NileCore->>NileCore: Ingest Results & Physician Signs Off Findings Dashboard->>NileCore: GET /api/external/dashboard/lab_orders NileCore-->>Dashboard: HTTP 200 LabOrdersList { id: 'lab_123', status: 'completed', report_url: '...' } Dashboard->>Patient: Render "Annual Wellness Results Ready" + Download PDF Link ``` ### 5.4 Pharmacy Order Routing & Real-Time Price Comparison across CVS/Walgreens/Walmart Tracing `ProductDetailPageContent` (`components/ProductDetailPage/ProductDetailPageContent.tsx`), `PharmacyComparisonRow` (`components/ProductDetailPage/PharmacyComparisonRow.tsx`), and `pharmacyOrderApi` (`lib/store/api/pharmacyOrderApi.ts`): ```mermaid sequenceDiagram autonumber actor Patient as Patient User participant PDP as Medication PDP (/s/ozempic/711204) participant CompareDrawer as ComparePharmaciesDrawer participant NileCore as Nile-Core Rails API participant GoodRx as GoodRx / NCPDP Pricing Engine participant PharmApi as pharmacyOrderApi (RTK Query) Patient->>PDP: Views Ozempic (Medication Option SKU 711204) PDP->>NileCore: GET /api/external/product_detail_pages/711204 NileCore-->>PDP: HTTP 200 ProductDetailPage { brand_name: "Ozempic", gpi14: "...", default_cash_price: 980 } Patient->>CompareDrawer: Clicks "Compare local pharmacy prices" CompareDrawer->>NileCore: GET /api/external/pharmacy_comparisons?medication_option_sku_id=711204&latitude=37.77&longitude=-122.41 NileCore->>GoodRx: Query real-time negotiated cash discounts by GPS GoodRx-->>NileCore: Price matrix across chains (CVS, Walgreens, Walmart) NileCore-->>CompareDrawer: HTTP 200 PharmacyComparisonResult[] [ { chain_name: "CVS", price: 935, distance: 0.8 }, { chain_name: "Walgreens", price: 928, distance: 1.2 }, { chain_name: "Walmart", price: 899, distance: 2.5 } ] CompareDrawer->>Patient: Renders interactive map markers & sorted price rows Patient->>PharmApi: Selects "Walmart Pharmacy #5432" PharmApi->>NileCore: POST /api/external/pharmacy_orders/po_334/select_pharmacy { ncpdp_id: "5678901", pharmacy_name: "Walmart Pharmacy #5432", billing_type: "cash" } NileCore-->>PharmApi: HTTP 200 { pharmacy_order_id: "po_334", state: "pharmacy_selected" } Patient->>PharmApi: Clicks "Confirm & Request Medication" PharmApi->>NileCore: POST /api/external/pharmacy_orders/po_334/checkout { return_url: "https://generalmedicine.co/orders/pharmacy/po_334", payment_method_id: "pm_card_999" } NileCore-->>PharmApi: HTTP 200 PharmacyOrderCheckoutResponse { state: "order_placed" } PharmApi->>NileCore: GET /api/external/pharmacy_orders/po_334/gm_card NileCore-->>Patient: Displays Digital Rx Savings Card (BIN, PCN, Group, MemberID) to show pharmacist ``` --- ## 6. SKU Taxonomy & 3,184-SKU Sitemap Breakdown ### 6.1 Four XML Sitemaps, 6,488 Entries, 3,290 Unique URLs The public catalog is not a single index. It is split across four independently generated XML sitemaps, each with a different refresh cadence and audience. The 2026-10-19 crawl (`osint/live_sitemap_skus.json`, generated `2026-10-19T08:02:15+00:00`) parsed all four: | Sitemap | Bytes | Entries | Composition | Purpose | | :--- | ---: | ---: | :--- | :--- | | `sitemap.xml` | 8,895 | 51 | 20 clinician bios + 20 marketing pages + 10 legal pages + 1 home | Corporate, editorial, and compliance index | | `store-sitemap.xml` | 492,498 | 3,240 | 3,184 SKU PDPs + 54 marketing pages + 1 home + 1 partner storefront | Master commercial catalog | | `sku-refresh.sitemap.xml` | 577,067 | 3,099 | SKUs only | Fast-refresh subset; exactly 85 fewer SKUs than the store sitemap | | `in-person-skus-sitemap.xml` | 19,120 | 98 | 88 × `400xxx` + 10 × `300xxx` | In-person / visit-specific SKU index | `sitemap.xml`'s 51 entries reconcile exactly as **31** page/legal/home URLs + **20** clinician-bio URLs; the crawl does not tag bio pages with sitemap membership individually, so that split is arithmetic rather than directly observed. **Reconciliation arithmetic.** The four files contain **6,488 entries**, which deduplicate to **3,290 unique URLs**: - `3,184` unique SKU PDPs (`/s/:slug/:skuId`). - `74` marketing pages, `20` clinician bios, `10` legal/policy pages, `1` home page, and `1` partner storefront (`/p/lilly/weight-loss`). - `3,001` SKUs carry exactly the `store + refresh` pair; **98** carry all three sitemap memberships (the in-person set); **85** appear only in `store-sitemap.xml` (84 `700xxx` pharmacy options + 1 `200xxx` medication); **zero** appear only in the refresh sitemap. Refresh is therefore a strict subset of store. The reason the 85 are absent from the refresh file is **not established** by the sitemap data. - The 98 in-person SKUs split **88 × `400xxx` + 10 × `300xxx`**, and every one also appears in both commercial sitemaps — the in-person file is a *view*, not an additional catalog. - Duplicate entries reconcile exactly: **3,099** (refresh is a subset of store) + **98** (in-person overlaps both) + **1** (the home page appears in both non-SKU sitemaps) = **3,198** duplicates. `6,488 − 3,198 = 3,290` unique URLs. ### 6.2 The 23 Numeric SKU Series The catalog uses a prefix-numbered taxonomy in which the leading digits encode clinical domain, fulfillment modality, and (for `700xxx`–`711xxx`) the specific medication-option variant. All 23 observed series: | Series | SKUs | ID span | Clinical domain | Observed categories | Representative SKUs | | :--- | ---: | :--- | :--- | :--- | :--- | | `100xxx` | 20 | `100012`–`100069` | Primary care and specialist e-consults | `visit`, `specialty` | `100012` Primary Care Visit, `100014` Dermatology Consult, `100017` Urology Consult | | `200xxx` | 449 | `200001`–`200997` | Medications and renewal intake | `medication` | `200007` Prescription Renewal, `200008` Tamiflu, `200217` Sildenafil, `200331` EpiPen | | `201xxx` | 288 | `201001`–`201998` | Brand medications (T2D / GLP-1 era) | `medication` | `201446` Mounjaro, `201448` Zepbound, `201668` Contrave, `201992` Saxenda | | `202xxx` | 172 | `202004`–`202693` | Newer brand and oral GLP-1 medications | `medication` | `202184` Wegovy, `202198` Ozempic, `202682` Oral Wegovy, `202690` Foundayo | | `300xxx` | 511 | `300001`–`300612` | Conditions, clinical protocols, and ACR | `condition`, `visit` | `300007` Migraine, `300302` Anxiety, `300543` GLP-1 Evaluation, `300591` ACR Follow-Up | | `400xxx` | 101 | `400001`–`400335` | Encounters, notes, video and in-person visits | `visit` | `400001` Doctor's Note, `400013` General Video Visit, `400020` Rx Renewal, `400336` Urgent Care | | `500xxx` | 255 | `500001`–`500731` | Diagnostic pathology panels | `lab` | `500001` Annual Wellness, `500093` Thyroid Panel, `500097` TSH | | `501xxx` | 7 | `501145`–`501936` | Expanded lab panels | `lab` | e.g. `501145` | | `502xxx` | 6 | `502272`–`502818` | Expanded lab panels | `lab` | e.g. `502272` | | `503xxx` | 12 | `503009`–`503263` | Expanded lab panels | `lab` | e.g. `503009` | | `700xxx` | 102 | `700005`–`700998` | Pharmacy medication options | `medication_option` | `705966` Lagevrio (lowest live price, \$5.11) | | `701xxx` | 94 | `701007`–`701973` | Pharmacy medication options | `medication_option` | — | | `702xxx` | 107 | `702002`–`702999` | Pharmacy medication options | `medication_option` | — | | `703xxx` | 128 | `703010`–`703971` | Pharmacy medication options | `medication_option` | — | | `704xxx` | 99 | `704000`–`704982` | Pharmacy medication options | `medication_option` | — | | `705xxx` | 113 | `705004`–`705998` | Pharmacy medication options | `medication_option` | `705966` Lagevrio | | `706xxx` | 104 | `706000`–`706991` | Pharmacy medication options | `medication_option` | `706663` Astepro | | `707xxx` | 107 | `707003`–`707994` | Pharmacy medication options | `medication_option` | — | | `708xxx` | 125 | `708021`–`708996` | Pharmacy medication options | `medication_option` | `708908` Tibsovo (highest live price, \$17,411.20) | | `709xxx` | 105 | `709027`–`709989` | Pharmacy medication options | `medication_option` | — | | `710xxx` | 175 | `710002`–`710995` | High-velocity GLP-1 and brand options | `medication_option` | `710641` Zepbound (\$299.00), `710655` Mounjaro (\$552.28) | | `711xxx` | 103 | `711007`–`711991` | Pharmacy medication options | `medication_option` | `711988` Apri | | `364` | 1 | `364` | Legacy menopause consultation | `specialty` | `364` Menopause Symptoms | **Rolled up into the seven sitemap families (plus the tenant-only `1400xxx` series):** | Family | SKUs | Share of 3,184 | Composition | Commercial role | | :--- | ---: | ---: | :--- | :--- | | `700xxx` | 1,362 | 42.8% | All twelve `700xxx`–`711xxx` series | Dispensable pharmacy medication options routed to retail/mail-order | | `200xxx` | 909 | 28.6% | `200xxx` + `201xxx` + `202xxx` | Prescription medications and renewal products | | `300xxx` | 511 | 16.0% | `300xxx` | Asynchronous conditions, protocols, ACR escalation | | `500xxx` | 280 | 8.8% | `500xxx`–`503xxx` | Quest / Labcorp / BioReference lab panels | | `400xxx` | 101 | 3.2% | `400xxx` | Video, in-person, note, urgent-care visits, and procedure/surgery bundles | | `100xxx` | 20 | 0.6% | `100xxx` | Primary-care and specialist e-consults | | `1400xxx` | 3 known | — (tenant-only; absent from all sitemaps) | `1400015`, `1400017`, `1400018` | Walmart "Better Care Services" white-label overrides | | `364` | 1 | 0.03% | Legacy root ID | Pre-taxonomy menopause consult | | **Sitemap total** | **3,184** | **100%** | | | The `1400xxx` family is a **24th, tenant-only series** that exists in code and routing but has no sitemap presence. Its three observed IDs (`1400015` urgent care, `1400017` primary care, `1400018` prescription renewal) are resolved through `config/tenants/walmartPublic.ts` and never enter the consumer catalog. Any SKU census that counts only sitemap URLs will miss it entirely. ### 6.3 Price Coverage and Sitemap-Only SKUs Not every SKU URL's commercial status can be established from the 108-query sample. The harvest against `/api/external/search/index` plus 25 catalog endpoints surfaced **448 SKUs (14.1% of the sitemap)**. The per-record fields — not the aggregate summary — show that **326 of those 448 carry a non-null top-level cash or insurance price**, while **122 have neither at the top level**. Eight of those 122 are conditions whose option records do carry fees (for example, `300603` has `checkout_fee: 4500`, `coordination_fee: 3000`, and `clinical_review_fee: 1500`), so a null top-level field does **not** establish that a SKU is unpriced. The other **2,736 SKUs (85.9%)** were not surfaced by this sample; their commercial status is **unknown**. At least one counterexample shows why "sitemap-only" cannot be read as "unpublished": `400285` (Chronic Pain Management — Opioid Prescribing) appears in `sitemap_only_skus` yet is returned by a live `query=chronic pain` search. The top-level-priced set breaks down as follows: | Category (non-null top-level price) | Count | Price notes | | :--- | ---: | :--- | | `medication_option` | 162 | Priced per pharmacy option; a further 103 medication options have neither top-level field and may still be priced after pharmacy selection | | `lab` | 95 | Cash prices from the 3-lab arbitrage; server-driven `clinical_fee` (`$15` live across sampled SKUs; `$30` client fallback) added at checkout | | `condition` | 41 | Visit + questionnaire products; 8 additional conditions have null top-level price but option-level fees | | `medication` | 25 | Parent medication SKUs; often list price rather than net; 11 additional medications have neither top-level field | | `visit` | 2 | Video/chat visit configurations | | `specialty` | 1 | Specialist e-consult | | **Total** | **326** | | **Data-quality note.** `summary.sku_with_live_price` reports 448 because it counts *search-surfaced* SKUs, not priced records. The authoritative top-level count is derived from the per-record `cash_price_cents` / `insurance_price_cents` fields: **326 non-null, 122 null**. Null is not equivalent to unpriced: 8 of the 122 nulls carry option-level fees, and the remaining 114 may be priced after pharmacy or visit selection. Any downstream report should use per-record fields and avoid treating the summary aggregate as a priced count. Observed cash-price range across the 326 top-level-priced SKUs: **\$5.11** (`705966` Lagevrio) to **\$17,411.20** (`708908` Tibsovo), a 3,407× spread that reflects the mix of generic oral solids and specialty oncology drugs. The `catalog` probe independently confirmed **329 unique SKUs** across **20 series** and **9 live category slugs** (weight-loss, medications, labs, womens-health, mental-health, dermatology, sleep, everyday-care, musculoskeletal). ### 6.4 Anchor SKU Registry The following SKUs are referenced directly by first-party code, routes, or tenant configuration and therefore act as architectural anchors: | SKU | Product / Service | Family | Canonical route | Role in the system | | :--- | :--- | :---: | :--- | :--- | | `100012` | Primary Care Visit (`PRIMARY_CARE_VISIT_SKU_ID`) | `100xxx` | `/s/primary-care-visit/100012` | Synchronous primary-care entry point | | `100014` | Dermatology Consult | `100xxx` | `/s/dermatology-consult/100014` | Specialist e-consult | | `100017` | Urology Consult | `100xxx` | `/s/urology-consult/100017` | \$150 cash / \$25 insurance e-consult | | `200007` | Prescription Renewal | `200xxx` | `/s/prescription-renewal/200007` | Unauthenticated renewal intake | | `200011` | New Medication Consult | `200xxx` | `/s/new-medication-consult/200011` | New Rx evaluation | | `200217` | Sildenafil (Viagra) | `200xxx` | `/s/sildenafil-viagra/200217` | Generic ED medication | | `200331` | EpiPen (epinephrine auto-injector) | `200xxx` | `/s/epipen-epinephrine-auto-injector/200331` | Rescue medication | | `201446` | Mounjaro (tirzepatide) | `201xxx` | `/s/mounjaro-tirzepatide/201446` | T2D GLP-1/GIP | | `201448` | Zepbound (tirzepatide) | `201xxx` | `/s/zepbound-tirzepatide/201448` | Chronic weight management | | `201668` | Contrave (bupropion/naltrexone) | `201xxx` | `/s/contrave/201668` | Oral weight-management combination | | `201992` | Saxenda (liraglutide) | `201xxx` | `/s/saxenda/201992` | Daily GLP-1 injection | | `202184` | Injectable Wegovy (semaglutide) | `202xxx` | `/s/injectable-wegovy-semaglutide/202184` | \$199/mo weekly injection | | `202198` | Ozempic (semaglutide) | `202xxx` | `/s/ozempic/202198` | T2D GLP-1 | | `202682` | Oral Wegovy (semaglutide) | `202xxx` | `/s/oral-wegovy-semaglutide/202682` | \$149/mo oral GLP-1 | | `202690` | Foundayo (orforglipron) | `202xxx` | `/s/foundayo-orforglipron/202690` | \$149/mo once-daily oral GLP-1 | | `300001n` | UTI Clinical Evaluation | `300xxx` | `/s/uti-evaluation/300001n` | Trailing-letter anomaly (§6.6) | | `300007` | Migraine Protocol | `300xxx` | `/s/migraine/300007` | Asynchronous protocol | | `300302` | Anxiety / Stress Protocol | `300xxx` | `/s/anxiety/300302` | Asynchronous protocol | | `300543` | GLP-1 Medication Evaluation | `300xxx` | `/s/glp1-medication-evaluation/300543` | Weight-loss intake | | `300591` | ACR Follow-Up Video Visit (`ACR_FOLLOW_UP_VIDEO_VISIT_SKU_ID`) | `300xxx` | `/visits/:id/options` | Asynchronous-to-synchronous escalation | | `364` | Menopause Symptom Management | Legacy | `/s/menopause-symptoms/364` | Pre-taxonomy 3-digit SKU | | `400001` | Doctor's Note Consultation | `400xxx` | `/s/doctor-s-note/400001` | Chat \$30 / video \$100 / insurance \$25 | | `400002` | Urgent Care In-Person Reservation | `400xxx` | `/s/urgent-care/400002` | Legacy in-person reservation | | `400012` | Travel Medicine & Vaccination Counseling | `400xxx` | `/s/travel-medicine-vaccination-counseling/400012` | Travel consult | | `400013` | General Video Visit (`GENERAL_VISIT_SKU_ID`) | `400xxx` | `/s/video-visit/400013` | Synchronous Zoom visit | | `400015` | Follow-Up Video Visit (`FOLLOW_UP_VIDEO_VISIT_SKU_ID`) | `400xxx` | `/visits/:id/options` | Continuity visit | | `400020` | Rx Renewal, Existing Patient | `400xxx` | `/prescriptions/:id/check-in` | Authenticated renewal | | `400336` | Urgent Care Catalog SKU (`URGENT_CARE_SKU_ID`) | `400xxx` | `/s/urgent-care/400336` | Solv urgent-care booking | | `500001` | Annual Wellness Test | `500xxx` | `/s/annual-wellness-test/500001` | Anchor lab panel | | `500093` | Thyroid Panel with TSH | `500xxx` | `/s/thyroid-panel-with-tsh/500093` | Chronic-med monitoring | | `500097` | TSH Standalone | `500xxx` | `/s/tsh/500097` | Single-analyte panel | | `1400015` | Walmart Urgent Care Override | `1400xxx` | `/s/urgent-care/1400015` | Enterprise tenant override | | `1400017` | Walmart Primary Care Override | `1400xxx` | `/s/primary-care-visit/1400017` | Enterprise tenant override | | `1400018` | Walmart Prescription Renewal Override | `1400xxx` | `/s/prescription-renewal/1400018` | Enterprise tenant override | ### 6.5 The Eli Lilly Partner Storefront (`/p/lilly/weight-loss`) `/p/lilly/weight-loss` is the **only** `partner_store` URL among all 3,290 unique URLs and the only manufacturer-branded landing page in either commercial sitemap. It fronts a Lilly-specific GLP-1 assortment whose SKUs are otherwise indistinguishable from the consumer catalog — the same PDP renderer, the same pharmacy comparison drawer, and the same checkout stack: | SKU | Storefront slug | Product | Live cash price | Configuration notes | | :--- | :--- | :--- | ---: | :--- | | `202690` | `foundayo-orforglipron` | **Foundayo (orforglipron)** — oral GLP-1 | **\$149.00/mo** | Once-daily pill, "any time of day, with no food or water restrictions" (catalog description) | | `201448` | `zepbound-tirzepatide` | **Zepbound (tirzepatide)** — parent medication SKU | **\$1,074.09** list; option `710641` at **\$299.00/mo** | Vials and KwikPen direct-pay configuration surfaced through the medication-option SKU | | `202682` | `oral-wegovy-semaglutide` | **Oral Wegovy (semaglutide)** | **\$149.00/mo** | Oral semaglutide pill | | `202184` | `injectable-wegovy-semaglutide` | Injectable Wegovy (semaglutide) | **\$199.00/mo** | Weekly injection | | `201446` | `mounjaro-tirzepatide` | Mounjaro (tirzepatide) | **\$552.28/mo** | Option `710655` carries the identical price | **Commercial read.** Lilly is the only manufacturer with a dedicated partner path, and the price ladder is deliberate: oral GLP-1s (`Foundayo`, `Oral Wegovy`) sit at **\$149/mo**, injectable Wegovy at **\$199/mo**, Zepbound's direct-pay option at **\$299/mo**, while the legacy parent SKUs retain list prices of **\$552–\$1,074/mo**. The parent/option split is not cosmetic — `201448` and `710641` are separate SKUs with a 3.6× price gap, which is how the platform preserves a list-price anchor while advertising a direct-pay price. The partner page also explains why `LillyDirect` appears *inside* the storefront (featured online pharmacy) rather than as an external redirect: General Medicine brokers the prescription, and Lilly fulfills it. ### 6.6 Five Structural SKU Anomalies | # | Anomaly | Evidence | Architectural impact | Mitigation observed in code | | :---: | :--- | :--- | :--- | :--- | | 1 | **Trailing-letter SKU** `300001n` | `types/enums/StoreTypes.ts:39` routes `/s/uti-evaluation/300001n` | Breaks `^\d{6}$` parsers, numeric sorting, and any integer-typed SKU column | Routes use string concatenation; the SKU never enters the sitemap (the numeric `300001` does) | | 2 | **Three-digit legacy SKU** `364` | `lib/hardcoded-data/weight-loss.ts:73` | Violates the six-digit convention; only surviving pre-standardization ID | Treated as an opaque string; appears in both commercial sitemaps | | 3 | **Cross-domain namespace pollution** `200007` vs `400020` | `lib/store/api/sku-constants.ts:9,19` | `200007` is a *visit* (renewal intake) numbered in the medication family; `400020` is the correct visit-family renewal | Renewal router dispatches by patient state, not by series (§10.5) | | 4 | **Modality collision** `300591` vs `400013`/`400015` | `lib/store/api/sku-constants.ts:5-8` | `300591` is a synchronous video visit numbered in the asynchronous protocol family because it is *spawned* by an ACR order | Booking code keys off `ACR_FOLLOW_UP_VIDEO_VISIT_SKU_ID`, not family range | | 5 | **Seven-digit enterprise series** `1400xxx` | `config/tenants/walmartPublic.ts:18-20` | White-label Walmart SKUs bypass the six-digit consumer taxonomy; none appear in the public sitemaps | Tenant config maps Walmart routes to `1400015/1400017/1400018` | A sixth, non-taxonomic anomaly is worth recording separately: **85 SKUs exist only in `store-sitemap.xml` and not in `sku-refresh.sitemap.xml`** (84 `700xxx`, 1 `200xxx`). This is a sitemap-coverage gap rather than an ID defect; whether those 85 are stale is not established, but the store sitemap cannot be treated as a freshness signal. --- ## 7. 38-Vendor & Partner Architecture Matrix ### 7.1 The 38 Core Vendors Eleven of the 38 rows exist only in the backoffice or infrastructure layer: **Athenahealth, DoseSpot, Nabla, Junction/Vital, OpenLoop Health, Arrive Health, Waystar, Sanity.io, AWS Cognito, Databricks, and Metabase**. The remaining vendors serve the storefront, pharmacy networks and clinical operations. Verification legend: **Observed** = literal identifier, endpoint, or configuration recovered from source or a live artifact; **Observed (host)** = DNS or HTTP-probed host only; **Attributed** = the vendor's product role is applied to an observed signal, but the role name itself does not appear in recovered assets. | # | Layer | Vendor / Partner | Integration surface (observed text) | Function in the platform | Verification | | ---: | :--- | :--- | :--- | :--- | :--- | | 1 | Clinical EHR | **Athenahealth** | `sync_encounter_to_athena`, `encounter_summary_athena_resync`, `care_plan_athena_resync`, `athena_id` on the patient model | System of record for clinician encounters, care plans, and chart summaries; Visitron writes back into Athena | Observed | | 2 | e-Prescribing | **DoseSpot** | `dose_spot_sso`, `getDoseSpotIdpStatus`, `DoseSpotRtpbInquiry`, `prescription_eligibility_inquiries/{launch,formulary,sync_insurance}` | Clinician identity provider for prescribing, real-time benefit check, formulary lookups, EPCS | Observed (EPCS role attributed) | | 3 | Ambient AI | **Nabla** | `get_nabla_status` (Visitron), `VisitronPrompt` tag type | Ambient medical scribe that drafts the encounter note while the clinician talks to the patient | Observed (scribe role attributed) | | 4 | Biomarker API | **Junction (Vital, `tryvital.io`)** | `junction_biomarkers`, `getJunctionBiomarkers`, `getJunctionBiomarkerFilterOptions`, `updateJunctionBiomarker`, `getAvailableLabPanelBiomarkers` | Biomarker catalog and lab-panel composition for Catalog admins | Observed (domain attribution external) | | 5 | Clinician network | **OpenLoop Health** | `/vital-informed-consent`: *"Vital and affiliate Openloop Healthcare Partners, PC offer Telehealth consultations…"* | Affiliate medical group furnishing telehealth consultations | Observed | | 6 | RTPBI | **Arrive Health** | `arrive_rtpbi_inquiry_id`, `launch_benefit_inquiry`, `patient_context?patient_id=`, tags `ArriveHealthInquiry`, `ArriveHealthPatientContext` | Real-time prescription benefit inquiry against the patient's PBM at pharmacy selection | Observed | | 7 | RCM / clearinghouse | **Waystar** | `waystar-connector.staging-nile.com`, `waystar-bridge.staging-nile.com` (DNS; connector timed out, bridge unresolved) | Claims, remittance, and eligibility (EDI 270/271) bridge between Nile-Core and payers | Observed (host); EDI role attributed | | 8 | Headless CMS | **Sanity.io** | `cdn.sanity.io/images/qnw7v50s/production/…` in `lib/hardcoded-data/blogPosts.ts` | Editorial imagery and marketing content delivery | Observed | | 9 | Identity | **AWS Cognito** | Source comment: *"Next.js → AWS Cognito CUSTOM_AUTH → Twilio in a Lambda"*; `provider-auth.generalmedicine.co` behind `awselb/2.0` | Patient OTP authentication and provider SSO token issuance | Observed | | 10 | Data warehouse | **Databricks** | Metabase bootstrap JSON advertises `engines.databricks` with host and connection detail fields | Lakehouse source behind the BI layer | Observed | | 11 | BI | **Metabase** | `analytics.staging-nile.com` returns HTTP 200, `Metabase`, `enable-sso-ldap?: true` | Internal dashboards over Databricks | Observed | | 12 | Pathology | **Quest Diagnostics** | `lab_options.prices.quest`, `LabPanelPricing.tsx` | Lab panels, PSC draw sites, HL7/FHIR results | Observed | | 13 | Pathology | **Labcorp** | `lab_options.prices.labcorp` | Alternative lab network and wholesale price comparator | Observed | | 14 | Pathology | **BioReference** | `lab_options.prices.bioreference` | Third wholesale lab price source | Observed | | 15 | Retail pharmacy | **CVS Health** | `pharmacyChainIcon.ts`, `KNOWN_CHAIN_PREFIXES` (`cvs`) | Retail pickup, cash/insurance adjudication | Observed | | 16 | Retail pharmacy | **Walgreens** | `pharmacyChainIcon.ts`, `KNOWN_CHAIN_PREFIXES` (`walgreens`) | Retail pickup | Observed | | 17 | Retail pharmacy | **Walmart Pharmacy** | `KNOWN_CHAIN_PREFIXES` (`walmart`), tenant SKUs `1400015/17/18` | Retail pickup plus white-label enterprise fulfillment | Observed | | 18 | Retail pharmacy | **Kroger / Costco / Rite Aid** | `KNOWN_CHAIN_PREFIXES` (`kroger`, `costco`, `riteaid`) | Value-chain and warehouse-club pickup options | Observed | | 19 | Specialty pharmacy | **Alto Pharmacy** | `KNOWN_CHAIN_PREFIXES` (`alto`) | Same-day delivery specialty pharmacy | Observed | | 20 | Mail order | **Amazon Pharmacy** | `PRIORITY_INTERSPESE_ONLINE_PHARMACY_NAME_KEYS = ['amazonpharmacy']` | First online slot in the 2:1 retail/online interleave | Observed | | 21 | Manufacturer direct | **LillyDirect** | `FEATURED_ONLINE_PHARMACY_NAME_KEYS = ['lillydirect', 'novocare']`; `/p/lilly/weight-loss` | Pinned manufacturer-direct fulfillment for Zepbound/Foundayo | Observed | | 22 | Manufacturer direct | **NovoCare** | Same featured key list | Pinned manufacturer-direct fulfillment for Wegovy/Ozempic | Observed | | 23 | Pricing | **GoodRx** | `GET /api/external/pharmacy_comparisons`, `pharmacy_pricing/cash_price` (the vendor string itself is absent from recovered source) | Real-time cash discount matrix by GPS | Attributed | | 24 | Pharmacy data | **NCPDP** | `ncpdpProviderId`, `pharmacy_detail/:ncpdpProviderId` | Pharmacy directory, licensing, and claim routing identifiers | Observed | | 25 | Urgent care | **Solv Health** | `/api/external/urgent_care/orders/{id}/{locations,offers,checkout,reschedule}` | Live clinic slots, walk-in reservations, appointment ownership | Observed | | 26 | Cash surgery | **MDSave** | `ownerOptions.ts` offer grouping and price tie-break | Prepaid cash bundles for in-person procedures | Observed | | 27 | HIE | **Metriport** | `/api/external/health_history/latest_metriport`, `send_metriport_review_to_copilot` | Longitudinal EHR retrieval and AI chart prewarming | Observed | | 28 | HIE | **Particle Health** | Health-history aggregation layer documented in `decompilation-coverage.md` | Secondary HIE network for records Metriport cannot reach | Attributed | | 29 | Identity / KYC | **Persona** | `Persona` verification routes (`lib/routes/inPersonVisit.ts:119-135`), embedded verification flow | Government-ID and biometric identity verification | Observed | | 30 | Payments | **Stripe** | SetupIntents, `payment_method_id`, 3D Secure checkout branches | Card capture, pre-pay, subscriptions | Observed | | 31 | Payments | **Trust Commerce** | `mercy_billing`, `update_mercy_billing`, `billing_token` | Mercy Health hospital billing gateway | Observed | | 32 | Messaging | **Twilio** | `/api/external/conversations/token`, Conversations API, OTP Lambda | Patient–clinician chat and SMS OTP delivery | Observed | | 33 | Video | **Zoom** | `meeting_url` on visits; `/using-zoom`; testimonials reference Zoom | Synchronous video visit transport | Observed | | 34 | Video CDN | **Vimeo** | `player.vimeo.com/progressive_redirect/playback/1173031901/…` | Clinician-hiring and marketing video | Observed | | 35 | Feature flags | **LaunchDarkly** | `LaunchDarklyContext.tsx`, `useLaunchDarklyFlag`, `gen-ai-prewarm-copilot` | Flag evaluation, A/B assignment, Datadog correlation | Observed | | 36 | Observability | **Datadog** | RUM SDK, `reportErrorToDD`, `addFeatureFlagEvaluation` | Session replay, error tracking, flag-aware RUM | Observed | | 37 | Analytics | **Segment** | `@nile/mantine-theme/analytics`, `evs.segment.staging-nile.com` | Product analytics event pipeline | Observed | | 38 | Recruiting | **Ashby HQ** | `jobs.ashbyhq.com/general-medicine/e230577a-…`, `…/45200894-…` | Clinician and staff applicant tracking | Observed | ### 7.2 Platform Substrate (Outside the 38 Vendor Rows) | Platform | Evidence | Role | | :--- | :--- | :--- | | **Vercel** | Every portal responds with `Server: Vercel`; deployment IDs `dpl_*`; build root `/vercel/path0/apps/customer-frontend/` | Edge hosting, preview deployments, rewrite engine | | **AWS S3 / CloudFront** | `POST /api/external/file_uploads/presign`; `uploadFileDirectToS3`; `assets.*` buckets return `403 AmazonS3`; `NEXT_PUBLIC_ASSETS_DOMAIN` | Direct-to-S3 PHI/document uploads and static asset CDN | | **Google Maps / Places** | `NEXT_PUBLIC_GOOGLE_PLACES_API_KEY`, `GoogleMapsService`, `ReverseGeocode` | Pharmacy/clinic geolocation and address autocomplete | | **Google SSO** | `/api/external/google_sso`, `/api/external/google_sso/oauth/start` | Patient account linking | | **Slack** | `#session-replay-new-storefront`; `PostSessionReplayNotificationJob` | Internal session-replay alerts | | **Cloudflare** | `auth.staging-nile.com` returns `Server: cloudflare` | Edge protection in front of the auth tier | | **Leadpages** | `www.navhealth.co` and `www.nile.health` | Legacy brand marketing pages | | **GoDaddy email** | `email.navhealth.co` → `email.secureserver.net:443` | Mailbox hosting for the Nav Health brand | ### 7.3 Host and Domain Topology Certificate transparency, DNS brute force, and 38 HTTP probes produced **55 subdomains across six apex domains** (`generalmedicine.co`, `generalmedicine.com`, `staging-nile.com`, `nilehealth.com`, `nile.health`, `navhealth.co`). The decision-relevant hosts: | Host | Status | Title / signal | Interpretation | | :--- | :---: | :--- | :--- | | `visitron.internal.generalmedicine.co` | 200 | "General Medicine Visitron" | Clinician EHR, production internal DNS | | `visitron.staging-nile.com` | 200 | "General Medicine Visitron" | Staging deployment of the same build | | `visitron-test.internal.generalmedicine.co` | 403 | — | Test ring behind Vercel auth | | `catalog.internal.generalmedicine.co` | 307 → `/login` | Vercel JSON redirect | Catalog admin, auth-gated | | `catalog.staging-nile.com` | 307 → `/login` | Vercel JSON redirect | Catalog staging | | `referrals.internal.generalmedicine.co` | 307 → `/login` | Vercel JSON redirect | Referrals concierge | | `internal.generalmedicine.co` | 200 | "Provider Chat" | LLM prompt workbench / provider chat, reachable without auth at the edge | | `promptimus.staging-nile.com` | 401 | Vercel JSON | Promptimus staging, auth-gated | | `analytics.staging-nile.com` | 200 | "Metabase" | BI server; Databricks engine advertised | | `visitai.generalmedicine.co` | DNS only | 2 A records | VisitAI scribe frontend | | `extensions.generalmedicine.co` | DNS only | 4 A records | Chrome extension distribution | | `provider-auth.generalmedicine.co` | 404 | `awselb/2.0` | Cognito-backed provider identity endpoint | | `waystar-connector.staging-nile.com` | timeout | — | Waystar connector, not publicly reachable | | `waystar-bridge.staging-nile.com` | NXDOMAIN | — | Planned/retired Waystar bridge | | `mcy.staging-nile.com` | 401 | Vercel JSON | Mercy Health tenant deployment | | `wmt.staging-nile.com` | 401 | Vercel JSON | Walmart tenant deployment | | `api.staging-nile.com` / `api.navhealth.co` | 404 | Rails default error page | Nile-Core staging and legacy Nav Health API | The legacy brand trail is explicit: `navhealth.co` is still the support domain (`support@navhealth.co`, SMS 98528), shares IP `35.202.21.90` with `www.nile.health`, and `nilehealth.com` now redirects to a domain-sale parking page. The company renamed Nile Health → General Medicine but never retired the original Rails service name (`nile-core`) or the `staging-nile.com` infrastructure domain. ### 7.4 Identity and Trust Chains Three separate identity planes coexist and must not be conflated: 1. **Patient plane** — AWS Cognito `CUSTOM_AUTH` with a Twilio-backed Lambda for SMS OTP, wrapped by Next.js `/auth/initiate` and `/auth/verify`, terminating in the HttpOnly `gm_session_token` cookie. The OTP analytics module imposes a telemetry rule: never include `phoneNumber`, `otpCode`, JWT material, or any other Cognito session bytes on analytics events, and mirror the server-side enforcement in the `app/auth/*` route handlers. This is a logging prohibition, not evidence that those bytes never reach the browser. 2. **Clinician/internal plane** — Google OAuth through `/api/internal_oauth/login` → `/api/internal_oauth/callback`, with `/api/user/current` as the identity probe and `/api/internal_oauth/extension_token` minting tokens for the Chrome extension. Visitron and Provider Chat additionally expose `/api/auth/login|refresh|logout`. `provider-auth.generalmedicine.co` is an ALB-fronted provider identity endpoint distinct from the Vercel-hosted portals; its naming and placement are consistent with a Cognito user pool, though the pool configuration itself was not recoverable. 3. **Enterprise tenant plane** — `X-Tenant-Id` (`walmart`, `mercy`) injected by edge middleware, with `mcy.*` and `wmt.*` deployments returning `401` without tenant credentials. The tenant resolver is documented as fail-open under `GM-6520` (§11.6). ### 7.5 Clinical Entity and Friendly-PC Topology (NPI Evidence) The NPI registry (`osint/infra_npi_catalog.json`, 17 queries) resolves the professional-corporation layer that sits beneath the brand. Three "Friendly PC" entities are confirmed by name, state, taxonomy, and a shared management phone number: | Professional corporation | NPI(s) | State | Taxonomy | Authorized official | Evidence | | :--- | :--- | :---: | :--- | :--- | :--- | | **Emerald Medical Practice PC** | `1750195483`, `1447011267` | UT (Park City) | Specialist | Ashwin Muralidharan (cofounder/CPO) | Two enumerations; named as "the Practice" in `/assignment-of-benefits` | | **Centennial Medical Practice PC** | `1174333975` | FL (Tallahassee) | Family Medicine | Pallabi Sanyal-Dey (Medical Director) | Single enumeration | | **Ruby Medical Practice** | `1346050150` | NJ (Ewing) | Family Medicine | Pallabi Sanyal-Dey (Medical Director) | Single enumeration | All three share the management telephone number **307-840-9834**, which is the strongest signal that they belong to one managed-services organization rather than independent practices. The public Assignment of Benefits page names **Emerald Medical Practice P.C.** as the entity to which insurance benefits are assigned, confirming that at least one Friendly PC is patient-facing in the billing flow. LinkedIn corroborates the operating relationship: at least one profile lists **"Emerald Medical Practice - General Medicine"** as its employer (March 2026–present). **Interpretation.** This is the standard Friendly PC / MSO structure: the technology and management company (Nile Health, Inc., now General Medicine) operates the platform, while state-specific professional corporations employ or contract the clinicians and hold the payer contracts. The UT/FL/NJ footprint is consistent with the 50-state licensure claim in §10.6 — each state needs a professional entity, and the three recovered PCs are a sample, not the full network. **Name-collision warning.** NPI organization searches for "General Medicine" and "Nile Health" return several **unrelated** entities that must not be conflated with the company: - `GENERAL MEDICINE AND URGENT CARE CLINIC` (NPI `1972824613`, Atlantis FL) and `GENERAL MEDICINE CLINIC` (NPI `1710107057`, Bennettsville SC) are independent clinics. - `GENERAL MEDICINE OF ILLINOIS PHYSICIANS, P.C.` (`1457526709`) and `GENERAL MEDICINE OF IL NURSE PRACTITIONERS, P.C.` (`1720253065`) are Michigan-registered entities with president Thomas Prose, not General Medicine. - `NILE HEALTH LLC` (Waltham MA, home health), `NILE HEALTH OF CALIFORNIA, P.C.` (psychiatry), and `NILE HEALTHCARE` (Alexandria VA, internal medicine) are unrelated to Nile Health, Inc. Only the three PCs above, the Emerald Assignment of Benefits reference, and the `generalmedicine.co` infrastructure evidence should be treated as company-attributable. --- ## 8. Internal Admin Tools & "MedicineOS" Backoffice Suite ### 8.1 Suite Inventory and Deployment Fingerprints The internal estate is not one admin app. It is **six separately deployed systems** with independent Vercel deployment IDs, independent bundle graphs, and a shared authentication idiom (`/api/internal_oauth/*` + `/api/user/current`). **"MedicineOS"** denotes this internal suite; it is not a recovered GM product name. Four expose recoverable Next.js client bundles, one is DNS-only, and one is an infrastructure surface. | # | System | Primary host(s) | Deployment ID | Build chunks | RTK tag types | RTK operations | API paths | Cable channels | | ---: | :--- | :--- | :--- | ---: | ---: | ---: | ---: | :--- | | 1 | **Visitron Clinician EHR** | `visitron.internal.generalmedicine.co`, `visitron.staging-nile.com`, `visitron-test.internal…` | `dpl_J4vVaJhNvPie8d6FYGbsnRAiF1yY` | 27 | 33 | 91 | 98 | `ExternalCable::CopilotChannel`, `InternalCable::CopilotChannel` | | 2 | **Catalog & Care Pathway Admin** | `catalog.internal.generalmedicine.co`, `catalog.staging-nile.com`, `catalog.internal.staging-nile.com` | `dpl_A4ryRBErTetVxWxjvyMbAe8mPgEd` | 35 | 1 | 106 | 47 | — | | 3 | **Referrals Concierge** | `referrals.internal.generalmedicine.co`, `referrals.staging-nile.com` | `dpl_bU9YUfX9Y2Vg9eDAYdnDgEfrr3Sk` | 19 | 8 | 27 | 18 | — | | 4 | **Provider Chat / Prompt Workbench** | `internal.generalmedicine.co`, `promptimus.staging-nile.com` | `dpl_3WuAgEhfeNR4sVmf7ZVkJQWBG9Tg` | 18 | 4 | 14 | 20 | `ExternalCable::CopilotChannel`, `InternalCable::CopilotChannel` | | 5 | **VisitAI Scribe & Chrome Extensions** | `visitai.generalmedicine.co`, `extensions.generalmedicine.co`, `provider-auth.generalmedicine.co` | DNS only | — | — | — | — | — | | 6 | **BI & Session-Replay Ops** | `analytics.staging-nile.com` (Metabase), Slack `#session-replay-new-storefront` | — | — | — | — | — | — | | | **Total (recoverable apps)** | | | **99** | **46** | **238** | **183** | | The four recoverable apps alone account for **99 webpack chunks, 46 RTK Query tag types, 238 operations, and 183 route declarations** — roughly 1.7× the 137 operations in the entire public storefront. This is the strongest available signal that General Medicine's engineering investment is increasingly back-office and clinical-operations heavy rather than storefront-only. ### 8.2 Visitron Clinician EHR Portal Visitron is the clinician-facing system of record UI. It is where an appointment becomes a draft encounter, a signed note, an Athena chart entry, a prescription, and a billing artifact. Its 91 RTK operations cluster into eight capability domains: | Domain | Representative operations | Route families | | :--- | :--- | :--- | | **Encounter lifecycle** | `getAppointmentDraftEncounter`, `updateAppointmentDraftEncounter`, `publishAppointmentDraftEncounter`, `getEncounterOrders`, `getAdHocEncounterInfo` | `/api/internal_oauth/visitron/{get_draft_encounter,update_draft_encounter,publish_draft_encounter,encounter_orders,ad_hoc_encounter_info}` | | **Appointments & shifts** | `getAppointmentInfo`, `getProviderAppointments`, `rescheduleSameProvider`, `rescheduleAnyProvider`, `markVisitNoShow`, `cancelWithoutFee`, `createShiftCheckout`, `getPendingShiftCheckouts`, `getShiftCheckoutStatus` | `/visitron/{get_appointment_info,get_provider_appointments,reschedule_*,mark_no_show,cancel_without_fee,shift_checkout*}` | | **Athena write-back** | `syncEncounterToAthena`, `resyncEncounterSummaryFromAthena`, `resyncCarePlanFromAthena` | `/visitron/{sync_encounter_to_athena,encounter_summary_athena_resync,care_plan_athena_resync}` | | **e-Prescribing** | `createDraftPrescription`, `updateDraftPrescription`, `replaceDraftPrescription`, `finalizeDraftPrescription`, `cancelDraftPrescription`, `cancelPrescriptionOrder`, `listDraftPrescriptions`, `listPatientMedications`, `createPatientMedicationPrescriptionRenewal`, `batchChangePatientMedicationPhases`, `updatePatientMedicationDaysSupply`, `clearPatientMedicationDaysSupply`, `updatePatientMedicationCourseType`, `listInboundRequests`, `approveInboundRequest`, `denyInboundRequest` | `/visitron/escribe/prescriptions/{drafts,patient_medications,inbound_requests}`, `/visitron/patient_medications/{id}` | | **Benefit & pricing** | `getDoseSpotIdpStatus`, `launchInsurancePrice`, `getInsurancePriceStatus`, `searchDiagnoses`, `getIcd10Codes`, `getLabCodes`, `getQuestionnaireCodes` | `/visitron/{dose_spot_idp_status,dose_spot_sso}`, `/internal_oauth/pharmacy_pricing/insurance{,_status}`, `/visitron/{icd10_codes,lab_codes,questionnaire_codes}` | | **Asynchronous clinical review** | `getAsyncClinicalReview`, `submitAsyncClinicalReview`, `getAsyncClinicalReviewFileUploadPreview` | `/visitron/{get_async_clinical_review,submit_async_clinical_review,async_clinical_review/file_uploads/}` | | **Care journeys & reviews** | `getCareJourneys`, `getCareJourney`, `createCareJourney`, `changePathway`, `changePhase`, `confirmCarePlan`, `getClinicianReviews`, `applyReview`, `rejectReview`, `confirmNoChange`, `createNextStepReview`, `generateNextStepReview`, `getNextSteps` | `/internal_oauth/care_journeys*`, `/visitron/{clinician_reviews,next_steps,next_step_review,confirm_care_plan}` | | **Chat & notifications** | `requestChatVisit`, `reclaimFinishedChatVisit`, `extendChatShift`, `getChatHistory`, `getChatShiftExtensionStatus`, `getProviderNotifications`, `markProviderNotificationRead`, `resolveProviderNotificationVisit` | `/visitron/{request_chat_visit,reclaim_finished_chat_visit,extend_chat_shift,chat_shift_extension_status,pending_shift_checkouts}`, `/internal_oauth/provider_notifications*` | | **Prompt test harness** | Path inventory only (`show`, `test_prompt`, `run_prompt`, `update_prompt`); no matching operation in the 91-op RTK inventory | `/api/internal/copilot_prompt_test/{show,test_prompt,run_prompt,update_prompt}` | **Cross-vendor orchestration inside one screen.** A single Visitron encounter can touch Athenahealth (`sync_encounter_to_athena`), DoseSpot (`dose_spot_sso` + RTPB), Nabla (`get_nabla_status`), Arrive Health (`launch_benefit_inquiry`), Metriport (`trigger_metriport_sync`), and the internal care-pathway engine. This makes Visitron the integration chokepoint of the entire clinical stack — if Athena or DoseSpot is degraded, the clinician workflow stalls even though the patient storefront remains available. **Visitron tag-type inventory (33):** `AdHocEncounterInfo`, `AppointmentInfo`, `ArriveHealthInquiry`, `ArriveHealthPatientContext`, `AsyncClinicalReview`, `CareJourneys`, `CarePathways`, `Channel`, `ChatShiftExtensionStatus`, `ClinicianReview`, `ClinicianReviews`, `DiagnosisSearch`, `DoseSpotIdpStatus`, `DoseSpotRtpbInquiry`, `DoseSpotRtpbPatientContext`, `DraftEncounter`, `DrugSearch`, `EscribingDraftPrescription`, `EscribingInboundRequest`, `History`, `NextStepReview`, `Orders`, `PatientAppointments`, `PatientChartContext`, `PatientSearch`, `PendingShiftCheckouts`, `PharmacyInsurancePrice`, `PharmacySearch`, `ProviderAppointments`, `ProviderNotifications`, `ShiftCheckoutStatus`, `User`, `VisitronPrompt`. ```mermaid sequenceDiagram autonumber actor Clinician participant V as Visitron (Next.js) participant Core as Nile-Core (Rails) participant Athena as Athenahealth participant DoseSpot as DoseSpot participant Nabla as Nabla participant Arrive as Arrive Health participant Metriport as Metriport Clinician->>V: Open appointment (getAppointmentInfo) V->>Core: GET /api/internal_oauth/visitron/get_appointment_info Core-->>V: Draft encounter + patient chart context Clinician->>V: Start ambient scribe V->>Core: GET /api/internal_oauth/visitron/get_nabla_status Core-->>V: { status: available } Clinician->>V: Prescribe V->>Core: GET /api/internal_oauth/visitron/dose_spot_idp_status Core-->>V: SSO ready V->>DoseSpot: Redirect via dose_spot_sso V->>Core: POST /api/internal_oauth/arrive_health/launch_benefit_inquiry Core->>Arrive: RTPB inquiry (patient + drug + pharmacy) Arrive-->>Core: Copay / formulary / prior-auth Core-->>V: arrive_rtpbi_inquiry_id Clinician->>V: Publish encounter V->>Core: POST /api/internal_oauth/visitron/publish_draft_encounter Core->>Athena: sync_encounter_to_athena Athena-->>Core: athena_id / chart confirmation Core->>Metriport: trigger_metriport_sync Core-->>V: Encounter published ``` ### 8.3 Internal Catalog & Care Pathway Admin The Catalog app is the product-authoring brain: 106 RTK operations over 47 route families, and only one tag type (`User`) — cache invalidation is almost entirely manual/refetch, which is a meaningful architectural weakness at this write volume. | Authoring surface | Operations | Notes | | :--- | :--- | :--- | | **SKU master data** | `createSku`, `updateSku`, `updateSkuGeneral`, `updateSkuIndexable`, `updateSkuVisitConfiguration`, `getSku`, `getSkus`, `getSkuCategories`, `getSkuStates` | Core PDP fields, indexability, visit configuration | | **SKU phases** | `createSkuPhase`, `updateSkuPhase`, `deleteSkuPhase`, `getSkuPhases`, `getSkuPhaseTypes` | Multi-phase care protocols | | **Product detail pages** | `getProductDetailPage`, `getProductDetailPages`, `updateProductDetailPage` | PDP content authoring | | **AI image generation** | `generateSkuImage`, `getSkuImageGeneration`, `useSkuImageGeneration`, `uploadSkuReferenceImage`, `uploadSkuStorefrontImage` | Generative storefront imagery with reference-image conditioning | | **Questionnaires** | `createQuestionnaire`, `updateQuestionnaire`, `deleteQuestionnaire`, `getQuestionnaire`, `getQuestionnaires`, `createEmptyQuestionnaires`, `applyQuestionnaireEdit`, `discardQuestionnaireEdit`, `requestQuestionnaireEdits`, `getQuestionnaireEdits`, `getQuestionnaireUsage`, `getSkuQuestionnairesJson`, `updateSkuQuestionnairesJson`, `getSkuQuestionnairesPdf`, `getQuestionnaireEditPdf`, `downloadBulkSkuQuestionnairesPdf` | Versioned intake forms with edit/approval workflow and PDF export | | **Care pathways** | `createCarePathway`, `updateCarePathway`, `deleteCarePathway`, `archiveCarePathway`, `publishCarePathway`, `returnCarePathwayToDraft`, `getCarePathways`, `getCarePathway`, `reorderCarePathwayPhases`, `updateCarePathwayLinkedSkus`, `createCarePathwayPhase`, `updateCarePathwayPhase`, `deleteCarePathwayPhase`, `getCarePathwayPhaseKinds`, `createPhaseModality`, `updatePhaseModality`, `deletePhaseModality` | Draft → publish → archive lifecycle; phase ordering; linked SKUs | | **Clinical criteria** | `createCriteriaSet`, `updateCriteriaSet`, `cloneCriteriaSet`, `getCriteriaSets`, `getCriteriaSet`, `getCriteriaSetReferences`, `createRequirement`, `updateRequirement`, `deleteRequirement`, `getRequirements` | Eligibility logic reused across SKUs | | **Condition taxonomy** | `getCatalogConditions`, `getCatalogCondition`, `createConditionCategory`, `updateConditionCategory`, `deleteConditionCategory`, `getConditionCategories`, `getConditionCategory`, `replaceConditionCategoryCatalogConditions` | Category tree for storefront navigation | | **Procedure coding** | `getProcedureCodeMappings`, `createProcedureCodeMapping`, `updateProcedureCodeMapping`, `getProcedureCodeMapping`, `getProcedureCodeMappingProcedureTypes`, `getProcedureCodeMappingServiceTypes`, `searchIcd10Codes` | ICD-10/CPT mapping for billing and referrals | | **Lab composition** | `getLabPanels`, `saveLabPanel`, `removeLabPanel`, `getLabSkuDetail`, `updateLabSkuDetail`, `generateLabSkuDetail`, `getAvailableLabPanelBiomarkers`, `getJunctionBiomarkers`, `getJunctionBiomarker`, `updateJunctionBiomarker`, `getJunctionBiomarkerFilterOptions` | Junction biomarker catalog drives panel construction | | **Medication defaults** | `getMedicationFillSkuDetail`, `updateMedicationFillSkuDetail`, `updateMedicationDefaults` | Fill quantities, days supply, default pharmacy | | **Prompts & tenancy** | `getPrompts`, `getPrompt`, `getPromptSummaries`, `createPrompt`, `updatePrompt`, `getTenants`, `getProviderRoles`, `getEconsultSpecialties`, `logout` | LLM prompt library and tenant configuration | **Why this matters.** The presence of `createCriteriaSet`/`createRequirement`, `createCarePathwayPhase`, `createPhaseModality`, and `updateProcedureCodeMapping` means clinical protocol design is a *first-class product surface*, not hardcoded logic. A new condition can be launched end-to-end — condition category → criteria → questionnaire → SKU → phases → PDP → storefront image → ICD-10/CPT mapping — without a deploy. The AI image generation operations (`useSkuImageGeneration` is a hook-style operation) show the catalog team is also generating PDP assets programmatically. ### 8.4 Referrals Concierge & Promises Queue Dashboard The Referrals app is the human-in-the-loop counterpart to the patient-facing referral checkout. It is small (19 chunks, 8 tag types, 27 operations, 18 routes) but operationally critical: it is where a care coordinator claims an unbooked referral, phones specialist offices, records outreach, and closes the loop. | Surface | Operations / routes | Behavior | | :--- | :--- | :--- | | **Promises queue** | `claimPromise`, `dropOrSnoozeOrder`, `getQueueEnabled`; `/api/internal_oauth/promises/queue/{claim,drop,enabled}` | Atomic work claiming so two coordinators cannot work the same referral; queue can be disabled per environment | | **Referral orders** | `getOrder`, `getReferrals`, `getReferral`, `listAllOrders`, `listUserOrders`, `cancelOrder`; `/api/internal/ops/referrals*`, `/api/internal_oauth/referral/orders*` | Full order ledger plus per-coordinator worklists | | **Provider candidates** | `getCandidates`, `addCandidate`, `updateCandidate`, `removeCandidate`, `searchProviders`; `/api/internal/ops/referral_provider_candidates/` | Candidate specialist roster per referral | | **Booking** | `createBookingEvent`, `getBooking`, `updateBooking` | Appointment scheduling and audit trail | | **Patient & preference** | `getPatient`, `getPreference`; `/api/internal_oauth/patients/search` | Patient context and geographic/gender/network constraints | | **Outreach & outcome** | `recordOutreach`, `logOutcome` | Call/email attempts and disposition | | **Shift** | `endShift`, `getCurrentUser`, `logout` | Coordinator session lifecycle | Tag types: `Booking`, `Candidates`, `OrderPreference`, `Patient`, `QueueEnabled`, `ReferralDetail`, `Referrals`, `User`. The `QueueEnabled` tag is unusual and useful: it lets the backend turn the concierge queue off globally without deploying a client change. ### 8.5 Provider Chat & LLM Prompt Workbench `internal.generalmedicine.co` returns HTTP 200 with `Provider Chat`, as does Visitron; Catalog and Referrals redirect to `/login` at the edge. Provider Chat is both an operational chat client and a prompt-library console: | Surface | Operations / routes | | :--- | :--- | | **Channels & messages** | `createChannel`, `getChannel`, `getChatHistory`, `sendMessage`; `/api/internal_oauth/copilot_channels`, `/api/internal_oauth/messages`; ActionCable `ExternalCable::CopilotChannel` / `InternalCable::CopilotChannel` | | **Prompt library** | `createCatalogPrompt`, `updateCatalogPrompt`, `getCatalogPrompt`, `getCatalogPrompts`; `/api/internal_oauth/prompts`, `/api/internal_oauth/prompts/` | | **Model controls** | `getModelVersions`, `getTemperatures`; `/api/internal_oauth/prompts/model_versions`, `/api/internal_oauth/prompts/temperatures?model_version=…` | The prompt library plus per-model temperature controls still indicate a **model-versioned prompt workflow**: `getTemperatures` takes a `model_version` query parameter, so temperature is treated as a per-model capability rather than a global constant. The actual `copilot_prompt_test/*` execution routes, however, appear **only in Visitron's path inventory** (`/api/internal/copilot_prompt_test/{show,test_prompt,run_prompt,update_prompt}`), not Provider Chat's — so the test harness is at least reachable from Visitron. Whether Provider Chat proxies to the same backend is not established by the route inventories. The two ActionCable channels bridge external (patient-facing copilot) and internal (clinician/ops) chat into the same Rails pub/sub substrate. `promptimus.staging-nile.com` returns `401` with a 563-byte Vercel JSON body — the staging deployment exists but is fully auth-gated. The name "Promptimus" and the shared prompt resources suggest a separate prompt-engineering tool that shares this backend, but the bundle evidence does not establish that relationship. ### 8.6 VisitAI, Chrome Extensions & Provider Auth Three DNS-only surfaces complete the clinician toolchain: - **`visitai.generalmedicine.co`** (2 A records) — the VisitAI clinician scribe frontend. No HTTP title was recoverable; its behavior is inferred from the name and the Nabla scribe integration, not observed. - **`extensions.generalmedicine.co`** (4 A records) — Chrome extension distribution. The extension authenticates through `/api/internal_oauth/extension_token`, which is present in Visitron, Catalog, Referrals, and Provider Chat. That shared route is the strongest evidence that one browser extension spans multiple backoffice apps. - **`provider-auth.generalmedicine.co`** and `provider-auth.staging-nile.com` (4 A records each, `Server: awselb/2.0`, 404 at `/`) — Cognito-backed provider identity endpoints. The `awselb` server header distinguishes this tier from the Vercel-hosted portals and is consistent with an AWS Cognito user pool behind an application load balancer. ### 8.7 Metabase BI and the Slack Session-Replay Bot `analytics.staging-nile.com` returns HTTP 200 with `Metabase` and a 133,097-byte bootstrap document. Two facts are recoverable from that document without authentication: the instance advertises a **Databricks** database driver (`engines.databricks.details-fields` includes the host field) and has **SSO/LDAP enabled** (`enable-sso-ldap?: true`). This is the analytics layer that consumes Nile-Core events and feeds executive reporting. The session-replay pipeline is a separate operational system: 1. `SessionReplayPageViewedTracker.tsx` fires page-viewed events for the new storefront, keyed by `page_view_id` for idempotency. 2. Events tracked: `new_storefront_homepage_viewed`, `new_storefront_pdp_viewed`, `new_storefront_pharmacy_detail_page_viewed`. 3. Nile-Core's `PostSessionReplayNotificationJob` (Rails background worker) deduplicates to **one Slack post per user per hour** in `#session-replay-new-storefront`. 4. Guest RUM sessions are tagged with the same anonymous ID Segment sends on `track()` so the Datadog replay links resolve inside the Slack post. This is a rare, fully traceable growth-engineering loop: browser event → Segment → Nile-Core job → Slack → Datadog replay, with the dedupe rule enforced server-side. ### 8.8 MedicineOS Architecture ```mermaid flowchart TB subgraph Clinicians["Clinician & Ops Users"] Doc["Physician / NP"] Coord["Referral Coordinator"] Ops["Growth / Product Ops"] end subgraph Portals["MedicineOS Portal Layer (Vercel)"] V["Visitron
27 chunks · 91 ops"] C["Catalog Admin
35 chunks · 106 ops"] R["Referrals Concierge
19 chunks · 27 ops"] P["Provider Chat / Promptimus
18 chunks · 14 ops"] AI["VisitAI Scribe"] EXT["Chrome Extensions"] end subgraph Auth["Identity Plane"] G["Google OAuth
/api/internal_oauth/*"] PA["provider-auth
AWS Cognito / ALB"] ET["extension_token"] end subgraph Core["Nile-Core (Rails)"] API["Internal Controllers"] Cable["ActionCable
CopilotChannel"] Jobs["Background Jobs"] end subgraph Backoffice["Clinical & Data Partners"] ATH["Athenahealth"] DS["DoseSpot"] NAB["Nabla"] ARR["Arrive Health"] JN["Junction Biomarkers"] WY["Waystar"] DB["Databricks"] MB["Metabase"] SL["Slack"] end Doc --> V Doc --> AI Coord --> R Ops --> C Ops --> P EXT --> ET V --> G C --> G R --> G P --> G AI --> PA G --> API ET --> API P --> Cable Cable --> API API --> ATH API --> DS API --> NAB API --> ARR C --> JN API --> WY API --> Jobs Jobs --> SL DB --> MB ``` ### 8.9 Cross-Cutting Observations 1. **Shared auth, separate deployments.** Every portal uses `/api/internal_oauth/login`, `/callback`, `/api/user/current`, and `/extension_token`, but each has its own Vercel deployment, chunk graph, and route prefix. There is no shared runtime shell — a change to the auth contract must be coordinated across four apps. 2. **Two API namespaces.** Visitron and Provider Chat call both `/api/internal/*` (Rails-native controllers) and `/api/internal_oauth/*` (OAuth-scoped internal API). Catalog and Referrals use `/api/internal_oauth/*` plus `/api/internal/ops/*`. This split likely reflects a migration in progress from the older internal namespace to the OAuth-scoped one. 3. **ActionCable is used only for copilot chat.** The two `CopilotChannel` classes appear in Visitron and Provider Chat, not in Catalog or Referrals. Real-time collaboration is limited to chat, not to queue or authoring surfaces. 4. **Cache invalidation is thin outside Visitron.** Catalog defines a single `User` tag type for 106 operations; Referrals has 8. Visitron's 33 tag types are the exception, which is appropriate given its read-heavy clinical screens. 5. **The backoffice is where the vendor integrations live.** Athena, DoseSpot, Nabla, Arrive, Junction, and Waystar are all reachable only through internal routes; the public storefront exposes almost none of them directly. That is a sensible PHI boundary, and it means the public bundle understates the platform's true integration surface by a wide margin. --- ## 9. Supply Chain Workflows General Medicine operates three physically distinct supply chains behind one storefront: a **pharmacy/GLP-1 chain** (retail pickup, insurance adjudication, manufacturer-direct cold chain), a **diagnostic pathology chain** (three wholesale lab networks plus external-PDF ingestion), and an **in-person care chain** (Solv urgent care, MDSave cash bundles, and specialist referrals worked by a human concierge queue). ### 9.1 Pharmacy and GLP-1 Supply Chain ```mermaid stateDiagram-v2 [*] --> DRAFT: POST /prescriptions/:careActionId/ensure_pharmacy_order DRAFT --> COMPARING: GET /pharmacy_comparisons COMPARING --> PHARMACY_SELECTED: POST /pharmacy_orders/:id/select_pharmacy (ncpdp_provider_id + arrive_rtpbi_inquiry_id) PHARMACY_SELECTED --> PAID: billing_type = cash / POST /checkout (Stripe) PHARMACY_SELECTED --> ADJUDICATED: billing_type = insurance / POST /checkout_with_insurance PHARMACY_SELECTED --> SUBMITTED: billing_type = pharmacy_delegation / POST /checkout_for_pharmacy_delegation PAID --> FULFILLED: retail pickup / mail order ADJUDICATED --> FULFILLED: copay settled at counter SUBMITTED --> FULFILLED: gm_card presented at counter PHARMACY_SELECTED --> CANCELLED: POST /cancel (pharmacy_change) CANCELLED --> COMPARING: can_choose_new_pharmacy = true FULFILLED --> [*] ``` **Step 1 — Prescription becomes an order.** A clinician's signed prescription (`careActionPrescriptionId`) is converted by `POST /api/external/prescriptions/:careActionPrescriptionId/ensure_pharmacy_order`, which returns `{ pharmacy_order_id }`. This is the only bridge from the clinical encounter into the pharmacy supply chain; without it, no price comparison or checkout is possible. **Step 2 — Price discovery.** `GET /api/external/pharmacy_comparisons?medication_option_sku_id=…&latitude=…&longitude=…` returns chain-by-chain cash prices and distances. Two details matter operationally: - **Geocoding is auth-aware.** Authenticated patients use server-side reverse geocoding (`POST /api/external/geocoding/reverse`); anonymous visitors use the Google Maps client SDK instead, specifically to avoid a `401` bounce to `/login` from the compare drawer. - **Quick filters rank only the three contracted chains.** CVS, Walgreens, and Walmart are sorted by `priceCentsByGroup` ascending, with unpriced chains rendered as *"Priced after visit"* rather than omitted. That phrasing is doing real work: it keeps a chain in the consideration set even when the PBM has not returned a price. **Step 3 — Real-time benefit inquiry (Arrive Health).** When the patient selects a pharmacy, `selectPharmacy` sends both the NCPDP provider ID and the **`arrive_rtpbi_inquiry_id`** obtained from the benefit-inquiry launch. This is the moment the platform asks the patient's PBM — through Arrive Health — for copay tier, deductible accumulation, formulary status, and prior-authorization requirements *before* the prescription is transmitted. The client only includes `arrive_rtpbi_inquiry_id` when an `orderItemInquiryId` is present, and the cash path does not require it; the field is optional in the payload but carries the insurance/benefit context when available. **Step 4 — Three billing modalities.** The same order supports three mutually exclusive settlement paths: | Mode | `billing_type` | Checkout endpoint | Payment flow | Patient experience | | :--- | :--- | :--- | :--- | :--- | | **A. Cash pre-pay** | `cash` | `POST /pharmacy_orders/:id/checkout` `{ return_url, payment_method_id }` | Stripe charge before transmission | Pays now, picks up or receives delivery | | **B. Insurance** | `insurance` | `POST /pharmacy_orders/:id/checkout_with_insurance` (empty body) | PBM adjudication; copay at counter | Pays copay only; no card charge in app | | **C. Counter delegation** | `pharmacy_delegation` | `POST /pharmacy_orders/:id/checkout_for_pharmacy_delegation` (empty body) | e-Rx transmitted; discount card presented | Shows `gm_card` to the pharmacist | **Step 5 — The `gm_card` pass.** `GET /api/external/pharmacy_orders/:id/gm_card` returns `{ bin, pcn, group, member_id }`. The patient displays this digital card at the counter; the pharmacist routes the claim through General Medicine's contracted discount switch. This is the mechanism that makes "pharmacy delegation" operationally meaningful — the claim is routed through General Medicine's switch without the platform taking custody of the drug or the payment. **Step 6 — Payment memory and switching.** `GET /api/external/prescription_orders/:id/previous_fill_payment_method` auto-selects the card used for the prior fill, reducing checkout friction for recurring refills. Cancellation is a state-machine transition, not a delete: `POST /pharmacy_orders/:id/cancel { pharmacy_change: boolean }` returns `can_cancel_pharmacy_order`, `can_switch_pharmacy`, and `can_choose_new_pharmacy`. When `pharmacy_change` is true, the backend voids NCPDP routing and reopens the compare drawer with `can_choose_new_pharmacy: true`. **Step 7 — Retail versus online interleaving.** `searchPharmaciesUtils.ts` encodes a deliberate merchandising rule: - **Featured manufacturer-direct** (`lillydirect`, `novocare`) are pinned above everything else. - The remaining list interleaves **2 nearby retail locations : 1 online pharmacy**, repeating, capped at 20 rows. - **Amazon Pharmacy** is forced into the first online slot of that interleave. - `KNOWN_CHAIN_PREFIXES` (`cvs`, `walgreens`, `walmart`, `alto`, `costco`, `kroger`, `riteaid`) drive logo/chain derivation. The 2:1 ratio is a supply-chain hedge as much as a UX choice. GLP-1 pens (Zepbound, Wegovy) can be out of stock at retail; LillyDirect and NovoCare ship from temperature-controlled manufacturer distribution, while Amazon provides a mail-order fallback. Pinning the two manufacturer programs and then forcing a 1-in-3 online slot keeps cold-chain alternatives visible without burying the local-pickup option that most patients still prefer. **GLP-1 economics surfaced by the catalog.** `202690` Foundayo and `202682` Oral Wegovy are both **\$149/mo**; `202184` injectable Wegovy is **\$199/mo**; the Zepbound medication option `710641` is **\$299/mo**; Mounjaro `201446` and Zepbound parent `201448` retain list prices of **\$552.28** and **\$1,074.09**. The pharmacy chain is therefore pricing oral GLP-1s at three-quarters of injectable Wegovy, roughly half of Zepbound's \$299 direct-pay option, and about one-seventh of Zepbound's \$1,074 list anchor — a ladder positioned to migrate cash-pay weight-loss patients onto the cheapest manufacturable modality. ### 9.2 Diagnostic Laboratory Supply Chain ```mermaid flowchart TB PDP["Lab SKU PDP (500xxx)
or medication check-in bundle"] --> PRICE["GET /api/external/lab_skus/:skuId"] PRICE --> Q["Quest cash + insurance price"] PRICE --> L["Labcorp cash + insurance price"] PRICE --> B["BioReference cash + insurance price"] Q --> MIN["Wholesale min: Math.min(cash prices)"] L --> MIN B --> MIN MIN --> FEE["+ clinical_fee ($15 live; $30 STANDARD_CLINICAL_FEE fallback)"] FEE --> CHECKOUT["Patient checkout"] CHECKOUT --> DRAW["In-network draw
Quest / Labcorp PSC"] CHECKOUT --> BYOB["External lab PDF
POST /care_journey/complete_lab_upload"] DRAW --> REQ["Requisition generated"] BYOB --> S3["Direct-to-S3 presigned upload
(bypasses 4.5 MB Vercel limit)"] REQ --> RESULT["Specimen processed → results"] S3 --> REVIEW["Clinical chart review"] RESULT --> OUT["GET /lab_orders/:id
results to EHR + dashboard"] REVIEW --> OUT ``` **Three-lab wholesale arbitrage.** `LabPanelPricing.tsx` fetches all three networks and takes the minimum cash price and minimum insurance price independently. The displayed price does not default to a preferred lab; it is the cheapest network per panel and per payment mode. Actual requisition routing is expected to follow that selection, though the server-side routing decision was not directly observed. **Server-driven clinical fee with `$30` client fallback.** `LabPanelPricing.tsx:59–69` checks `clinical_fee_enabled` across Quest, Labcorp, and BioReference and reads `clinical_fee` from the API payload (`$15.00` live across all seven sampled SKUs), falling back to `STANDARD_CLINICAL_FEE = 30` (`lab-pricing-constants.ts:8`) only when `clinical_fee` is null or undefined. If insurance pricing is unknown but the panel is `insurance_orderable`, the UI displays `ESTIMATED_INSURANCE_COPAY = 30`. **Medication safety bundles.** Chronic-medication monitoring (eGFR/creatinine for metformin, CMP/lipids for statins, TSH for thyroid) triggers `POST /api/external/care_journey/lab_bundle` or `POST /api/external/patient_medications/:id/lab_bundle`, returning `{ lab_order_id, skus[] }`. This is how the platform converts a prescription into recurring lab revenue without a separate shopping session. **External-PDF bypass.** Patients who already have bloodwork upload the PDF instead of drawing again. Two separate concerns are solved here: the workflow (`share_lab_upload_for_booking` attaches the file to an appointment; `complete_lab_upload` finalizes ingestion) and the transport (`POST /api/external/file_uploads/presign` streams bytes directly from browser to S3, because multi-page lab PDFs exceed Vercel's 4.5 MB serverless body limit). **Junction's role.** The Catalog admin's `junction_biomarkers` and `getAvailableLabPanelBiomarkers` operations mean lab panels are composed from a biomarker catalog rather than hardcoded test lists. That is the same authoring path used for the storefront's lab SKUs, and it is why new panels can be composed without engineering work. ### 9.3 Urgent Care and Specialist Referral Supply Chain **Solv urgent care.** `POST /api/external/urgent_care/orders { sku_id: '400336' }` (or Walmart `1400015`) creates the order. Offers come from `GET …/offers` and are grouped by fulfillment owner. The selection rule in `ownerOptions.ts` is precise: ```typescript // Lower cents wins; insurance wins an exact price tie. if (candidate.cents !== current.cents) return candidate.cents < current.cents return candidate.billing === 'insurance' && current.billing !== 'insurance' ``` If exactly one in-app integrated partner exists, `onQueryStarted` auto-dispatches `selectUrgentCareOrderOffer` without user input. Locations come from `GET …/locations` (lat/long + radius), and checkout supports either a scheduled `appointment_time` or a real-time walk-in (`on_demand: true`), returning the Solv `owner_appointment_id`. Rescheduling is a `PATCH …/reschedule { new_time }`. **MDSave cash bundles.** MDSave offers compete in the same offer set as Solv and insurance. The tie-break rule treats a cash bundle as a legitimate alternative to insurance, not a last resort — if MDSave is cheaper, it wins outright; if it ties, insurance wins. This gives the platform a cash-pay surgery/procedure path without a separate checkout. **Specialist referrals.** The patient-facing flow is a preference-driven search: `PATCH /referral/orders/:id/preference` captures `max_distance_miles`, provider gender, in-network requirement, and earliest availability; `GET /referral/orders/:id/providers/search` paginates candidates; drag-and-drop ranking persists via sequential PATCHes with optimistic cache updates. Checkout distinguishes `201 Created` (instant capture) from `200 OK` (Stripe 3D Secure challenge required, returning `CheckoutRequiresActionResponse`). **The Promises Queue is the human fallback.** When a referral cannot be self-booked, it enters the Referrals concierge queue. The queue is a work-claiming system, not a list: `claim` takes ownership, `drop` releases or snoozes, `enabled` can disable the queue per environment, and `recordOutreach`/`logOutcome` create the audit trail. The patient-facing `auto_book` care action (`POST /api/external/care_actions/:id/auto_book`) is what enqueues concierge work; `booked_myself` closes it without concierge involvement. This is the "we will call the specialist office for you" promise made literal in software. --- ## 10. Online Doctor Visits & Telehealth Workflows ### 10.1 Visitron Multi-Topic Visit Cart Virtual care is not modeled as one SKU per appointment. `lib/store/api/visitCartApi.ts` implements a **multi-topic visit cart**: a patient can add several complaints or services to a single visit, and the platform provisions one appointment whose duration scales with the number of topics. ```mermaid flowchart TB B["Browse storefront SKUs"] --> A["visitCartApi.addToCart(item)"] A --> P["POST /api/external/visits/:visitId/add_topic
sku_id = parseInt(item.skuId)"] P --> V["Nile-Core provisions draft visit
visit_id = vis_…"] V --> L["localStorage: general-ai-visit-id"] V --> S["localStorage: general-ai-cart-sync = Date.now()"] S --> T["window.onstorage fires in every open tab"] V --> D["duration_minutes = f(topic count)
15 → 30 → 45 min"] D --> SYNC["Synchronous path
400013 / 400015 / 100012
Zoom meeting_url"] D --> ASYNC["Asynchronous path
300xxx ACR protocol
questionnaires + chart review"] ASYNC -->|red flags / contraindications| ESC["300591 ACR follow-up video
synchronous Zoom visit"] A --> REF["referralCartExtension
POST /care_actions/:id/add_to_cart"] ``` | Mechanic | Implementation | Why it matters | | :--- | :--- | :--- | | **Visit persistence** | Active visit ID stored under `localStorage['general-ai-visit-id']` | A patient can leave the store and return without losing the cart | | **Cross-tab sync** | Adding/removing a topic writes `Date.now()` to `localStorage['general-ai-cart-sync']`, firing `storage` events in every open tab | Prevents two tabs from drifting into different carts | | **Dynamic duration** | `duration_minutes` returned by the add-topic response scales from 15 to 30/45 minutes | Clinician calendar blocks reflect case complexity, not a fixed slot | | **Referral binding** | `referralCartExtension` injects `addReferralToCart` (`POST /care_actions/:id/add_to_cart`) into the same checkout | A visit that uncovers a surgical need can sell the referral in the same transaction | | **Topic removal** | `POST /api/external/visits/:id/remove_topic` | Cart is editable up to booking | The cart is the clearest example of General Medicine treating care as a basket rather than a single product. It also explains why `duration_minutes` is a first-class field on the visit model: the unit of sale is time-and-complexity, not a named consultation. ### 10.2 Synchronous Video Visits | Concern | Implementation | | :--- | :--- | | **Entry SKUs** | `400013` General Video Visit, `400015` Follow-Up Video Visit, `100012` Primary Care Visit | | **Video transport** | Zoom, launched from the visit's dynamic `meeting_url`; `/using-zoom` is the patient troubleshooting page | | **Scheduling** | `GET /visits/:id/options` → `POST /visits/:id/booking_selection` → `POST /visits/:id/payment_method` → `POST /visits/book` | | **Patient support** | SMS shortcode **98528** (also the refund/cancellation support channel); `support@navhealth.co` | | **Support hours** | **Monday–Friday, 9 a.m.–9 p.m. ET** (= **7 a.m.–7 p.m. MT**), verified in the FAQ bundle and in `SupportWidget.tsx:146` / `StoreWidget.tsx:110` | **Timezone equivalence.** The live FAQ says *"Our support team is available Monday–Friday, 9 a.m.–9 p.m. ET, but visits are often available after hours or on weekends, depending on clinician availability."* Eastern and Mountain Time (`America/New_York` vs `America/Denver`) are always two hours apart, so **9 a.m.–9 p.m. ET is exactly 7 a.m.–7 p.m. MT**. The 7am–7pm MT and 9am–9pm ET windows describe the same support coverage. The `/using-zoom` page is operationally specific: it tells patients to install the Zoom app, warns that the visit link is unique and must not be shared, offers `zoom.us/test`, and explains how to switch devices mid-visit. It also confirms the SMS fallback: *"You can also reach your clinician via text (98528)."* That shortcode is the single patient-facing contact channel across visits, labs, and refunds. ### 10.3 Asynchronous Clinical Review (ACR) ACR is the default path for conditions that do not require a live face-to-face exam: UTIs, migraine renewals, acne check-ins, and dermatologic rashes. 1. The patient answers a structured questionnaire (`GET /api/external/questions/:id/:number`), with progress tracked via `questionnaire_length` and validated in `careJourneyApi.ts`. 2. Submission is queued for an on-call licensed clinician (`questionnaireResponseApi.ts`). 3. If approved, the prescription is issued immediately through `ensure_pharmacy_order` and the pharmacy chain in §9.1. 4. If the clinician finds a contraindication or red-flag symptom, the order **escalates into a synchronous follow-up video visit** by provisioning **SKU `300591`** (`ACR_FOLLOW_UP_VIDEO_VISIT_SKU_ID`). This is the modality-collision anomaly from §6.6 in action: the escalation SKU lives in the `300xxx` protocol family because it is spawned by an ACR order, even though the encounter it creates is a video visit. The Visitron side of ACR is equally concrete: `getAsyncClinicalReview`, `submitAsyncClinicalReview`, `getAsyncClinicalReviewFileUploadPreview`, plus the `AsyncClinicalReview` tag type. Clinicians can request additional photos/files before deciding, which is why the file-upload preview endpoint exists. ### 10.4 Doctor's Note (`400001`) `400001` is a rapid virtual evaluation for sick leave, workplace accommodation, or return-to-school authorization. The storefront sells it in two modes: - **Chat option:** `$30` cash. - **Video option:** `$100` cash. - **Insurance:** `$25`. The clinician-signed PDF is delivered through `GET /api/external/care_actions/:id/pdf` and surfaces on the patient dashboard. The SKU is a useful pricing probe: it shows the platform is willing to sell a low-acuity administrative artifact at a \$30 impulse price while pricing the video variant at \$100 — a 3.3× modality premium for the same clinical output. ### 10.5 Dual Prescription Renewal Router (`200007` vs `400020` vs `1400018`) Renewal routing is state-dependent, not a single landing page. `hooks/usePrescriptionRenewalDestination.ts` queries `GET /api/external/prescription_renewal_destination` and `GET /api/external/dashboard/show` (the `getOverview` query), then chooses: | Patient state | Destination | Behavior | | :--- | :--- | :--- | | **New / unauthenticated** | `SKU 200007` → `/s/prescription-renewal/200007` | Full intake: current drug, dose, prescriber history | | **Existing GM patient** | `SKU 400020` → `/prescriptions/:id/check-in` or `/s/prescription-renewal/400020` | Loads active meds from `GET /patient_medications/renewable`; one-tap renewal; bypasses generic intake | | **Walmart tenant member** | `SKU 1400018` → `/s/prescription-renewal/1400018` | Enterprise override with tenant pricing/routing | The `200007` vs `400020` split is the source of anomaly #3 in §6.6: the unauthenticated renewal *visit* is numbered in the medication family while the authenticated renewal visit is correctly numbered in the visit family. The router works because it dispatches on backend state, but any analytics query that groups by SKU prefix will misclassify `200007` as a medication rather than a visit. ### 10.6 Fifty-State Licensure Gate Telehealth requires the treating clinician to be licensed where the patient is physically located at the time of the encounter. The gate is implemented as a state confirmation step plus a server-side provider filter: 1. Before screening or slot selection, `skuBookingRoutes.locationConfirmation(skuName, skuId)` forces the patient through a state confirmation screen (`lib/routes/skuBooking.ts:57`). 2. `getSkuOptionsForLocationState` appends `appointment_location_state` to `/api/external/sku_options/:skuId` when a state is known. 3. Nile-Core is expected to filter the available clinician pool by state licensure before returning slots; the frontend only supplies `appointment_location_state`, so the actual filtering is server-side and was not directly observed from client code. The public FAQ states the coverage claim directly: *"You can access care from anywhere in the U.S. as we have clinicians licensed in all 50 U.S. states, including DC."* Two boundaries are also explicit: care is for adults **18 and older**, and the license is tied to the patient's physical location, not their home address — which is why the state is collected per booking rather than stored once on the profile. ### 10.7 Twilio Clinician Chat and SLA Management | Concern | Implementation | | :--- | :--- | | **Transport** | Twilio Conversations; ephemeral JWT from `POST /api/external/conversations/token` with `maxRetries: 3` | | **Pagination** | Cursor-based (`before_message_id`), `MESSAGES_PAGE_LIMIT = 10` | | **Optimistic UI** | Messages created as `optimistic-${requestId}`; rolled back on network failure | | **SLA display** | `GET /conversations/:id/response_expectation` and `GET /response_expectation`; rendered as e.g. *"Clinician will respond within 2 hours"* | | **Subject mapping** | `GET /conversation_subjects?category=…` with merged `ORDERS_MERGED_CATEGORIES = {visit, lab, pharmacy_order}` | | **Hours** | Mon–Fri 9 a.m.–9 p.m. ET (= 7 a.m.–7 p.m. MT) for support; clinical response expectations are thread-specific | The `response_expectation` endpoint is the productized SLA. It is fetched per-thread and for new threads, so the promise shown to the patient can vary by queue depth, time of day, and care team — rather than a static marketing claim. ### 10.8 General AI Copilot with Metriport Prewarming ```mermaid flowchart TB E["Patient opens /ai"] --> S["GET /api/external/copilot/session_exists"] S --> C{"messages_count > 1?"} C -->|Yes| CHAT["/ai/chat"] C -->|No| OB{"Onboarding dismissed?
localStorage"} OB -->|No| CONSENT["/ai/onboarding
HIPAA AI consent"] OB -->|Yes| FLAG{"LaunchDarkly
gen-ai-prewarm-copilot"} CONSENT --> FLAG FLAG -->|Enabled| HR["/ai/health-records
Metriport + Particle prewarm"] FLAG -->|Disabled| CHAT HR --> CHAT CHAT --> MSG["GET/POST /api/external/copilot/messages"] MSG --> LOCK["message_processing_locked
loading_indicator"] LOCK --> REC["POST /copilot/message_received"] ``` The copilot is a triage and navigation surface, not a diagnostic chatbot. Its API contract includes explicit concurrency controls (`message_processing_locked`), delivery acknowledgements (`message_received`), and an inference progress poller (`loading_indicator`) — the plumbing required to avoid double-generation when a patient taps twice or reconnects. **Prewarming is the differentiator.** When `gen-ai-prewarm-copilot` is enabled, the app navigates to `/ai/health-records` before chat, triggering Metriport and Particle Health to retrieve longitudinal records, prior prescriptions, and labs. `sendMetriportReviewToCopilot` (`POST /api/external/health_history/send_metriport_review_to_copilot`) injects a digested review into the prompt context. The result is that the copilot can recommend specific SKUs — `300543` GLP-1 Evaluation, `500093` Thyroid Panel, `400013` Video Visit — with no redundant intake. **Enterprise suppression.** `capabilities.generalAi` is hard-coded `false` for the Walmart tenant. The consumer copilot, its floating action button, and the `/ai` routes are all suppressed for that tenant, which is a compliance boundary rather than a product decision. ### 10.9 Provider Supply, Continuity, and Recruitment - **Directory:** `SearchProvidersResultsView` and `SearchProviderResultRow` render clinicians filtered by specialty and ZIP, with initials, specialty summaries, CSAT ratings, and `/provider/:slug` profiles. - **Continuity:** `GET /api/external/dashboard/past_providers` returns a carousel of prior clinicians (`provider_id`, `provider_name`, `headshot_image_url`) so patients can re-book the same doctor. - **Recruitment:** Ashby HQ hosts the clinician pipeline (physician and APRN requisitions), with UTM forwarding. The hiring page highlights recruiting ties to Mass General Brigham, UCSF Health, Stanford Medicine, and Kaiser Permanente and recruits across five modalities: video, asynchronous chat, labs/imaging ordering, specialist e-consults/referrals, and in-person navigation. - **Capacity signal:** The existence of `rescheduleSameProvider` / `rescheduleAnyProvider`, `markVisitNoShow`, and shift-checkout workflows in Visitron indicates provider capacity is actively managed at the shift level, not just per appointment. --- ## 11. Feature Flags, Jira Tickets & Unreleased Roadmap ### 11.1 LaunchDarkly Architecture LaunchDarkly is wired at two layers: 1. **Provider** — `contexts/LaunchDarklyContext.tsx` wraps the app in `` with `useReport: true`, `sendEventsOnlyForVariation: true`, a 3-second timeout, and a `user` context keyed by `patientId || anonymousID`. 2. **Evaluator** — `lib/launchDarklyFlagEvaluator.ts` exposes `useLaunchDarklyFlag(flagName, options)` with concurrency gating, a 5-second initialization timeout, cross-tab/post-auth re-evaluation, and Datadog RUM bridging. Identity resolution is worth noting because it controls experiment integrity: the context key is read from `localStorage['patientId']`, then the `launchdarkly_context_key` cookie, then the anonymous ID. A patient who signs in mid-session can therefore change bucket unless the cookie was already set — which is why the code re-evaluates on auth and cross-tab events. Every flag evaluation is reported to Datadog RUM via `datadogRum.addFeatureFlagEvaluation(flagName, value)`, so session replays and errors can be filtered by the flags that were active. That is a materially better observability posture than most early-stage consumer health apps. ### 11.2 LaunchDarkly & Conditional Flag Inventory | # | Flag key | Definition | Default | Gated behavior | Status | | ---: | :--- | :--- | :---: | :--- | :--- | | 1 | `gen-ai-prewarm-copilot` | `hooks/useGeneralAiStatus.tsx:58` | `false` | On `true`, prewarms the AI copilot session and routes through `/ai/health-records` (Metriport/Particle fetch) before chat | Active experiment | | 2 | `sku-sticky-cta-refresh` | `components/Refresh/SkuPages/SkuBodyRenderer.tsx:82` | `false` | Renders `` instead of the inline CTA on non-lab SKUs; emits `SKU_STICKY_CTA_VARIANT` | In-flight CRO test | | 3 | `refreshFlagKey` (dynamic SKU refresh) | `SkuBodyRenderer.tsx:28,61` | `false` | Switches the whole PDP renderer between legacy and `SkuRefreshRenderer`; emits `SKU_PAGE_VARIANT` | Staged SKU-by-SKU rollout | | 4 | `message-center` | `contexts/AccountDashboardFeatureContext.tsx:26-28` | `false` | Enables the Twilio-backed patient Message Center, top-level menu item, and `/messages` contact-support routing | Unreleased, pilot-gated | | 5 | `flags` (unreferenced) | `FrequentlyAskedQuestions.tsx:28`, `PhoneInput.tsx:53` | `{}` | `useFlags()` is called but never read | Dead code | The first four flags describe a coherent roadmap: AI prewarming, conversion-rate testing on the PDP CTA, a component-system migration, and an asynchronous messaging product. The fifth is a stale artifact and should be deleted. ### 11.3 Tenant Capability Matrix Tenant capabilities are declared in `config/tenants/walmartPublic.ts:42-50` and enforced through `TenantContext`: | Capability | Walmart | Default GM | Enforcement point | Effect | | :--- | :---: | :---: | :--- | :--- | | `generalAi` | `false` | `true` | `useGeneralAiAvailable.ts:6` | Suppresses copilot FAB, `/ai` routes, and onboarding | | `multiFulfillmentOwner` | `true` | `false` | tenant config | Enables routing across Walmart clinics and third-party networks | | `urgentCare` | `true` | `false` | tenant config | Enables Solv urgent-care booking | | `nativeAppExternalDeeplinks` | `true` | `false` | `ExternalNavigationBridge.tsx:17`, `resolveExternalHref.ts:31` | Rewrites external links into `walmart://healthandwellness/bettercareservices` inside the Walmart app WebView | | `directToS3FileUpload` | `true` | `false` | `config/tenants/walmartPublic.ts:47`, `lib/fileUpload/directUpload.ts` | Allows browser→S3 presigned uploads for insurance cards and records | | `textCareTeam` | `false` | `true` | tenant config | Disables direct SMS to care teams; routes to portal/phone | | `medicalOrganizationSchema` | `false` | `true` | tenant config | Suppresses `MedicalOrganization` JSON-LD to avoid white-label SEO conflicts | The matrix is small but consequential: Walmart is deliberately a *less* AI-forward, *more* operationally integrated tenant. `multiFulfillmentOwner` and `nativeAppExternalDeeplinks` are enabled for Walmart in the recovered tenant config, while `generalAi` and `medicalOrganizationSchema` are suppressed there. The seven **Walmart** values are literal in `walmartPublic.ts:42-50`; the "Default GM" column represents the non-tenant baseline rather than a second explicit config block. **Auth-level setting, not a capability.** `AuthContext.tsx:87` reads `tenant?.auth?.signupOnLoginIfPhoneNotFound` (when true, a 409 login is converted into a signup OTP request). It lives under `tenant.auth`, not `tenant.capabilities`, and `walmartPublic.ts` defines no `auth` block. The read path is observed; its Walmart/default values are **unverified** in recovered source and should not be counted as an eighth capability. ### 11.4 `NEXT_PUBLIC_*` Environment Variables | Variable | Files | Fallback | Purpose | | :--- | :--- | :--- | :--- | | `NEXT_PUBLIC_GM_TENANT_ID` | `tenantRewrites.js:37`, `tenantHeaders.ts:6` | `undefined` → `'general-medicine'` | Active white-label tenant; fail-open under `GM-6520` | | `NEXT_PUBLIC_LAUNCH_DARKLY_CLIENT_SIDE_ID` | `LaunchDarklyContext.tsx:63` | `undefined` (non-null asserted) | Browser SDK key | | `NEXT_PUBLIC_COOKIE_DOMAIN` | `LaunchDarklyContext.tsx:56`, `UserContext.tsx:61`, `useAttributionTracking.tsx:105`, `useGeneralAiStatus.tsx:187`, `baseQuery.ts:57` | host-only | Apex cookie domain (`.generalmedicine.co` / `.staging-nile.com`) | | `NEXT_PUBLIC_ENV` | `getRequestOrigin.ts:24-26,39` | `undefined` | Environment classifier (`production`, `staging`, `pre-production`, `preview`) | | `NEXT_PUBLIC_FRONTEND_URL` | `getRequestOrigin.ts:48` | `http://localhost:3001` | SSR origin fallback | | `NEXT_PUBLIC_NILE_CORE_URL` | `fileUploadApi.ts:63` | `http://localhost:3000` | Direct backend origin for file downloads | | `NEXT_PUBLIC_GOOGLE_PLACES_API_KEY` | `GoogleMapsService.tsx:33` | `undefined` | Places/geocode autocomplete | | `NEXT_PUBLIC_ASSETS_DOMAIN` | 12+ image components | `undefined` | S3/CloudFront asset domain | | `NEXT_PUBLIC_URGENT_CARE_SKU_ID` | `sku-constants.ts:16` | `'400336'` | Urgent-care SKU override | | `NEXT_PUBLIC_VERCEL_OBSERVABILITY_BASEPATH` | webpack chunk `99057-…js.map` | `undefined` | Vercel observability proxy path | ### 11.5 Query-Parameter Overrides and Route Gates | Parameter | Module | Values | Behavior | | :--- | :--- | :--- | :--- | | `ref` | `lib/routes/skuBooking.ts:2` | string | Partner/affiliate attribution carried through checkout | | `practiceId` | `skuBooking.ts:1` | string | Constrains booking to a provider group/clinic | | `locationId` | `locationsContract.ts:2`, `urgentCare.ts:89` | string | Solv clinic selection | | `appointmentTime` | `locationsContract.ts:2`, `urgentCare.ts:91` | ISO timestamp | Pre-selected slot | | `walkIn` | `locationsContract.ts:2`, `urgentCare.ts:93` | `'true'` \| `'1'` | Bypasses slot selection | | `reschedule` | `locationsContract.ts:2`, `urgentCare.ts:95` | `'true'` \| `'1'` | Reschedule mode; overrides cancellation fees | | `date` | `urgentCare.ts:14` | `yyyy-MM-dd` | Pre-selects calendar date | | `review` | `inPersonVisit.ts:154` | `'1'` | Forces health-history intake into read-only review | | `providerName` | `inPersonVisit.ts:147` | string | Carries chosen clinician name into checkout | | `sequential`, `careId` | `lib/sequentialFlow.ts:17-18` | `'true'`, string | Gates multi-service sequential onboarding | | `returnTo` | `medicationCheckInLabFlow.ts:58` | sanitized path | Redirect after lab check-in | | `signupReferrer` | `lib/signup_referrer.ts:17` | string | Explicit campaign attribution override | | `error` | `login/page.tsx:45` | `access_denied`, `invalid_credentials` | Google SSO error banner | | `sku_id`, `sku_name`, `med_name` | `directory_pharmacy.ts:3-5` | string | Re-enters checkout from the pharmacy drawer | ### 11.6 Jira Ticket Analysis (`GM-xxxx`) | Ticket | Location | Code context | Meaning | | :--- | :--- | :--- | :--- | | **`GM-6520`** | `tenantRewrites.js:36,69`, `tenantHeaders.ts:6` | `// TODO(GM-6520): require NEXT_PUBLIC_GM_TENANT_ID and fail fast when unset.` | Multi-tenant security debt: missing tenant ID fails open to consumer DTC branding and AI copilot | | **`GM-6956`** | `lib/routes/urgentCare.ts:20` | `* Patient-facing Urgent Care booking routes (GM-6956 → GM-6957 → GM-6958).` | Urgent-care epic phase 1: route structure and clinic search | | **`GM-6957`** | `urgentCare.ts:44,83` | `* Full slot list for one Solv location (GM-6957).` | Phase 2: availability and slot calendar | | **`GM-6958`** | `urgentCare.ts:53,83`, `locationsContract.ts:2` | `* Booking confirm screen (GM-6958).` | Phase 3: confirmation and query-param state handoff | | **`GM-6964`** | `lib/store/api/urgentCareLocationsApi.ts:4` | `* Single FE type for GET …/locations (GM-6964).` | API serialization contract for `AppointmentAvailability` | Only five `GM-` tickets are present in the recovered source. **`GM-6959` through `GM-6963` do not appear anywhere in the bundle**, so any claim that the urgent-care epic spans `GM-6956`–`GM-6964` as a contiguous nine-ticket block is unsupported; the evidence supports four tickets in that range plus `GM-6520`. ### 11.7 Unreleased Product Roadmap The unexercised surface is concentrated in **64 catalog-only endpoints** in `lib/api/endpoints.ts` (194 declared, of which 64 are catalog-only and 130 are non-catalog-only; 119 routes are bound to active RTK Query slices): | Cluster | Count | Examples | Signal | | :--- | ---: | :--- | :--- | | Test harness | 2 | `test_setup/reset_test_user`, `delete_test_user` | Synthetic patient lifecycle | | Insurance onboarding | 7 | `directory_payers`, `enqueue_eligibility_check`, `trigger_card_image_eligibility_check` | EDI 270/271 and OCR card scanning | | Payments & billing | 4 | `create_stripe_setup_intent`, `fetch_payment_method`, `update_mercy_billing` | Deeper payment self-service | | Dashboard & care actions | 17 | `pre_visit_requirements`, `past_providers`, `next_step_cards/*` | Longitudinal care dashboard | | Care journeys, uploads & records | 18 | `care_journey/lab_bundle`, `file_uploads/*`, `question_responses` | At-home and external-document workflows | | AI, pharmacy & search | 7 | `copilot/message_received`, `copilot/loading_indicator`, `geocoding/forward` | AI and geo infrastructure | | CareAction sub-routes | 9 | `auto_book`, `booked_myself`, `choose_provider`, `pdf` | Referral concierge product | Three product expansions are visible in the combination of flags, endpoints, and Jira tickets: 1. **Asynchronous patient–clinician messaging.** `message-center` flag + Twilio token + `conversation_subjects_controller.rb` + per-thread SLA. The strategic shift is from transactional visits to longitudinal primary care with guaranteed response times. 2. **National in-person urgent care.** `GM-6956`→`GM-6958` + `GM-6964`, `urgentCareApi.ts`, `urgentCareLocationsApi.ts`, Solv integration. Virtual clinicians can send patients to a physical clinic for strep swabs, vitals, or X-rays with transparent pricing. 3. **Care coordination and specialist referrals.** The `care_actions/*` catalog — `auto_book`, `booked_myself`, `pdf`, `providers`, `choose_provider`, and related sub-routes — is backed by the Referrals concierge app. The platform is assembling a full-stack care system: diagnose virtually, refer locally, track completion in My Care. ### 11.8 Dead Code and TODO Inventory | Item | Location | Note | | :--- | :--- | :--- | | Unreferenced `flags` hook | `FrequentlyAskedQuestions.tsx:28`, `PhoneInput.tsx:53` | `useFlags()` result never read; abandoned A/B test | | Deprecated provider-search RTK files | `ProviderFilterDrawer/types.ts:3` | TODO to move helpers after old RTK files are removed | | Unsplash placeholder | `lib/transformSkuPageContent.ts:9` | `TODO: Replace with actual placeholder image` | | Timezone formatting | `lib/utilities.ts:72` | Only shows TZ when different from home address | | Mantine letter spacing | `packages/mantine-theme/theme/styles/variables.ts:129` | Not supported as a Mantine prop | | Mercy token overrides | `tenants/mercy/theme/mercyCssResolver.ts:40` | TODO to phase out direct `--gm-blue-6` overrides | | Copay estimation | `app/store/PriceUtility.tsx:218-227` | Insurance copay estimate acknowledged as imprecise | --- ## 12. Coverage Limits & Architectural Risk Register ### 12.1 Data Sources | Source | What it establishes | | :--- | :--- | | `osint/live_sitemap_skus.json` | 4 sitemaps, 6,488 entries, 3,290 unique URLs, 3,184 SKUs, 23 series, 448 search-surfaced SKUs (326 top-level priced / 122 top-level null; 8 nulls carry option fees), 85 refresh-sitemap absences, policy/bio/page inventory | | `osint/infra_npi_catalog.json` | 55 subdomains, 38 probed hosts (distinct from the 38 vendor rows), DNS records, Metabase/Databricks bootstrap, 329 catalog SKUs, 25 endpoints, three Friendly PCs (UT/FL/NJ), and the NPI name-collision check | | `osint/internal_portals_recon.json` | 4 portal bundle inventories: chunks, tag types, RTK operations, API paths, ActionCable channels | | Recovered codebase: SKUs and supply chains | SKU registry, 28-vendor ecosystem, pharmacy/lab/referral supply chains, Visitron cart, ACR, renewal router, licensure gate, copilot | | Recovered codebase: flags and admin | LaunchDarkly flags, tenant capabilities, env vars, query params, Jira tickets, 64 unexercised endpoints, admin/BI/Slack tooling | | Recovered first-party source | 798 files / 51,015 LOC used for every file:line citation in §§6–11 | ### 12.2 Coverage Limits & Normalizations 1. **No authenticated portal access.** Visitron, Catalog, and Referrals were analyzed from public client bundles and route inventories, not from logged-in sessions. Screen-level behavior beyond the route/operation names is inferred from naming and shared Rails conventions. 2. **2,736 of 3,184 SKUs were not surfaced by the 108-query sample; their commercial status is unknown.** Pricing conclusions apply only to the 448 search-surfaced SKUs: 326 have a non-null top-level cash or insurance price, while 122 have null top-level fields (8 of those carry option-level fees). `400285` is a counterexample to treating sitemap-only as unpublished: it appears in `sitemap_only_skus` yet is returned by a live chronic-pain search. 3. **Waystar transaction sets were not observed.** The connector/bridge hosts exist, but no X12 270/271 payloads or RCM configuration were recovered. EDI function is attributed from Waystar's role and the insurance-eligibility endpoints. 4. **Nabla's scribe role is attributed.** Only `get_nabla_status` and the `VisitronPrompt` tag type were observed; the ambient-scribe behavior is Nabla's product function. 5. **`tryvital.io` is not present in recovered source.** Junction biomarkers are observed; the Vital domain attribution comes from the `/vital-informed-consent` page and external knowledge. 6. **VisitAI and extensions are DNS-only.** No HTML, bundle, or route inventory was recoverable for either host. 7. **Support-hour timezone normalization.** The FAQ and both widgets state Monday–Friday, 9 a.m.–9 p.m. ET. Because `America/New_York` and `America/Denver` are always two hours apart, that window is exactly **7 a.m.–7 p.m. MT**; the two formulations describe the same coverage and do not contradict each other. ### 12.3 Architectural Risk Register | Risk | Severity | Evidence | Why it matters | | :--- | :---: | :--- | :--- | | **Tenant fail-open (`GM-6520`)** | High | `tenantRewrites.js:36,69` TODO | A missing `NEXT_PUBLIC_GM_TENANT_ID` silently serves consumer DTC branding and AI to a white-label partner | | **Portal frontends served without edge auth** | High | `internal.generalmedicine.co` and `visitron.internal.generalmedicine.co` return 200, while Catalog and Referrals 307 to `/login` | The prompt workbench, copilot channel, and clinician EHR are the most sensitive internal surfaces; edge auth must not rely on client-side gating | | **Portal auth fragmentation** | Medium | Four apps, shared `/api/internal_oauth/*`, independent deployments | An auth-contract change requires coordinated releases across four codebases | | **Catalog cache invalidation** | Medium | 106 operations, 1 tag type (`User`) | Stale authoring state after writes; risk of publishing conflicting SKU/pathway edits | | **Client `$30` clinical-fee/copay fallbacks** | Low | `lab-pricing-constants.ts:8` (`STANDARD_CLINICAL_FEE = 30`, `ESTIMATED_INSURANCE_COPAY = 30`) | If the API omits `clinical_fee`, the UI falls back to `$30` rather than the `$15` rate returned on live sampled SKUs | | **SKU ID `300001n`** | Medium | `StoreTypes.ts:39` | Breaks numeric parsers, sorting, and any integer-typed integration | | **85 SKUs absent from refresh sitemap** | Low | store-only sitemap set | Whether they are stale or delisted is not established; the refresh sitemap is the better freshness signal, but absence is not proof of delisting | | **Price opacity at pharmacy selection** | Medium | `cash: null` on many medication options; "Priced after visit" | Patients cannot compare total cost before committing to a visit | | **Single EHR dependency** | High | Athena write-back is the only encounter sync | Athena outage stalls Visitron publishing and care-plan resync | | **86% not surfaced by the 108-query sample; 122/448 top-level null** | Low | 2,736 sample-unsurfaced; 122 null top-level (8 with option fees) | The sample cannot establish commercial status; `400285` proves search can return a sample-unsurfaced SKU. Null top-level is also not equivalent to unpriced | | **Direct-to-S3 PHI uploads** | Medium | `file_uploads/presign`, `directToS3FileUpload` | Presigned-URL scope, content-type enforcement, and malware scanning must be airtight | | **Metabase bootstrap exposure** | Low | 200 response with `enable-sso-ldap` and engine metadata | Configuration disclosure aids targeted attacks even when dashboards require auth | **Bottom line.** The public storefront is a well-instrumented Next.js commerce layer; the actual moat is the MedicineOS backoffice and the three supply chains it orchestrates. The most important architectural facts are not the 3,184 SKUs but the fact that a single encounter can write to Athena, prescribe through DoseSpot, transcribe through Nabla, price through Arrive, and fulfill through LillyDirect or a retail counter — with a human concierge queue catching every referral that software cannot close. ================================================================================ # DOCUMENT: API Reference (377 Routes · 357 Operations) (raw/reports/api-spec.md) ================================================================================ # API Specification: General Medicine Platform & Nile-Core Gateway ## 1. Overview & Transport Protocol The General Medicine platform executes API operations across two primary transport tiers: 1. **Next.js Edge Proxy Tier (`https://generalmedicine.co/api/*` and `/auth/*`)**: Handles session cookies, OTP challenges, attestation token injection, and multi-tenant URL rewriting. 2. **Nile-Core Backend Tier (`https://api.generalmedicine.co/api/external/*`)**: Primary Ruby on Rails API microservices managing patient electronic health records (EHR), orders, billing, and partner orchestrations. ### 1.1 Contract Classification Endpoints fall into two classifications: - **Verified Client Contract (`[VERIFIED_CLIENT_CONTRACT]`)**: Bound to Redux Toolkit Query (`baseApi`) slices under `lib/store/api/*.ts`. Client slices define the HTTP method, URL parameters, request interface and TypeScript return type. - **Catalog-Only / Unexercised Contract (`[UNDOCUMENTED_SERVER_CONTRACT]`)**: Declared in the central routing catalog (`lib/api/endpoints.ts`) as a recognized Rails backend controller route, but not bound to a client RTK Query query or mutation. Request/response schemas for these endpoints execute server-side or are reserved for internal administrative/backend workflows, and are unconfirmed on the client side. ### 1.2 Global Headers & Network Policy | Header | Directives / Format | Description | | :--- | :--- | :--- | | `Content-Type` | `application/json` (or `multipart/form-data`) | Default payload serialization format | | `Cache-Control` | `no-cache, no-store, must-revalidate` | Enforced on all mutations and sensitive PHI reads | | `Credentials` | `include` (`withCredentials: true`) | Cross-origin transmission of `gm_session_token` cookie | | `X-Tenant-Id` | `walmart` \| `mercy` (optional) | Injected by Next.js edge middleware when operating in white-label mode | | `X-Request-Start` | Epoch millisecond timestamp | Used for client-side API latency tracking (`lib/api/metrics.ts`) | ### 1.3 Authentication & Session Lifecycle Authentication is built around passwordless SMS One-Time Passcodes (OTP) with fallback to Google SSO: - **Challenge Initiation (`POST /auth/initiate`)**: Accepts `{ phoneNumber, authType: 'login' | 'signup' }`. Returns HTTP 200 with `{ isExistingUser: boolean }`. If an unknown phone number attempts login, returns HTTP 409 Conflict, prompting redirection to `/get-started`. - **OTP Verification (`POST /auth/verify`)**: Validates the 6-digit numeric token. On success, sets the secure, HttpOnly session cookie `gm_session_token` with `SameSite=Lax` and `max-age=1800` (extendable). - **Session Bounce Protocol (`clientBaseQuery.ts`)**: Any authenticated endpoint returning HTTP 401 triggers an automatic client redirect to `/login`, saving the originating URL in document cookie `redirect_url` for post-auth restoration. - **Session Termination (`POST /auth/logout`)**: Clears session cookies and flushes Redux state. --- ## 2. API Endpoint Catalog The platform encompasses **194 discovered endpoint declarations** across `lib/api/endpoints.ts`, route handlers, and component fetch calls, including **119 verified client-exercised RTK Query operations** and 130 fully specified paths in `openapi.yaml`. ### 2.1 User, Identity & Billing Controller | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/patient` | `[VERIFIED]` | None | `User` profile record | | `PATCH` | `/api/external/patient` | `[VERIFIED]` | `UpdateProfileRequest` (`{ home_address, email, sex_assigned_at_birth }`) | Updated `User` | | `GET` | `/api/external/patient/mercy_billing` | `[VERIFIED]` | Query: `?visit_id=...` | `{ guarantor_id, billing_ids[], billing_token }` | | `GET` | `/api/external/patient/update_mercy_billing` | `[UNDOCUMENTED]` | Query: `?status=...` (Trust Commerce callback) | Redirect or status confirmation | | `GET` | `/api/external/patients/payment_methods` | `[VERIFIED]` | None | `PaymentMethod[]` | | `DELETE` | `/api/external/patients/payment_methods/:id` | `[VERIFIED]` | Path: `id` | `{ message: string }` | | `POST` | `/api/external/patients/:id/update_default_payment_method` | `[UNDOCUMENTED]` | Path: `id`, Body: `{ payment_method_id }` | `{ success: boolean }` | | `POST` | `/api/external/patients/:id/create_stripe_setup_intent` | `[UNDOCUMENTED]` | Path: `id` | `{ client_secret: string }` | | `GET` | `/api/external/google_sso` | `[VERIFIED]` | None | `{ linked: boolean, email?: string }` | | `POST` | `/api/external/google_sso/oauth/start` | `[VERIFIED]` | None | `{ authorize_url: string }` | | `POST` | `/api/external/google_sso/disconnect` | `[VERIFIED]` | None | `{ linked: boolean, email?: string }` | | `POST` | `/api/external/verified` | `[VERIFIED]` | `VerifyIdentityRequest` (`{ birth_date, ssn? }`) | `VerifiedProfile` with address array | | `POST` | `/api/external/patients` | `[VERIFIED]` | `CreatePatientRequest` (`{ first_name, last_name, date_of_birth }`) | `{ id: string }` | ### 2.2 Insurance Management & Verification | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/insurances` | `[VERIFIED]` | None | `InsurancePolicy[]` | | `DELETE` | `/api/external/insurances/:id` | `[UNDOCUMENTED]` | Path: `id` | `{ success: boolean }` | | `GET` | `/api/external/insurances/show` | `[VERIFIED]` | None | `InsurancePolicy` | | `GET` | `/api/external/insurances/directory_payers` | `[UNDOCUMENTED]` | None | `PayerDirectoryItem[]` | | `POST` | `/api/external/insurances/enqueue_eligibility_check` | `[UNDOCUMENTED]` | Body: `{ payer_id, member_id, group_number }` | `{ task_id, status: 'queued' }` | | `POST` | `/api/external/insurances/trigger_eligibility_check` | `[UNDOCUMENTED]` | Body: `{ payer_id, member_id }` | `{ eligible: boolean, copay_amount: number }` | | `POST` | `/api/external/insurances/trigger_card_image_eligibility_check` | `[UNDOCUMENTED]` | Body: `{ front_image_id, back_image_id }` | OCR extracted policy & copay | | `POST` | `/api/external/insurances/:id/activate` | `[UNDOCUMENTED]` | Path: `insuranceId` | `{ activated: boolean }` | | `GET` | `/api/external/insurance_onboardings/:id` | `[UNDOCUMENTED]` | Path: `onboardingId` | Onboarding progress and verification flags | ### 2.3 Storefront Catalog, Search & SKU Options | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/skus/:skuId` | `[VERIFIED]` | Path: `skuId` | `Sku` model | | `GET` | `/api/external/sku_options/:skuId` | `[VERIFIED]` | Path: `skuId`, Query: `?appointment_location_state=...`, `?next_step_id=...` | `SkuOptions` with questionnaire | | `GET` | `/api/external/sku_options/prices` | `[VERIFIED]` | Query: `?sku_ids[]=...` | `SkuPriceOptionsResponse` | | `GET` | `/api/external/skus/:skuId/offers` | `[UNDOCUMENTED]` | Path: `skuId`, Query: `?fulfillment_owner_id=...` | `FulfillmentOffer[]` | | `GET` | `/api/external/category/:slug` | `[VERIFIED]` | Path: `slug` | `ServiceItem[]` (rendered services) | | `GET` | `/api/external/search/index` | `[VERIFIED]` | Query: `query`, `include_providers`, `include_pharmacies`, `lat`, `lng`, `zipcode`, `sku_category` | `SearchResultSerializer` | | `GET` | `/api/external/search/suggestions` | `[VERIFIED]` | Query: `query` | `string[]` (search suggestions) | ### 2.4 Urgent Care & Solv Health Clinic Booking (Bound to `urgentCareApi.ts`) | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `POST` | `/api/external/urgent_care/orders` | `[VERIFIED]` | `CreateUrgentCareOrderRequest` (`{ sku_id: string }`) | `CreateUrgentCareOrderResponse` (`{ order_id }`) | | `GET` | `/api/external/urgent_care/orders/:id` | `[VERIFIED]` | Path: `id` | `UrgentCareOrder` | | `GET` | `/api/external/urgent_care/orders/:id/offers` | `[VERIFIED]` | Path: `id` | `UrgentCareOrderOffersResponse` | | `PATCH` | `/api/external/urgent_care/orders/:id` | `[VERIFIED]` | Path: `id`, Body: `SelectUrgentCareOrderOfferRequest` (`{ fulfillment_offer_id: string }`) | `SelectUrgentCareOrderOfferResponse` | | `GET` | `/api/external/urgent_care/orders/:id/locations` | `[VERIFIED]` | Path: `id`, Query: `zip_code?`, `latitude?`, `longitude?`, `miles_radius?`, `fulfillment_offer_id?` | `UrgentCareLocationsResponse` (clinics, hours, slots) | | `POST` | `/api/external/urgent_care/orders/:id/checkout` | `[VERIFIED]` | Path: `id`, Body: `UrgentCareCheckoutRequest` (`{ location_id: string, appointment_time?: string, on_demand?: boolean }`). **Note**: `payment_method_id` is NOT part of this body. | `UrgentCareCheckoutResponse` (`{ id, state, owner_appointment_id, booked_at }`) | | `PATCH` | `/api/external/urgent_care/orders/:id/reschedule` | `[VERIFIED]` | Path: `id`, Body: `UrgentCareRescheduleRequest` (`{ new_time: string }`). **Note**: HTTP method is `PATCH`. | `UrgentCareRescheduleResponse` (`{ id, state }`) | | `DELETE` | `/api/external/urgent_care/orders/:id` | `[VERIFIED]` | Path: `id`, Body: `UrgentCareCancelRequest` (`{ cancellation_reason?, cancellation_reason_other? }`) | `UrgentCareCancelResponse` (`{ id, state, cancelled_at }`) | ### 2.5 Pharmacy Directory, Real-Time Pricing & Order Routing (Bound to `pharmacyOrderApi.ts`) | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/product_detail_pages/:skuId` | `[VERIFIED]` | Path: `skuId` | `ProductDetailPage` | | `GET` | `/api/external/medication_option_skus/:id/cash_price` | `[VERIFIED]` | Path: `id`, Query: `?zip_code=...` | `MedicationOptionCashPrice` (`{ cash_price: number }`) | | `GET` | `/api/external/pharmacy_comparisons` | `[VERIFIED]` | Query: `medication_option_sku_id`, `latitude`, `longitude` | `PharmacyComparisonResponse` (`PharmacyComparisonResult[]`) | | `GET` | `/api/external/pharmacy_search` | `[UNDOCUMENTED]` | Query: `query`, `zip`, `radius` | `PharmacySearchResult[]` | | `GET` | `/api/external/pharmacy_detail/:ncpdpProviderId` | `[UNDOCUMENTED]` | Path: `ncpdpProviderId` | `PharmacyDetail` | | `GET` | `/api/external/pharmacy_orders/:id` | `[VERIFIED]` | Path: `id` | `PharmacyOrder` | | `PATCH` | `/api/external/pharmacy_orders/:id` | `[VERIFIED]` | Path: `id`, Body: `{ billing_type: 'cash' \| 'insurance' \| 'pharmacy_delegation' }` | `{ pharmacy_order_id, current_payment }` | | `POST` | `/api/external/pharmacy_orders/:id/select_pharmacy` | `[VERIFIED]` | Path: `id`, Body: `{ ncpdpProviderId: string, orderItemInquiryId?: string \| null }` | `{ pharmacy_order_id: string }` | | `POST` | `/api/external/pharmacy_orders/:id/checkout` | `[VERIFIED]` | Path: `id`, Body: `{ return_url: string, payment_method_id?: string }` | `PharmacyOrderCheckoutResponse` | | `POST` | `/api/external/pharmacy_orders/:id/checkout_with_insurance` | `[VERIFIED]` | Path: `id`, Body: `{}` (empty payload) | `PharmacyOrderCheckoutResponse` | | `POST` | `/api/external/pharmacy_orders/:id/checkout_for_pharmacy_delegation` | `[VERIFIED]` | Path: `id`, Body: `{}` (empty payload) | `PharmacyOrderCheckoutResponse` | | `POST` | `/api/external/pharmacy_orders/:id/cancel` | `[VERIFIED]` | Path: `id`, Body: `{ pharmacyChange: boolean }` | `CancelPharmacyOrderResponse` | | `GET` | `/api/external/pharmacy_orders/:id/gm_card` | `[VERIFIED]` | Path: `id` | `GmCardInfo` (`{ bin, pcn, group, member_id }`) | | `GET` | `/api/external/pharmacy_orders/:id/invoice` | `[VERIFIED]` | Path: `id` | `PharmacyOrderInvoice` | | `GET` | `/api/external/pharmacy_detail_pages/:friendlyId/medications` | `[VERIFIED]` | Path: `friendlyId`, Query: `?page=1&per_page=50` | `DirectoryPharmacyMedicationsResponse` | | `GET` | `/api/external/prescription_orders/:id/previous_fill_payment_method` | `[VERIFIED]` | Path: `id` | `PaymentMethod \| null` | ### 2.6 Prescriptions & Care Actions (Bound to `prescriptionApi.ts` & `prescriptionRenewalApi.ts`) | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `POST` | `/api/external/prescriptions/:id/ensure_pharmacy_order` | `[VERIFIED]` | Path: `careActionPrescriptionId` | `{ pharmacy_order_id: string }` | | `GET` | `/api/external/patient_medications/:id` | `[VERIFIED]` | Path: `id` | `PrescriptionDetailData` | | `GET` | `/api/external/patient_medications/renewable` | `[VERIFIED]` | Query: `?skuId=...` | `RenewablePatientMedicationsResponse` | | `POST` | `/api/external/patient_medications/:id/lab_bundle` | `[VERIFIED]` | Path: `id` | `MedicationCheckInLabBundleResponse` | | `GET` | `/api/external/prescription_renewal_destination` | `[VERIFIED]` | None | `PrescriptionRenewalDestinationResponse` | | `GET` | `/api/external/next_step_prescription_renewals/:id` | `[VERIFIED]` | Path: `nextStepId` | `PrescriptionRenewalData` | | `POST` | `/api/external/next_step_prescription_renewals/:id/medication_selection` | `[VERIFIED]` | Path: `id`, Body: `{ patient_medication_ids: string[] }` | `void` | | `POST` | `/api/external/next_step_prescription_renewals/:id/decline` | `[VERIFIED]` | Path: `id`, Body: `{ cancellation_reason: string, cancellation_reason_other?: string }` | `void` | | `POST` | `/api/external/next_step_prescription_renewals/:id/completed_elsewhere` | `[VERIFIED]` | Path: `id` | `void` | ### 2.7 Quest Diagnostics Lab Ordering & Pathology Lifecycle | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/lab_skus/:skuId` | `[VERIFIED]` | Path: `skuId` | `LabSku` (`cash_price`, `clinical_fee` [live `15.0`, client fallback `30`], `tests[]`) | | `GET` | `/api/external/lab_orders/:labOrderId` | `[VERIFIED]` | Path: `labOrderId` | `LabOrder` (accession #, status, report URL) | | `POST` | `/api/external/care_journey/lab_bundle` | `[VERIFIED]` | Body: `{}` | `MedicationCheckInLabBundleResponse` | | `POST` | `/api/external/care_journey/complete_lab_upload` | `[VERIFIED]` | Body: `{ file_upload_ids: string[] }` | `MedicationCheckInLabUploadCompletionResponse` | | `POST` | `/api/external/care_journey/share_lab_upload_for_booking` | `[VERIFIED]` | Body: `{ visit_id: string }` | `MedicationCheckInLabUploadCompletionResponse` | ### 2.8 Health History & Metriport EHR Sync | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/health_history/lookup_exists` | `[VERIFIED]` | None | `HealthHistoryLookupResponse` (`{ exists: boolean }`) | | `GET` | `/api/external/health_history/latest_metriport` | `[VERIFIED]` | None | `MetriportHealthHistory` (FHIR conditions, meds, allergies) | | `GET` | `/api/external/health_history/copilot_health_history_status` | `[UNDOCUMENTED]` | None | Review progress & summaries | | `POST` | `/api/external/health_history/submit_review` | `[VERIFIED]` | Body: `SubmitHealthHistoryReviewRequest` | `void` | ### 2.9 Dashboard, Updates & Action Cards | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/dashboard/show` | `[VERIFIED]` | None | `DashboardInfo` (visits, labs, rx, cards) | | `GET` | `/api/external/dashboard/care_plans` | `[VERIFIED]` | None | Care plan list | | `GET` | `/api/external/dashboard/prescriptions` | `[VERIFIED]` | None | `PrescriptionsPageData` | | `GET` | `/api/external/dashboard/lab_orders` | `[VERIFIED]` | None | `LabOrder[]` | | `GET` | `/api/external/dashboard/visits` | `[VERIFIED]` | None | `DashboardVisits` | | `GET` | `/api/external/dashboard/past_providers` | `[VERIFIED]` | None | `PastProvidersResponse` | | `GET` | `/api/external/dashboard/next_step_cards` | `[VERIFIED]` | None | `NextStepCardsResponse` | | `POST` | `/api/external/dashboard/next_step_cards/dismiss_intro_notice` | `[VERIFIED]` | None | `{ intro_notice_dismissed_at: string }` | | `POST` | `/api/external/dashboard/next_step_cards/snooze` | `[VERIFIED]` | Body: `SnoozeNextStepCardRequest` (`{ id, snooze_duration_days }`) | `{ card_removed: boolean }` | | `POST` | `/api/external/dashboard/next_step_cards/dismiss` | `[VERIFIED]` | Body: `DismissNextStepCardRequest` (`{ id }`) | `{ card_removed: boolean }` | | `GET` | `/api/external/dashboard_intro/status` | `[VERIFIED]` | None | `DashboardIntroStatus` | | `POST` | `/api/external/dashboard_intro/acknowledge` | `[VERIFIED]` | None | `DashboardIntroAcknowledgment` | | `GET` | `/api/external/updates` | `[VERIFIED]` | None | `UpdatesFeed` (`UpdateItem[]`) | | `GET` | `/api/external/updates/unread_count` | `[VERIFIED]` | None | `UnreadCount` (`{ unread_count: number }`) | | `POST` | `/api/external/updates/read` | `[VERIFIED]` | Body: `MarkUpdateReadArg` (`{ id, update_type }`) | `UnreadCount` | | `POST` | `/api/external/updates/read_all` | `[VERIFIED]` | None | `UnreadCount` (`{ unread_count: 0 }`) | | `GET` | `/api/external/my_care` | `[VERIFIED]` | Query: `?status=...` | `MyCareFeed` | | `GET` | `/api/external/orders` | `[VERIFIED]` | None | `PatientOrdersResponse` | | `POST` | `/api/campaign-touches` | `[VERIFIED]` | Body: `{ campaign_source, campaign_medium, campaign_name }` | `{ success: boolean }` | | `POST` | `/api/tracked-links/confirm` | `[VERIFIED]` | Body: `{ tracked_link_codes: string[] }` | Confirmation | ### 2.10 Message Center (Twilio Chat Integration) | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/conversations` | `[VERIFIED]` | None | `ListConversationsResponse` | | `POST` | `/api/external/conversations` | `[VERIFIED]` | Body: `{ message: string, file_upload_ids?: string[], subject_id?: string }` | `CreateConversationResponse` | | `GET` | `/api/external/conversations/:id` | `[VERIFIED]` | Path: `id` | `{ conversation: ConversationSummary }` | | `POST` | `/api/external/conversations/:id/messages` | `[VERIFIED]` | Path: `id`, Body: `{ message: string, file_upload_ids?: string[] }` | `SendConversationMessageResponse` | | `GET` | `/api/external/conversations/:id/response_expectation` | `[VERIFIED]` | Path: `id` | `GetResponseExpectationResponse` | | `GET` | `/api/external/response_expectation` | `[VERIFIED]` | None | `GetResponseExpectationResponse` | | `POST` | `/api/external/conversations/token` | `[VERIFIED]` | None | `CreateTwilioTokenResponse` (`{ token, identity }`) | | `GET` | `/api/external/conversation_subjects` | `[VERIFIED]` | Query: `?category=...` | `ListConversationSubjectsResponse` | ### 2.11 Referral Orders (In-Person Specialist Care) | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/referral/orders` | `[VERIFIED]` | None | `ReferralOrder[]` | | `POST` | `/api/external/referral/orders` | `[VERIFIED]` | Body: `ReferralOrderCreateRequest` | `ReferralOrder` | | `GET` | `/api/external/referral/orders/:id` | `[VERIFIED]` | Path: `id` | `ReferralOrder` | | `PATCH` | `/api/external/referral/orders/:id` | `[VERIFIED]` | Path: `id`, Body: `ReferralOrderUpdateRequest` | `ReferralOrder` | | `GET` | `/api/external/referral/orders/:id/preference` | `[VERIFIED]` | Path: `id` | `ReferralPreference` | | `POST` | `/api/external/referral/orders/:id/preference` | `[VERIFIED]` | Path: `id`, Body: `ReferralPreferenceUpdateRequest` | `ReferralPreference` | | `GET` | `/api/external/referral/orders/:id/providers` | `[VERIFIED]` | Path: `id` | `ReferralOrderProvider[]` | | `POST` | `/api/external/referral/orders/:id/providers` | `[VERIFIED]` | Path: `id`, Body: `ReferralOrderProviderRequest` | `ReferralOrderProvider` | | `DELETE` | `/api/external/referral/orders/:id/providers/:provId` | `[VERIFIED]` | Path: `id`, `provId` | `void` | | `GET` | `/api/external/referral/orders/:id/providers/search/:searchId`| `[VERIFIED]` | Path: `id`, `searchId` | `ReferralProviderDetailResult` | | `POST` | `/api/external/in_person_visit/orders/:id/providers/pricing` | `[VERIFIED]` | Path: `id`, Body: `ReferralProviderPricingRequest` | `ReferralProviderPricingResponse` | | `GET` | `/api/external/in_person_visit/orders/:id/pricing` | `[VERIFIED]` | Path: `id` | `ReferralOrderPricingResponse` | | `POST` | `/api/external/referral/orders/:id/checkout` | `[VERIFIED]` | Path: `id`, Body: `ReferralOrderCheckoutRequest` | `CheckoutRequiresActionResponse \| undefined` | | `GET` | `/api/external/referral/orders/:id/payment` | `[VERIFIED]` | Path: `id` | `PaymentCheckout` | | `POST` | `/api/external/referral/orders/:id/payment` | `[VERIFIED]` | Path: `id` | `PaymentCheckout` | ### 2.12 Direct-to-S3 File Uploads | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `POST` | `/api/external/file_uploads` | `[VERIFIED]` | `CreateFileUploadRequest` (`{ file_name, content_type, byte_size }`) | `CreateFileUploadResponse` | | `POST` | `/api/external/file_uploads/presign` | `[VERIFIED]` | `CreateDirectFileUploadRequest` | `CreateFileUploadResponse` (`{ upload_url, file_id }`) | | `GET` | `/api/external/file_uploads/:id/status` | `[VERIFIED]` | Path: `id` | `FileUploadStatusResponse` | | `GET` | `/api/external/file_uploads/:id/download` | `[VERIFIED]` | Path: `id` | `FileDownloadViewModel` (`{ download_url }`) | | `DELETE` | `/api/external/file_uploads/:id` | `[VERIFIED]` | Path: `id` | `void` | ### 2.13 Clinical AI Copilot & Partner Consents | Method | Endpoint | Verification Status | Request Body / Params | Response Model | | :--- | :--- | :---: | :--- | :--- | | `GET` | `/api/external/copilot/messages` | `[VERIFIED]` | None | Copilot message history | | `POST` | `/api/external/copilot/messages` | `[VERIFIED]` | Body: `{ message: string }` | Copilot AI response | | `GET` | `/api/external/copilot/consent/status` | `[VERIFIED]` | None | `{ consent_given: boolean }` | | `POST` | `/api/external/copilot/consent/mark` | `[VERIFIED]` | None | `{ success: boolean }` | | `POST` | `/api/chat/feedback` | `[VERIFIED]` | Body: `SubmitMessageFeedbackRequest` (`{ message_id, feedback, comment? }`) | `MessageFeedbackResponse` | | `GET` | `/api/partner/consents` | `[VERIFIED]` | None | `PartnerConsentsMatrix` | | `POST` | `/api/partner/consents/:partnerFriendlyName/revoke` | `[VERIFIED]` | Path: `partnerFriendlyName`, Body: `{ consents: string[] }` | `PartnerConsentsMatrix` | | `GET` | `/api/external/tenant_integrations/phone_number` | `[VERIFIED]` | None | `TenantPhoneNumberResponse` | ### 2.14 Catalog-Only Unexercised Endpoints (`[UNDOCUMENTED_SERVER_CONTRACT]`) The following endpoints are declared in `lib/api/endpoints.ts` but lack an active RTK Query slice in client code. Their internal schemas are server-encapsulated: - **Test Harness**: `POST /api/external/test_setup/reset_test_user`, `DELETE /api/external/test_setup/delete_test_user`. - **Care Actions**: `GET /api/external/care_actions`, `GET /api/external/care_actions/:id`, `POST /api/external/care_actions/:id/snooze`, `POST /.../decline`, `POST /.../booked_myself`, `POST /.../auto_book`, `GET /.../pdf`, `GET /.../providers`, `POST /.../choose_provider`, `POST /.../checkout`. - **Questionnaires**: `GET /api/external/question_responses?sku_id=...`, `GET /api/external/questions/:id/:number`. - **Analytics Feeds**: `POST /api/external/analytics/visits`, `POST /api/external/analytics/events`. --- ## 3. Internal MedicineOS API Surface: 183 Routes & 238 RTK Query Operations ### 3.1 Counting Rules and Transport This section documents the API surface of the four recoverable internal applications, extracted from their production/staging Next.js bundles (`osint/internal_portals_recon.json`). These routes are **not** part of the public Nile-Core contract in §2; they are the internal OAuth-scoped API used by clinicians, catalog operators, referral coordinators, and prompt engineers. "MedicineOS" is used here as the umbrella label for these internal apps; it is not a string recovered from source. Architectural context for the systems is in `architecture.md` §8. | Application | Host(s) | Build chunks | RTK tag types | RTK Query operations | Route declarations | | :--- | :--- | ---: | ---: | ---: | ---: | | **Visitron** | `visitron.internal.generalmedicine.co`, `visitron.staging-nile.com` | 27 | 33 | 91 | 98 | | **Catalog** | `catalog.internal.generalmedicine.co`, `catalog.staging-nile.com` | 35 | 1 | 106 | 47 | | **Referrals** | `referrals.internal.generalmedicine.co`, `referrals.staging-nile.com` | 19 | 8 | 27 | 18 | | **Provider Chat** | `internal.generalmedicine.co`, `promptimus.staging-nile.com` | 18 | 4 | 14 | 20 | | **Total** | | **99** | **46** | **238** | **183** | **Counting rules.** 1. **Route declarations are per application and are not globally deduplicated.** Shared paths such as `/api/internal_oauth`, `/api/internal_oauth/login`, `/api/internal_oauth/callback`, `/api/internal_oauth/google_client_id`, `/api/internal_oauth/extension_token`, and `/api/user/current` appear in multiple apps. The 183 figure is the sum of each app's declared route set, which is the correct denominator for per-app attack-surface and auth analysis. 2. **Paths ending in `/` are collection or parameterized families.** `/api/internal_oauth/care_journeys/` represents `/care_journeys/:id`; the bundle stores the prefix. They are counted as one declaration each. 3. **HTTP verbs were not captured by the bundle inventory.** Route tables therefore preserve the exact declaration and describe intent. Where an operation name encodes a verb (`create`, `update`, `publish`, `claim`), the verb is noted in the purpose column but is not asserted as the literal HTTP method. 4. **All internal routes are OAuth-scoped.** The common prefix `/api/internal_oauth/*` denotes the Google-OAuth-issued internal session; `/api/internal/ops/*` is a Rails-native operations namespace used by Referrals; `/api/internal/cable` and `/api/external/cable` are ActionCable WebSocket endpoints. ### 3.2 Visitron — 98 Route Declarations, 91 RTK Query Operations #### 3.2.1 Auth, session, and transport | Route declaration | Purpose | | :--- | :--- | | `/api/admin/logout` | Destroy the admin session | | `/api/auth/login` | Legacy auth-tier login | | `/api/auth/logout` | Legacy auth-tier logout | | `/api/auth/refresh` | Rotate/refresh the access token | | `/api/external/` | Nile-Core external namespace root | | `/api/external/cable` | ActionCable WebSocket endpoint (external channel namespace) | | `/api/internal/` | Rails internal namespace root | | `/api/internal/cable` | ActionCable WebSocket endpoint (internal channel namespace) | | `/api/internal_oauth` | Internal OAuth entry point | | `/api/internal_oauth/callback` | OAuth authorization-code callback | | `/api/internal_oauth/login` | Start Google OAuth login | | `/api/internal_oauth/google_client_id` | Fetch the configured OAuth client ID | | `/api/internal_oauth/extension_token` | Mint a Chrome-extension bearer token | | `/api/user/current` | Current clinician identity and roles | #### 3.2.2 Copilot, prompts, and care journeys | Route declaration | Purpose | | :--- | :--- | | `/api/internal/copilot_channels/` | Internal copilot channel family | | `/api/internal/copilot_prompt_test/run_prompt` | Execute a prompt against a selected model/version | | `/api/internal/copilot_prompt_test/show` | Load a prompt test fixture | | `/api/internal/copilot_prompt_test/test_prompt` | Dry-run a prompt before saving | | `/api/internal/copilot_prompt_test/update_prompt` | Persist a prompt edit from the workbench | | `/api/internal_oauth/copilot_channels` | Copilot channel collection | | `/api/internal_oauth/copilot_channels/` | Single copilot channel | | `/api/internal_oauth/prompts` | Prompt library collection | | `/api/internal_oauth/prompts/` | Single prompt | | `/api/internal_oauth/care_journeys` | Care journey collection | | `/api/internal_oauth/care_journeys/` | Single care journey | | `/api/internal_oauth/care_journeys/published_pathways` | Published pathway catalog for journey assignment | #### 3.2.3 Benefit inquiries, e-prescribing, drug and pharmacy search | Route declaration | Purpose | | :--- | :--- | | `/api/internal_oauth/arrive_health/` | Arrive Health namespace root | | `/api/internal_oauth/arrive_health/launch_benefit_inquiry` | Start an RTPBI inquiry for patient + drug + pharmacy | | `/api/internal_oauth/arrive_health/patient_context?patient_id=` | Patient context payload for the RTPBI launch | | `/api/internal_oauth/dose_spot/prescription_eligibility_inquiries/` | DoseSpot eligibility inquiry collection | | `/api/internal_oauth/dose_spot/prescription_eligibility_inquiries/formulary` | Formulary lookup | | `/api/internal_oauth/dose_spot/prescription_eligibility_inquiries/launch` | Launch a DoseSpot eligibility inquiry | | `/api/internal_oauth/dose_spot/prescription_eligibility_inquiries/patient_context?patient_id=` | Patient context for DoseSpot | | `/api/internal_oauth/dose_spot/prescription_eligibility_inquiries/sync_insurance` | Sync insurance data into DoseSpot | | `/api/internal_oauth/drug_search/` | Drug search namespace root | | `/api/internal_oauth/drug_search/resolve_medication_selection` | Resolve a clinician selection to a canonical drug | | `/api/internal_oauth/drug_search/search` | Search the drug database | | `/api/internal_oauth/patients/search` | Patient search | | `/api/internal_oauth/pharmacy_pricing/insurance` | Insurance price for a pharmacy/order | | `/api/internal_oauth/pharmacy_pricing/insurance_status?order_id=` | Poll insurance pricing status | | `/api/internal_oauth/pharmacy_search` | Pharmacy directory search | | `/api/internal_oauth/provider_notifications` | Provider notification collection | | `/api/internal_oauth/provider_notifications/` | Single notification | | `/api/internal_oauth/provider_notifications/open_visit` | Open the visit referenced by a notification | | `/api/internal_oauth/visitron/dose_spot_idp_status` | DoseSpot identity-provider status | | `/api/internal_oauth/visitron/dose_spot_sso` | DoseSpot SSO launch | | `/api/internal_oauth/visitron/escribe/diagnoses` | Diagnosis search for e-prescribing | | `/api/internal_oauth/visitron/escribe/inbound_requests` | Inbound prescription/refill requests | | `/api/internal_oauth/visitron/escribe/prescriptions/drafts` | Draft prescription collection | | `/api/internal_oauth/visitron/escribe/prescriptions/drafts/` | Single draft prescription | | `/api/internal_oauth/visitron/escribe/prescriptions/patient_medications` | Patient medication list for prescribing | | `/api/internal_oauth/visitron/escribe/request/` | e-Scribe request family | | `/api/internal_oauth/visitron/patient_medications/` | Patient medication detail/update family | #### 3.2.4 Clinical encounter, review, and shift core | Route declaration | Purpose | | :--- | :--- | | `/api/internal_oauth/visitron/ad_hoc_encounter_info` | Ad hoc encounter context | | `/api/internal_oauth/visitron/apply_latest_prewarm` | Apply the latest prewarmed chart context | | `/api/internal_oauth/visitron/async_clinical_review/file_uploads/` | ACR attachment upload family | | `/api/internal_oauth/visitron/attest_manual_id_verification` | Clinician attestation of manual ID verification | | `/api/internal_oauth/visitron/cancel_without_fee` | Cancel a visit without a cancellation fee | | `/api/internal_oauth/visitron/care_plan_athena_resync` | Re-pull the care plan from Athena | | `/api/internal_oauth/visitron/chat_shift_extension_status` | Chat shift extension status | | `/api/internal_oauth/visitron/clinician_review` | Clinician review resource | | `/api/internal_oauth/visitron/clinician_reviews` | Review collection | | `/api/internal_oauth/visitron/clinician_reviews/` | Single review | | `/api/internal_oauth/visitron/confirm_care_plan` | Confirm/sign the care plan | | `/api/internal_oauth/visitron/create_next_step_review` | Create a next-step review | | `/api/internal_oauth/visitron/encounter_orders` | Orders attached to the encounter | | `/api/internal_oauth/visitron/encounter_summary_athena_resync` | Re-pull the encounter summary from Athena | | `/api/internal_oauth/visitron/extend_chat_shift` | Extend a clinician chat shift | | `/api/internal_oauth/visitron/generate_next_step_review` | Generate a next-step review draft | | `/api/internal_oauth/visitron/get_appointment_info` | Appointment detail and patient context | | `/api/internal_oauth/visitron/get_async_clinical_review` | ACR detail | | `/api/internal_oauth/visitron/get_draft_encounter` | Draft encounter | | `/api/internal_oauth/visitron/get_nabla_status` | Nabla ambient-scribe availability/status | | `/api/internal_oauth/visitron/get_provider_appointments` | Clinician schedule | | `/api/internal_oauth/visitron/icd10_codes` | ICD-10 code search | | `/api/internal_oauth/visitron/lab_codes` | Lab code search | | `/api/internal_oauth/visitron/mark_no_show` | Mark a visit as no-show | | `/api/internal_oauth/visitron/next_step_review` | Next-step review resource | | `/api/internal_oauth/visitron/next_step_review/` | Single next-step review | | `/api/internal_oauth/visitron/next_steps` | Next-step catalog | | `/api/internal_oauth/visitron/past_visits` | Patient visit history | | `/api/internal_oauth/visitron/patient_chart_context` | Chart context for the encounter | | `/api/internal_oauth/visitron/pending_shift_checkouts` | Clinician shifts awaiting checkout | | `/api/internal_oauth/visitron/providers` | Provider directory | | `/api/internal_oauth/visitron/publish_draft_encounter` | Publish/sign the encounter | | `/api/internal_oauth/visitron/questionnaire_codes` | Questionnaire code catalog | | `/api/internal_oauth/visitron/reclaim_finished_chat_visit` | Reclaim a finished chat visit | | `/api/internal_oauth/visitron/request_chat_visit` | Request a synchronous chat visit | | `/api/internal_oauth/visitron/reschedule_any_provider` | Reschedule with any available clinician | | `/api/internal_oauth/visitron/reschedule_same_provider` | Reschedule with the same clinician | | `/api/internal_oauth/visitron/shift_checkout` | Check out of a shift | | `/api/internal_oauth/visitron/shift_checkout_status` | Shift checkout status | | `/api/internal_oauth/visitron/skus` | SKU lookup for the encounter | | `/api/internal_oauth/visitron/state_options` | State/licensure options | | `/api/internal_oauth/visitron/submit_async_clinical_review` | Submit an ACR decision | | `/api/internal_oauth/visitron/sync_encounter_to_athena` | Push the encounter to Athenahealth | | `/api/internal_oauth/visitron/trigger_metriport_sync` | Trigger a Metriport health-history sync | | `/api/internal_oauth/visitron/update_draft_encounter` | Update the draft encounter | #### 3.2.5 Visitron RTK Query operation inventory (91) ```text applyAppointmentLatestPrewarm, applyReview, approveInboundRequest, attestManualIdVerification, batchChangePatientMedicationPhases, cancelDraftPrescription, cancelPrescriptionOrder, cancelWithoutFee, changePathway, changePhase, clearPatientMedicationDaysSupply, confirmCarePlan, confirmNoChange, createCareJourney, createChannel, createDraftPrescription, createNextStepReview, createPatientMedicationPrescriptionRenewal, createShiftCheckout, denyInboundRequest, extendChatShift, finalizeDraftPrescription, generateNextStepReview, getAdHocEncounterInfo, getAppointmentDraftEncounter, getAppointmentInfo, getAsyncClinicalReview, getAsyncClinicalReviewFileUploadPreview, getCareJourney, getCareJourneys, getChannel, getChatHistory, getChatShiftExtensionStatus, getClinicianReview, getClinicianReviews, getCurrentUser, getDoseSpotIdpStatus, getDraftPrescription, getEncounterOrders, getFileUploadPreview, getGoogleClientId, getIcd10Codes, getInsurancePriceStatus, getLabCodes, getNablaStatus, getNextSteps, getOAuthLoginUrl, getPastVisits, getPatientChartContext, getPendingReview, getPendingShiftCheckouts, getProviderAppointments, getProviderNotifications, getProviders, getPublishedPathways, getQuestionnaireCodes, getShiftCheckoutStatus, getSkus, getStateOptions, getVisitronPrompts, handleOAuthCallback, launchInsurancePrice, listDraftPrescriptions, listInboundRequests, listPatientMedications, markProviderNotificationRead, markVisitNoShow, publishAppointmentDraftEncounter, reclaimFinishedChatVisit, rejectReview, replaceDraftPrescription, requestChatVisit, rescheduleAnyProvider, rescheduleSameProvider, resolveProviderNotificationVisit, resyncCarePlanFromAthena, resyncEncounterSummaryFromAthena, searchDiagnoses, searchPatients, submitAsyncClinicalReview, submitClinicianReview, syncClinicianReviewEncounterToAthena, syncEncounterToAthena, triggerMetriportSync, updateAppointmentDraftEncounter, updateClinicianReviewEncounterDraft, updateClinicianReviewRejectionExplanation, updateDraftPrescription, updateNextStepReview, updatePatientMedicationCourseType, updatePatientMedicationDaysSupply ``` ### 3.3 Catalog — 47 Route Declarations, 106 RTK Query Operations The Catalog app has the highest operation-to-route ratio in the suite (2.26 ops per route), reflecting heavy CRUD over a small set of resource families. It defines only one RTK tag type (`User`), so most mutations rely on explicit refetch. #### 3.3.1 Auth, shared, and tenancy | Route declaration | Purpose | | :--- | :--- | | `/api/admin/logout` | Destroy the admin session | | `/api/internal_oauth` | Internal OAuth entry point | | `/api/internal_oauth/callback` | OAuth callback | | `/api/internal_oauth/extension_token` | Chrome-extension token | | `/api/internal_oauth/google_client_id` | OAuth client ID | | `/api/internal_oauth/login` | Start Google OAuth | | `/api/user/current` | Current operator identity | | `/api/internal_oauth/catalog/tenants` | Tenant list for catalog scoping | #### 3.3.2 Care pathways, conditions, and criteria | Route declaration | Purpose | | :--- | :--- | | `/api/internal_oauth/catalog/care_pathways` | Care pathway collection | | `/api/internal_oauth/catalog/care_pathways/` | Single pathway (draft/publish/archive) | | `/api/internal_oauth/catalog/care_pathways/phase_kinds` | Allowed phase kinds | | `/api/internal_oauth/catalog/catalog_conditions` | Catalog condition collection | | `/api/internal_oauth/catalog/catalog_conditions/` | Single condition | | `/api/internal_oauth/catalog/condition_categories` | Condition category collection | | `/api/internal_oauth/catalog/condition_categories/` | Single category and membership | | `/api/internal_oauth/catalog/sku_criteria_sets` | Criteria set collection | | `/api/internal_oauth/catalog/sku_criteria_sets/` | Single criteria set (clone/update) | #### 3.3.3 SKUs, phases, and PDPs | Route declaration | Purpose | | :--- | :--- | | `/api/internal_oauth/catalog/skus` | SKU collection (create/list) | | `/api/internal_oauth/catalog/skus/` | Single SKU (general/indexable/visit config) | | `/api/internal_oauth/catalog/skus/bulk_questionnaires_pdf` | Bulk questionnaire PDF export | | `/api/internal_oauth/catalog/skus/econsult_specialties` | E-consult specialty options | | `/api/internal_oauth/catalog/skus/phase_types` | SKU phase type options | | `/api/internal_oauth/catalog/skus/provider_roles` | Provider role options | | `/api/internal_oauth/catalog/sku_categories` | SKU category taxonomy | | `/api/internal_oauth/catalog/sku_phases/` | SKU phase family | | `/api/internal_oauth/catalog/sku_states` | SKU state machine values | | `/api/internal_oauth/catalog/product_detail_pages` | PDP collection | | `/api/internal_oauth/catalog/product_detail_pages/` | Single PDP | | `/api/internal_oauth/catalog/fulfillment_owners` | Fulfillment owner options | #### 3.3.4 Clinical data: labs, biomarkers, medication fills, coding | Route declaration | Purpose | | :--- | :--- | | `/api/internal_oauth/catalog/junction_biomarkers` | Junction biomarker collection | | `/api/internal_oauth/catalog/junction_biomarkers/` | Single biomarker | | `/api/internal_oauth/catalog/junction_biomarkers/filter_options` | Biomarker filter options | | `/api/internal_oauth/catalog/lab_sku_details/` | Lab SKU detail family | | `/api/internal_oauth/catalog/lab_sku_details/generate` | Generate lab SKU detail from panel data | | `/api/internal_oauth/catalog/medication_fill_sku_details/` | Medication fill SKU detail/defaults | | `/api/internal_oauth/catalog/icd10_codes` | ICD-10 search | | `/api/internal_oauth/catalog/procedure_code_mappings` | Procedure code mapping collection | | `/api/internal_oauth/catalog/procedure_code_mappings/` | Single mapping | | `/api/internal_oauth/catalog/procedure_code_mappings/procedure_types` | Procedure type enum | | `/api/internal_oauth/catalog/procedure_code_mappings/service_types` | Service type enum | #### 3.3.5 Questionnaires and prompt library | Route declaration | Purpose | | :--- | :--- | | `/api/internal_oauth/questionnaires` | Questionnaire collection | | `/api/internal_oauth/questionnaires/` | Single questionnaire | | `/api/internal_oauth/catalog/questionnaire_edits` | Edit-request collection | | `/api/internal_oauth/catalog/questionnaire_edits/` | Single edit request (apply/discard) | | `/api/internal_oauth/prompts` | Prompt collection | | `/api/internal_oauth/prompts/` | Single prompt | | `/api/internal_oauth/prompts/summary` | Prompt summaries for list views | #### 3.3.6 Catalog RTK Query operation inventory (106) ```text applyQuestionnaireEdit, archiveCarePathway, cloneCriteriaSet, createCarePathway, createCarePathwayPhase, createConditionCategory, createCriteriaSet, createEmptyQuestionnaires, createPhaseModality, createProcedureCodeMapping, createPrompt, createQuestionnaire, createRequirement, createSku, createSkuPhase, deleteCarePathway, deleteCarePathwayPhase, deleteConditionCategory, deletePhaseModality, deleteQuestionnaire, deleteRequirement, deleteSkuPhase, discardQuestionnaireEdit, downloadBulkSkuQuestionnairesPdf, generateLabSkuDetail, generateSkuImage, getAvailableLabPanelBiomarkers, getCarePathway, getCarePathwayPhaseKinds, getCarePathways, getCatalogCondition, getCatalogConditions, getConditionCategories, getConditionCategory, getCriteriaSet, getCriteriaSetReferences, getCriteriaSets, getCurrentUser, getEconsultSpecialties, getGoogleClientId, getJunctionBiomarker, getJunctionBiomarkerFilterOptions, getJunctionBiomarkers, getLabPanels, getLabSkuDetail, getMedicationFillSkuDetail, getOAuthLoginUrl, getProcedureCodeMapping, getProcedureCodeMappingProcedureTypes, getProcedureCodeMappingServiceTypes, getProcedureCodeMappings, getProductDetailPage, getProductDetailPages, getPrompt, getPromptSummaries, getProviderRoles, getQuestionnaire, getQuestionnaireEditPdf, getQuestionnaireEdits, getQuestionnaireUsage, getQuestionnaires, getRequirements, getSku, getSkuCategories, getSkuImageGeneration, getSkuPhaseTypes, getSkuPhases, getSkuQuestionnairesJson, getSkuQuestionnairesPdf, getSkuStates, getSkus, getTenants, handleOAuthCallback, logout, publishCarePathway, removeLabPanel, reorderCarePathwayPhases, replaceConditionCategoryCatalogConditions, requestQuestionnaireEdits, returnCarePathwayToDraft, saveLabPanel, searchIcd10Codes, updateCarePathway, updateCarePathwayLinkedSkus, updateCarePathwayPhase, updateConditionCategory, updateCriteriaSet, updateJunctionBiomarker, updateLabSkuDetail, updateMedicationDefaults, updateMedicationFillSkuDetail, updatePhaseModality, updateProcedureCodeMapping, updateProductDetailPage, updatePrompt, updateQuestionnaire, updateRequirement, updateSku, updateSkuGeneral, updateSkuIndexable, updateSkuPhase, updateSkuQuestionnairesJson, updateSkuVisitConfiguration, uploadSkuReferenceImage, uploadSkuStorefrontImage, useSkuImageGeneration ``` ### 3.4 Referrals — 18 Route Declarations, 27 RTK Query Operations | Route declaration | Purpose | | :--- | :--- | | `/api/admin/logout` | Destroy the coordinator session | | `/api/internal_oauth` | Internal OAuth entry point | | `/api/internal_oauth/callback` | OAuth callback | | `/api/internal_oauth/extension_token` | Chrome-extension token | | `/api/internal_oauth/google_client_id` | OAuth client ID | | `/api/internal_oauth/login` | Start Google OAuth | | `/api/internal_oauth/patients/` | Patient detail family | | `/api/internal_oauth/patients/search` | Patient search | | `/api/internal_oauth/promises/queue/claim` | Claim a referral promise for this coordinator | | `/api/internal_oauth/promises/queue/drop` | Drop, release, or snooze a claimed promise | | `/api/internal_oauth/promises/queue/enabled` | Feature-gate the concierge queue | | `/api/internal_oauth/referral/orders` | Referral order collection | | `/api/internal_oauth/referral/orders/` | Single referral order | | `/api/internal_oauth/referral/orders/all` | All orders (supervisor view) | | `/api/internal/ops/referrals` | Rails-native ops referral collection | | `/api/internal/ops/referrals/` | Rails-native single referral | | `/api/internal/ops/referral_provider_candidates/` | Provider candidate family | | `/api/user/current` | Current coordinator identity | ```text addCandidate, cancelOrder, claimPromise, createBookingEvent, dropOrSnoozeOrder, endShift, getBooking, getCandidates, getCurrentUser, getGoogleClientId, getOAuthLoginUrl, getOrder, getPatient, getPreference, getQueueEnabled, getReferral, getReferrals, handleOAuthCallback, listAllOrders, listUserOrders, logOutcome, logout, recordOutreach, removeCandidate, searchProviders, updateBooking, updateCandidate ``` RTK tag types (8): `Booking`, `Candidates`, `OrderPreference`, `Patient`, `QueueEnabled`, `ReferralDetail`, `Referrals`, `User`. ### 3.5 Provider Chat / Prompt Workbench — 20 Route Declarations, 14 RTK Query Operations | Route declaration | Purpose | | :--- | :--- | | `/api/auth/login` | Legacy auth-tier login | | `/api/auth/logout` | Legacy auth-tier logout | | `/api/auth/refresh` | Refresh access token | | `/api/external/` | External namespace root | | `/api/external/cable` | ActionCable endpoint (external channel) | | `/api/internal/` | Internal namespace root | | `/api/internal/cable` | ActionCable endpoint (internal channel) | | `/api/internal_oauth` | Internal OAuth entry point | | `/api/internal_oauth/callback` | OAuth callback | | `/api/internal_oauth/copilot_channels` | Copilot channel collection | | `/api/internal_oauth/copilot_channels/` | Single copilot channel | | `/api/internal_oauth/extension_token` | Chrome-extension token | | `/api/internal_oauth/google_client_id` | OAuth client ID | | `/api/internal_oauth/login` | Start Google OAuth | | `/api/internal_oauth/messages` | Message send/history endpoint | | `/api/internal_oauth/prompts` | Prompt collection | | `/api/internal_oauth/prompts/` | Single prompt | | `/api/internal_oauth/prompts/model_versions` | Available model versions | | `/api/internal_oauth/prompts/temperatures?model_version=` | Temperature options for a model version | | `/api/user/current` | Current operator identity | ```text createCatalogPrompt, createChannel, getCatalogPrompt, getCatalogPrompts, getChannel, getChatHistory, getCurrentUser, getGoogleClientId, getModelVersions, getOAuthLoginUrl, getTemperatures, handleOAuthCallback, sendMessage, updateCatalogPrompt ``` RTK tag types (4): `Channel`, `History`, `Prompt`, `User`. ### 3.6 Cross-Cutting Internal API Conventions | Concern | Convention | Evidence | | :--- | :--- | :--- | | **Authentication** | Google OAuth authorization-code flow: `/api/internal_oauth/login` → provider consent → `/api/internal_oauth/callback` → session cookie; `/api/user/current` is the identity probe | All four apps | | **Extension auth** | `/api/internal_oauth/extension_token` mints a scoped bearer token for the Chrome extension; present in all four apps | All four apps | | **Authorization failure** | Vercel returns `307` with a JSON body and `Location: /login` for Catalog/Referrals; Visitron and Provider Chat expose a legacy `/api/auth/*` tier returning `401` | `osint/infra_npi_catalog.json` HTTP probes | | **Real-time** | ActionCable over `/api/internal/cable` and `/api/external/cable`; channels `ExternalCable::CopilotChannel` and `InternalCable::CopilotChannel` | Visitron, Provider Chat | | **Path versioning** | None. There is no `/v1` or `/v2`; breaking changes are coordinated by deploying apps and Rails together | All route inventories | | **Tenancy** | No `X-Tenant-Id` header on internal routes; tenant isolation is achieved by separate deployments (`mcy.*`, `wmt.*`) and the `catalog/tenants` resource | Catalog, DNS topology | | **Pagination** | Cursor/params are operation-specific; no shared pagination envelope is recoverable from the route inventory | All four apps | | **Response schemas** | Not recoverable from the route inventory; schemas are server-encapsulated. Only operation names and route declarations are asserted here | Route inventory limit | **Security observations for this surface.** 1. `internal.generalmedicine.co` (Provider Chat) and `visitron.internal.generalmedicine.co` (Visitron) both returned HTTP 200 at the edge, while Catalog and Referrals returned `307 → /login`. Client-side gating may still protect data, but those two deployments do not enforce edge auth. The prompt test routes (`/api/internal/copilot_prompt_test/*`) are declared in Visitron's bundle, not Provider Chat's; combined with the EHR and e-prescribing surface, Visitron is the highest-value internal target. Provider Chat remains sensitive because it exposes copilot channels and the prompt library. 2. `promptimus.staging-nile.com`, `catalog.*`, `referrals.*`, `mcy.*`, and `wmt.*` all correctly return `401`/`307`/`308` without credentials; `visitron-test.internal…` returns `403`. The inconsistency is confined to the production Visitron and Provider Chat hosts. 3. The `extension_token` route is a shared trust primitive across four apps. Its scope, lifetime, and revocation behavior were not recoverable from client bundles and should be treated as a priority security item. 4. Catalog's single `User` tag type means a stale-cache bug after a mutation is a realistic operational risk; any UI showing "saved" without a refetch should be verified server-side. 5. The internal portals live on separate hosts and are not part of the consumer app's route tree; the consumer tenant rewrite denylist (`config/tenants/tenantRewrites.js`) protects only that app's own API proxy, Cognito handlers, sitemaps, and static paths. Internal route isolation is therefore a DNS/deployment property, not a path-level rewrite rule. ================================================================================ # DOCUMENT: Data Models & Browser Storage (raw/reports/data-models.md) ================================================================================ # Data Models & Schemas: General Medicine Platform ## 1. Domain Entity Relationship Diagram The Mermaid ER diagram below covers the core clinical, ordering, billing, and identity entities as first-party TypeScript models and RTK Query serialization types define them: ```mermaid erDiagram PATIENT ||--o{ PAYMENT_METHOD : stores PATIENT ||--o{ INSURANCE_POLICY : maintains PATIENT ||--|| HEALTH_HISTORY : possesses PATIENT ||--o{ VISIT : books PATIENT ||--o{ URGENT_CARE_ORDER : creates PATIENT ||--o{ PHARMACY_ORDER : initiates PATIENT ||--o{ LAB_ORDER : receives PATIENT ||--o{ CONVERSATION : conducts PATIENT { string id PK string first_name string last_name string email string phone_number UK date date_of_birth string sex_assigned_at_birth boolean id_verified boolean blocked string home_address_time_zone } PAYMENT_METHOD { string id PK string patient_id FK string brand string last_four int exp_month int exp_year boolean is_default } INSURANCE_POLICY { string id PK string patient_id FK string payer_name string member_id string plan_name string external_state float copay_amount } HEALTH_HISTORY { string id PK string patient_id FK json conditions json medications json allergies json procedures string sync_source datetime last_metriport_sync } VISIT { string id PK string patient_id FK string sku_id string clinician_id string state string billing_type datetime scheduled_start string meeting_url } URGENT_CARE_ORDER { string id PK string patient_id FK string sku_id string solv_clinic_id string solv_offer_id string clinic_name datetime appointment_time boolean walk_in string state string confirmation_code } PHARMACY_ORDER { string id PK string patient_id FK string medication_sku_id string ncpdp_id string pharmacy_name string billing_type float cash_price float insurance_price string state string gm_card_bin string gm_card_pcn } LAB_ORDER { string id PK string patient_id FK string sku_id string lab_provider string accession_number float clinical_fee float test_fee string status string pdf_report_url } CONVERSATION { string id PK string patient_id FK string clinician_id string subject string twilio_channel_sid datetime last_message_at } ``` --- ## 2. TypeScript & Zod Domain Models ### 2.1 Patient & Identity Verification Models ```typescript export interface HomeAddress { line_1?: string line_2?: string city?: string state?: string zip?: string time_zone?: string latitude?: number longitude?: number } export interface User { id: string first_name: string last_name?: string email?: string phone_number?: string date_of_birth?: string sex_assigned_at_birth?: 'Male' | 'Female' | 'Other' | 'Unknown' id_verified?: boolean home_address?: HomeAddress | null home_address_time_zone?: string blocked: boolean } /** In-memory demographic profile produced by 1-click Nile Verified lookup. Never persisted to browser storage. */ export interface VerifiedProfile { firstName: string lastName: string birthDate: string gender: 'Male' | 'Female' | '' addresses: VerifiedAddress[] selectedAddressIndex: number } export interface VerifyIdentityRequest { birth_date: string // YYYY-MM-DD ssn?: string // Last 4 digits or 9 digits } ``` ### 2.2 Clinical Health History & EHR Sync Models ```typescript export interface GenericChartItem { id: string name: string code?: string system?: string source: 'metriport' | 'particle' | 'manual' date?: string } export interface Condition extends GenericChartItem { icd10?: string clinicalStatus?: 'active' | 'recurrence' | 'relapse' | 'remission' | 'resolved' } export interface Medication extends GenericChartItem { dosage?: string frequency?: string rxnorm?: string } export interface Allergy extends GenericChartItem { reaction?: string severity?: 'mild' | 'moderate' | 'severe' } export interface Procedure extends GenericChartItem { cpt?: string } export interface HealthHistory { conditions: Condition[] medications: Medication[] allergies: Allergy[] procedures: Procedure[] no_conditions: boolean no_medications: boolean no_allergies: boolean no_procedures: boolean } ``` ### 2.3 Solv Health Urgent Care Order Models ```typescript export interface UrgentCareLocation { location_id: string name: string address: HomeAddress distance_miles: number walk_in_allowed: boolean current_wait_minutes?: number available_slots: { slot_id: string start_time: string // ISO 8601 end_time: string }[] daily_hours: { weekday: string open_time: string close_time: string }[] } export interface UrgentCareOrder { order_id: string state: 'draft' | 'offer_selected' | 'confirmed' | 'cancelled' sku_id: string fulfillment_offer_id?: string | null location_id?: string | null clinic_name?: string appointment_time?: string | null // ISO 8601 walk_in: boolean reschedule: boolean confirmation_code?: string } ``` ### 2.4 Pharmacy Routing, Real-Time Pricing & GoodRx Models ```typescript export interface PharmacyComparisonResult { fulfillment_owner: string // 'cvs' | 'walgreens' | 'walmart' | 'lillydirect' | 'amazonpharmacy' chain_name: string ncpdp_id: string pharmacy_name: string address: HomeAddress price: number distance_miles: number in_stock: boolean } export interface PharmacyOrder { pharmacy_order_id: string state: 'created' | 'pharmacy_selected' | 'order_placed' | 'dispensed' | 'cancelled' pharmacy_name?: string ncpdp_id?: string billing_type: 'cash' | 'insurance' | 'pharmacy_delegation' medication_name: string cash_price: number insurance_price?: number | null can_cancel_pharmacy_order: boolean can_switch_pharmacy: boolean current_payment?: { payment_method_id: string amount_cents: number } } export interface GmCardInfo { bin: string pcn: string group: string member_id: string } ``` ### 2.5 Quest Diagnostics Lab Panel Models ```typescript export interface LabSku { sku_id: string name: string cash_price: number clinical_fee: number // Server-driven (15.0 live on sampled SKUs; falls back to 30 via STANDARD_CLINICAL_FEE) estimated_insurance_copay: number // Fixed at $30 (ESTIMATED_INSURANCE_COPAY) tests_included: string[] specimen_type: 'serum' | 'urine' | 'swab' fasting_required: boolean } export interface LabOrder { id: string sku_id: string patient_id: string status: 'requisition_ready' | 'sample_collected' | 'processing' | 'results_ready' accession_number?: string clinical_fee: number test_fee: number report_url?: string created_at: string } ``` --- ## 3. Redux Toolkit State Architecture & RTK Query Tags The application state is centralized in `@reduxjs/toolkit` with RTK Query managing server synchronization: ### 3.1 RTK Query Base API Configuration - **Store Configuration (`lib/store/store.ts`)**: Configures `store` mounting `baseApi.reducer` and `baseApi.middleware`. - **Base Query (`lib/store/api/baseQuery.ts`)**: Implements `fetchBaseQuery` targeting `getRequestOrigin()`, enforcing `credentials: 'include'` and `Cache-Control: no-cache`. Includes automatic HTTP 401 session bounce to `/login`. ### 3.2 Registered Domain Tag Types (52 Tags) The `baseApi` registers 52 cache tags for real-time UI synchronization: - **Core Entities**: `User`, `Dashboard`, `Prescription`, `Channel`, `ChatHistory`, `Sku`, `SearchSuggestions`, `HealthHistory`, `VisitCart`, `Payment`, `Appointment`, `Provider`. - **Insurance**: `InsuranceOnboarding`, `InsuranceFlow`, `Insurance`, `Specialty`, `MercyBilling`, `PaymentMethods`. - **Pharmacy & Pricing**: `PharmacyOrder`, `PharmacySearch`, `PharmacyDetail`, `PharmacyCashPrice`, `PharmacyInsurancePrice`, `MedicationOptionCashPrice`, `PharmacyComparison`, `DirectoryPharmacy`, `PharmacyMedications`, `ProductDetailPage`. - **Urgent Care & Referrals**: `UrgentCareOrder`, `UrgentCareOrderLocations`, `ReferralOrder`, `ReferralOrderPreference`, `ReferralOrderProvider`, `ReferralOrderPayment`, `PartnerConsents`. - **Care Plans & Files**: `CareJourney`, `MedicationCheckInLabUpload`, `FileUpload`, `CarePlan`, `CarePlanConditionGroups`, `Updates`, `UpdatesUnreadCount`, `MessageCenter`, `MyCare`, `NextStepCards`, `PreVisitRequirements`, `DashboardIntro`, `GoogleSso`. --- ## 4. Browser Storage Key Inventory | Storage Type | Key / Cookie Name | Lifecycle | Payload / Schema | Purpose | | :--- | :--- | :--- | :--- | :--- | | **HttpOnly Cookie** | `gm_session_token` | Session / 30 mins | Encrypted JWT | Authenticated patient session token | | **Document Cookie** | `redirect_url` | 30 minutes | URL string (e.g. `/account`) | Preserves destination during 401 login bounce | | **Document Cookie** | `tracked_link_codes` | Transient | Encrypted attestation string | Attribution touchpoint tracking for Nile-Core | | **Vercel Cookie** | `dpl` | Deployment duration | `dpl_6pe1LEVDiPKqKbNVwntrJwZnBVzE` | Pinned deployment version routing | | **localStorage** | `phoneNumber` | Persistent | E.164 string (`+15550001234`) | Remembers phone number for faster login | | **localStorage** | `currentLoginSignupStep` | Persistent | Route path string | Resume multi-step onboarding on refresh | | **localStorage** | `storeSearchHistory` | Persistent | JSON string array | Autocomplete history in universal search | | **localStorage** | `wmt_attribution` | Persistent | Campaign attribution string | Walmart partner referral tracking | | **sessionStorage** | `isExistingUser` | Tab session | `'true'` \| `'false'` | Distinguishes login vs signup routing | | **sessionStorage** | `userInsurance` | Tab session | Serialized `InsurancePolicy` | Prevents redundant insurance lookups during visit booking | | **sessionStorage** | `appointmentRequestContext`| Tab session | Serialized appointment request state | Preserves selected clinic and provider in booking flow | ================================================================================ # DOCUMENT: Source Recovery Coverage (raw/reports/decompilation-coverage.md) ================================================================================ # Source Coverage: General Medicine (`generalmedicine.co`) ## 1. Coverage Summary - **Application**: General Medicine Patient Portal & Telehealth Storefront (`generalmedicine.co`) - **Origin**: `https://generalmedicine.co/` (Vercel Edge Network) - **Backend**: Nile-Core Rails API (`https://api.generalmedicine.co/api/external/...`) - **Coverage Method**: Static JavaScript application graph - **Coverage Inputs**: 406 production chunk bundles and 400 SourceMap v3 manifests - **Chunks**: **406 / 406 (100.0%)** production bundles (16.27 MB JS) - **Source Map Coverage**: **400 / 406 (98.5%)** live SourceMap v3 `.js.map` files (30.06 MB maps; the remaining 6 chunks are 200-byte webpack bootstrap delegators without source code) - **Recovered Source Files**: **2,443 files** (208,387 total lines of source code) - **First-Party Sources**: **798 files** (51,015 LOC: 208 `.ts`, 333 `.tsx`, 1 `.jsx`, 115 `.css`, 1 `.js`, 140 image/icon assets) - **Third-Party Sources**: **1,645 files** (157,372 LOC across `@reduxjs/toolkit`, Mantine UI, Framer Motion, Axios, LaunchDarkly, Shiki) - **Static AST Metrics**: 806 input files analyzed, 406 JavaScript files parsed, 1,234,301 AST nodes visited, 2,653 modules indexed, 11,352 findings, 0 parse failures. - **Gaps**: client-side code only. Nile-Core server code, database DDL, and server environment variables are not represented. --- ## 2. Chunk Discovery & Coverage Ledger The 406 chunks comprise runtime, route, lazy-feature and shared-component bundles: | Artifact Category | Discovered Chunks | Downloaded Chunks | Live Source Maps | Recovered Sources | Source LOC | Extraction Status | | :--- | :---: | :---: | :---: | :---: | :---: | :--- | | **Webpack & Next.js Runtime** | 4 | 4 | 4 | 148 | 8,920 | 100% Extracted (`webpack-*.js`, `main-app-*.js`, `1528-*.js`, `polyfills-*.js`) | | **App Router Page & Layout Chunks** | 22 | 22 | 16 | 215 | 18,430 | 100% Extracted (6 delegator chunks delegate to numeric modules) | | **Dynamic Lazy & Feature Chunks** | 315 | 315 | 315 | 1,650 | 128,450 | 100% Extracted (Discovered via `i.u` chunk map function) | | **Shared Component & Vendor Chunks** | 65 | 65 | 65 | 430 | 52,587 | 100% Extracted (Discovered via route HTML crawl) | | **Total Artifact Footprint** | **406** | **406** | **400** | **2,443** | **208,387** | **100.0% Source Tree Recovered** | --- ## 3. First-Party Subsystem Breakdown The 798 first-party source files span these domains: | Subsystem Directory | File Count | TypeScript / TSX | CSS / Styles | Assets | Primary Responsibilities | | :--- | :---: | :---: | :---: | :---: | :--- | | `components/` | 394 | 321 | 73 | 0 | UI components: PDP, search, Visitron, insurance, lab pricing, pharmacy compare | | `lib/` | 140 | 134 | 6 | 0 | Core utilities: API endpoints (`endpoints.ts`), RTK Query slices (`lib/store/api/`), routing, metrics, attribution | | `assets/` | 132 | 0 | 0 | 132 | Medical icons, pharmacy chain wordmarks, badges, marketing imagery | | `packages/` | 56 | 32 | 24 | 0 | Monorepo internal packages: `@nile/mantine-theme`, `@nile/ai-assistant`, analytics wrappers | | `tenants/` | 26 | 16 | 10 | 0 | Multi-tenant theming and overrides for **Walmart** ("Better Care Services") and **Mercy Health** | | `app/` | 15 | 14 | 1 | 0 | Next.js App Router entry clients: `s/[sku-name]/[sku-id]`, `ai/`, `get-started/`, `error.tsx`, `not-found.tsx` | | `contexts/` | 14 | 14 | 0 | 0 | React Contexts: `ApiContext`, `AuthContext`, `CareContext`, `HealthHistoryContext`, `InsuranceContext`, `TenantContext` | | `hooks/` | 14 | 14 | 0 | 0 | Custom hooks: `useUniversalSearch`, `useGeneralAiStatus`, `useAttributionTracking`, `useBreakpoints` | | `types/` | 4 | 4 | 0 | 0 | Runtime TypeScript enums: `sku-constants.ts`, `ServiceItem.ts`, `lab-pricing-constants.ts`, `StoreTypes.ts` | | `config/` | 2 | 2 | 0 | 0 | Tenant routing rewrites (`tenantRewrites.js`) and public config (`walmartPublic.ts`) | | `utils/` | 1 | 1 | 0 | 0 | General utility helpers | | **Total First-Party** | **798** | **542** | **114** | **142** | **Full client-side source with symbol names and comments** | --- ## 4. Fact vs. Inference Boundary Observations fall into two groups: facts read directly from recovered source, and architectural inferences: ### 4.1 Observed in Recovered Source - **TypeScript Source Authenticity**: 100% of the 798 first-party files come from un-minified `sourcesContent` payloads inside live SourceMap v3 files hosted at `https://generalmedicine.co/_next/static/chunks/*.js.map`. Variable names, type annotations, internal comments, and function implementations match the developers' IDE code byte for byte. - **API Catalog & RTK Query Binding**: The centralized route catalog (`lib/api/endpoints.ts`) and route handlers define 194 distinct API endpoint references. Of these, **119 operations** are bound to Redux Toolkit Query slices (`lib/store/api/`), with request body, query parameter, and response models read from recovered source. **130 paths** are fully specified in `openapi.yaml`. The remaining endpoints are catalog-only entries (`[UNDOCUMENTED_SERVER_CONTRACT]`) whose internal schemas remain server-encapsulated. - **Clinical Pricing & SKU Logic**: The $30 clinical fee is a missing-fee fallback (`STANDARD_CLINICAL_FEE`), sampled live lab SKUs return $15.00, and the estimated insurance copay is $30. Core SKU IDs (`400013` General Visit, `100012` Primary Care, `400002`/`400336` Urgent Care, `200007` Rx Renewal, `500001` Annual Wellness Test) are confirmed in source. - **Multi-Tenant System**: Dedicated tenant configurations exist for `walmart` (brand: "Better Care Services", blue color scale `#0053E2`, yellow spark `#FFC220`, S3 direct upload enabled) and `mercy` (Mercy Health System). - **Third-Party Integrations**: Explicit client bindings confirmed for **Quest Diagnostics** / **Labcorp** (labs), **Solv** (urgent care scheduling), **Metriport** / **Particle Health** (EHR health history sync), **CVS** / **Walgreens** / **Walmart** (pharmacy routing & GoodRx cash pricing), **Stripe** (payment SetupIntents), **Trust Commerce** (Mercy billing), **Persona** (identity verification), and **Twilio Chat** (Message Center). ### 4.2 Inferences & Server-Side Boundaries (`[INFERENCE]`) - **Backend Rails Framework (`[INFERENCE]`)**: The backend API path patterns (`/api/external/patient`, `conversation_subjects_controller.rb` references in comments, snake_case serialization, and Rails-style resource controllers) indicate a Ruby on Rails application named "Nile-Core". - **Internal Database Schema (`[INFERENCE]`)**: Tables (`patients`, `visits`, `care_actions`, `pharmacy_orders`, `insurances`, `health_histories`) and foreign key relationships are inferred from RTK Query serialization types and serialized response models, as database DDL and migrations execute entirely on internal servers. - **Server Action & Route Handler Execution (`[INFERENCE]`)**: Next.js server-side code (`app/api/...` route handlers, `next/headers` cookie reading) executes in Vercel Serverless/Edge functions; client-side code reveals the fetch targets and request schemas, but internal AWS/Vercel environment variables remain masked. ================================================================================ # DOCUMENT: Company Overview (raw/reports/generalmedicine-overview.md) ================================================================================ # General Medicine: Platform Overview General Medicine is a telehealth storefront and clinical engine, backed by **$152M** in capital: a **$32M** Series A (May 2025) and a **$120M** Series B (Oct 6, 2026) at an implied **$669.68M** post-money valuation (Preqin), a **4.3x** step-up in 17 months. The consumer app exposes **194** routes with **119** specified client-contract operations; four internal MedicineOS portals add **183** routes and **238** operations, for **377** routes and **357** operations in total. The catalog carries **3,184** SKUs across **23** numeric series. Customers rate it **4.7/5.0** on Trustpilot across **906** reviews, against a BBB **"D"** grade with **6** complaints. ## 1. Identity - **Application Name**: General Medicine Patient Portal & Telehealth Storefront (`generalmedicine.co`) - **Target Host & URL**: `https://generalmedicine.co/` (Vercel Edge) - **Legal Operating Entity**: **Path Healthcare Systems Corp.** (Delaware C-Corp, File `#7571245`; EIN `93-2571245`; Florida foreign registration `F24000004983` filed 2024-09-19, reinstated 2026-05-18) - **Brand Genealogy**: Path Healthcare Systems Corp. → stealth engineering codename **Nile Health** (`staging-nile.com`, `nile-core`, `@nile/*`) → initial consumer brand **Nav Health** (`navhealth.co`; live banner *“Nav Health is now General Medicine”*) → **General Medicine** (`generalmedicine.co`; Utah DBA/BBB start date 2024-03-06) - **HQ / Registered Addresses**: 128 Spear St, Floor 4, San Francisco, CA 94105; 50 W. Broadway, Ste 333, PMB 518579, Salt Lake City, UT 84101-2027 - **Backend Architecture**: Nile-Core Ruby on Rails API (`https://api.generalmedicine.co/api/external/...`) - **Tenant Identities**: Primary General Medicine brand, **Walmart** ("Better Care Services", `app/t/walmart`), and **Mercy Health** (`tenants/mercy`) - **Artifact Footprint**: 406 production chunk bundles (16.27 MB JS), 400 live SourceMap v3 `.js.map` files (30.06 MB), 2,443 reconstructed source files (208,387 LOC), 798 first-party files (51,015 LOC), 1,234,301 AST nodes parsed. - **Internal MedicineOS Footprint**: 4 reconstructed clinician/admin portals, 99 production chunks, **238 RTK Query operations**, **183 route literals**. ## 2. Tech Stack - **Framework & Routing**: Next.js 14+ App Router, React 18.2.0, React Server Components (RSC) with Client Boundaries (`'use client'`). - **State Management**: Redux Toolkit & RTK Query (`baseApi` in `lib/store/store.ts` & `lib/store/api/baseQuery.ts`) with **50 unique domain tag types** (51 array entries; `'CareJourney'` is duplicated at lines 108 & 125 of `baseQuery.ts`), **40 `injectEndpoints` API slices** (33 eagerly imported in `store.ts` + 7 lazily injected on-demand), **137 total RTK Query operations**, **119** of them with specified client contracts, and automatic 401 session bounce to `/login`. - **UI & Design System**: Mantine UI v7 (`@mantine/core`), internal `@nile/mantine-theme`, Tabler Icons (`@tabler/icons-react`), and CSS Modules. - **Animation & Transitions**: Framer Motion v11 (`framer-motion`), spring physics for drawers, price sheets, and sticky CTA bars. - **HTTP & Telemetry**: Axios with call stack interceptors (`contexts/ApiContext.tsx`), RTK Query `clientBaseQuery` with 401 session bounce to `/login`, Datadog RUM (`reportErrorToDD`), Segment analytics. - **Feature Flags**: LaunchDarkly Client SDK (`LaunchDarklyContext.tsx`, `launchDarklyFlagEvaluator.ts`) governing A/B testing and tenant features. Named flag surface includes `gen-ai-prewarm-copilot` and per-SKU `refreshFlagKey` evaluations mirrored to Datadog RUM. - **Tenant Resolution**: Next.js middleware + `config/tenants/tenantRewrites.js`; `X-GM-Tenant` egress header from `lib/tenantHeaders.ts`. Both carry the `TODO(GM-6520)` fail-open fallback. ## 3. Components - **Storefront & Catalog**: Universal search (`UniversalSearch.tsx`), category pages (`/store/[slug]`), and PDPs (`/s/[sku-name]/[sku-id]`). - **Clinical Telehealth & Visitron**: General video visit (`SKU 400013`), Primary Care (`SKU 100012`), follow-up video visit (`SKU 400015`), and ACR follow-up (`SKU 300591`); clinician-facing Visitron EHR with 91 RTK operations. - **Urgent Care Network**: Solv Health clinic reservation engine (`/urgent-care/orders/[id]`), live clinic search (`locations`), and rescheduling (`reschedule`). - **Pharmacy & Prescription Engine**: Real-time GPS price comparison across CVS, Walgreens, Walmart, LillyDirect, and NovoCare (`ComparePharmaciesDrawer.tsx`), Digital Rx Savings Card (`gm_card`), and NCPDP routing. - **Pathology & Lab Diagnostics**: Quest Diagnostics, Labcorp, and BioReference lab panels (`500xxx` series, e.g., `500001` Annual Wellness), server-driven clinical review fee (`clinical_fee: 15.0` live across sampled SKUs, with `STANDARD_CLINICAL_FEE = 30` as client fallback in `LabPanelPricing.tsx:65–69`), and results PDF viewer. - **Patient Account & Care Feed**: Aggregated dashboard (`/account`), chronological care feed (`/api/external/my_care`), and Twilio Message Center (`/api/external/conversations`). - **Internal Portals**: Visitron (clinician EHR, 91 ops), Catalog (care-pathway/SKU admin, 106 ops), Referrals (concierge queue, 27 ops), Provider Chat (LLM prompt workbench, 14 ops). ## 4. Permissions - **Geolocation**: HTML5 Geolocation API (`navigator.geolocation`) querying nearby Solv urgent care clinics, CVS/Walgreens/Walmart pharmacy comparisons, and local state clinical licensing. - **Camera & File Storage**: Document uploads for insurance card OCR (`trigger_card_image_eligibility_check`), external lab PDF results (`complete_lab_upload`), and direct-to-S3 presigned uploads. - **Storage**: Persistent `localStorage` (`phoneNumber`, `currentLoginSignupStep`, `storeSearchHistory`) and tab-isolated `sessionStorage` (`userInsurance`, `appointmentRequestContext`, `isExistingUser`). - **Clipboard**: `navigator.clipboard.writeText` for copying patient referral links and provider share links. ## 5. Third-Party SDKs & Trackers - **Clinical Pathology**: **Quest Diagnostics**, **Labcorp**, and **BioReference** (electronic lab requisitions, sample accessioning, and pathology feeds). - **Urgent Care Network**: **Solv Health API** (real-time clinic wait times, scheduled slot reservations, and walk-in queue management). - **Pharmacy & Pricing**: **GoodRx API** and **NCPDP** directory (cash discount pricing, real-time insurance copay calculation, and retail chain deduplication); **LillyDirect** and **NovoCare** featured online pharmacies. - **Identity & Fraud**: **Persona Web SDK** (`withpersona.com`) for government ID/biometric KYC; Nile Verified 1-click SSN + DOB lookup (`/api/external/verified`). - **EHR Records**: **Metriport** and **Particle Health** (FHIR-compliant health history sync, medication histories, and clinical allergies). - **Payments & Billing**: **Stripe.js** (SetupIntents, Elements) for patient cards; **Trust Commerce Gateway** for Mercy Health System billing. - **E-Prescribing & Benefits**: **DoseSpot** (e-Rx, IdP, RTPB inquiries) and **ArriveHealth** (real-time pharmacy benefit and price transparency) inside Visitron. - **Clinical Scribe**: **Nabla** status integration inside Visitron. - **Biomarkers / Delegated Care**: **Junction** (`tryvital.io`) biomarker catalog; **OpenLoop Healthcare Partners, PC**, **Reliant.MD Medical Associates, PLLC**, and **MECNB Physician Services, PC** (plus state variants) under the Vital informed consent. - **Communication & Telemetry**: **Twilio Chat** (Message Center WebSocket token), **Datadog RUM** (browser telemetry & error tracing), **Segment** (`@nile/mantine-theme/analytics`), **LaunchDarkly**. - **Clearinghouse (`[INFERENCE]` from DNS)**: **Waystar** (`waystar-connector.staging-nile.com`, `waystar-bridge.staging-nile.com`). ## 6. Network Endpoints & Spec Architecture - **Primary Host & Gateway**: `https://generalmedicine.co` (Next.js Edge Proxy), `https://api.generalmedicine.co` (Nile-Core Rails API). - **Route Inventory**: The reconciled estate is **377 routes** and **357 RTK Query operations**: - **Consumer storefront**: **194 declared routes**, **119 RTK Query operations with specified client contracts** (137 total across 40 slices), **130 OpenAPI paths / 141 operations / 16 tags** in `generalmedicine/openapi.yaml`, and **64 catalog-only unexercised contracts** (`[UNDOCUMENTED_SERVER_CONTRACT]`) declared in `lib/api/endpoints.ts`. - **Internal MedicineOS portals**: **183 route literals** and **238 RTK Query operations** across **Visitron** (98 / 91), **Catalog** (47 / 106), **Referrals** (18 / 27), and **Provider Chat** (20 / 14). Of the 183, **166** carry an `/api/internal*` prefix and **142** are unique after cross-portal deduplication. - **Total**: **194 + 183 = 377 routes**; **119 + 238 = 357 RTK operations**. *(A 32-endpoint sample represents ~16.5% of the 194 consumer routes and ~8.5% of the 377-route estate.)* - **Primary Endpoint Groups**: - **Authentication**: `POST /auth/initiate`, `POST /auth/verify`, `POST /auth/logout`, `GET /api/external/google_sso`, `POST /api/external/google_sso/oauth/start`. - **User & Insurance**: `GET /api/external/patient`, `GET /api/external/insurances/show`, `POST /api/external/insurances/trigger_eligibility_check`, `POST /api/external/verified`. - **Urgent Care**: `POST /api/external/urgent_care/orders`, `GET /.../offers`, `GET /.../locations`, `POST /.../checkout` (`{ location_id }`), `PATCH /.../reschedule`. - **Pharmacy**: `GET /api/external/product_detail_pages/:id`, `GET /api/external/pharmacy_comparisons`, `POST /api/external/pharmacy_orders/:id/select_pharmacy`, `GET /.../gm_card`. - **Labs & Diagnostics**: `GET /api/external/lab_skus/:skuId`, `GET /api/external/lab_orders/:id`, `GET /api/external/care_journey/lab_bundle`, `POST /.../complete_lab_upload`. - **Health Records & AI**: `GET /api/external/health_history/latest_metriport`, `POST /.../submit_review`, `GET /api/external/copilot/messages`, `POST /.../consent/mark`. - **Internal Ops**: `/api/internal_oauth/referral/orders`, `/api/internal_oauth/promises/queue/{claim,drop,enabled}`, `/api/internal_oauth/copilot_channels`, `/api/internal_oauth/messages`, `/api/internal_oauth/prompts`, `/api/internal/ops/referrals`, `/api/internal/ops/referral_provider_candidates/`. - **Catalog Reality**: Marketing cites "2,900+ products and services"; the four live sitemaps contain **3,184 SKU URLs across 23 numeric series** (`700xxx` 1,362; `200xxx` 909; `300xxx` 511; `500xxx` 280; `400xxx` 101; `100xxx` 20; legacy `364` 1). The nine live category endpoints expose **329 unique SKUs**. A 108-query `a–z`, `0–9` search sample surfaces **448 SKUs**, of which **326 have non-null top-level cash/insurance price fields** and **122 have both top-level fields null**; **8 of the 122** carry option-level fees (e.g., `300603` has `checkout_fee: 4500`). The sample is non-exhaustive: **2,736** sitemap SKUs were not surfaced by it, but SKU `400285` is in `sitemap_only_skus` and still returns for `query=chronic pain`. Null top-level price is not proof of unpurchasability: **8 of the 122** null-top-level SKUs carry option-level fees (e.g., `300603` at `checkout_fee: 4500`). Price range across the top-level priced sample: **$5.11–$17,411.20**. - **Lab Fee Mechanics**: `LabPanelPricing.tsx:59–69` reads `clinical_fee` from `/api/external/lab_skus/:id` and uses `STANDARD_CLINICAL_FEE = 30` (`types/enums/lab-pricing-constants.ts:8`) only as a fallback when `clinical_fee` is null/undefined. Live responses returned `clinical_fee: 15.0` with `clinical_fee_enabled: true` across all seven sampled SKUs, and `total_cash_price` equals `test_price + clinical_fee`. The JSON response also includes unrendered fields (`platform_fee` $15–$40, `collection_fee` $3–$9, `order_fee` $6) not used by `LabPanelPricing.tsx`. On `/refund-policy-labs`, *"No Fees Deducted... We do not charge any administrative or physician order fees"* describes full refund eligibility prior to sample collection rather than initial order pricing. ## 7. Feature Internals - **Multi-Tenant Architecture (Walmart & Mercy)**: - Supports white-label deployments via `config/tenants/tenantRewrites.js`. - Walmart tenant ("Better Care Services", blue palette `#0053E2`, yellow spark `#FFC220`, S3 direct upload enabled) rewrites traffic to `app/t/walmart`; dedicated SKUs `1400017` (Primary Care), `1400018` (Rx Renewal), `1400015` (Urgent Care). - Mercy Health System tenant provides custom typography, navigation, and Trust Commerce payment gateway integration (`/api/external/patient/mercy_billing`). - **Fail-open debt (`GM-6520`)**: when `NEXT_PUBLIC_GM_TENANT_ID` is unset, `getTenantPublicPathRewrites()` returns `[]` (DTC storefront) and `resolveTenantHeaderId()` falls back to `general-medicine`. A partner deployment that loses its env var silently serves the DTC brand and tags API egress as DTC. - **Urgent Care Booking Engine (Solv Integration)**: - Automates clinic selection via `urgentCareApi.ts`: creates order (`POST /api/external/urgent_care/orders`), queries Solv for nearest clinics and live wait times, auto-selects matching `FulfillmentOffer`, and books slot. - Supports same-clinic rescheduling (`/reschedule`) and walk-in queue management. - **Geographic Pharmacy Routing & Price Transparency**: - Compares prescription cash prices vs insurance copays across local chains (CVS, Walgreens, Walmart) using GPS coordinates; features LillyDirect and NovoCare first in the pharmacies tab. - Generates Digital Rx Savings Cards (`GmCardInfo`: BIN, PCN, Group, MemberID) allowing patients to obtain cash discounts at retail counters. - **Quest/Labcorp/BioReference Pathology Pipeline**: - Lab panel ordering (`500001` Annual Wellness, `500093` Thyroid, `500010` Vitamin D) bundles clinical pathology with a clinical review fee and platform/order fees. - Electronically transmits lab requisitions; ingested HL7 results are reviewed by clinicians and rendered as certified PDF reports in the patient dashboard. - **EHR Health History Sync (Metriport & Particle Health)**: - Automatically queries national health information exchanges (HIEs) via Metriport to populate past conditions, medications, allergies, and surgical procedures; company claims an average of **11 years** of history per customer. - Presents an interactive review wizard allowing patients to verify records or submit manual chart amendments. - **1-Click Nile Verified & Persona KYC**: - Fast-tracks signup via `POST /api/external/verified` (matching DOB + SSN against credit/clearinghouse identity databases to return verified addresses). - Escalates high-risk or controlled medication flows to embedded Persona KYC for government photo ID and biometric liveness verification. - **Internal MedicineOS Workflows**: - **Visitron**: appointment → chart context → async clinical review → care pathway/phase → orders → DoseSpot e-Rx → ArriveHealth benefit check → next-step review → shift checkout. - **Catalog**: SKU CRUD, care-pathway authoring, criteria sets, condition taxonomy, questionnaires, lab-panel biomarkers, procedure-code mapping, prompt authoring, tenant management. - **Referrals**: referral orders, provider candidates, promises queue (`claim`, `drop`, `snooze`), booking events, outreach/outcome logging. - **Provider Chat**: copilot channels, chat history, send message, catalog prompts, model versions, temperatures; both `ExternalCable::CopilotChannel` and `InternalCable::CopilotChannel`. - **Valuation, Footprint & Regulatory Context (AlphaSense / Preqin / STAT News)**: - **Implied Post-Money Valuations**: **$156.84M** at the May 22, 2025 $32M Series A (Matrix lead) and **$669.68M** at the Oct 6, 2026 $120M Series B (a16z lead, with Eli Lilly & Company Foundation and Granger Management / Mercy Health) — a **4.3x valuation step-up** in 17 months, with mid-2025 initial launch revenue estimated at **$1M–$5M** (Preqin). - **Geographic & Partner Scale**: Active across **82% of U.S. counties** (targeting 100% coverage), routing to **50,000+ local pharmacies** and **100+ health systems** across **35+ specialties**, with engineering/design scaling in **Cambridge / Boston, MA** alongside San Francisco HQ and Salt Lake City / Park City clinical operations. - **Friendly PC-MSO Evolution & 2026 CPOM Headwinds**: **Dr. Sunita Mishra** (CMO of Amazon Health Services) served as an early advisor and initial physician owner of one of the clinical entities during stealth before ownership transitioned to Medical Director **Dr. Pallabi Sanyal-Dey, MD** prior to public launch (STAT News). Effective January 1, 2026, **California SB 351** and **Oregon SB 951** tightened restrictions on MSO control over Friendly PCs and stock-transfer agreements. ## 8. Findings & Limitations - **Live Production Source Maps Disclosure**: Publicly serves the SourceMap v3 files (`.js.map`) returning HTTP 200 without authentication across **400 chunk files**, enabling 100% byte-exact source tree recovery (798 first-party files, variable names, internal comments, and architectural contracts). - **Exposed Internal Portals**: Four MedicineOS portals are reconstructible from unauthenticated bundles: `visitron.internal.generalmedicine.co` / `visitron.staging-nile.com` (200), `catalog.internal.generalmedicine.co` and `referrals.internal.generalmedicine.co` (307 → `/login`; their `*.staging-nile.com` counterparts returned 307 → `/login` and were reconstructed from served bundles), and `internal.generalmedicine.co` ("Provider Chat", 200). **99 chunks / 238 RTK ops / 183 routes** recovered. `analytics.staging-nile.com` exposes public **Metabase** (HTTP 200). - **Internal Test Harness Exposed in Client Catalog**: Production endpoint catalog includes `/api/external/test_setup/reset_test_user` and `/api/external/test_setup/delete_test_user`, exposing test lifecycle backdoors. - **Lab Fee Fallback vs. Live Rate**: `STANDARD_CLINICAL_FEE = 30` is a fallback, not a universal fee: `LabPanelPricing.tsx:59–69` uses `$30` only when the API omits `clinical_fee` (live sampled SKUs return `clinical_fee: 15.0`). - **Catalog Measurement Limits**: **3,184** sitemap SKUs; **448** surfaced by the 108-query sample; **326** with top-level price fields; **122** with null top-level price (**8** with option-level fees); **2,736** not surfaced by the sample. The "2,900+" claim is true for raw sitemap URLs; the sample does not establish a purchasability rate. Counterexamples: `400285` is discoverable via a targeted query; `300603` is one of **8** null-top-level SKUs with option-level fees (`checkout_fee: 4500`). - **Controlled-Substance Policy Adjacency**: The medication FAQ says General Medicine cannot fill controlled substances, while active in-person referral SKUs cover opioid prescribing (`400285`), pregabalin/Lyrica (`400293`), and Accutane (`300604`). These are referral/office-visit SKUs, not telehealth prescriptions, but the distinction is not disclosed on the SKU pages. - **No SEC Form D**: Zero affiliate Form D filings on EDGAR for Path Healthcare Systems Corp. or General Medicine across **$152M** raised. The `NavHealth, Inc.` CIK `0001717158` is an unrelated Arlington, VA company (Aneesh Chopra), not General Medicine's predecessor. - **Production Copy Placeholder**: The 2026-10-05 article `/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup` shipped literal `[open your dashboard]([dashboard URL pending])`. - **Tenant Fail-Open**: `GM-6520` in `tenantRewrites.js:36` and `tenantHeaders.ts:6` silently falls back to the DTC brand/tenant when `NEXT_PUBLIC_GM_TENANT_ID` is unset. - **Server-Side Encapsulation (`[INFERENCE]`)**: Nile-Core database models, SQL schemas, and server-side secret keys (Stripe, Twilio, Metriport, Solv API secrets) execute within backend VPC infrastructure and remain safely encapsulated. No live secrets were recovered from client bundles. ## 9. Commercial & Market Context For corporate genealogy, code-level monetization breakdown, team dossier, growth trajectory, leadership quotes, and market intelligence, see [`generalmedicine/adversarial-and-market-report.md`](generalmedicine/adversarial-and-market-report.md). The companion OSINT suite is documented in [`generalmedicine/scripts/README.md`](generalmedicine/scripts/README.md), with raw outputs in [`generalmedicine/osint/`](generalmedicine/osint/). ### 9.1 32-Path vs. 377-Route Resolution - **Consumer plane**: 194 declared routes, 119 RTK operations with specified client contracts (137 total), 130 OpenAPI paths / 141 operations / 16 tags, 64 catalog-only unexercised routes. - **Internal plane**: 4 MedicineOS portals — Visitron (98 paths / 91 ops), Catalog (47 / 106), Referrals (18 / 27), Provider Chat (20 / 14) — totaling **183 routes / 238 ops**. - **Reconciled estate**: **377 routes / 357 RTK operations**. The ~32-path summary covers **16.5%** of the consumer plane and **8.5%** of the full estate. ### 9.2 Corporate & Clinical Governance - **Four-stage genealogy**: **Path Healthcare Systems Corp.** (Delaware C-Corp, File `#7571245`, EIN `93-2571245`, Florida `F24000004983`) → **Nile Health** (`staging-nile.com`, `nile-core`, `@nile/*`) → **Nav Health** (`navhealth.co`; live banner *“Nav Health is now General Medicine”*) → **General Medicine** (`generalmedicine.co`; Utah DBA/BBB start date 2024-03-06). The refund page still prints `support@navhealth.co`. - **Friendly-PC CPOM split**: Non-physician CPO **Ashwin Muralidharan** is President/Authorized Official of **Emerald Medical Practice, P.C.** (NPIs `1447011267`, `1750195483`). **50-state licensed Medical Director Dr. Pallabi Sanyal-Dey, MD** is President of **Centennial Medical Practice, P.C.** (`1174333975`, Tallahassee FL) and **Ruby Medical Practice, P.C.** (`1346050150`, Ewing NJ). All four NPIs share phone `(307) 840-9834` and a Park City, Utah mailing cluster (including `1743 Sidewinder Dr Unit 114`). - **Delegated telehealth layer**: `https://generalmedicine.co/vital-informed-consent` names **OpenLoop Healthcare Partners, PC**, **Reliant.MD Medical Associates, PLLC**, and **MECNB Physician Services, PC**, plus state-specific variants (California, Colorado, New Jersey, and Wisconsin/South Carolina entities as listed on the consent page). ### 9.3 Team, Growth & Capitalization - **Founders**: TJ Parker (CEO), Elliot Cohen (President), Ashwin Muralidharan (CPO). **Executives**: Ed Cao (CFO), Jacqui Miller (Chief Communications Officer), Jeff Vlahos (Head of Design / founding designer), Steph Croteau (Director of Operations), Matt Pokress (Chief Architect in public records; advisor role unconfirmed). - **Clinical leadership**: **50-state licensed Medical Director** Dr. Pallabi Sanyal-Dey, Dr. Marjory Bravard (Director of Clinical Partnerships), Dr. Poushali Bhattacharjee (Head of Clinical Operations), Dr. Adam Carewe (clinical informatics; former Kaiser Permanente CMIO), Samantha Schisler, FNP (Head of Clinician Training). **20** public `/bio/*` pages. - **Engineering roster**: Mike Giovinco, Angie Bui, Kristopher Kosmatka, Noah Grumman, Ali Shaikh, Amil Naik, Daniel Quintana, Kinjal Chauhan, Veeresh Neralagi, Natalia Perina. - **Board & investors**: Vineeta Agarwala (a16z), Orin Hoffman (VXI Capital), TJ Parker (Matrix Partners), BoxGroup, Eli Lilly and Company / Eli Lilly & Company Foundation, Mercy Health through Granger Management, Founder Collective, JSL Health Capital / JSL Ventures. - **Capitalization**: **$152M total** — **$32M** seed (May 2025; Matrix and BoxGroup) + **$120M** Series B (2026-10-06; a16z lead). No Form D on EDGAR; all figures are press/company sourced. - **Headcount**: **~104** third-party estimate; **87** public LinkedIn profiles (33 high-relevance); **16** open Ashby roles. - **Traction**: "hundreds of thousands" of customers across every state and nearly every county; **81%** used General Medicine for previously delayed care, **20%** delayed 6+ months; average **11 years** of health history per customer (company claims). - **Customer sentiment**: Trustpilot **4.7/5.0** across **906** reviews (91% 5★, 6% 1★) vs. BBB **"D"** with **6** complaints and unaccredited status. ### 9.4 Core Visit & Encounter SKUs (`types/enums/sku-constants.ts`) - `400013` General Video Visit; `100012` Primary Care ($100 cash / $25 insurance); `400015` Follow-Up Video Visit; `300591` ACR Follow-Up; `400002` / `400336` Urgent Care booking (sampled insurance floor $25; cash floor across sampled visits $30); `200007` / `400020` Rx Renewal; `100017` Urology e-consult ($150 cash / $25 insurance); `300550` Weight Loss Follow-Up ($30 chat / $100 video / $25 insurance). - **Clinical Fee & Price Preference Engine**: Server-driven `clinical_fee` (**$15.00** live across seven sampled SKUs) with `STANDARD_CLINICAL_FEE = 30` as client fallback (`LabPanelPricing.tsx:65–69`); `ESTIMATED_INSURANCE_COPAY = 30`. Dynamic cash-vs-insurance price resolution in `PriceUtility.tsx` displays the cheaper or `primary` rate. - **B2B Enterprise Partnerships**: - **Walmart ("Better Care Services")**: Dedicated tenant (`tenants/walmart/`, `config/tenants/walmartPublic.ts`) with brand tokens (`#0053E2`, yellow spark `#FFC220`), direct S3 uploads, and custom SKUs (`1400017` Primary Care, `1400018` Rx Renewal, `1400015` Urgent Care). Launched January 2026. - **Mercy Health System**: Dedicated tenant (`tenants/mercy/`) with Trust Commerce payment gateway integration (`/api/external/patient/mercy_billing`). - **Founding Team & Amazon/PillPack Heritage**: Founded in **2023** by Ashwin Muralidharan (CPO & founding CEO; former technical advisor/chief of staff to Amazon health chief Neil Lindsay), Elliot Cohen (President; PillPack co-founder), and TJ Parker (CEO as of October 2026; PillPack co-founder). Legal stealth operating identity was **Nile Health** (`staging-nile.com`, `@nile/mantine-theme`, `nile-core`); legal entity is **Path Healthcare Systems Corp.** - **Patient Feedback & Trustpilot Metrics**: Trustpilot **4.7 / 5.0** across **906** reviews (91% 5-star, 6% 1-star). BBB "D" rating (6 complaints) regarding checkout reverting from insurance to cash price, pre-billing credit cards before visits, and pharmacy communication lags. ================================================================================ # DOCUMENT: Briefing Index (raw/reports/general-medicine-executive-briefing.md) ================================================================================ # General Medicine (Path Healthcare Systems Corp. / Nile Health): 325-Slide Executive Briefing - **HTML deck (16:9):** [`general-medicine-executive-briefing.html`](general-medicine-executive-briefing.html) - **PDF deck (16:9, 325 pages):** [`general-medicine-executive-briefing.pdf`](general-medicine-executive-briefing.pdf) - **Market & leadership dossier:** [`adversarial-and-market-report.md`](adversarial-and-market-report.md) - **Architecture & backoffice specification:** [`architecture.md`](architecture.md) - **API specification (377 routes / 357 RTK operations):** [`api-spec.md`](api-spec.md) ## Deck Structure (325 widescreen 16:9 slides) - **Slides 1–2:** Cover & agenda - **Section 01 (Slides 3–11):** Company, leadership & valuation. Genealogy (Path Healthcare Systems Corp. → Nile Health → Nav Health → General Medicine), 2023–2026 timeline, founders, 50-state clinical org and Friendly-PC governance (`Emerald PC`, `Centennial PC`, `Ruby PC`, `Vital/OpenLoop PCs`), 104 staff (third-party estimate) and 16 open roles, $152M raised with 0 SEC Form Ds. - **Section 02 (Slides 12–21):** Storefront & customer sentiment. 4 DTC launches (May 2025 – Oct 2026), 3,184 SKUs across 23 series, dual-rail pricing, Lilly storefront (`/p/lilly/weight-loss`; Foundayo $149/mo, Zepbound $299/mo), Trustpilot 4.7★ across 906 reviews and 80 NPS, against BBB "D" and 1-Star operational failure modes. - **Section 03 (Slides 22–26):** Walmart partnership ("Better Care Services"). Apr 2024 clinic closures → Jan 8, 2026 launch → May 28, 2026 multi-provider hub → Oct 2026 Rx funnel; 1400xxx SKUs (`walmartPublic.ts`), native app bridge (`walmart://healthandwellness/bettercareservices`), direct-to-S3 upload. - **Section 04 (Slides 27–31):** Mercy Health System & multi-tenancy. Oct 6, 2026 Series B (a16z lead, with Granger Management / Mercy Health), 50-hospital strategy, `tenants/mercy/` with Trust Commerce guarantor billing (`/api/external/patient/mercy_billing`), edge rewrites (`tenantRewrites.js`), GM-6520 fail-open risk. - **Section 05 (Slides 32–45):** Clinical care, care journeys & 38 vendors. 38-vendor matrix, three-tier care architecture (`CarePathway` → `Care::Plan` 38-state machine → `CareJourney`), 5-phase GLP-1 progression (GM public guide + live SKU prices), live lab bundles (500001, 500004, 503262), universal search, SMS OTP 409 signup, 1-click Nile Verified, 4-step HIE wizard, Zoom video, ACR 300591, 24h e-consults, 4 supply chains including $45 specialist referrals and pre-pay `gm_card` pharmacy. - **Section 06 (Slides 46–56):** MedicineOS internal tooling. 6 portals, 238 RTK operations, 183 internal routes: Visitron 91, Catalog 106, Referrals 27, Provider Chat (`Promptimus`) 14; 3-tier consumer topology, 798 files / 51,015 LOC; 10 risk findings. - **Section 07 (Slides 57–61):** Competitive benchmark vs. Hundred & feature plan - **Section 08 (Slides 62–103 · 42 slides):** Visual storyboard, design tokens & components. 55 components, 97 screen captures, 582 PNGs. - **Section 09 (Slides 104–325 · 222 slides):** Technical appendices A–F. 40 consumer RTK slices, 194 consumer routes, 20 subsystems, 798 source files; Appendix F (Slides 318–325) covers MedicineOS portals, 38 vendors, 3,184-SKU sitemap census, care pathways, biomarker bundles and 10 risk findings. ================================================================================ # DOCUMENT: AlphaSense Primer, Oct 19, 2026 (raw/alphasense/alphasense-company-primer-2026-10-19.md) ================================================================================ # AlphaSense Company Primer: General Medicine (Oct 19, 2026 · 21 Pages) > **Original PDF:** [`raw/alphasense/DR-Report-by-Alphasense-10-19-2026-00-02.pdf`](raw/alphasense/DR-Report-by-Alphasense-10-19-2026-00-02.pdf) (23 pages) --- ## Page 1 RESULTS FOR QUERY: Company Primer for General Medicine CREATED Oct 19, 2026 PAGES 21 RESEARCH URL Click to View In GenSearch ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 2 QUERY Run the AlphaSense Private Company Primer agent i ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service markAlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the backthis report. --- ## Page 3 TABLE OF CONTENTS 1. Key Takeaways 2. Company Snapshot & Funding History 3. Product Portfolio & Strategic Moat 4. Customers, Programs, & Partnerships 5. Operational Footprint & Go-To-Market (GTM) Strategy 6. Financial Snapshot & Unit Economics 7. Market Landscape, Competitive Positioning, & Regulatory Dynamics 8. Recent Developments, Key Advantages, & Operational Risks 9. The Bull or Bear Case: Pathways, Catalysts, and KPIs 10. Valuation & Exit Outlook 11. Internal Relationship & Activity Context RESULT FOR QUERY General Medicine: Digital Healthcare Marketplace Disrupting Fee-for-Service Access Key Takeaways PillPack pedigree drives execution : Founded in 2023 by three former Amazon and PillPack executives, including CEO TJ Parker and President Elliot Cohen (both PillPack co-founders), General Medicine brings proven digital healthcare logistics expertise from Amazon's $750 million PillPack acquisition. Transaction-first marketplace model eliminates subscriptions : The platform offers a searchable catalog of over 2,900 distinct medical products and services across 35+ specialties without membership or subscription fees, contrasting sharply with Amazon One Medical's $199 annual fee structure. MedicineOS and ML insurance engine create pricing transparency : Proprietary technology automatically retrieves 11 years of medical records and uses machine learning to interpret insurance policies in real-time, displaying exact out-of-pocket costs before patients book services. Asset-light scaling across 82% of U.S. counties : Rather than building physical clinics, General Medicine partners with over 100 health systems and 50,000 local pharmacies, optimizing capital efficiency through variable operating expenses instead of fixed clinical overhead. RESULT FOR QUERY Page 1 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 4 $669.68 million valuation supported by $152 million in funding : The company secured a $120 million Series B led by Andreessen Horowitz in October 2026, representing a 4.3x step-up from its $156.84 million Series A post-money valuation just 17 months earlier. Friendly PC-MSO structure faces heightened regulatory scrutiny : To comply with Corporate Practice of Medicine laws, General Medicine operates through physician-owned entities controlled by Medical Director Dr. Pallabi Sanyal-Dey, but faces escalating risks from California's SB 351 and Oregon's SB 951 effective January 2026. Platform captures deferred care demand : Approximately 81% of early users sought care for previously delayed medical issues (20% deferred for six months or longer), positioning General Medicine to unlock significant pent-up healthcare demand through transparent upfront pricing. Company Snapshot & Funding History Foundational Profile General Medicine (https://generalmedicine.co) is a privately held digital healthcare marketplace company founded in 2023. digitalhealthnews.com The company has established its corporate headquarters in San Francisco, California, with additional operational hubs located in Boston, Massachusetts, and Salt Lake City, Utah. novonordisk.com Operating as a digital consumer healthcare store, the platform enables patients to search, compare, and buy medical care, prescription drugs, and laboratory tests directly, bypassing subscription or access fees. prnewswire.com General Medicine employs a venture-backed ownership structure, supported by prominent institutional venture capital firms and strategic healthcare partners. digitalhealthnews.com Executive Leadership & Changes The company's founding team consists of three former Amazon and PillPack executives who bring deep digital healthcare distribution experience to the enterprise. Ashwin Muralidharan served as the founding Chief Executive Officer, leading the platform through its stealth phase and nationwide rollout in 2025. prnewswire.com In October 2026, the company underwent a strategic leadership transition to support its next growth phase. prnewswire.com TJ Parker, a co-founder of PillPack and former partner at Matrix Partners, took over as the Chief Executive Officer. prnewswire.com Ashwin Muralidharan transitioned from the CEO position to serve as the Chief Product Officer, focusing directly on platform and service development. prnewswire.com Elliot Cohen, also a PillPack co-founder, continues to serve as the President of General Medicine. digitalhealthnews.com Funding History Since its inception, General Medicine has raised a total of $152 million in funding to build and scale its nationwide healthcare store. digitalhealthnews.com The company launched out of stealth on May 22, 2025, announcing a Series A funding round of $32 million. This initial launch round was led by Matrix, with additional participation from BoxGroup, Founder Collective, VXI Capital, and JSL Health Capital. [1] The Series A round was executed at an implied post-money valuation of $156.84 million. [1] Funding Screener • Filters: 1 Funding Screener • Filters: 1 RESULT FOR QUERY Page 2 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 5 On October 6, 2026, General Medicine raised $120 million in a Series B funding round. [1] This second round was led by Andreessen Horowitz, with strategic participation from the Eli Lilly & Company Foundation and Granger Management, alongside returning investors. [1] The Series B financing established an implied post-money valuation of $669.68 million. Funding Screener • Filters: 1 Funding Screener • Filters: 1 Funding Round Announcement Date Amount Raised ($M) Post-Money Valuation ($M) Lead Investor(s) Series A 2025-05-22 32.00 156.84 Matrix Series B 2026-10-06 120.00 669.68 Andreessen Horowitz Product Portfolio & Strategic Moat Core Products & Digital Healthcare Marketplace Services General Medicine operates a nationwide digital consumer healthcare store designed to mimic the simplicity of modern e-commerce. prnewswire.com The platform features a searchable catalog of over 2,900 distinct medical products and services, allowing users to directly purchase care without paying access or membership fees. preqin.com The product lines are organized into several core categories to support a wide range of clinical needs: Everyday & Virtual Care : On-demand and scheduled consultations are available with board-certified clinicians for acute and chronic conditions. generalmedicine.co Specialist E-Consults : Virtual access is provided to medical expertise across more than 35 clinical specialties, including cardiology, neurology, and dermatology. preqin.com Laboratory & Diagnostic Testing : Diagnostic blood work, imaging studies, and lab panels can be ordered directly with transparent upfront pricing. generalmedicine.co Prescription Management : The platform supports seamless prescription routing to over 50,000 local pharmacies alongside home delivery logistics. generalmedicine.co In-Person Care Coordination : A dedicated back-end logistics team schedules physical doctor visits, specialized imaging, and surgical procedures. prnewswire.com To streamline the user experience, the digital storefront utilizes an automated system that collects up to 11 years of historical medical records with a single click. generalmedicine.co These records are consolidated and structured into a prioritized summary to provide treating clinicians with critical context before care begins. generalmedicine.co Revenue Model & Contribution RESULT FOR QUERY Page 3 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 6 General Medicine generates revenue through a transaction-based, direct-to-consumer (DTC) model rather than relying on recurring subscription plans. preqin.com The platform operates like a traditional fee-for-service provider, billing patients and their insurers on a per-visit or per-service basis. slhn.org Patients can purchase individual consultations, order specific diagnostics, or fulfill prescriptions directly through the marketplace. slhn.org During its initial startup phase in mid-2025, the company's early revenue was estimated to be in the range of $1 million to $5 million. preqin.com Following its nationwide rollout and subsequent expansion, General Medicine has scaled its operations to cover 82% of all United States counties. slhn.org The company's revenue contribution is expected to increase significantly as it deploys its $120 million Series B funding to broaden its catalog of shoppable medical procedures. prnewswire.com Proprietary Technology Stack: MedicineOS & AI Capabilities The technical backbone of General Medicine's platform is "MedicineOS," a proprietary integration layer modeled after the PillPack "PharmacyOS" architecture. vcsheet.com MedicineOS aggregates fragmented healthcare data by connecting electronic health records (EHRs), lab systems, and pharmacy networks into a single operational interface. vcsheet.com This software automates complex administrative tasks, including medical record retrieval, diagnostic scheduling, and care pathway routing. vcsheet.com The platform integrates two core proprietary artificial intelligence and machine learning technologies to automate care workflows. vcsheet.com Machine Learning Insurance Interpretation : General Medicine uses machine learning models trained to interpret individual insurance policies in real-time. vcsheet.com This system calculates exact out-of-pocket costs, deductibles, and co-insurance requirements before a patient books a service. vcsheet.com "General AI" Triage Assistant : The user interface features an open-ended conversational assistant that allows patients to describe symptoms in plain text to navigate clinical pathways. generalmedicine.co Regulatory Licenses & "Friendly PC-MSO" Ownership Structure To comply with the Corporate Practice of Medicine (CPOM) doctrine, which prohibits non-clinical corporations from practicing medicine, General Medicine employs a "Friendly PC-MSO" structural model. healthlawalliance.com Under this framework, the corporate entity (Path Healthcare Systems Corp) operates as the Management Services Organization (MSO) handling non-clinical operations. slhn.org The MSO owns the underlying platform, manages administrative tasks, and provides support via a Management Services Agreement (MSA). cuvo.co The clinical care itself is delivered by separate professional corporations (PCs) owned entirely by licensed physicians. cuvo.co Dr. Sunita Mishra : The Chief Medical Officer of Amazon Health Services served as an early advisor and was the initial physician owner of one of the clinical entities. [2] 2 • STAT News RESULT FOR QUERY Page 4 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 7 Dr. Pallabi Sanyal-Dey : To ensure independence from outside corporate entities, General Medicine transitioned ownership of its clinical practices to Dr. Sanyal-Dey prior to launch. Dr. Sanyal-Dey serves as the Medical Director of General Medicine and holds active, multi-state medical licenses. albme.gov Her professional licensure spans multiple jurisdictions, including California, Colorado, Alabama, Georgia, and Utah. albme.gov This dual-entity structure ensures that clinical decisions, treatment protocols, and prescribing patterns remain under strict physician control, satisfying rigorous state-level medical board standards. georgia.gov Competitive Differentiation General Medicine competes across multiple categories of virtual care, distinguishing itself through its horizontal breadth and deep insurance integration. generalmedicine.co While specialized telehealth platforms focus on narrow vertical segments such as hair loss or weight management, General Medicine acts as a broad-spectrum medical provider. generalmedicine.co Additionally, the company eliminates the upfront financial barriers associated with virtual primary care models by charging zero membership or subscription fees. vcsheet.com Competitor Category Core Rivals Primary Differentiation Sources Virtual Primary Care Amazon's One Medical General Medicine charges no subscription or membership fees. vcsheet.co m Specialized Telehealth Ro, Hims & Hers General Medicine offers a horizontal, full-loop catalog spanning over 35 specialties, diagnostics, and procedures. generalme dicine.co Retail Health Stores Sesame Care General Medicine integrates proprietary ML insurance pricing engines rather than focusing primarily on cash-pay rates. prnewswir e.com Customers, Programs, & Partnerships Consumer Segment & Target Demographics The customer base of General Medicine is predominantly comprised of direct-to-consumer (DTC) patients who utilize the platform to bypass traditional subscription fees and access transparent upfront pricing. fiercehealthcare.com This digital marketplace has proven highly effective at capturing individuals with previously deferred clinical needs. fiercehealthcare.com Approximately 81% of the platform's early users sought care for medical issues that they had actively put off, with 20% of those patients having delayed treatment for six months or longer. fiercehealthcare.com The consumer segment utilizes the platform for immediate, routine care needs, such as urinary tract infections and dermatological concerns, as well as complex care coordination requiring specialized attention. fiercehealthcare.com Since its nationwide launch in May 2025, General Medicine has RESULT FOR QUERY Page 5 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 8 successfully fulfilled over 800 different types of healthcare visits across more than 35 medical specialties. fiercehealthcare.com Health System & Provider Group Networks Rather than operating as a closed clinical loop, General Medicine acts as an active healthcare navigator that integrates with existing local and regional networks. prnewswire.com The platform establishes commercial routing pathways to connect patients with community providers, local ambulatory clinics, diagnostic laboratories, and imaging centers. fiercehealthcare.com Through these structured navigation channels, customers have completed referred appointments with more than 100 distinct provider groups and health systems across the United States. fiercehealthcare.com This broad collaborative network allows the digital storefront to facilitate physical diagnostic follow-ups and complex specialty procedures that cannot be fully resolved through virtual consultations alone. prnewswire.com Payer & Insurance Partnerships To lower financial barriers for its customers, General Medicine maintains active partnerships with a broad range of healthcare payers. prnewswire.com While many early-stage virtual care platforms operate strictly as cash-pay services, General Medicine's marketplace is designed to accept most major health insurance plans. prnewswire.com The platform's proprietary transaction engine displays real-time insurance-adjusted rates alongside flat cash prices side-by-side, allowing patients to make informed financial decisions. prnewswire.com This dual-pricing model helps the company capture both insured patients looking to utilize their benefits and uninsured or underinsured consumers seeking competitive cash rates. prnewswire.com Physician-Owned Clinical Affiliations In order to deliver clinical care nationwide while strictly complying with state-level Corporate Practice of Medicine (CPOM) regulations, General Medicine partners with independent, physician-owned professional practices. [3] The company maintains clinical affiliation agreements with separate medical entities that are owned and directed by licensed physicians. [4] Prior to the platform's public rollout, General Medicine transitioned the ownership of all its affiliated clinical practices to its primary physician owner, Dr. Pallabi Sanyal-Dey. [5] The design and compliance strategy of these clinical affiliations was supported by early advisory from Dr. Sunita Mishra, the Chief Medical Officer of Amazon Health Services, who originally held ownership of one of the participating medical practices. [6] This structure ensures that clinical protocols, treatment regimens, and prescribing decisions remain entirely under independent medical oversight rather than being influenced by the platform's corporate management. [7] 3 4 5 6 7 • STAT News Operational Footprint & Go-To-Market (GTM) Strategy Regional Operational Footprint & Corporate Hubs General Medicine has established a strategic operational footprint designed to balance centralized corporate oversight with highly distributed nationwide service delivery. novonordisk.com The company maintains its RESULT FOR QUERY Page 6 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 9 corporate headquarters in San Francisco, California, which serves as the primary node for its product engineering, product development, and executive leadership. novonordisk.com To support its clinical coordination, customer support, and logistics operations, General Medicine has established secondary operational hubs in Boston, Massachusetts, and Salt Lake City, Utah. novonordisk.com This multi-region physical footprint allows the company to effectively oversee a digital consumer healthcare platform that successfully extends its reach to 82% of all counties in the United States. slhn.org Virtual and Physical Care Hub Integration The company's core service delivery relies on a dual-layered, "hub-and-spoke" operational architecture that seamlessly merges its proprietary virtual platform with physical local healthcare infrastructure. summithealth.com Virtual Care Hub : General Medicine’s online platform acts as a borderless virtual hub, offering patients immediate access to everyday and specialty care without the administrative friction or subscription fees of traditional digital primary care models. generalmedicine.co This virtual layer is supported by automated health record retrieval systems, symptom-based triage assistants, and automated clinical summaries that provide clinicians with critical medical context before a consultation begins. generalmedicine.co Physical Care Integration : Because virtual consultations cannot resolve high-acuity or complex clinical needs, General Medicine coordinates directly with a decentralized network of physical local healthcare provider groups, ambulatory facilities, and diagnostic laboratories. fiercehealthcare.com This hybrid care model effectively bridges the gap between digital convenience and physical clinical care, allowing patients to complete physical doctor visits, advanced diagnostic imaging, and complex procedures locally. prnewswire.com Sourcing Strategy & Third-Party Clinic Networks To scale its clinical offerings rapidly without incurring massive capital expenditures (CapEx), General Medicine utilizes an asset-light, partnership-heavy sourcing strategy. technavio.com Asset-Light Operational Model : Instead of building out its own physical clinics, General Medicine leverages third-party provider networks and existing health system infrastructures to deliver in-person care. technavio.com This transition from fixed clinical overhead to variable, transactional operating expenses enables the platform to optimize its capital efficiency. technavio.com Collaborative Provider Networks : The company has developed routing pathways and coordination programs with over 100 distinct health systems and physician groups nationwide. fiercehealthcare.com These clinical affiliations enable the platform to route patients to verified, high-quality local clinical sites when in-person follow-ups are necessary. fiercehealthcare.com Downstream Logistics Sourcing : General Medicine partners with over 50,000 local physical pharmacies and diagnostic laboratory chains across the country. generalmedicine.co This extensive network ensures that prescriptions and diagnostic orders generated during virtual consults can be fulfilled seamlessly near the patient’s home. generalmedicine.co RESULT FOR QUERY Page 7 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 10 Go-To-Market (GTM) & Patient Acquisition Strategy General Medicine’s GTM strategy deviates from high-friction, subscription-based models in favor of a transaction- based, consumer-centric acquisition motion. preqin.com Direct-to-Consumer (DTC) E-Commerce Channels : The company positions its platform as a frictionless digital store where patients can directly search, compare, and purchase care. prnewswire.com By eliminating upfront access fees, General Medicine lowers the initial barrier to entry, specifically targeting the high volume of consumers who historically defer healthcare due to cost uncertainty. fiercehealthcare.com Insurance-Integrated Pricing Engine : A major driver of conversion is the platform's proprietary machine learning engine, which calculates and presents real-time insurance-adjusted out-of-pocket costs alongside clear cash-pay rates. vcsheet.com This transparent dual-pricing model captures both commercially insured individuals seeking to utilize their plans and cash-pay patients looking for the best market rate. prnewswire.com Seamless Navigation Pathways : The platform utilizes automated scheduling and self-serve booking channels to maximize acquisition efficiency, mitigating the standard "friction tax" associated with traditional phone- based booking systems. netsuite.com By offering a retail-like scheduling experience, General Medicine minimizes patient drop-off and significantly lowers its customer acquisition costs. netsuite.com Financial Snapshot & Unit Economics Funding and Estimated Cash Runway General Medicine has fortified its balance sheet with a total of $152 million in capital raised since inception. [8] This capital was raised across two key institutional funding rounds: a $32 million Series A in May 2025 and a $120 million Series B in October 2026. [8] The Series B round, led by Andreessen Horowitz, established an implied post-money valuation of $669.68 million, representing a substantial step-up from its Series A post-money valuation of $156.84 million. [8] With a fresh $120 million injection, the company's cash balance is highly fortified to support its rapid nationwide scaling. This cash position extends General Medicine's capital runway well beyond the late 2026 venture benchmark of 18 to 24 months for growth-stage digital health startups. koalagains.com Funding Screener • Filters: 1 Funding Screener • Filters: 1 Funding Screener • Filters: 1 Estimated Revenue Trajectory During its initial launch phase in 2025, General Medicine operated as a lean digital health storefront with early transaction-based revenue estimated to be in the low single-digit millions. prnewswire.com Following its nationwide expansion to 82% of all United States counties, the company is leveraging its Series B capital to significantly scale its searchable e-commerce catalog of over 2,900 medical products and services. preqin.com While the private startup does not publicly disclose its current annual recurring revenue (ARR) or exact burn rate, its consumer-centric transactional model is designed to optimize capital efficiency by avoiding high-overhead physical clinics. technavio.com RESULT FOR QUERY Page 8 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 11 Digital Health Unit Economics Benchmarks As General Medicine utilizes its marketplace model to capture patient demand, its operational model aligns closely with the unit economics of the digital primary care and virtual general medicine sector. neolytix.com Customer Acquisition Cost (CAC) Efficiency : Customer acquisition costs within the digital primary care sector typically range from $75 to $400. neolytix.com Acquisition efficiency is highly optimized because healthcare search ads see robust conversion rates of approximately 11.6%. imatrix.com The average cost per lead (CPL) for clinicians in these digital channels is around $56.83, which is 19% lower than the cross-industry average. imatrix.com Payback and LTV Profiles : With average revenue per virtual clinical visit ranging from $150 to $300, transactional platforms often achieve customer payback on the first visit. medicalppcagency.com The estimated lifetime value (LTV) for standard insurance-based primary care ranges between $2,000 and $6,000, yielding strong LTV:CAC ratios between 7.5:1 and 20:1. neolytix.com Retention and Tenure Impact : Direct primary care (DPC) models demonstrate high capital efficiency, with a median LTV:CAC ratio of 15.7x and an average patient tenure of 5.2 years. macbach.com Implementing structured patient retention workflows can lead to a 64% median increase in overall patient LTV. macbach.com Sector Operational Pressures : Despite strong customer acquisition metrics, general medical providers face ongoing margin headwinds from rising operational expenses. aha.org Total medical expenses grew by 7.5% in 2025, driven by a 5.6% increase in workforce costs and a 13.6% surge in drug pricing. aha.org Comparative Corporate Margin Context For strategic comparison, mature "General Medicine" (GenMed) business units within the traditional pharmaceutical industry operate on a different financial scale and margin structure. gedeonrichter.com These mature segments typically act as low-growth, high-volume cash cows that fund high-burn R&D in other therapeutic areas. gsk.com Mature pharmaceutical operators are actively transitioning these legacy GenMed segments toward digital-first commercial platforms. deloitte.com This strategic operational shift is projected to reduce mature-market selling, general, and administrative (SG&A) costs by 15% to 20%, illustrating the structural cost advantages of General Medicine's native digital e-commerce storefront model. deloitte.com RESULT FOR QUERY Page 9 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 12 Corporate Division Gross Margin Contribution / EBIT Margin Primary Dynamics & Headwinds Sources Gedeon Richter GenMed 67.60% 10.70% Impacted by weak seasonal OTC sales and distributor inventory rationalization. gedeonric hter.com Sanofi GenMed 77.50% 28.60% Shifting toward core assets; operating margins recovering as R&D investment troughs. sanofi.co m GSK GenMed N/A N/A Turnover of £10 billion; facing 7% decline from generic erosion and Medicare design shifts. gsk.com Market Landscape, Competitive Positioning, & Regulatory Dynamics Market Landscape & Addressable Market Sizing The global digital health market, representing the Total Addressable Market (TAM) for virtual health technologies, is projected to expand from approximately $347.35 billion in 2025 to $946.04 billion by 2030 . marketsandmarkets.com This growth reflects a compound annual growth rate (CAGR) of 22.20% . marketsandmarkets.com Within this, the Serviceable Addressable Market (SAM) for digital healthcare platforms and marketplaces is estimated to reach $156.00 billion in 2025 and is projected to rise to $420.00 billion by 2030 , growing at a CAGR of approximately 23.00% . marketsandmarkets.com For individual platform players like General Medicine, the Serviceable Obtainable Market (SOM) in North America is highly competitive yet lucrative, with the regional market projected to grow from $130.00 billion in 2025 to $356.00 billion by 2030 . marketsandmarkets.com Source: marketsandmarkets.com This rapid expansion is sustained by several critical industry catalysts. marketsandmarkets.com The rising incidence of chronic diseases, government digital transformation mandates, and a massive shift toward patient- centered preventive care are key structural drivers. marketsandmarkets.com Furthermore, cloud-based deployment models hold over Market Metric 2025 Estimate 2030 Projection Growth Rate (CAGR) TAM (Global Digital Health) $347.35 Billion $946.04 Billion 22.20% SAM (Platforms & Marketplaces) $156.00 Billion $420.00 Billion 23.00% SOM (North America Market) $130.00 Billion $356.00 Billion 22.50% RESULT FOR QUERY Page 10 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 13 63.20% of the market share, facilitating the growth of scalable, borderless healthcare marketplaces. databridgemarketresearch.com Competitive Positioning General Medicine positions itself as a universal entry point for all health needs through a "catalog-first" approach to digital healthcare. remoterocketship.com The platform differentiates itself across multiple dimensions against key competitors, including Amazon’s One Medical, traditional telehealth veterans, and direct-to-consumer (DTC) wellness platforms. mgmtboston.com Dime nsion General Medicine Amazon One Medical Legacy Telehealth (Teladoc/Amwell) DTC Platforms (Hims & Hers/Ro) Source s Busin ess Mode l Transactional "healthcare store" with transparent upfront pricing. mgmtboston.com Subscription-based concierge clinic model with physical locations. mgmtboston.com Virtual-first primary care and employer- sponsored packages. generalmedicine.co Direct-to-consumer digital clinics with a focus on subscription wellness. generalmedicine.co mgmtb oston.c om Mem bersh ip Fees Zero upfront membership or access fees. mgmtboston.com Annual membership fee of $199 (discounts available for Prime). mgmtboston.com Typically subscription-based for employers; pay- per-visit varies. telehealth.com No general membership, but products require monthly subscriptions. generalmedicine.co mgmtb oston.c om Platfo rm Selec tion Over 2,900 distinct medical services covering 35+ specialties. signalnewscolumbia sc.com Closed clinic network focused on physical and virtual primary care. generalmedicine.co Broad on-demand urgent and mental health care. telehealth.com Narrow, highly specialized clinical lifestyle verticals (e.g., hair loss). generalmedicine.co signaln ewscol umbias c.com Insur ance Integr ation ML insurance interpretation showing real-time out-of-pocket costs. generalmedicine.co Closed insurer billing integrated with Amazon ecosystem. generalmedicine.co Heavily integrated with traditional employer and payer benefits. generalmedicine.co Predominantly cash- pay subscription models. generalmedicine.co general medici ne.co Philosophical Rivalry with Amazon's One Medical : Amazon’s One Medical model represents a closed system focused on building a long-term primary care relationship that often requires a subscription. generalmedicine.co By contrast, General Medicine is an open storefront designed for transactional efficiency across multiple independent providers, specialists, and laboratories. generalmedicine.co While One Medical’s RESULT FOR QUERY Page 11 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 14 core strength lies in physical clinic density in major metropolitan areas, General Medicine serves consumers in 82% of U.S. counties through virtual care and community lab networks, routing in-person care to local partners. generalmedicine.co Direct-to-Consumer & Legacy Telehealth : Specialized DTC platforms like Hims & Hers and Ro focus primarily on high-margin, narrow lifestyle medical verticals like hair loss, sexual health, and weight management. generalmedicine.co General Medicine differentiates itself by operating as a broad-spectrum medical provider covering over 35 medical specialties . generalmedicine.co Traditional telehealth giants like Teladoc and Amwell lead in employer-sponsored health plan contracts but often lack the upfront pricing retail experience and instant insurance pricing tools built by General Medicine. generalmedicine.co Macroeconomic and Technological Catalysts The integration of Artificial Intelligence (AI) and Machine Learning (ML) serves as a primary technological catalyst for General Medicine. marketsandmarkets.com The company utilizes its proprietary MedicineOS stack, which features machine learning engines designed to parse complex, multi-page insurance benefit documents in real- time, showing patients their exact out-of-pocket costs before booking. generalmedicine.co Furthermore, the AI- assisted symptom triage layer guides patients through clinical pathways, significantly reducing administrative friction and helping the company mitigate the "friction tax" associated with traditional clinical booking processes. generalmedicine.co However, the digital healthcare marketplace sector is currently confronting notable macroeconomic headwinds. aha.org Total medical expenses rose by 7.50% in 2025 , driven by a 5.60% increase in workforce costs and a 13.60% surge in drug pricing. aha.org These rising operational costs exert continuous margin pressure on digital- first healthcare platforms, necessitating highly efficient capital allocation and asset-light provider networks. aha.org Regulatory Dynamics and Compliance Structure Physician-owned digital health practices operate within a highly complex legal framework governed by state-level medical licensing and corporate regulations. healthlawalliance.com Corporate Practice of Medicine (CPOM) Doctrine : This legal doctrine prohibits non-clinical corporations from practicing medicine or employing physicians to deliver clinical care, ensuring that financial motives do not interfere with professional medical judgment. healthlawalliance.com To remain fully compliant with CPOM regulations, General Medicine employs a "Friendly PC-MSO" structural model. healthlawalliance.com Management Services Organization (MSO) Alignment : Under this framework, the corporate entity (Path Healthcare Systems Corp) acts as the MSO, managing non-clinical administrative workflows, marketing, billing, and platform logistics under a formal Management Services Agreement (MSA). cuvo.co Independent Professional Corporations (PCs) : The clinical care is delivered exclusively by independent professional corporations owned entirely by licensed physicians. cuvo.co To establish absolute corporate separation, General Medicine transitioned ownership of its affiliated clinical practices to Dr. Pallabi Sanyal-Dey prior to launch. albme.gov Dr. Sanyal-Dey holds active, multi-state medical licenses across multiple RESULT FOR QUERY Page 12 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 15 jurisdictions, including California, Colorado, Alabama, Georgia, and Utah. albme.gov This ensures that clinical protocols, treatment regimens, and prescribing decisions remain entirely under independent clinical control, satisfying state-level medical board standards and fee-splitting regulations. georgia.gov Recent Developments, Key Advantages, & Operational Risks Post-Launch Scaling & Strategic Hires General Medicine has scaled its operations to cover 82% of all United States counties following its public rollout in May 2025. slhn.org To support this massive expansion and transition from its stealth phase, the company executed key strategic leadership additions in October 2026. prnewswire.com Most notably, TJ Parker, a co- founder of PillPack and former partner at Matrix Partners, joined the company as Chief Executive Officer. prnewswire.com Simultaneously, Ashwin Muralidharan, the founding CEO who guided the platform through its nationwide launch, transitioned to the role of Chief Product Officer to focus strictly on platform and service development. prnewswire.com The leadership team is further bolstered by Elliot Cohen, also a PillPack co- founder, who serves as President, bringing deep expertise in digital healthcare logistics to the platform. digitalhealthnews.com This high-profile team is utilizing its $120 million Series B funding round, secured in October 2026, to scale the digital store's catalog of shoppable medical procedures and services. prnewswire.com Key Technological, Cost, and Relationship Differentiators General Medicine's strategic advantage is anchored in its proprietary integration layer known as "MedicineOS." vcsheet.com Unlike traditional healthcare models, this technology automatically retrieves up to 11 years of historical medical records with a single click, summarizing critical patient context for treating clinicians. generalmedicine.co The platform incorporates machine learning models to interpret complex insurance policies in real-time, displaying exact out-of-pocket costs and deductibles to patients before any booking occurs. vcsheet.com By operating as an open transaction-based marketplace without any upfront membership or subscription fees, General Medicine lowers customer acquisition barriers compared to subscription-based models. vcsheet.com Further, the company's asset-light sourcing strategy avoids the high capital expenditures of physical clinics by routing patients to a collaborative network of over 100 distinct health systems and provider groups. fiercehealthcare.com Barriers to Entry and Founder Dependency The company benefits from steep barriers to entry established by its proprietary MedicineOS infrastructure, which aggregates highly fragmented electronic health records, lab systems, and pharmacy networks. vcsheet.com Replicating this nationwide integration, which spans over 50,000 local pharmacies, represents a substantial technical and logistical hurdle for new entrants. generalmedicine.co However, General Medicine faces notable founder dependency and key-person risks, as its strategic direction and product vision are heavily reliant on its core executives who previously scaled PillPack. digitalhealthnews.com If these key leaders were to depart, the platform's ability to maintain its rapid scaling trajectory and secure institutional backing could be significantly compromised. soferadvisors.com RESULT FOR QUERY Page 13 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 16 Operational, Regulatory, and Governance Risks Because General Medicine operates as a digital marketplace connecting patients to clinical care, it is highly sensitive to the complex Corporate Practice of Medicine (CPOM) doctrine. healthlawalliance.com To comply with CPOM laws that prohibit non-clinical corporations from practicing medicine, General Medicine separates its operations into a corporate Management Services Organization (MSO) and independent, physician-owned professional corporations (PCs). cuvo.co To establish absolute corporate separation, the company transitioned ownership of its clinical practices to its Medical Director, Dr. Pallabi Sanyal-Dey, prior to launch. albme.gov This MSO-PC transition structure faces escalating regulatory scrutiny as states enact stricter oversight of corporate influence in clinical operations. milbank.org California Regulatory Shifts : Effective January 1, 2026, California's SB 351 codifies strict CPOM limits specifically on corporate and private equity influence over clinical operations, empowering the State Attorney General to seek injunctive relief for violations. paulhastings.com Oregon Legislative Crackdowns : Effective January 1, 2026, Oregon's SB 951 significantly tightens CPOM laws by targeting MSO control over physician practices and restricting stock transfer agreements that allow corporate entities to dictate clinical ownership. medpathcompliance.com Insurance Clawback Threats : If state regulators or payers find that an MSO-PC arrangement exercises de facto corporate control over clinical decisions, insurers can demand the clawback and repayment of all disbursed funds with triple damages. permithealth.com Clinical Governance Interference : Compliance risks are highest if Management Services Agreements (MSAs) allow the MSO to influence clinical hiring, doctor compensation, or coding procedures, which regulators view as unlicensed practice of medicine. ct.gov Data and Cybersecurity Vulnerabilities : As a digital-first platform holding massive amounts of structured patient medical records, General Medicine faces severe operational risks from cyberattacks and data breaches, which remain a top regulatory concern for consolidated health systems in 2026. milbank.org The Bull or Bear Case: Pathways, Catalysts, and KPIs The strategic outlook for General Medicine can be analyzed through distinct bull and bear trajectories that reflect its disruptive transactional marketplace model. preqin.com These scenarios depend heavily on the company's ability to maintain high customer satisfaction while navigating intense regulatory and competitive headwinds. generalmedicine.co The Bull Case: Scalability and Market Disruption PillPack Leadership Pedigree : The company is led by co-founders TJ Parker and Elliot Cohen, who bring a proven track record of scaling highly complex digital healthcare logistics. prnewswire.com RESULT FOR QUERY Page 14 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 17 High-Velocity "Healthcare Store" Model : Unlike traditional closed systems or subscription-based models, General Medicine operates a friction-free transactional e-commerce platform offering over 2,900 products and services. preqin.com Unlocking Deferred Healthcare Demand : The direct-to-consumer marketplace effectively captures patients who traditionally delay care due to cost uncertainty, with 83% of users addressing previously deferred medical issues. prnewswire.com Deep Technical and AI Advantage : The integration of MedicineOS and machine learning models enables automated retrieval of up to 11 years of historical medical records. prnewswire.com Specialized Therapeutic Tailwinds : The platform is strategically positioned to capitalize on the massive consumer demand for metabolic and chronic care solutions, particularly GLP-1 weight-loss medications. generalmedicine.co Substantive Growth Funding : A newly closed $120 million Series B funding round led by Andreessen Horowitz provides the necessary capital runway to support aggressive national expansion efforts. prnewswire.com The Bear Case: Operational Friction and Structural Barriers Scaling and Operational Growing Pains : Customer reviews indicate that rapid expansion has introduced technical glitches, missed clinical appointments, and communication bottlenecks. trustpilot.com Intense Multi-Front Competition : General Medicine faces formidable competition from established virtual primary care networks, retail medical clinics, and specialized wellness giants such as Hims & Hers. generalmedicine.co Complex Billing and Insurance Friction : Managing transactional per-visit payments across a highly fragmented network of major insurance payers presents continuous billing challenges and risk of consumer dissatisfaction. trustpilot.com Escalating CPOM Regulatory Scrutiny : The Friendly PC-MSO structure faces strict and evolving state-level Corporate Practice of Medicine regulations, such as California's SB 351. paulhastings.com Tighter State Compliance Audits : Legislative updates like Oregon's SB 951 introduce tighter oversight regarding corporate influence over clinical practices. medpathcompliance.com Data Security and Platform Vulnerabilities : Because the digital-first storefront consolidates vast amounts of historical patient data, it remains highly vulnerable to cybersecurity threats and data breaches. milbank.org Leading Indicators and Measurable Milestones To evaluate General Medicine's progress toward achieving its long-term strategic targets, stakeholders should monitor several key operational and geographic milestones: RESULT FOR QUERY Page 15 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 18 Geographic Coverage Target : The primary near-term milestone is expanding its geographic reach from covering 82% of U.S. counties to achieving 100% nationwide coverage. mgmtboston.com Catalog and Specialty Expansion : Growth tracking should focus on the expansion of the platform's searchable catalog beyond the current 2,900 products and services. signalnewscolumbiasc.com High-Value Clinical Categories : Monitoring the successful launch of complex, shoppable diagnostic procedures such as imaging services will indicate market-share expansion. mgmtboston.com Customer Satisfaction Benchmarks : Maintaining an exceptionally high Net Promoter Score of 80 or above is critical to validating the platform's retail-first patient experience. prnewswire.com Referral Network Density : Stakeholders should track the growth of active referral pathways, which currently connect users to more than 100 distinct health systems. mgmtboston.com Human Capital Scaling : Monitoring recruitment metrics and the expansion of the engineering and design office in Cambridge, Massachusetts, will reflect the company's technical execution capacity. mgmtboston.com Key Performance Indicator Current Metric (2026) Target / Milestone Sources Geographic Coverage 82% of U.S. counties 100% Nationwide Coverage mgmtboston.com Service Catalog Size 2,900+ Products & Services Expansion into Imaging & Procedures signalnewscolumbiasc .com Referral Network 100+ Health Systems Multi-system expansion mgmtboston.com Customer Satisfaction 80+ Net Promoter Score (NPS) Maintain NPS of 80+ prnewswire.com Engineering Hub Presence Cambridge/Boston Office Cambridge recruitment scaling mgmtboston.com Valuation & Exit Outlook Private Valuation History & Funding Context General Medicine has experienced a rapid valuation step-up over its short operational history, driven by aggressive expansion and high-profile institutional backing. prnewswire.com The company emerged from stealth in May 2025 with a Series A funding round of $32 million led by Matrix. prnewswire.com This initial funding round established an implied post-money valuation of $156.84 million. prnewswire.com In October 2026, the company secured a massive $120 million Series B funding round led by Andreessen Horowitz. startbase.com This financing RESULT FOR QUERY Page 16 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 19 round valued the company at an implied post-money valuation of $669.68 million, demonstrating robust investor confidence in its transaction-based digital marketplace model. prnewswire.com Comparable Transactions & Historical Context The strategic trajectory of General Medicine is heavily informed by the past exit success of its founding team. President Elliot Cohen and CEO TJ Parker previously co-founded PillPack, a digital pharmacy pioneer. prnewswire.com In 2018, Amazon acquired PillPack for approximately $750 million, which subsequently formed the foundation of Amazon Pharmacy. This landmark transaction illustrates the premium that tech-enabled healthcare delivery platforms can command from mega-cap strategic acquirers. [9] 9 • STAT News Other historical transactions in the digital pharmacy and healthcare spaces provide additional valuation benchmarks, demonstrating how strategic buyers consolidate digital health players. [10] For instance, Webmed Pharmacy was acquired by Vulcan Two Group Plc in March 2026 for a deal value of $2.84 million, reflecting an implied EV/Sales multiple of 0.78x. [10] Additionally, Hyperdrug Pharmaceuticals was acquired by Vulcan Two Group Plc in March 2026 for $4.87 million, executing at an EV/Sales multiple of 0.40x and an EV/EBITDA multiple of 7.20x. [10] Walgreens Boots Alliance also acquired Medly Health in February 2023 for $19.35 million in cash to expand its digital delivery capabilities. [10] M&A Screener • Filters: 1 M&A Screener • Filters: 1 M&A Screener • Filters: 1 M&A Screener • Filters: 1 Industry Valuation Multiples & Market Benchmarks As a digital-first healthcare storefront, General Medicine's market valuation is benchmarked against broader digital health and primary care sectors. svb.com While traditional primary care and general practices trade at modest EV/EBITDA multiples of 3x to 5x, tech-enabled platforms with proprietary infrastructure command substantial premiums. soferadvisors.com In the private markets, digital healthcare services multiples have stabilized at an average EV/EBITDA of 11.5x in 2025, down from historical peaks of over 14x in 2024. svb.com Furthermore, platforms integrating advanced artificial intelligence and machine learning—such as General Medicine's MedicineOS pricing engine—command a 19% to 61% valuation premium over legacy peers. fiercehealthcare.com Strategic Exit Pathways & IPO Readiness Public Market Readiness & IPO Timeline A future public listing represents a highly viable long-term liquidity option for General Medicine, although the company must achieve specific operational milestones to build IPO readiness. startupintros.com Public market investors in 2026 demand proven profitability or a highly visible near-term path to positive cash flow, a stark departure from previous growth-at-all-costs environments. focusib.com To execute a successful IPO, General Medicine will likely need to surpass an annual run-rate revenue threshold of $200 million and expand its multi- state clinician network to achieve true national coverage. startupintros.com Consequently, while an IPO is a prospective medium-term goal for 2027 or beyond, the company's current phase remains focused on high-velocity scaling using its Series B capital. startupintros.com RESULT FOR QUERY Page 17 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 20 Acquisition & Strategic Divestiture Outlook In the near term, strategic acquisition represents the most probable exit pathway for General Medicine due to a wave of corporate consolidation. healthcare.digital The platform's ability to seamlessly bridge virtual triage with physical health system routing makes it a highly attractive target for multiple buyer segments. startupintros.com Commercial Payers and Insurers : Insurance companies are aggressively seeking to own the virtual "front door" of healthcare to control downstream referral pathways. startupintros.com General Medicine's transparent insurance-adjustment engine presents a powerful tool for steering patients toward cost-effective care networks. prnewswire.com Private Equity Roll-Ups : Private equity firms, such as Clayton, Dubilier & Rice and Warburg Pincus, are actively deploying "buy-and-build" strategies in tech-enabled clinical services. startupintros.com General Medicine fits the profile of a "platform asset" that can absorb smaller virtual specialists and localized diagnostics providers. startupintros.com Strategic Health Systems : Large hospital systems seek digital platforms that minimize billing friction and simplify administrative intake. startupintros.com Acquiring General Medicine's retail storefront would allow a major network to capture patient demand and reduce downstream patient leakage. startupintros.com Internal Relationship & Activity Context Based on a comprehensive review of internal systems, there is no documented relationship history or internal engagement record with General Medicine (https://generalmedicine.co) within our organization's CRM platform or real-time communications channels. This absence of prior touchpoints indicates that General Medicine represents a net-new relationship opportunity rather than an existing portfolio company or active deal pipeline prospect. The CRM Agent query returned zero logged contacts, meeting histories, or deal pipeline stages associated with General Medicine, its parent entity Path Healthcare Systems Corp, or its key executives including CEO TJ Parker, President Elliot Cohen, Chief Product Officer Ashwin Muralidharan, or Medical Director Dr. Pallabi Sanyal-Dey. Similarly, the Realtime Comms Agent detected no internal emails, calendar events, Slack discussions, or collaborative workspace mentions referencing the company across the organization's communication infrastructure during the analysis period. This comprehensive absence suggests that General Medicine has not previously been evaluated for investment, partnership, or commercial engagement by our internal teams. The lack of internal activity context presents both strategic opportunities and operational gaps for future engagement. From an opportunity perspective, this clean slate allows our organization to establish a first-mover relationship with a high-growth digital healthcare marketplace that has successfully raised $152 million across two institutional funding rounds and achieved an implied post-money valuation of $669.68 million as of October 2026. The company's founding team, comprised of proven PillPack alumni who previously executed a $750 million acquisition by Amazon in 2018, represents a battle-tested executive group with demonstrated exit success in the digital pharmacy sector. Given that General Medicine has scaled to cover 82% of U.S. counties and fulfilled over 800 different types of healthcare visits across more than 35 medical specialties since its May 2025 RESULT FOR QUERY Page 18 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 21 launch, the platform has achieved meaningful commercial traction that warrants proactive outreach and relationship development. However, the absence of internal intelligence also highlights critical knowledge gaps that must be addressed through structured engagement protocols. Our organization lacks firsthand insights into General Medicine's unit economics, customer acquisition cost (CAC) payback periods, lifetime value (LTV) profiles, and contribution margin dynamics. We possess no internal perspectives on the company's operational challenges, such as the scaling and operational growing pains documented in external customer reviews, nor do we have visibility into management's strategic priorities for deploying its recent $120 million Series B capital . Furthermore, we have no internal assessment of the regulatory compliance robustness of General Medicine's Friendly PC-MSO structure, particularly in light of tightening state-level Corporate Practice of Medicine (CPOM) oversight through legislative updates like California's SB 351 and Oregon's SB 951 , which became effective January 1, 2026. To establish a meaningful internal relationship framework, our organization should prioritize immediate outreach initiatives focused on securing exploratory conversations with General Medicine's executive leadership. Initial engagement should target CEO TJ Parker and President Elliot Cohen to discuss the company's go-to-market expansion strategy, particularly its plans to extend geographic coverage from 82% to 100% of U.S. counties and expand its catalog beyond the current 2,900 products and services . Parallel outreach to Chief Product Officer Ashwin Muralidharan would provide critical insights into the technical roadmap for MedicineOS, including planned enhancements to the machine learning insurance interpretation engine and the "General AI" triage assistant. Additionally, engaging Medical Director Dr. Pallabi Sanyal-Dey would allow our team to assess the clinical governance structure and evaluate the independence of physician-owned professional corporations under the current MSO arrangement. Beyond executive-level engagement, our organization should deploy structured monitoring protocols to track General Medicine's progress against key performance indicators and measurable milestones. These monitoring frameworks should include quarterly tracking of geographic coverage expansion, service catalog growth, referral network density (currently exceeding 100 health systems ), and customer satisfaction benchmarks (with a current Net Promoter Score of 80+ ). Internal stakeholders should also establish alert mechanisms to flag significant corporate developments, such as additional funding rounds, strategic hires, regulatory enforcement actions, or acquisition rumors involving potential acquirers like commercial payers, private equity roll-up platforms, or strategic health systems. From a forward-looking perspective, the establishment of an internal relationship with General Medicine aligns with broader industry trends favoring digital-first, transaction-based healthcare marketplaces over legacy subscription models. The company's asset-light operational footprint, which avoids high capital expenditures by routing patients to collaborative provider networks, mirrors the structural cost advantages that mature pharmaceutical operators are pursuing through digital transformation initiatives projected to reduce selling, general, and administrative (SG&A) costs by 15% to 20% . Furthermore, General Medicine's strategic positioning within the rapidly expanding digital health market—projected to grow from $347.35 billion in 2025 to $946.04 billion by 2030 at a CAGR of 22.20% —suggests that early relationship cultivation could yield substantial strategic value. RESULT FOR QUERY Page 19 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 22 The absence of historical internal engagement also necessitates the development of clear relationship objectives and success metrics moving forward. Our organization should define specific goals for the General Medicine relationship, whether focused on investment evaluation, strategic partnership exploration, competitive intelligence gathering, or talent pipeline development. These objectives should be documented within the CRM platform with defined ownership assignments, engagement cadences, and milestone-based progression criteria. Additionally, cross-functional stakeholders across investment, business development, and research teams should be briefed on the company's profile to ensure coordinated outreach and prevent redundant or conflicting engagement efforts. In summary, while General Medicine currently represents a zero-history relationship from an internal perspective, the company's proven leadership pedigree, substantial venture backing, rapid scaling trajectory, and positioning within a high-growth market segment warrant immediate and structured engagement. Our organization should prioritize establishing initial contact touchpoints, deploying systematic monitoring frameworks, and defining clear relationship objectives to capitalize on the strategic opportunities presented by this emerging digital healthcare marketplace leader. Citations [1] Funding Screener • Source: Crunchbase [2]  [3]  [4]  [5]  [6]  [7]  [9] STAT News • Amazon.com Inc • 28 May 25 • "STAT+: PillPack founders’ new health care marketplace has deep roots with Amazon" [8] Funding Screener • Source: Crunchbase [10] M&A Screener • Source: FactSet RESULT FOR QUERY Page 20 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 23 Legal Notices This content was generated using AI and may contain errors, ambiguities, or outdated information. AlphaSense does not guarantee the accuracy or completeness of this content. Users assume full responsibility for any use of or reliance upon any content contained in the service. Users should independently validate all information before using or relying on it. This content does not reflect the views or opinions of AlphaSense or any of its personnel and does not constitute legal, investment, or other professional advice. This content is proprietary and protected under copyright and other intellectual property laws. No part of this content may be used in connection with any language models or generative AI systems outside of AlphaSense. Any unauthorized use, including but not limited to the training or fine-tuning of any language models or other AI models, is strictly prohibited. ================================================================================ # DOCUMENT: AlphaSense Expert Calls, Oct 18, 2026 (raw/alphasense/alphasense-operational-financial-analysis-2026-10-18.md) ================================================================================ # AlphaSense Operational & Financial Analysis: Expert Calls (Oct 18, 2026 · 12 Pages) > **Original PDF:** [`raw/alphasense/DR-Report-by-Alphasense-10-18-2026-16-29.pdf`](raw/alphasense/DR-Report-by-Alphasense-10-18-2026-16-29.pdf) (14 pages) --- ## Page 1 RESULTS FOR QUERY: Operational and Financial Analysis of General Medicine CREATED Oct 18, 2026 PAGES 12 RESEARCH URL Click to View In GenSearch ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 2 QUERY General Medicine@@ (consumer health/longevity company): find expert call transcripts and Expert Insights on members, revenue, CAC, retention/renewal, employer or B2B strategy, lab costs, weaknesses, and what former employees or competitors say. Prefer specific numbers, short verbatim quotes, and include each source title, date, and expert role. i ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service markAlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the backthis report. --- ## Page 3 TABLE OF CONTENTS 1. Key Takeaways 2. Membership, Revenue, and Unit Economics (CAC & Retention) 3. Employer and B2B Strategy 4. Lab Costs and Operational Infrastructure 5. Weaknesses, Competitor Dynamics, and Former Employee Perspectives RESULT FOR QUERY General Medicine Deep-Dive: Membership Economics, B2B Strategy, Lab Costs, and Competitive Weaknesses Key Takeaways Direct primary care delivers a median patient tenure of 5.20 years with an exceptional LTV:CAC ratio of 15.70x , while traditional concierge medicine boasts 6.80 years tenure and an outstanding 19.40x ratio, far surpassing traditional primary care's standard 3.00x ratio. Corporate B2B clients demand "careful clinical oversight by clinicians" and are willing to pay premium prices when digital health platforms achieve employee enrollment rates "over 10% of employees inside an employer," creating highly resilient retention businesses that employers value for active staff utilization. Diagnostic laboratory operations are dominated by reagents and consumables representing approximately 80% of direct operating costs, while staff labor constitutes only 20% , making procurement scale the primary driver of unit economics. At-home diagnostic testing faces severe operational challenges with sample failure rates typically between 5-10% due to logistics difficulties, sample quality issues, and regulatory compliance barriers that undermine consumer longevity business models. Internal organizational weaknesses including "strict internal firewalls" between commercial, payer, and medical affairs teams have impeded launch excellence across general medicine products, compounded by aggressive reorganizations that led to "talent loss and challenges in recruiting experienced professionals, particularly in medical affairs." Membership, Revenue, and Unit Economics (CAC & Retention) General Medicine, P.C. Market Positioning RESULT FOR QUERY Page 1 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 4 The findings do not support the premise that mature internal membership, revenue, or customer acquisition cost (CAC) metrics are available for General Medicine, P.C. ; the company is in an early post-funding growth phase having recently raised $120 million in a Series B round on October 6, 2026. [1] Led by Andreessen Horowitz , this capital injection is designated to build healthcare's consumer layer and "everything store," operating as a transaction-focused digital storefront. [2] The platform is designed to connect consumers directly to providers to address specific medical needs or symptoms, treating healthcare access like e-commerce. [3] Because the company is currently building out its initial storefront infrastructure, historical subscriber metrics are not yet detailed, but the economics of its target market can be analyzed through competitor benchmarks. [4] 1 2 4 • Fitt Insider 3 • FierceHealthcare Competitor Membership Pricing & Segment Economics The membership medicine sector is highly segmented by annual price points, which directly dictate service intensity and patient panel dynamics. [5] At the mass-market end, players like One Medical provide a slightly improved fee-for-service primary care experience for a couple hundred dollars a year. [6] In the mid-market concierge segment, the total addressable market at a $2,000 annual price point is estimated at nearly 14 million Americans. [7] For high-end luxury models, pricing is typically age-based, ranging from $4,500 to $8,000 per year, while elite personalized models can reach low six figures annually. 5 6 7 • Expert Call Model / Tier Price Point (Annual) Economic Focus & Panel Dynamics Sour ces Mass-Market / Tech-Forward ~$199 to a couple hundred dollars Slightly improved fee-for-service primary care experience with high digital integration [8] Mid-Tier Concierge ~$2,000 Large market of 14 million Americans where adding and retaining physicians drives value [9] High-End Concierge $4,500 to $8,000 Age-based pricing with additional à la carte charges for services beyond basic care [10] Ultra-Luxury Low six figures (personalized) High-touch involvement and intensive personalized clinical models [11] Subscriber Retention and Renewal Trends In established luxury primary care networks, patient retention is exceptionally high, with average year-on-year retention rates exceeding 95% . [12] The small cohort of patients who do choose to leave are typically very healthy individuals who realize after several years that they are paying for a membership they do not actively utilize. [13] In the broader digital healthcare and professional association space, new members renew at a median rate of 72% in their first year, whereas overall retention averages 82% . i4a.com Once subscribers survive the first-year hurdle, RESULT FOR QUERY Page 2 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 5 long-term stickiness improves, with median annual plan renewals climbing to 60% to 79% by the third renewal cohort. revenuecat.com 12 13 • Expert Call To maximize this retention architecture, primary care integration acts as the ultimate anchor because patients are highly resistant to changing their personal physicians. [14] A former healthcare consultant emphasized the value of this relationship, stating that "that primary care, that's the stickiness that keeps the member." [15] Retaining members past the first two years significantly increases lifetime value (LTV) and lowers the amortized customer acquisition costs over time. [16] 14 15 16 • Expert Call Unit Economics, CAC, and LTV Metrics From an operational perspective, employing physicians and owning the full P&L can yield 70% better contribution dollars per physician compared to traditional affiliation-only models. [17] This P&L ownership model allows operators to leverage fixed costs, which represents superior unit-level economic potential. [18] Transitioning to payer-focused or insurance-integrated models generally results in lower per-unit margins but leads to higher patient retention and greater overall lifetime value. [19] For instance, cross-referrals between medical prescribers and therapists serve as a growing channel that extends patient lifetime value by ensuring continuity of care. [20] 17 18 • Expert Call 19 • Expert Call 20 • Expert Call In the direct primary care (DPC) model, a median patient tenure of 5.20 years delivers an exceptional LTV:CAC ratio of 15.70x . macbach.com Traditional concierge medicine boasts a median patient tenure of 6.80 years and an outstanding LTV:CAC ratio of 19.40x , whereas traditional primary care often operates near a standard 3.00x ratio. macbach.com Blended customer acquisition costs (CAC) reflect these structural differences, with solo primary care ranging from $145 to $185 , direct primary care ranging from $82 to $400 , and premium concierge medicine running between $265 and $487 . macbach.com Employer and B2B Strategy Direct-to-Consumer (D2C) vs. Enterprise Channel Distribution In the evolving commercial landscape of general medicine and digital health storefronts, companies frequently grapple with the strategic pivot from direct-to-consumer (D2C) operations to institutional B2B channels. [21] While D2C models allow for rapid, transactional patient acquisition, the enterprise space requires a fundamentally different operational framework. [22] 21 • Expert Call 22 • Expert Call Clinical Oversight Demands : In the direct-to-consumer market, many digital prescribing platforms leverage a "low barrier to entry" model built around cheap, direct transactions or compounded medication. [23] However, as noted by the former Chief Medical Officer at Noom, Inc. in "Former Chief Medical Officer at Noom, Inc Believes Integration and Personalization Are Key to Advancing Digital Obesity Care Models" (September 27, 2026), corporate clients are "investing quite a bit of money into their employees' health and wellbeing" and consequently demand "careful clinical oversight by clinicians" to monitor safety and prove outcomes. [24] 23 24 • Expert Call RESULT FOR QUERY Page 3 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 6 The Advantage of Established Consumer Brands : A strong D2C consumer brand can serve as a powerful engine for enterprise B2B sales by driving high employee engagement. [25] According to a former VP at Noom in "Former VP at Noom Skeptical About Long-Term Viability of Compounded GLP-1 Business Model" (April 13, 2026), leveraging a recognizable consumer brand enabled them to achieve enrollment rates of "over 10% of employees inside an employer," creating a highly resilient "high net revenue retention business" because employers value offering services their staff actively utilize. [26] 25 26 • Expert Call Contrasting Channel Dynamics : The D2C and B2B channels exhibit contrasting economic profiles. [27] As explained by the former Clinical Operations Manager at Grow Therapy in "Former Clinical Operations Manager at Grow Therapy Sees Employer Channel as Key Growth Driver in Digital Mental Health" (April 09, 2026), direct- to-consumer platforms must actively manage conversion funnels across a broad targeted audience, whereas B2B models focus heavily on employee utilization, which typically hovers around 5% to 10% of the eligible population. [28] Furthermore, B2B employee assistance programs (EAPs) that are completely free to the end- user can sometimes attract "lower-intent" referrals, resulting in a lower lifetime value (LTV) compared to members who are financially invested through co-pays. [29] 27 28 29 • Expert Call Strategic Suitability : General medicine, preventative therapies, and long-term care management are highly suited for D2C marketing models. The former Product Strategy Leader at Amgen noted in "Former Product Strategy Leader at Amgen Believes Company Is Well-Positioned for Growth in New Therapeutic Areas" (March 24, 2026) that direct-to-consumer approaches make commercial sense for general medicine categories like osteoporosis and psoriasis, whereas highly complex fields like oncology must remain strictly provider- and payer-focused. [30] 30 • Expert Call Partnerships with Benefit Managers, Health Plans, and Corporate Clients Integrating a clinical storefront or therapeutic service into institutional networks requires navigating highly defensive partnerships with major commercial payers and Pharmacy Benefit Managers (PBMs). [31] 31 • Expert Call Payer Resistance and Economic Alignment : Health plans frequently resist point solutions and site-of-care carve-outs due to fears of margin erosion, particularly regarding high-markup specialty drugs. [32] However, a former Senior VP at The Cigna Group noted in "Former Senior VP at The Cigna Group Believes Economic Benefits Drive Adoption of Site-of-Care Solutions" (April 09, 2026) that this carrier resistance can be overcome if the digital vendor actively aligns with health plans on IT integration, cost-sharing structures, and "compelling economic benefits for employers." [33] 32 33 • Expert Call Preference and Referrals from PBMs : Establishing relationships with downstream benefit plans is heavily influenced by recommendation flywheels. [34] The Director of Strategic Operations at Omada Health in "Director of Strategic Operations at Omada Health Believes Evolving Partnerships Are Key to Addressing GLP- 1 Market Dynamics" (September 29, 2026) explained that corporate clients frequently seek guidance from trusted partners, meaning that any vendor that can secure "strong relationship and almost preference from health plan, PBM, etc." will achieve the highest commercial success. [35] 34 35 • Expert Call RESULT FOR QUERY Page 4 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 7 Carve-In vs. Carve-Out Models : Large commercial clients face choice structures between integrated "carve- in" models and third-party "carve-out" point solutions. [36] As described by a Technology Executive in "Technology Executive at Healthcare Company Sees Integrated Medical and Pharmacy Benefits Leading to Cost Savings and Improved Care Coordination" (October 06, 2023), integrated models yield administrative simplicity and 8% to 12% total premium savings, while making it financially punitive for employers to switch back, as returning to a carve-out model can incur penalties "up to 25% of annual per-employee costs." [37] 36 37 • Expert Call Barriers to Employer Adoption and Contract Dynamics B2B expansion for wellness and clinical storefront platforms is restricted by rising market friction, point solution fatigue, and intense pressure to demonstrate immediate, hard financial returns. [38] 38 • Expert Call Point Solution Fatigue : Employers are increasingly overwhelmed by managing multiple disparate clinical solutions. [39] According to the SVP and General Manager at Cancer Care Direct in "SVP, General Manager at Cancer Care Direct Believes Employer Demand Drives Shift to Home Infusion Programs Despite Health Plan Resistance" (April 10, 2026), corporate buyers are actively searching for multi-platform solutions to avoid going through "different contracting processes and manage multiple vendors." [40] 39 40 • Expert Call The Demise of "Fuzzy" ROI Calculations : HR and benefits departments are no longer accepting generic book- of-business studies and are instead demanding client-specific, verified actuarial data. [41] A Strategy & Finance Executive at Modern Health highlighted in "Strategy & Finance Executive at Modern Health Believes Holistic Benefits Solutions Are Key to Employee Engagement" (August 12, 2026) that if vendors fail to calculate and deliver direct client-specific updates, "they basically get cut." [42] Furthermore, while broader metrics like lower absenteeism, improved retention, and increased productivity are valued, financially strict buyers evaluate satisfaction and performance guarantees "only on healthcare claims" because those numbers are cut and dry. [43] 41 42 43 • Expert Call Disbelief in Vendor-Sponsored Metrics : There is a prevailing industry skepticism regarding the data quality of digital health clinical trials. [44] A Healthcare Management Consultant at Milliman in "Healthcare Management Consultant at Milliman Sees Livongo and Omada Leading in Digital Cardiology Solutions with Multipronged Approaches" (May 08, 2022) pointed out that employers prefer independent, multi-centric clinical validation over "vendor-sponsored clinical studies" to prove true clinical and economic utility. [45] 44 45 • Expert Call Contract Lengths and Risk Sharing : B2B sales cycles in the employer space are lengthy, typically taking over a year to complete. [47] Once closed, contract durations are relatively short, with average healthcare and HR technology platforms carrying terms of "a year, maybe two years, maybe three at the most," placing substantial pressure on annual renewal rates. [48] To hedge this risk, B2B buyers frequently demand fee-at-risk arrangements, where digital health vendors must put a portion of their service fees at stake. [46] As noted by the former Vice President at Teladoc Health, Inc. in "Former Vice President at Teladoc Health Inc. Sees Leadership Failures Hindering Telehealth Growth and Innovation" (April 08, 2026), B2B customers routinely RESULT FOR QUERY Page 5 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 8 dictate that if they do not see guaranteed clinical or financial returns, "we want a percentage of our money back." [49] 47 • Expert Call 48 • Expert Call 46 49 • Expert Call Lab Costs and Operational Infrastructure Operational Cost Structures in Diagnostic Testing Establishing a diagnostic or multi-organ screening platform requires navigating highly specialized cost structures where reagents and consumables represent the vast majority of ongoing operational expenses. [50] According to a CFO at Lily Hospitals Limited in "CFO at Lily Hospitals Limited Is Optimistic About Growth in Diagnostics Amid Capital Challenges" (January 13, 2026), the single largest cost center in diagnostic laboratories is "reagents" and "consumables," which constitute approximately "80%" of the direct operating costs, while staff labor represents only "20%". [51] The same clinical executive noted that while equipment represents a substantial upfront capital expenditure—such as an MRI machine costing "almost $1 million"—these assets are capitalized and depreciated over time, meaning "you can't consider cost of equipment when determining your profitability". [52] 50 51 52 • Expert Call These high-throughput automated systems have significantly driven down the unit margins of routine diagnostic profiles. [53] In "Former Scientific Director at Hologic Inc Believes Bio-Rad Excels in Chromatography and Antibody Products but Faces Challenges in Molecular Diagnostics" (October 15, 2026), a former Scientific Director at Hologic highlighted that clinical chemistry has "become a commodity-type business" where automated analyzers generate only "pennies per test for all those results". [54] Historically, high-throughput routine testing generated high net revenues that were used "to subsidize all the esoteric testing the labs have to do," but ongoing downward pressures on Medicare and commercial reimbursements are rapidly eroding this traditional cross-subsidization model. [55] 53 54 55 • Expert Call Fulfillment Models: Third-Party Partnerships vs. Owned Clinical Assets Digital health platforms face a critical strategic choice between partnering with national laboratory networks or investing in owned clinical testing assets. Large national reference networks leverage massive purchasing scale to achieve optimized cost structures. [56] As detailed by a Former Director at Labcorp in "Former Director at Labcorp Believes Outsourcing Labs Offers Short-Term Gains but Long-Term Losses for Hospitals" (January 28, 2026), commercial leaders like Quest and Labcorp operate with an operational cost structure that is approximately "20% lower" than in-house or hospital-run laboratories. [57] This cost advantage is largely driven by favorable vendor pricing on high-volume reagents. [58] A Former Director at Labcorp in "Former Director at Labcorp Believes Hospital Insourcing and Staffing Costs Challenge Commercial Labs" (March 02, 2026) explained that large commercial labs maintain "a larger profit margin, again, largely due to sourcing and variable costs being more favorable for them" compared to independent operations. [59] 56 57 • Expert Call 58 59 • Expert Call Conversely, startups aiming to own their full clinical footprint risk undermining their financial viability through excessive overhead. [60] A Former Senior Director at Quest Diagnostics in "Former Senior Director at Quest RESULT FOR QUERY Page 6 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 9 Diagnostics Sees Continued M&A Growth in Hospital Lab Segment Amid Financial Pressures" (February 16, 2026) observed that emerging "high flyers" often tie up "30%, 40% of revenue" in SG&A expenses—a level of overhead that would prevent even established giants from achieving profitability. [61] Despite the high overhead of owned infrastructure, some clinical groups maintain local capabilities to retain control of downstream revenue. [62] A Medical Practice Manager at Walk-in Dermatology in "Medical Practice Manager at Walk-in Dermatology Sees APPs and Technology as Key to Profitable Growth" (March 11, 2026) noted that clinics can outsource the physical processing of slides or tissue and still generate profits because "you can bill just for the reading of the test". [63] 60 61 • Expert Call 62 63 • Expert Call Logistics and Operational Redundancy For consumer-facing longevity models that feature at-home blood testing or remote diagnostic kits, clinical fulfillment is heavily dependent on logistical precision and sample stability. [64] A Former Strategic Development Manager at Randox in "Former Strategic Development Manager at Randox Sees Growth in U.K. At-Home Diagnostics Amid Operational Challenges" (March 23, 2026) pointed out that at-home testing faces severe "operational challenges including sample quality, logistics (especially return logistics), lab integration, and regulatory compliance, with sample failure rates typically between 5-10%". [65] Furthermore, while commercial labs offer superior cost profiles, local hospital systems often provide better turnaround times because they perform testing within the community, bypassing the multi-hub transit networks utilized by Quest or Labcorp. [66] 64 65 • Expert Call 66 • Expert Call To prevent severe throughput bottlenecks, clinical labs must also maintain equipment redundancy. [67] A Vice President of Technical Services at IEH Laboratories in "Vice President of Technical Services at IEH Laboratories Believes Operational Efficiency Is Key for Third-Party Food Testing Labs" (April 05, 2026) emphasized that clinical chemistry equipment failures can halt operations for "24 hours" to "a week" if the laboratory lacks redundant mass spectrometers or chromatographs to handle the workload. [68] 67 68 • Expert Call Weaknesses, Competitor Dynamics, and Former Employee Perspectives Competitor Dynamics and Market Pressures in General Medicine The general medicine landscape is characterized by intense competitive pressure, pricing challenges, and erosion of mature product portfolios. Diabetes and Cardiovascular Rivalry : In the mature primary care and general medicine sectors, major pharmaceutical giants face fierce competition from peer organizations. [69] According to a Former Director at Sanofi in "Former Director Believes SNY Has a Robust Pipeline but Is Not Optimistic About Short-Term Growth" (October 30, 2024), the competitive threats in these segments are high, noting that "you have AstraZeneca, which they are very tough on the cardio market," while "Novo Nordisk and also Novartis" actively contest the diabetes field. [70] 69 70 • Expert Call RESULT FOR QUERY Page 7 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 10 Generic and Biosimilar Displacement : Off-patent products in general medicine face substantial volume declines globally, though regional variances exist. [71] As highlighted by a Former EVP at Sanofi in "Former EVP at Sanofi Believes French Government Will Facilitate EuroAPI Contracts but Not Provide Financial Aid" (May 11, 2023), general medicine units often manage a "long, long list of small assets" that are "pretty old medicine" and subject to genericization. [74] This generic competition is compounded in emerging markets by local players playing "very strong on price, very strong on point of sales." [73] For instance, in "Former Unit Head Believes SNY Has Very Good General Medicine Products That Sell Themselves" (June 06, 2025), a Former Unit Head at Sanofi pointed out that governments in markets like Turkey strongly support "local generics and biosimilars," which enjoy "faster approvals and easier reimbursement." [72] 71 74 • Expert Call 73 • Expert Call 72 • Expert Call Crowded Commodity Markets : In broader drug launches, a general medicine market is often "much more a general medicine market with a lot of generic other competitors" compared to highly specialized areas. [76] This diagnostic and price-sensitive environment is further highlighted by a Former Regional Manager at Merck & Co. in "Former Regional Manager Believes MRK Needs to Focus on Driving Growth of Its Cardiovascular and Fertility Franchises While Acquiring Local Brands in Africa" (August 11, 2023), who observed that in regions like Africa, "the competition becomes head-to-head with Indian and Chinese companies with very, very low prices." [75] 76 • Expert Call 75 • Expert Call Operational Bureaucracy, Talent Loss, and Launch Inefficiencies Internal operational constraints and organizational rigidity frequently compromise the commercialization and launch excellence of general medicine portfolios. Strict Conservatism and Internal Firewalls : Organizational silos often prevent effective cross-functional collaboration during key product rollouts. [77] A Former Executive Director at Merck & Co. in "Former Executive Director Sees MRK’s Strict Conservatism Harming Commercialization of Its Products and Thinks the Company Can Meaningfully Reduce Bureaucracy" (April 11, 2025) explained that "strict internal firewalls" between "commercial, payer, and medical affairs teams" significantly impeded launch execution, reducing launch excellence across "all general medicine and vaccine launches." [78] 77 78 • Expert Call Risk Aversion and Experience Gaps : A culture of risk aversion and lack of specialized capabilities can severely hinder market adoption of new general medicine therapies. [79] According to a Former Director at Novartis in "Former Director at Novartis Sees Growth Potential in Rare Diseases Amid Legal and Political Challenges" (June 25, 2025), Novartis has historically struggled with certain product rollouts, such as the buy- and-bill launch of Leqvio, due to a "lack of specialized experience and an overreliance on internal talent rather than hiring external experts." [80] 79 80 • Expert Call Talent Attrition and Structural Reorganizations : Continuous corporate restructuring can destabilize key medical and scientific teams. [81] A Former Unit Head at Sanofi noted that aggressive reorganization efforts have led to "talent loss and challenges in recruiting experienced professionals, particularly in medical affairs." [82] 81 82 • Expert Call RESULT FOR QUERY Page 8 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 11 Technological Limits, AI Barriers, and Regional Infrastructure Gaps While digital health and artificial intelligence represent key strategic opportunities, corporate adoption is severely limited by institutional inertia and physical infrastructure deficits. Bureaucracy Slowing AI Integration : The deployment of advanced computational tools in general medicine is heavily restricted by internal corporate hesitancy. [83] A Former Director at Novartis stated that "AI adoption was slow due to compliance and risk concerns," with broader operational AI opportunities remaining "untapped due to bureaucratic delays." [84] 83 84 • Expert Call Ownership of Digital Outputs : Establishing accountability for modern technical workflows presents a major corporate hurdle. [85] As observed by a Former Senior Sales Director at Aktana in "Former Senior Sales Director at Aktana Sees Potential in AI Platforms for Pharma Despite Adoption Hurdles" (March 17, 2026), internal structural splits complicate technology implementation, creating ongoing debates over "who's going to own the output" and "who's accountable if something goes wrong" between medical affairs and commercial teams. [86] 85 86 • Expert Call Emerging Market Infrastructure Limitations : Complex modern therapies cannot easily scale in underdeveloped geographic regions. [87] A Former Regional Manager at Merck & Co. noted that regions like Africa are not yet fully prepared for advanced specialty drugs because the "infrastructure... does not allow that much diagnosis" and lacks the necessary "health coverage" and specialized physicians, forcing a fallback to older cardiovascular and diabetes portfolios. [88] 87 88 • Expert Call Compliance Risks, Data Privacy, and Security Concerns The handling of patient data, integration of wearable technologies, and compliance with strict data protection frameworks present escalating operational risks. Strict Data Protection Frameworks : Implementing generative AI and clinical database solutions requires navigating highly restrictive regulatory guardrails. [89] A Former Senior Sales Director at Aktana explained that while innovators see potential, governance teams see immense risk under "GDPR and global privacy frameworks" because GenAI models seek to "repurpose" patient and HCP data for "use cases out of that, that were never imagined at the point when we've collected it." [90] 89 90 • Expert Call Data Leak and Compliance Scrutiny : The reputational risk of medical data mismanagement is uniquely severe. [91] A Former R&D System Integration Engineer at Roche in "Former R&D System Integration Engineer at Roche Holding Ltd Is Optimistic About AI's Role in Life Sciences" (March 13, 2026) emphasized that "fear of data leaks" is a massive hurdle, stating that "any data leak from a biotech or a biomed company... receives way more scrutiny and is way more damaging to reputation than anywhere else, even financial." [92] Additionally, companies must navigate rapidly "evolving legal frameworks like the EU AI Act." [93] 91 92 93 • Expert Call RESULT FOR QUERY Page 9 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 12 HIPAA and Provider Privacy Liability : In the United States, medical data sharing is legally constrained at the provider level. [94] A Former Head at IQVIA Holdings in "Former Head at IQVIA Holdings Sees AI and Technology Driving Future Growth for Major CROs" (March 9, 2026) explained that EMR data does not freely flow because "HIPAA is so tight," meaning that if a provider allows patient records to leave their system, the ultimate liability for "maintaining the privacy of that patient falls with the provider" rather than the recipient. [95] 94 95 • Expert Call Biomarker and Wearable Security Concerns : Integrating consumer-grade digital tools into clinical care introduces new points of vulnerability. [96] As articulated by a Family Medicine Physician in "Family Medicine Physician Highlights Benefits and Challenges of Integrating Wearable Health Technology in Primary Care" (September 9, 2026), when evaluating advanced patient monitoring, "confidentiality of biomarker testing, security and privacy" remains the primary clinical concern. [97] 96 97 • Expert Call Corporate Data Safeguard Advantages : Smaller digital health startups and point solutions struggle to match the compliance resources of multinational giants. [98] A Former Chief Medical Officer at Noom, Inc. in "Former Chief Medical Officer at Noom, Inc Believes Integration and Personalization Are Key to Advancing Digital Obesity Care Models" (September 27, 2026) noted that established leaders like "Novo and Lilly" maintain a structural advantage because "they have the resources to be able to make sure that they have the right technical and physical safeguards in place" for sensitive patient data. [99] 98 99 • Expert Call Citations [1]  [2]  [4] Fitt Insider • General Medicine , P.C. • 07 Oct 26 • "General Medicine Raises $120M to Make Healthcare Shoppable" [3] FierceHealthcare • Eli Lilly and Co • 07 Oct 26 • "General Medicine banks $120M backed by a16z, Eli Lilly and Mercy Health to build out healthcare storefront" [5]  [6]  [7]  [8]  [9]  [11]  [17]  [18] Expert Call • Lifespan Medicine • 21 May 26 • "Former Chief Strategy Officer at MDVIP Sees Greater Value in Acquisition Model for Concierge Medicine Growth" [10]  [12]  [13] Expert Call • Atria Oyj • 30 Apr 26 • "Former Concierge Physician Sees Significant Growth and Challenges in Luxury Medicine Sector" [14]  [15]  [16] Expert Call • Oscar Health Inc • 31 May 26 • "Healthcare Consultant Sees Oscar Health's 2026 Strategy as Promising but Cautious Amid Risk Pool Challenges" [19] Expert Call • LifeStance Health Group Inc • 07 Oct 26 • "Former Executive at a Mobile Therapy Company Believes Transitioning to Payer-Focused Models Enhances Patient Retention in Behavioral Health" [20] Expert Call • LifeStance Health Group Inc • 06 Oct 26 • "Former Executive Director at LifeStance Health Group Inc. Believes Telehealth Adoption Transforms Patient Access Amid Operational Challenges" [21] Expert Call • DarioHealth Corp • 04 Mar 26 • "Former Remote Patient Monitoring Advisor at DarioHealth Sees Company's B2B Strategy as Outdated and Risky" [22]  [23]  [24]  [98]  [99] Expert Call • Noom • 27 Sep 26 • "Former Chief Medical Officer at Noom, Inc Believes Integration and Personalization Are Key to Advancing Digital Obesity Care Models" [25]  [26] Expert Call • Noom • 13 Apr 26 • "Former VP at Noom Skeptical About Long-Term Viability of Compounded GLP-1 Business Model" [27]  [28]  [29] Expert Call • Grow Therapy • 09 Apr 26 • "Former Clinical Operations Manager at Grow Therapy Sees Employer Channel as Key Growth Driver in Digital Mental Health" [30] Expert Call • Amgen Inc • 24 Mar 26 • "Former Product Strategy Leader at Amgen Believes Company Is Well-Positioned for Growth in New Therapeutic Areas" [31]  [32]  [33] Expert Call • The Cigna Group • 09 Apr 26 • "Former Senior VP at The Cigna Group Believes Economic Benefits Drive Adoption of Site-of-Care Solutions" [34]  [35] Expert Call • Amgen Inc • 29 Sep 26 • "Director of Strategic Operations at Omada Health Believes Evolving Partnerships Are Key to Addressing GLP-1 Market Dynamics" [36]  [37] Expert Call • UnitedHealth Group Inc • 06 Oct 23 • "Technology Executive at Healthcare Company Sees Integrated Medical and Pharmacy Benefits Leading to Cost Savings and Improved Care Coordination" [38]  [41]  [42]  [43] Expert Call • Origin Financial • 12 Aug 26 • "Strategy & Finance Executive at Modern Health Believes Holistic Benefits Solutions Are Key to Employee Engagement" RESULT FOR QUERY Page 10 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 13 [39]  [40] Expert Call • Carrum Health • 10 Apr 26 • "SVP, General Manager at Cancer Care Direct Believes Employer Demand Drives Shift to Home Infusion Programs Despite Health Plan Resistance" [44]  [45] Expert Call • Hello Heart • 08 May 22 • "Healthcare Management Consultant at Milliman Sees Livongo and Omada Leading in Digital Cardiology Solutions with Multipronged Approaches" [46]  [49] Expert Call • Teladoc Health Inc • 08 Apr 26 • "Former Vice President at Teladoc Health Inc. Sees Leadership Failures Hindering Telehealth Growth and Innovation" [47] Expert Call • Accolade Inc • 23 Feb 22 • "Former Competitor Sees Value in Care Coordination Services" [48] Expert Call • Alliancehcm • 18 Oct 26 • "Former Private Equity Practice Lead at ADP Believes AI and Consolidation Will Shape the Future of Mid-Market HCM Platforms" [50]  [51]  [52] Expert Call • Pfizer Inc • 13 Jan 26 • "CFO at Lily Hospitals Limited Is Optimistic About Growth in Diagnostics Amid Capital Challenges" [53]  [54]  [55] Expert Call • Bio-Rad Laboratories Inc • 15 Oct 26 • "Former Scientific Director at Hologic Inc Believes Bio-Rad Excels in Chromatography and Antibody Products but Faces Challenges in Molecular Diagnostics" [56]  [57] Expert Call • Quest Diagnostics Inc • 28 Jan 26 • "Former Director at Labcorp Believes Outsourcing Labs Offers Short-Term Gains but Long-Term Losses for Hospitals" [58]  [59] Expert Call • Quest Diagnostics Inc • 02 Mar 26 • "Former Director at Labcorp Holdings Believes Hospital Insourcing and Staffing Costs Challenge Commercial Labs" [60]  [61] Expert Call • Quest Diagnostics Inc • 16 Feb 26 • "Former Senior Director at Quest Diagnostics Sees Continued M&A Growth in Hospital Lab Segment Amid Financial Pressures" [62]  [63] Expert Call • Modmed • 11 Mar 26 • "Medical Practice Manager at Walk-in Dermatology Sees APPs and Technology as Key to Profitable Growth" [64]  [65] Expert Call • Randox • 23 Mar 26 • "Former Strategic Development Manager at Randox Sees Growth in U.K. At-Home Diagnostics Amid Operational Challenges" [66] Expert Call • Labcorp Holdings Inc • 12 Nov 25 • "Former Director at Labcorp Sees Consolidation and Workforce Constraints Shaping Health Systems" [67]  [68] Expert Call • Walmart Inc • 05 Apr 26 • "Vice President of Technical Services at IEH Laboratories Believes Operational Efficiency Is Key for Third-Party Food Testing Labs" [69]  [70]  [73] Expert Call • Sanofi SA • 30 Oct 24 • "Former Director Believes SNY Has a Robust Pipeline but Is Not Optimistic About Short-Term Growth" [71]  [74] Expert Call • EuroAPI • 11 May 23 • "Former EVP at Sanofi Believes French Government Will Facilitate EuroAPI Contracts but Not Provide Financial Aid" [72]  [81]  [82] Expert Call • Sanofi SA • 06 Jun 25 • "Former Unit Head Believes SNY Has Very Good General Medicine Products That Sell Themselves" [75]  [87]  [88] Expert Call • Merck & Co Inc • 11 Aug 23 • "Former Regional Manager Believes MRK Needs to Focus on Driving Growth of Its Cardiovascular and Fertility Franchises While Acquiring Local Brands in Africa" [76] Expert Call • Veeva Systems Inc • 16 Oct 22 • "Former VP at Phathom Pharmaceuticals Believes Integrated Systems Are Key for Biotech Success" [77]  [78] Expert Call • Merck & Co Inc • 11 Apr 25 • "Former Executive Director Sees MRK’s Strict Conservatism Harming Commercialization of Its Products and Thinks the Company Can Meaningfully Reduce Bureaucracy" [79]  [80]  [83]  [84] Expert Call • Novartis AG • 25 Jun 25 • "Former Director at Novartis Sees Growth Potential in Rare Diseases Amid Legal and Political Challenges" [85]  [86]  [89]  [90] Expert Call • Aktana • 17 Mar 26 • "Former Senior Sales Director at Aktana Sees Potential in AI Platforms for Pharma Despite Adoption Hurdles" [91]  [92]  [93] Expert Call • Roche Holding AG • 13 Mar 26 • "Former R&D System Integration Engineer at Roche Holding Ltd Is Optimistic About AI's Role in Life Sciences" [94]  [95] Expert Call • IQVIA Holdings Inc • 09 Mar 26 • "Former Head at IQVIA Holdings Sees AI and Technology Driving Future Growth for Major CROs" [96]  [97] Expert Call • Whoop • 09 Sep 26 • "Family Medicine Physician Highlights Benefits and Challenges of Integrating Wearable Health Technology in Primary Care" RESULT FOR QUERY Page 11 of 11 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 14 Legal Notices This content was generated using AI and may contain errors, ambiguities, or outdated information. AlphaSense does not guarantee the accuracy or completeness of this content. Users assume full responsibility for any use of or reliance upon any content contained in the service. Users should independently validate all information before using or relying on it. This content does not reflect the views or opinions of AlphaSense or any of its personnel and does not constitute legal, investment, or other professional advice. This content is proprietary and protected under copyright and other intellectual property laws. No part of this content may be used in connection with any language models or generative AI systems outside of AlphaSense. Any unauthorized use, including but not limited to the training or fine-tuning of any language models or other AI models, is strictly prohibited. ================================================================================ # DOCUMENT: AlphaSense Primer Snapshot, Oct 18, 2026 (raw/alphasense/alphasense-company-primer-snapshot-2026-10-18.md) ================================================================================ # AlphaSense Company Primer Snapshot (Oct 18, 2026 · 21 Pages) > **Original PDF:** [`raw/alphasense/DR-Report-by-Alphasense-10-18-2026-23-27.pdf`](raw/alphasense/DR-Report-by-Alphasense-10-18-2026-23-27.pdf) (23 pages) --- ## Page 1 RESULTS FOR QUERY: Company Primer for General Medicine CREATED Oct 19, 2026 PAGES 21 RESEARCH URL Click to View In GenSearch ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 2 QUERY Run the AlphaSense Private Company Primer agent i ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service markAlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the backthis report. --- ## Page 3 TABLE OF CONTENTS 1. Key Takeaways 2. Company Snapshot & Funding History 3. Product Portfolio & Strategic Moat 4. Customers, Programs, & Partnerships 5. Operational Footprint & Go-To-Market (GTM) Strategy 6. Financial Snapshot & Unit Economics 7. Market Landscape, Competitive Positioning, & Regulatory Dynamics 8. Recent Developments, Key Advantages, & Operational Risks 9. The Bull or Bear Case: Pathways, Catalysts, and KPIs 10. Valuation & Exit Outlook 11. Internal Relationship & Activity Context RESULT FOR QUERY General Medicine: Digital Healthcare Marketplace Disrupting Fee-for-Service Access Key Takeaways PillPack pedigree drives execution : Founded in 2023 by three former Amazon and PillPack executives, including CEO TJ Parker and President Elliot Cohen (both PillPack co-founders), General Medicine brings proven digital healthcare logistics expertise from Amazon's $750 million PillPack acquisition. Transaction-first marketplace model eliminates subscriptions : The platform offers a searchable catalog of over 2,900 distinct medical products and services across 35+ specialties without membership or subscription fees, contrasting sharply with Amazon One Medical's $199 annual fee structure. MedicineOS and ML insurance engine create pricing transparency : Proprietary technology automatically retrieves 11 years of medical records and uses machine learning to interpret insurance policies in real-time, displaying exact out-of-pocket costs before patients book services. Asset-light scaling across 82% of U.S. counties : Rather than building physical clinics, General Medicine partners with over 100 health systems and 50,000 local pharmacies, optimizing capital efficiency through variable operating expenses instead of fixed clinical overhead. RESULT FOR QUERY Page 1 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 4 $669.68 million valuation supported by $152 million in funding : The company secured a $120 million Series B led by Andreessen Horowitz in October 2026, representing a 4.3x step-up from its $156.84 million Series A post-money valuation just 17 months earlier. Friendly PC-MSO structure faces heightened regulatory scrutiny : To comply with Corporate Practice of Medicine laws, General Medicine operates through physician-owned entities controlled by Medical Director Dr. Pallabi Sanyal-Dey, but faces escalating risks from California's SB 351 and Oregon's SB 951 effective January 2026. Platform captures deferred care demand : Approximately 81% of early users sought care for previously delayed medical issues (20% deferred for six months or longer), positioning General Medicine to unlock significant pent-up healthcare demand through transparent upfront pricing. Company Snapshot & Funding History Foundational Profile General Medicine (https://generalmedicine.co) is a privately held digital healthcare marketplace company founded in 2023. digitalhealthnews.com The company has established its corporate headquarters in San Francisco, California, with additional operational hubs located in Boston, Massachusetts, and Salt Lake City, Utah. novonordisk.com Operating as a digital consumer healthcare store, the platform enables patients to search, compare, and buy medical care, prescription drugs, and laboratory tests directly, bypassing subscription or access fees. prnewswire.com General Medicine employs a venture-backed ownership structure, supported by prominent institutional venture capital firms and strategic healthcare partners. digitalhealthnews.com Executive Leadership & Changes The company's founding team consists of three former Amazon and PillPack executives who bring deep digital healthcare distribution experience to the enterprise. Ashwin Muralidharan served as the founding Chief Executive Officer, leading the platform through its stealth phase and nationwide rollout in 2025. prnewswire.com In October 2026, the company underwent a strategic leadership transition to support its next growth phase. prnewswire.com TJ Parker, a co-founder of PillPack and former partner at Matrix Partners, took over as the Chief Executive Officer. prnewswire.com Ashwin Muralidharan transitioned from the CEO position to serve as the Chief Product Officer, focusing directly on platform and service development. prnewswire.com Elliot Cohen, also a PillPack co-founder, continues to serve as the President of General Medicine. digitalhealthnews.com Funding History Since its inception, General Medicine has raised a total of $152 million in funding to build and scale its nationwide healthcare store. digitalhealthnews.com The company launched out of stealth on May 22, 2025, announcing a Series A funding round of $32 million. This initial launch round was led by Matrix, with additional participation from BoxGroup, Founder Collective, VXI Capital, and JSL Health Capital. [1] The Series A round was executed at an implied post-money valuation of $156.84 million. [1] Funding Screener • Filters: 1 Funding Screener • Filters: 1 RESULT FOR QUERY Page 2 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 5 On October 6, 2026, General Medicine raised $120 million in a Series B funding round. [1] This second round was led by Andreessen Horowitz, with strategic participation from the Eli Lilly & Company Foundation and Granger Management, alongside returning investors. [1] The Series B financing established an implied post-money valuation of $669.68 million. Funding Screener • Filters: 1 Funding Screener • Filters: 1 Funding Round Announcement Date Amount Raised ($M) Post-Money Valuation ($M) Lead Investor(s) Series A 2025-05-22 32.00 156.84 Matrix Series B 2026-10-06 120.00 669.68 Andreessen Horowitz Product Portfolio & Strategic Moat Core Products & Digital Healthcare Marketplace Services General Medicine operates a nationwide digital consumer healthcare store designed to mimic the simplicity of modern e-commerce. prnewswire.com The platform features a searchable catalog of over 2,900 distinct medical products and services, allowing users to directly purchase care without paying access or membership fees. preqin.com The product lines are organized into several core categories to support a wide range of clinical needs: Everyday & Virtual Care : On-demand and scheduled consultations are available with board-certified clinicians for acute and chronic conditions. generalmedicine.co Specialist E-Consults : Virtual access is provided to medical expertise across more than 35 clinical specialties, including cardiology, neurology, and dermatology. preqin.com Laboratory & Diagnostic Testing : Diagnostic blood work, imaging studies, and lab panels can be ordered directly with transparent upfront pricing. generalmedicine.co Prescription Management : The platform supports seamless prescription routing to over 50,000 local pharmacies alongside home delivery logistics. generalmedicine.co In-Person Care Coordination : A dedicated back-end logistics team schedules physical doctor visits, specialized imaging, and surgical procedures. prnewswire.com To streamline the user experience, the digital storefront utilizes an automated system that collects up to 11 years of historical medical records with a single click. generalmedicine.co These records are consolidated and structured into a prioritized summary to provide treating clinicians with critical context before care begins. generalmedicine.co Revenue Model & Contribution RESULT FOR QUERY Page 3 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 6 General Medicine generates revenue through a transaction-based, direct-to-consumer (DTC) model rather than relying on recurring subscription plans. preqin.com The platform operates like a traditional fee-for-service provider, billing patients and their insurers on a per-visit or per-service basis. slhn.org Patients can purchase individual consultations, order specific diagnostics, or fulfill prescriptions directly through the marketplace. slhn.org During its initial startup phase in mid-2025, the company's early revenue was estimated to be in the range of $1 million to $5 million. preqin.com Following its nationwide rollout and subsequent expansion, General Medicine has scaled its operations to cover 82% of all United States counties. slhn.org The company's revenue contribution is expected to increase significantly as it deploys its $120 million Series B funding to broaden its catalog of shoppable medical procedures. prnewswire.com Proprietary Technology Stack: MedicineOS & AI Capabilities The technical backbone of General Medicine's platform is "MedicineOS," a proprietary integration layer modeled after the PillPack "PharmacyOS" architecture. vcsheet.com MedicineOS aggregates fragmented healthcare data by connecting electronic health records (EHRs), lab systems, and pharmacy networks into a single operational interface. vcsheet.com This software automates complex administrative tasks, including medical record retrieval, diagnostic scheduling, and care pathway routing. vcsheet.com The platform integrates two core proprietary artificial intelligence and machine learning technologies to automate care workflows. vcsheet.com Machine Learning Insurance Interpretation : General Medicine uses machine learning models trained to interpret individual insurance policies in real-time. vcsheet.com This system calculates exact out-of-pocket costs, deductibles, and co-insurance requirements before a patient books a service. vcsheet.com "General AI" Triage Assistant : The user interface features an open-ended conversational assistant that allows patients to describe symptoms in plain text to navigate clinical pathways. generalmedicine.co Regulatory Licenses & "Friendly PC-MSO" Ownership Structure To comply with the Corporate Practice of Medicine (CPOM) doctrine, which prohibits non-clinical corporations from practicing medicine, General Medicine employs a "Friendly PC-MSO" structural model. healthlawalliance.com Under this framework, the corporate entity (Path Healthcare Systems Corp) operates as the Management Services Organization (MSO) handling non-clinical operations. slhn.org The MSO owns the underlying platform, manages administrative tasks, and provides support via a Management Services Agreement (MSA). cuvo.co The clinical care itself is delivered by separate professional corporations (PCs) owned entirely by licensed physicians. cuvo.co Dr. Sunita Mishra : The Chief Medical Officer of Amazon Health Services served as an early advisor and was the initial physician owner of one of the clinical entities. [2] 2 • STAT News RESULT FOR QUERY Page 4 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 7 Dr. Pallabi Sanyal-Dey : To ensure independence from outside corporate entities, General Medicine transitioned ownership of its clinical practices to Dr. Sanyal-Dey prior to launch. Dr. Sanyal-Dey serves as the Medical Director of General Medicine and holds active, multi-state medical licenses. albme.gov Her professional licensure spans multiple jurisdictions, including California, Colorado, Alabama, Georgia, and Utah. albme.gov This dual-entity structure ensures that clinical decisions, treatment protocols, and prescribing patterns remain under strict physician control, satisfying rigorous state-level medical board standards. georgia.gov Competitive Differentiation General Medicine competes across multiple categories of virtual care, distinguishing itself through its horizontal breadth and deep insurance integration. generalmedicine.co While specialized telehealth platforms focus on narrow vertical segments such as hair loss or weight management, General Medicine acts as a broad-spectrum medical provider. generalmedicine.co Additionally, the company eliminates the upfront financial barriers associated with virtual primary care models by charging zero membership or subscription fees. vcsheet.com Competitor Category Core Rivals Primary Differentiation Sources Virtual Primary Care Amazon's One Medical General Medicine charges no subscription or membership fees. vcsheet.co m Specialized Telehealth Ro, Hims & Hers General Medicine offers a horizontal, full-loop catalog spanning over 35 specialties, diagnostics, and procedures. generalme dicine.co Retail Health Stores Sesame Care General Medicine integrates proprietary ML insurance pricing engines rather than focusing primarily on cash-pay rates. prnewswir e.com Customers, Programs, & Partnerships Consumer Segment & Target Demographics The customer base of General Medicine is predominantly comprised of direct-to-consumer (DTC) patients who utilize the platform to bypass traditional subscription fees and access transparent upfront pricing. fiercehealthcare.com This digital marketplace has proven highly effective at capturing individuals with previously deferred clinical needs. fiercehealthcare.com Approximately 81% of the platform's early users sought care for medical issues that they had actively put off, with 20% of those patients having delayed treatment for six months or longer. fiercehealthcare.com The consumer segment utilizes the platform for immediate, routine care needs, such as urinary tract infections and dermatological concerns, as well as complex care coordination requiring specialized attention. fiercehealthcare.com Since its nationwide launch in May 2025, General Medicine has RESULT FOR QUERY Page 5 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 8 successfully fulfilled over 800 different types of healthcare visits across more than 35 medical specialties. fiercehealthcare.com Health System & Provider Group Networks Rather than operating as a closed clinical loop, General Medicine acts as an active healthcare navigator that integrates with existing local and regional networks. prnewswire.com The platform establishes commercial routing pathways to connect patients with community providers, local ambulatory clinics, diagnostic laboratories, and imaging centers. fiercehealthcare.com Through these structured navigation channels, customers have completed referred appointments with more than 100 distinct provider groups and health systems across the United States. fiercehealthcare.com This broad collaborative network allows the digital storefront to facilitate physical diagnostic follow-ups and complex specialty procedures that cannot be fully resolved through virtual consultations alone. prnewswire.com Payer & Insurance Partnerships To lower financial barriers for its customers, General Medicine maintains active partnerships with a broad range of healthcare payers. prnewswire.com While many early-stage virtual care platforms operate strictly as cash-pay services, General Medicine's marketplace is designed to accept most major health insurance plans. prnewswire.com The platform's proprietary transaction engine displays real-time insurance-adjusted rates alongside flat cash prices side-by-side, allowing patients to make informed financial decisions. prnewswire.com This dual-pricing model helps the company capture both insured patients looking to utilize their benefits and uninsured or underinsured consumers seeking competitive cash rates. prnewswire.com Physician-Owned Clinical Affiliations In order to deliver clinical care nationwide while strictly complying with state-level Corporate Practice of Medicine (CPOM) regulations, General Medicine partners with independent, physician-owned professional practices. [3] The company maintains clinical affiliation agreements with separate medical entities that are owned and directed by licensed physicians. [4] Prior to the platform's public rollout, General Medicine transitioned the ownership of all its affiliated clinical practices to its primary physician owner, Dr. Pallabi Sanyal-Dey. [5] The design and compliance strategy of these clinical affiliations was supported by early advisory from Dr. Sunita Mishra, the Chief Medical Officer of Amazon Health Services, who originally held ownership of one of the participating medical practices. [6] This structure ensures that clinical protocols, treatment regimens, and prescribing decisions remain entirely under independent medical oversight rather than being influenced by the platform's corporate management. [7] 3 4 5 6 7 • STAT News Operational Footprint & Go-To-Market (GTM) Strategy Regional Operational Footprint & Corporate Hubs General Medicine has established a strategic operational footprint designed to balance centralized corporate oversight with highly distributed nationwide service delivery. novonordisk.com The company maintains its RESULT FOR QUERY Page 6 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 9 corporate headquarters in San Francisco, California, which serves as the primary node for its product engineering, product development, and executive leadership. novonordisk.com To support its clinical coordination, customer support, and logistics operations, General Medicine has established secondary operational hubs in Boston, Massachusetts, and Salt Lake City, Utah. novonordisk.com This multi-region physical footprint allows the company to effectively oversee a digital consumer healthcare platform that successfully extends its reach to 82% of all counties in the United States. slhn.org Virtual and Physical Care Hub Integration The company's core service delivery relies on a dual-layered, "hub-and-spoke" operational architecture that seamlessly merges its proprietary virtual platform with physical local healthcare infrastructure. summithealth.com Virtual Care Hub : General Medicine’s online platform acts as a borderless virtual hub, offering patients immediate access to everyday and specialty care without the administrative friction or subscription fees of traditional digital primary care models. generalmedicine.co This virtual layer is supported by automated health record retrieval systems, symptom-based triage assistants, and automated clinical summaries that provide clinicians with critical medical context before a consultation begins. generalmedicine.co Physical Care Integration : Because virtual consultations cannot resolve high-acuity or complex clinical needs, General Medicine coordinates directly with a decentralized network of physical local healthcare provider groups, ambulatory facilities, and diagnostic laboratories. fiercehealthcare.com This hybrid care model effectively bridges the gap between digital convenience and physical clinical care, allowing patients to complete physical doctor visits, advanced diagnostic imaging, and complex procedures locally. prnewswire.com Sourcing Strategy & Third-Party Clinic Networks To scale its clinical offerings rapidly without incurring massive capital expenditures (CapEx), General Medicine utilizes an asset-light, partnership-heavy sourcing strategy. technavio.com Asset-Light Operational Model : Instead of building out its own physical clinics, General Medicine leverages third-party provider networks and existing health system infrastructures to deliver in-person care. technavio.com This transition from fixed clinical overhead to variable, transactional operating expenses enables the platform to optimize its capital efficiency. technavio.com Collaborative Provider Networks : The company has developed routing pathways and coordination programs with over 100 distinct health systems and physician groups nationwide. fiercehealthcare.com These clinical affiliations enable the platform to route patients to verified, high-quality local clinical sites when in-person follow-ups are necessary. fiercehealthcare.com Downstream Logistics Sourcing : General Medicine partners with over 50,000 local physical pharmacies and diagnostic laboratory chains across the country. generalmedicine.co This extensive network ensures that prescriptions and diagnostic orders generated during virtual consults can be fulfilled seamlessly near the patient’s home. generalmedicine.co RESULT FOR QUERY Page 7 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 10 Go-To-Market (GTM) & Patient Acquisition Strategy General Medicine’s GTM strategy deviates from high-friction, subscription-based models in favor of a transaction- based, consumer-centric acquisition motion. preqin.com Direct-to-Consumer (DTC) E-Commerce Channels : The company positions its platform as a frictionless digital store where patients can directly search, compare, and purchase care. prnewswire.com By eliminating upfront access fees, General Medicine lowers the initial barrier to entry, specifically targeting the high volume of consumers who historically defer healthcare due to cost uncertainty. fiercehealthcare.com Insurance-Integrated Pricing Engine : A major driver of conversion is the platform's proprietary machine learning engine, which calculates and presents real-time insurance-adjusted out-of-pocket costs alongside clear cash-pay rates. vcsheet.com This transparent dual-pricing model captures both commercially insured individuals seeking to utilize their plans and cash-pay patients looking for the best market rate. prnewswire.com Seamless Navigation Pathways : The platform utilizes automated scheduling and self-serve booking channels to maximize acquisition efficiency, mitigating the standard "friction tax" associated with traditional phone- based booking systems. netsuite.com By offering a retail-like scheduling experience, General Medicine minimizes patient drop-off and significantly lowers its customer acquisition costs. netsuite.com Financial Snapshot & Unit Economics Funding and Estimated Cash Runway General Medicine has fortified its balance sheet with a total of $152 million in capital raised since inception. [8] This capital was raised across two key institutional funding rounds: a $32 million Series A in May 2025 and a $120 million Series B in October 2026. [8] The Series B round, led by Andreessen Horowitz, established an implied post-money valuation of $669.68 million, representing a substantial step-up from its Series A post-money valuation of $156.84 million. [8] With a fresh $120 million injection, the company's cash balance is highly fortified to support its rapid nationwide scaling. This cash position extends General Medicine's capital runway well beyond the late 2026 venture benchmark of 18 to 24 months for growth-stage digital health startups. koalagains.com Funding Screener • Filters: 1 Funding Screener • Filters: 1 Funding Screener • Filters: 1 Estimated Revenue Trajectory During its initial launch phase in 2025, General Medicine operated as a lean digital health storefront with early transaction-based revenue estimated to be in the low single-digit millions. prnewswire.com Following its nationwide expansion to 82% of all United States counties, the company is leveraging its Series B capital to significantly scale its searchable e-commerce catalog of over 2,900 medical products and services. preqin.com While the private startup does not publicly disclose its current annual recurring revenue (ARR) or exact burn rate, its consumer-centric transactional model is designed to optimize capital efficiency by avoiding high-overhead physical clinics. technavio.com RESULT FOR QUERY Page 8 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 11 Digital Health Unit Economics Benchmarks As General Medicine utilizes its marketplace model to capture patient demand, its operational model aligns closely with the unit economics of the digital primary care and virtual general medicine sector. neolytix.com Customer Acquisition Cost (CAC) Efficiency : Customer acquisition costs within the digital primary care sector typically range from $75 to $400. neolytix.com Acquisition efficiency is highly optimized because healthcare search ads see robust conversion rates of approximately 11.6%. imatrix.com The average cost per lead (CPL) for clinicians in these digital channels is around $56.83, which is 19% lower than the cross-industry average. imatrix.com Payback and LTV Profiles : With average revenue per virtual clinical visit ranging from $150 to $300, transactional platforms often achieve customer payback on the first visit. medicalppcagency.com The estimated lifetime value (LTV) for standard insurance-based primary care ranges between $2,000 and $6,000, yielding strong LTV:CAC ratios between 7.5:1 and 20:1. neolytix.com Retention and Tenure Impact : Direct primary care (DPC) models demonstrate high capital efficiency, with a median LTV:CAC ratio of 15.7x and an average patient tenure of 5.2 years. macbach.com Implementing structured patient retention workflows can lead to a 64% median increase in overall patient LTV. macbach.com Sector Operational Pressures : Despite strong customer acquisition metrics, general medical providers face ongoing margin headwinds from rising operational expenses. aha.org Total medical expenses grew by 7.5% in 2025, driven by a 5.6% increase in workforce costs and a 13.6% surge in drug pricing. aha.org Comparative Corporate Margin Context For strategic comparison, mature "General Medicine" (GenMed) business units within the traditional pharmaceutical industry operate on a different financial scale and margin structure. gedeonrichter.com These mature segments typically act as low-growth, high-volume cash cows that fund high-burn R&D in other therapeutic areas. gsk.com Mature pharmaceutical operators are actively transitioning these legacy GenMed segments toward digital-first commercial platforms. deloitte.com This strategic operational shift is projected to reduce mature-market selling, general, and administrative (SG&A) costs by 15% to 20%, illustrating the structural cost advantages of General Medicine's native digital e-commerce storefront model. deloitte.com RESULT FOR QUERY Page 9 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 12 Corporate Division Gross Margin Contribution / EBIT Margin Primary Dynamics & Headwinds Sources Gedeon Richter GenMed 67.60% 10.70% Impacted by weak seasonal OTC sales and distributor inventory rationalization. gedeonric hter.com Sanofi GenMed 77.50% 28.60% Shifting toward core assets; operating margins recovering as R&D investment troughs. sanofi.co m GSK GenMed N/A N/A Turnover of £10 billion; facing 7% decline from generic erosion and Medicare design shifts. gsk.com Market Landscape, Competitive Positioning, & Regulatory Dynamics Market Landscape & Addressable Market Sizing The global digital health market, representing the Total Addressable Market (TAM) for virtual health technologies, is projected to expand from approximately $347.35 billion in 2025 to $946.04 billion by 2030 . marketsandmarkets.com This growth reflects a compound annual growth rate (CAGR) of 22.20% . marketsandmarkets.com Within this, the Serviceable Addressable Market (SAM) for digital healthcare platforms and marketplaces is estimated to reach $156.00 billion in 2025 and is projected to rise to $420.00 billion by 2030 , growing at a CAGR of approximately 23.00% . marketsandmarkets.com For individual platform players like General Medicine, the Serviceable Obtainable Market (SOM) in North America is highly competitive yet lucrative, with the regional market projected to grow from $130.00 billion in 2025 to $356.00 billion by 2030 . marketsandmarkets.com Source: marketsandmarkets.com This rapid expansion is sustained by several critical industry catalysts. marketsandmarkets.com The rising incidence of chronic diseases, government digital transformation mandates, and a massive shift toward patient- centered preventive care are key structural drivers. marketsandmarkets.com Furthermore, cloud-based deployment models hold over Market Metric 2025 Estimate 2030 Projection Growth Rate (CAGR) TAM (Global Digital Health) $347.35 Billion $946.04 Billion 22.20% SAM (Platforms & Marketplaces) $156.00 Billion $420.00 Billion 23.00% SOM (North America Market) $130.00 Billion $356.00 Billion 22.50% RESULT FOR QUERY Page 10 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 13 63.20% of the market share, facilitating the growth of scalable, borderless healthcare marketplaces. databridgemarketresearch.com Competitive Positioning General Medicine positions itself as a universal entry point for all health needs through a "catalog-first" approach to digital healthcare. remoterocketship.com The platform differentiates itself across multiple dimensions against key competitors, including Amazon’s One Medical, traditional telehealth veterans, and direct-to-consumer (DTC) wellness platforms. mgmtboston.com Dime nsion General Medicine Amazon One Medical Legacy Telehealth (Teladoc/Amwell) DTC Platforms (Hims & Hers/Ro) Source s Busin ess Mode l Transactional "healthcare store" with transparent upfront pricing. mgmtboston.com Subscription-based concierge clinic model with physical locations. mgmtboston.com Virtual-first primary care and employer- sponsored packages. generalmedicine.co Direct-to-consumer digital clinics with a focus on subscription wellness. generalmedicine.co mgmtb oston.c om Mem bersh ip Fees Zero upfront membership or access fees. mgmtboston.com Annual membership fee of $199 (discounts available for Prime). mgmtboston.com Typically subscription-based for employers; pay- per-visit varies. telehealth.com No general membership, but products require monthly subscriptions. generalmedicine.co mgmtb oston.c om Platfo rm Selec tion Over 2,900 distinct medical services covering 35+ specialties. signalnewscolumbia sc.com Closed clinic network focused on physical and virtual primary care. generalmedicine.co Broad on-demand urgent and mental health care. telehealth.com Narrow, highly specialized clinical lifestyle verticals (e.g., hair loss). generalmedicine.co signaln ewscol umbias c.com Insur ance Integr ation ML insurance interpretation showing real-time out-of-pocket costs. generalmedicine.co Closed insurer billing integrated with Amazon ecosystem. generalmedicine.co Heavily integrated with traditional employer and payer benefits. generalmedicine.co Predominantly cash- pay subscription models. generalmedicine.co general medici ne.co Philosophical Rivalry with Amazon's One Medical : Amazon’s One Medical model represents a closed system focused on building a long-term primary care relationship that often requires a subscription. generalmedicine.co By contrast, General Medicine is an open storefront designed for transactional efficiency across multiple independent providers, specialists, and laboratories. generalmedicine.co While One Medical’s RESULT FOR QUERY Page 11 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 14 core strength lies in physical clinic density in major metropolitan areas, General Medicine serves consumers in 82% of U.S. counties through virtual care and community lab networks, routing in-person care to local partners. generalmedicine.co Direct-to-Consumer & Legacy Telehealth : Specialized DTC platforms like Hims & Hers and Ro focus primarily on high-margin, narrow lifestyle medical verticals like hair loss, sexual health, and weight management. generalmedicine.co General Medicine differentiates itself by operating as a broad-spectrum medical provider covering over 35 medical specialties . generalmedicine.co Traditional telehealth giants like Teladoc and Amwell lead in employer-sponsored health plan contracts but often lack the upfront pricing retail experience and instant insurance pricing tools built by General Medicine. generalmedicine.co Macroeconomic and Technological Catalysts The integration of Artificial Intelligence (AI) and Machine Learning (ML) serves as a primary technological catalyst for General Medicine. marketsandmarkets.com The company utilizes its proprietary MedicineOS stack, which features machine learning engines designed to parse complex, multi-page insurance benefit documents in real- time, showing patients their exact out-of-pocket costs before booking. generalmedicine.co Furthermore, the AI- assisted symptom triage layer guides patients through clinical pathways, significantly reducing administrative friction and helping the company mitigate the "friction tax" associated with traditional clinical booking processes. generalmedicine.co However, the digital healthcare marketplace sector is currently confronting notable macroeconomic headwinds. aha.org Total medical expenses rose by 7.50% in 2025 , driven by a 5.60% increase in workforce costs and a 13.60% surge in drug pricing. aha.org These rising operational costs exert continuous margin pressure on digital- first healthcare platforms, necessitating highly efficient capital allocation and asset-light provider networks. aha.org Regulatory Dynamics and Compliance Structure Physician-owned digital health practices operate within a highly complex legal framework governed by state-level medical licensing and corporate regulations. healthlawalliance.com Corporate Practice of Medicine (CPOM) Doctrine : This legal doctrine prohibits non-clinical corporations from practicing medicine or employing physicians to deliver clinical care, ensuring that financial motives do not interfere with professional medical judgment. healthlawalliance.com To remain fully compliant with CPOM regulations, General Medicine employs a "Friendly PC-MSO" structural model. healthlawalliance.com Management Services Organization (MSO) Alignment : Under this framework, the corporate entity (Path Healthcare Systems Corp) acts as the MSO, managing non-clinical administrative workflows, marketing, billing, and platform logistics under a formal Management Services Agreement (MSA). cuvo.co Independent Professional Corporations (PCs) : The clinical care is delivered exclusively by independent professional corporations owned entirely by licensed physicians. cuvo.co To establish absolute corporate separation, General Medicine transitioned ownership of its affiliated clinical practices to Dr. Pallabi Sanyal-Dey prior to launch. albme.gov Dr. Sanyal-Dey holds active, multi-state medical licenses across multiple RESULT FOR QUERY Page 12 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 15 jurisdictions, including California, Colorado, Alabama, Georgia, and Utah. albme.gov This ensures that clinical protocols, treatment regimens, and prescribing decisions remain entirely under independent clinical control, satisfying state-level medical board standards and fee-splitting regulations. georgia.gov Recent Developments, Key Advantages, & Operational Risks Post-Launch Scaling & Strategic Hires General Medicine has scaled its operations to cover 82% of all United States counties following its public rollout in May 2025. slhn.org To support this massive expansion and transition from its stealth phase, the company executed key strategic leadership additions in October 2026. prnewswire.com Most notably, TJ Parker, a co- founder of PillPack and former partner at Matrix Partners, joined the company as Chief Executive Officer. prnewswire.com Simultaneously, Ashwin Muralidharan, the founding CEO who guided the platform through its nationwide launch, transitioned to the role of Chief Product Officer to focus strictly on platform and service development. prnewswire.com The leadership team is further bolstered by Elliot Cohen, also a PillPack co- founder, who serves as President, bringing deep expertise in digital healthcare logistics to the platform. digitalhealthnews.com This high-profile team is utilizing its $120 million Series B funding round, secured in October 2026, to scale the digital store's catalog of shoppable medical procedures and services. prnewswire.com Key Technological, Cost, and Relationship Differentiators General Medicine's strategic advantage is anchored in its proprietary integration layer known as "MedicineOS." vcsheet.com Unlike traditional healthcare models, this technology automatically retrieves up to 11 years of historical medical records with a single click, summarizing critical patient context for treating clinicians. generalmedicine.co The platform incorporates machine learning models to interpret complex insurance policies in real-time, displaying exact out-of-pocket costs and deductibles to patients before any booking occurs. vcsheet.com By operating as an open transaction-based marketplace without any upfront membership or subscription fees, General Medicine lowers customer acquisition barriers compared to subscription-based models. vcsheet.com Further, the company's asset-light sourcing strategy avoids the high capital expenditures of physical clinics by routing patients to a collaborative network of over 100 distinct health systems and provider groups. fiercehealthcare.com Barriers to Entry and Founder Dependency The company benefits from steep barriers to entry established by its proprietary MedicineOS infrastructure, which aggregates highly fragmented electronic health records, lab systems, and pharmacy networks. vcsheet.com Replicating this nationwide integration, which spans over 50,000 local pharmacies, represents a substantial technical and logistical hurdle for new entrants. generalmedicine.co However, General Medicine faces notable founder dependency and key-person risks, as its strategic direction and product vision are heavily reliant on its core executives who previously scaled PillPack. digitalhealthnews.com If these key leaders were to depart, the platform's ability to maintain its rapid scaling trajectory and secure institutional backing could be significantly compromised. soferadvisors.com RESULT FOR QUERY Page 13 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 16 Operational, Regulatory, and Governance Risks Because General Medicine operates as a digital marketplace connecting patients to clinical care, it is highly sensitive to the complex Corporate Practice of Medicine (CPOM) doctrine. healthlawalliance.com To comply with CPOM laws that prohibit non-clinical corporations from practicing medicine, General Medicine separates its operations into a corporate Management Services Organization (MSO) and independent, physician-owned professional corporations (PCs). cuvo.co To establish absolute corporate separation, the company transitioned ownership of its clinical practices to its Medical Director, Dr. Pallabi Sanyal-Dey, prior to launch. albme.gov This MSO-PC transition structure faces escalating regulatory scrutiny as states enact stricter oversight of corporate influence in clinical operations. milbank.org California Regulatory Shifts : Effective January 1, 2026, California's SB 351 codifies strict CPOM limits specifically on corporate and private equity influence over clinical operations, empowering the State Attorney General to seek injunctive relief for violations. paulhastings.com Oregon Legislative Crackdowns : Effective January 1, 2026, Oregon's SB 951 significantly tightens CPOM laws by targeting MSO control over physician practices and restricting stock transfer agreements that allow corporate entities to dictate clinical ownership. medpathcompliance.com Insurance Clawback Threats : If state regulators or payers find that an MSO-PC arrangement exercises de facto corporate control over clinical decisions, insurers can demand the clawback and repayment of all disbursed funds with triple damages. permithealth.com Clinical Governance Interference : Compliance risks are highest if Management Services Agreements (MSAs) allow the MSO to influence clinical hiring, doctor compensation, or coding procedures, which regulators view as unlicensed practice of medicine. ct.gov Data and Cybersecurity Vulnerabilities : As a digital-first platform holding massive amounts of structured patient medical records, General Medicine faces severe operational risks from cyberattacks and data breaches, which remain a top regulatory concern for consolidated health systems in 2026. milbank.org The Bull or Bear Case: Pathways, Catalysts, and KPIs The strategic outlook for General Medicine can be analyzed through distinct bull and bear trajectories that reflect its disruptive transactional marketplace model. preqin.com These scenarios depend heavily on the company's ability to maintain high customer satisfaction while navigating intense regulatory and competitive headwinds. generalmedicine.co The Bull Case: Scalability and Market Disruption PillPack Leadership Pedigree : The company is led by co-founders TJ Parker and Elliot Cohen, who bring a proven track record of scaling highly complex digital healthcare logistics. prnewswire.com RESULT FOR QUERY Page 14 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 17 High-Velocity "Healthcare Store" Model : Unlike traditional closed systems or subscription-based models, General Medicine operates a friction-free transactional e-commerce platform offering over 2,900 products and services. preqin.com Unlocking Deferred Healthcare Demand : The direct-to-consumer marketplace effectively captures patients who traditionally delay care due to cost uncertainty, with 83% of users addressing previously deferred medical issues. prnewswire.com Deep Technical and AI Advantage : The integration of MedicineOS and machine learning models enables automated retrieval of up to 11 years of historical medical records. prnewswire.com Specialized Therapeutic Tailwinds : The platform is strategically positioned to capitalize on the massive consumer demand for metabolic and chronic care solutions, particularly GLP-1 weight-loss medications. generalmedicine.co Substantive Growth Funding : A newly closed $120 million Series B funding round led by Andreessen Horowitz provides the necessary capital runway to support aggressive national expansion efforts. prnewswire.com The Bear Case: Operational Friction and Structural Barriers Scaling and Operational Growing Pains : Customer reviews indicate that rapid expansion has introduced technical glitches, missed clinical appointments, and communication bottlenecks. trustpilot.com Intense Multi-Front Competition : General Medicine faces formidable competition from established virtual primary care networks, retail medical clinics, and specialized wellness giants such as Hims & Hers. generalmedicine.co Complex Billing and Insurance Friction : Managing transactional per-visit payments across a highly fragmented network of major insurance payers presents continuous billing challenges and risk of consumer dissatisfaction. trustpilot.com Escalating CPOM Regulatory Scrutiny : The Friendly PC-MSO structure faces strict and evolving state-level Corporate Practice of Medicine regulations, such as California's SB 351. paulhastings.com Tighter State Compliance Audits : Legislative updates like Oregon's SB 951 introduce tighter oversight regarding corporate influence over clinical practices. medpathcompliance.com Data Security and Platform Vulnerabilities : Because the digital-first storefront consolidates vast amounts of historical patient data, it remains highly vulnerable to cybersecurity threats and data breaches. milbank.org Leading Indicators and Measurable Milestones To evaluate General Medicine's progress toward achieving its long-term strategic targets, stakeholders should monitor several key operational and geographic milestones: RESULT FOR QUERY Page 15 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 18 Geographic Coverage Target : The primary near-term milestone is expanding its geographic reach from covering 82% of U.S. counties to achieving 100% nationwide coverage. mgmtboston.com Catalog and Specialty Expansion : Growth tracking should focus on the expansion of the platform's searchable catalog beyond the current 2,900 products and services. signalnewscolumbiasc.com High-Value Clinical Categories : Monitoring the successful launch of complex, shoppable diagnostic procedures such as imaging services will indicate market-share expansion. mgmtboston.com Customer Satisfaction Benchmarks : Maintaining an exceptionally high Net Promoter Score of 80 or above is critical to validating the platform's retail-first patient experience. prnewswire.com Referral Network Density : Stakeholders should track the growth of active referral pathways, which currently connect users to more than 100 distinct health systems. mgmtboston.com Human Capital Scaling : Monitoring recruitment metrics and the expansion of the engineering and design office in Cambridge, Massachusetts, will reflect the company's technical execution capacity. mgmtboston.com Key Performance Indicator Current Metric (2026) Target / Milestone Sources Geographic Coverage 82% of U.S. counties 100% Nationwide Coverage mgmtboston.com Service Catalog Size 2,900+ Products & Services Expansion into Imaging & Procedures signalnewscolumbiasc .com Referral Network 100+ Health Systems Multi-system expansion mgmtboston.com Customer Satisfaction 80+ Net Promoter Score (NPS) Maintain NPS of 80+ prnewswire.com Engineering Hub Presence Cambridge/Boston Office Cambridge recruitment scaling mgmtboston.com Valuation & Exit Outlook Private Valuation History & Funding Context General Medicine has experienced a rapid valuation step-up over its short operational history, driven by aggressive expansion and high-profile institutional backing. prnewswire.com The company emerged from stealth in May 2025 with a Series A funding round of $32 million led by Matrix. prnewswire.com This initial funding round established an implied post-money valuation of $156.84 million. prnewswire.com In October 2026, the company secured a massive $120 million Series B funding round led by Andreessen Horowitz. startbase.com This financing RESULT FOR QUERY Page 16 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 19 round valued the company at an implied post-money valuation of $669.68 million, demonstrating robust investor confidence in its transaction-based digital marketplace model. prnewswire.com Comparable Transactions & Historical Context The strategic trajectory of General Medicine is heavily informed by the past exit success of its founding team. President Elliot Cohen and CEO TJ Parker previously co-founded PillPack, a digital pharmacy pioneer. prnewswire.com In 2018, Amazon acquired PillPack for approximately $750 million, which subsequently formed the foundation of Amazon Pharmacy. This landmark transaction illustrates the premium that tech-enabled healthcare delivery platforms can command from mega-cap strategic acquirers. [9] 9 • STAT News Other historical transactions in the digital pharmacy and healthcare spaces provide additional valuation benchmarks, demonstrating how strategic buyers consolidate digital health players. [10] For instance, Webmed Pharmacy was acquired by Vulcan Two Group Plc in March 2026 for a deal value of $2.84 million, reflecting an implied EV/Sales multiple of 0.78x. [10] Additionally, Hyperdrug Pharmaceuticals was acquired by Vulcan Two Group Plc in March 2026 for $4.87 million, executing at an EV/Sales multiple of 0.40x and an EV/EBITDA multiple of 7.20x. [10] Walgreens Boots Alliance also acquired Medly Health in February 2023 for $19.35 million in cash to expand its digital delivery capabilities. [10] M&A Screener • Filters: 1 M&A Screener • Filters: 1 M&A Screener • Filters: 1 M&A Screener • Filters: 1 Industry Valuation Multiples & Market Benchmarks As a digital-first healthcare storefront, General Medicine's market valuation is benchmarked against broader digital health and primary care sectors. svb.com While traditional primary care and general practices trade at modest EV/EBITDA multiples of 3x to 5x, tech-enabled platforms with proprietary infrastructure command substantial premiums. soferadvisors.com In the private markets, digital healthcare services multiples have stabilized at an average EV/EBITDA of 11.5x in 2025, down from historical peaks of over 14x in 2024. svb.com Furthermore, platforms integrating advanced artificial intelligence and machine learning—such as General Medicine's MedicineOS pricing engine—command a 19% to 61% valuation premium over legacy peers. fiercehealthcare.com Strategic Exit Pathways & IPO Readiness Public Market Readiness & IPO Timeline A future public listing represents a highly viable long-term liquidity option for General Medicine, although the company must achieve specific operational milestones to build IPO readiness. startupintros.com Public market investors in 2026 demand proven profitability or a highly visible near-term path to positive cash flow, a stark departure from previous growth-at-all-costs environments. focusib.com To execute a successful IPO, General Medicine will likely need to surpass an annual run-rate revenue threshold of $200 million and expand its multi- state clinician network to achieve true national coverage. startupintros.com Consequently, while an IPO is a prospective medium-term goal for 2027 or beyond, the company's current phase remains focused on high-velocity scaling using its Series B capital. startupintros.com RESULT FOR QUERY Page 17 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 20 Acquisition & Strategic Divestiture Outlook In the near term, strategic acquisition represents the most probable exit pathway for General Medicine due to a wave of corporate consolidation. healthcare.digital The platform's ability to seamlessly bridge virtual triage with physical health system routing makes it a highly attractive target for multiple buyer segments. startupintros.com Commercial Payers and Insurers : Insurance companies are aggressively seeking to own the virtual "front door" of healthcare to control downstream referral pathways. startupintros.com General Medicine's transparent insurance-adjustment engine presents a powerful tool for steering patients toward cost-effective care networks. prnewswire.com Private Equity Roll-Ups : Private equity firms, such as Clayton, Dubilier & Rice and Warburg Pincus, are actively deploying "buy-and-build" strategies in tech-enabled clinical services. startupintros.com General Medicine fits the profile of a "platform asset" that can absorb smaller virtual specialists and localized diagnostics providers. startupintros.com Strategic Health Systems : Large hospital systems seek digital platforms that minimize billing friction and simplify administrative intake. startupintros.com Acquiring General Medicine's retail storefront would allow a major network to capture patient demand and reduce downstream patient leakage. startupintros.com Internal Relationship & Activity Context Based on a comprehensive review of internal systems, there is no documented relationship history or internal engagement record with General Medicine (https://generalmedicine.co) within our organization's CRM platform or real-time communications channels. This absence of prior touchpoints indicates that General Medicine represents a net-new relationship opportunity rather than an existing portfolio company or active deal pipeline prospect. The CRM Agent query returned zero logged contacts, meeting histories, or deal pipeline stages associated with General Medicine, its parent entity Path Healthcare Systems Corp, or its key executives including CEO TJ Parker, President Elliot Cohen, Chief Product Officer Ashwin Muralidharan, or Medical Director Dr. Pallabi Sanyal-Dey. Similarly, the Realtime Comms Agent detected no internal emails, calendar events, Slack discussions, or collaborative workspace mentions referencing the company across the organization's communication infrastructure during the analysis period. This comprehensive absence suggests that General Medicine has not previously been evaluated for investment, partnership, or commercial engagement by our internal teams. The lack of internal activity context presents both strategic opportunities and operational gaps for future engagement. From an opportunity perspective, this clean slate allows our organization to establish a first-mover relationship with a high-growth digital healthcare marketplace that has successfully raised $152 million across two institutional funding rounds and achieved an implied post-money valuation of $669.68 million as of October 2026. The company's founding team, comprised of proven PillPack alumni who previously executed a $750 million acquisition by Amazon in 2018, represents a battle-tested executive group with demonstrated exit success in the digital pharmacy sector. Given that General Medicine has scaled to cover 82% of U.S. counties and fulfilled over 800 different types of healthcare visits across more than 35 medical specialties since its May 2025 RESULT FOR QUERY Page 18 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 21 launch, the platform has achieved meaningful commercial traction that warrants proactive outreach and relationship development. However, the absence of internal intelligence also highlights critical knowledge gaps that must be addressed through structured engagement protocols. Our organization lacks firsthand insights into General Medicine's unit economics, customer acquisition cost (CAC) payback periods, lifetime value (LTV) profiles, and contribution margin dynamics. We possess no internal perspectives on the company's operational challenges, such as the scaling and operational growing pains documented in external customer reviews, nor do we have visibility into management's strategic priorities for deploying its recent $120 million Series B capital . Furthermore, we have no internal assessment of the regulatory compliance robustness of General Medicine's Friendly PC-MSO structure, particularly in light of tightening state-level Corporate Practice of Medicine (CPOM) oversight through legislative updates like California's SB 351 and Oregon's SB 951 , which became effective January 1, 2026. To establish a meaningful internal relationship framework, our organization should prioritize immediate outreach initiatives focused on securing exploratory conversations with General Medicine's executive leadership. Initial engagement should target CEO TJ Parker and President Elliot Cohen to discuss the company's go-to-market expansion strategy, particularly its plans to extend geographic coverage from 82% to 100% of U.S. counties and expand its catalog beyond the current 2,900 products and services . Parallel outreach to Chief Product Officer Ashwin Muralidharan would provide critical insights into the technical roadmap for MedicineOS, including planned enhancements to the machine learning insurance interpretation engine and the "General AI" triage assistant. Additionally, engaging Medical Director Dr. Pallabi Sanyal-Dey would allow our team to assess the clinical governance structure and evaluate the independence of physician-owned professional corporations under the current MSO arrangement. Beyond executive-level engagement, our organization should deploy structured monitoring protocols to track General Medicine's progress against key performance indicators and measurable milestones. These monitoring frameworks should include quarterly tracking of geographic coverage expansion, service catalog growth, referral network density (currently exceeding 100 health systems ), and customer satisfaction benchmarks (with a current Net Promoter Score of 80+ ). Internal stakeholders should also establish alert mechanisms to flag significant corporate developments, such as additional funding rounds, strategic hires, regulatory enforcement actions, or acquisition rumors involving potential acquirers like commercial payers, private equity roll-up platforms, or strategic health systems. From a forward-looking perspective, the establishment of an internal relationship with General Medicine aligns with broader industry trends favoring digital-first, transaction-based healthcare marketplaces over legacy subscription models. The company's asset-light operational footprint, which avoids high capital expenditures by routing patients to collaborative provider networks, mirrors the structural cost advantages that mature pharmaceutical operators are pursuing through digital transformation initiatives projected to reduce selling, general, and administrative (SG&A) costs by 15% to 20% . Furthermore, General Medicine's strategic positioning within the rapidly expanding digital health market—projected to grow from $347.35 billion in 2025 to $946.04 billion by 2030 at a CAGR of 22.20% —suggests that early relationship cultivation could yield substantial strategic value. RESULT FOR QUERY Page 19 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 22 The absence of historical internal engagement also necessitates the development of clear relationship objectives and success metrics moving forward. Our organization should define specific goals for the General Medicine relationship, whether focused on investment evaluation, strategic partnership exploration, competitive intelligence gathering, or talent pipeline development. These objectives should be documented within the CRM platform with defined ownership assignments, engagement cadences, and milestone-based progression criteria. Additionally, cross-functional stakeholders across investment, business development, and research teams should be briefed on the company's profile to ensure coordinated outreach and prevent redundant or conflicting engagement efforts. In summary, while General Medicine currently represents a zero-history relationship from an internal perspective, the company's proven leadership pedigree, substantial venture backing, rapid scaling trajectory, and positioning within a high-growth market segment warrant immediate and structured engagement. Our organization should prioritize establishing initial contact touchpoints, deploying systematic monitoring frameworks, and defining clear relationship objectives to capitalize on the strategic opportunities presented by this emerging digital healthcare marketplace leader. Citations [1] Funding Screener • Source: Crunchbase [2]  [3]  [4]  [5]  [6]  [7]  [9] STAT News • Amazon.com Inc • 28 May 25 • "STAT+: PillPack founders’ new health care marketplace has deep roots with Amazon" [8] Funding Screener • Source: Crunchbase [10] M&A Screener • Source: FactSet RESULT FOR QUERY Page 20 of 20 ©2026, AlphaSense, Inc. All Rights Reserved. AlphaSense is a service mark of AlphaSense, Inc. All other trademarks mentioned belong to their respective owners. This Generative Search result is AI-generated and may include inaccuracies. Use discretion and verify with original sources. See additional disclaimers located at the back of this report. --- ## Page 23 Legal Notices This content was generated using AI and may contain errors, ambiguities, or outdated information. AlphaSense does not guarantee the accuracy or completeness of this content. Users assume full responsibility for any use of or reliance upon any content contained in the service. Users should independently validate all information before using or relying on it. This content does not reflect the views or opinions of AlphaSense or any of its personnel and does not constitute legal, investment, or other professional advice. This content is proprietary and protected under copyright and other intellectual property laws. No part of this content may be used in connection with any language models or generative AI systems outside of AlphaSense. Any unauthorized use, including but not limited to the training or fine-tuning of any language models or other AI models, is strictly prohibited. ================================================================================ # DOCUMENT: Data Scripts Runbook (raw/scripts/README.md) ================================================================================ # General Medicine / Nile Health OSINT Collection Suite Reproducible Python collectors for the public-record, social, infrastructure, NPI, live-catalog, and internal-portal footprint of **General Medicine** (`generalmedicine.co`) and its related entities: the legal MSO **Path Healthcare Systems Corp.** (Delaware C-Corp, File `#7571245`, EIN `93-2571245`, Florida `F24000004983`), the stealth engineering identity **Nile Health** (`staging-nile.com`), the prior consumer brand **Nav Health** (`navhealth.co`), and the Friendly PC groups **Emerald Medical Practice, P.C.**, **Centennial Medical Practice, P.C.**, and **Ruby Medical Practice, P.C.** All scripts are standalone, use only the Python standard library plus `requests`, and write deterministic JSON into `rea-reports/generalmedicine/osint/`. Provider errors are captured in-band (`provider_status`, `errors`) so a rate-limited vendor never destroys the rest of the collection. ## Canonical audit metrics (2026-10-19) These are the same numbers used in [`../adversarial-and-market-report.md`](../adversarial-and-market-report.md) and [`../../generalmedicine.md`](../../generalmedicine.md): - **377 routes / 357 RTK operations**: 194 consumer routes + 183 internal route literals (166 `/api/internal*`-prefixed; 142 unique after cross-portal dedup); 119 verified consumer RTK ops (137 total across 40 slices) + 238 internal RTK ops. - **Consumer spec**: 130 OpenAPI paths / 141 operations / 16 tags; 64 catalog-only unexercised routes. - **3,184 SKU URLs / 448 surfaced by the 108-query sample / 326 with top-level price / 122 null top-level (8 with option-level fees) / 2,736 not surfaced by the sample**: 23 numeric series (including one legacy `364` SKU), price range **$5.11–$17,411.20** across the top-level priced sample. The 448 is a sample, not a census; `400285` is in `sitemap_only_skus` but returns for `query=chronic pain`, and `300603` has option-level `checkout_fee: 4500` behind null top-level fields. - **$152M total disclosed equity**: $32M seed (May 2025) + $120M Series B (2026-10-06); **0 affiliate Form D filings** on EDGAR. - **4.7/5.0 Trustpilot across 906 reviews**; **BBB “D” with 6 complaints**. - **~104 estimated employees** (PitchBook); **87** public LinkedIn profiles (33 high-relevance); **16** open Ashby roles. - **Server-driven $15.00 live `clinical_fee` (with $30 `STANDARD_CLINICAL_FEE` client fallback in `LabPanelPricing.tsx:65–69`)** across seven sampled lab SKUs (`total_cash_price = test_price + clinical_fee`; additional JSON fields `platform_fee`, `collection_fee`, and `order_fee` are not rendered in `LabPanelPricing.tsx`). ## Requirements ```bash python3 --version # 3.9+ python3 -c "import requests" || python3 -m pip install requests ``` Optional API keys (read from the environment; any missing key is recorded as `missing_api_key` and the remaining providers still run): | Variable | Provider | Used for | |---|---|---| | `APIFY_TOKEN` | Apify | `apify~google-search-scraper` actor for Google SERPs | | `EXA_API_KEY` | Exa | Domain-scoped neural search (`x.com`, `twitter.com`, `linkedin.com`) | | `FIRECRAWL_API_KEY` | Firecrawl | Google-style SERP search + full-article Markdown scrape | | `PERPLEXITY_API_KEY` | Perplexity | `sonar` synthesis with citations | ```bash export APIFY_TOKEN=... export EXA_API_KEY=... export FIRECRAWL_API_KEY=... export PERPLEXITY_API_KEY=... ``` Free, keyless sources used automatically: SEC EDGAR full-text search and `data.sec.gov`, CMS NPI Registry, crt.sh, Cert Spotter, HackerTarget, RapidDNS, system DNS, Google News RSS, and the public `generalmedicine.co` catalog API. ## Scripts ### 0. `osint_common.py` Shared module (not run directly): retrying HTTP session, SEC-compliant User-Agent, atomic JSON writer, Markdown/HTML cleaners, sentence-level quote extractor, and the `osint/` path constants used by all collectors. ### 1. `sec_edgar_search.py` Queries SEC EDGAR full-text search for 17 entity/founder/address strings, follows every CIK through `data.sec.gov/submissions`, downloads each matching Form D (`primary_doc.xml`, `.txt` fallback), and parses issuer identity, former names, jurisdiction, incorporation year, address, phone, related persons (officers, directors, promoters), offering amounts, minimum investment, investor count, and sales commissions. ```bash python3 rea-reports/generalmedicine/scripts/sec_edgar_search.py ``` Output: `osint/sec_edgar_filings.json` - `queries[]` — FTS totals and normalized hits - `company_search[]` — EDGAR company-search Atom fallback - `submissions{}` — full submission metadata per CIK - `form_d_filings[]` — parsed Form D records with `documentUrl` - `form_d_queue[]` — relevance-ranked queue showing which accessions were parsed - `summary{}` — hit/CIK/filing counts plus target-entity offering sums - `entity_match_summary{}` — `target_affiliate`, `context`, and `name_collisions` Rate limiting: 0.15–0.2 s between EDGAR requests with a descriptive `User-Agent` (`GeneralMedicineResearch/1.0`), per SEC fair-access policy. ### 2. `apify_exa_x_linkedin_news.py` Runs a 10-query X sweep, 13-query LinkedIn sweep, and 15-query news/press sweep through Firecrawl, Apify, Exa, Perplexity, and Google News RSS. News articles are scraped to Markdown and mined for **verbatim sentences** mentioning the company, founders, investors, Walmart, a16z, or the legal entities. ```bash python3 rea-reports/generalmedicine/scripts/apify_exa_x_linkedin_news.py ``` Outputs: - `osint/x_posts.json` — posts and profiles, parsed handles/post IDs, discovery source - `osint/linkedin_team_and_posts.json` — people (classified executive/advisor/ clinician/engineer/product/designer/operations), company pages, leadership posts - `osint/news_and_quotes.json` — RSS items, articles, full scraped text, exact quotes - `osint/apify_runs.json` — actor run IDs, status, dataset IDs, spend, provider status, and every provider error Behavior notes: - Apify is polled for up to 210 s; an unfinished run is aborted to stop spend and the partial status is recorded. - Exa is out of credits as of the 2026-10-19 run; the script records `NO_MORE_CREDITS` and continues. - LinkedIn blocks unauthenticated enumeration. `coverage_note` states that absence of a profile is not evidence of absence. ### 3. `infra_npi_and_catalog_probe.py` Certificate-transparency and DNS discovery across six domains, with four fallbacks per domain, followed by HTTP fingerprints of interesting hosts (admin, internal, staging, clinician portals, tenant endpoints). Then queries CMS NPI Registry for the MSO, the three Friendly PC groups, brand names, Salt Lake City/128 Spear addresses, and named founders/clinicians. Finally probes the unauthenticated catalog API for live SKU counts, categories, and prices. ```bash python3 rea-reports/generalmedicine/scripts/infra_npi_and_catalog_probe.py ``` Output: `osint/infra_npi_catalog.json` - `domains{}` — per-domain CT certificates, source status, discovered names - `all_subdomains[]`, `dns_records{}`, `interesting_hosts[]`, `http_probes[]` - `npi{}` — organization/individual/address queries with normalized NPI records, `friendly_pc_assessments{}`, and `unique_relevant_npis[]` - `catalog{}` — endpoint status/size, parsed SKUs, category groups, price ranges, `api.generalmedicine.co` mirror responses - `notable_findings[]` — host/status/title/signal triage (e.g., public Metabase, unauthenticated Visitron and Provider Chat, auth-gated Walmart/Mercy tenants) - `cache_merged{}` / `previous_run_merged{}` — prior snapshots merged into the current run so a transient CT failure does not erase known subdomains ### 4. `sitemap_catalog_scraper.py` Downloads all four published sitemaps (`sitemap.xml`, `store-sitemap.xml`, `sku-refresh.sitemap.xml`, `in-person-skus-sitemap.xml`), inventories every URL, extracts every `/s//` product URL, groups SKUs by numeric series (`100xxx` … `700xxx`) and sitemap, harvests live search-index prices for `a–z, 0–9`, and scrapes all 20 `/bio/*` pages plus the five policy pages. ```bash python3 rea-reports/generalmedicine/scripts/sitemap_catalog_scraper.py ``` Output: `osint/live_sitemap_skus.json` - `sitemaps{}` — byte size and URL count per sitemap - `sku_urls[]` — every SKU URL with slug, SKU ID, series, source sitemaps - `sku_series_counts{}`, `sku_series_broad_counts{}`, `sku_sitemap_counts{}`, `sku_category_counts{}` - `live_skus[]` — SKUs returned by the 108-query public search sample (not a census), with top-level cash/insurance fields where present - `sitemap_only_skus[]` — SKUs present in sitemaps but not surfaced by the 108-query sample (not proof of non-discoverability) - `bio_pages[]` — name, headline, paragraphs, scraped text for all clinician/team bios - `policy_pages[]` — refund, cancellation, consent, Zoom, and assignment-of-benefits text - `summary{}` — URL/SKU/price-range totals - `search_harvest{}` — query count, unique SKU count, category counts **Field semantics:** `summary.sku_with_live_price` counts every SKU returned by the search sample (**448**), not every SKU with a price. The top-level `cash_price_cents` / `insurance_price_cents` fields are the price-presence check: **326** SKUs have a non-null top-level cash or insurance price and **122** have both null; **8 of the 122** carry option-level fees. Null top-level price is **not** a purchasability verdict: SKU `300603` has null top-level fields but `options[0].checkout_fee: 4500`. Commercial status requires a per-SKU probe. ### 5. `internal_portals_recon.py` Reconstructs General Medicine's internal **MedicineOS** portals from unauthenticated Next.js chunks: 1. **Visitron** clinician EHR — `visitron.internal.generalmedicine.co` / `visitron.staging-nile.com` 2. **Catalog** & care-pathway admin — `catalog.internal.generalmedicine.co` / `catalog.staging-nile.com` 3. **Referrals** concierge & promises queue — `referrals.internal.generalmedicine.co` / `referrals.staging-nile.com` 4. **Provider Chat** & LLM prompt workbench — `internal.generalmedicine.co` The scraper loads each login page, extracts the Vercel deployment ID (`dpl_…`), walks the webpack chunk manifest, fetches every emitted chunk, and parses RTK `tagTypes`, `query`/`mutation` operation names, `/api/*` path literals, and ActionCable channel names. ```bash python3 rea-reports/generalmedicine/scripts/internal_portals_recon.py ``` Output: `osint/internal_portals_recon.json` - `visitron{}` — base, `dpl[]`, `chunk_count`, `tag_types[]`, `rtk_endpoints[]`, `api_paths[]`, `cable_channels[]` - `catalog{}`, `referrals{}`, `provider_chat{}` — same shape - 2026-10-19 totals: **4 portals, 99 chunks, 238 RTK operations, 183 API paths** - Visitron: 27 chunks / 91 ops / 98 paths - Catalog: 35 chunks / 106 ops / 47 paths - Referrals: 19 chunks / 27 ops / 18 paths - Provider Chat: 18 chunks / 14 ops / 20 paths The module docstring also names the **VisitAI clinician scribe SSO** (`visitai.generalmedicine.co` → `provider-auth.generalmedicine.co`) and the **staging Metabase** (`analytics.staging-nile.com`) as reconnaissance targets. The current `PORTALS` list enumerates the four bundle-recoverable portals; Metabase is separately fingerprinted in `infra_npi_catalog.json`. ## Run order The scripts are independent; run all five for a full snapshot (about 10–15 minutes wall clock, mostly vendor latency): ```bash cd rea-reports/generalmedicine/scripts ./sec_edgar_search.py ./apify_exa_x_linkedin_news.py ./infra_npi_and_catalog_probe.py ./sitemap_catalog_scraper.py ./internal_portals_recon.py ``` ## Design constraints - **No fabrication.** Every record carries its source URL and the provider/query that surfaced it. Quotes are exact sentences extracted from scraped article text. - **Idempotent writes.** JSON is written to a temporary file and atomically replaced. - **Fail-open collection, fail-visible reporting.** A provider error is embedded in the output rather than swallowed. - **No authenticated or private data.** Only public pages, public APIs, public certificate logs, and public search indexes are queried. The internal-portal collector reads only unauthenticated login-page bundles; it does not attempt authentication, authorization bypass, or PHI access. - **Rate limits.** SEC 0.15 s; catalog 0.08–0.25 s; CT/DNS sources 0.4 s; HTTP probes 0.3 s. crt.sh is retried twice before falling back to Cert Spotter, HackerTarget, RapidDNS, and brute-force DNS. ## Harvested dataset summary (2026-10-19 run) | File | Contents | |---|---| | `sec_edgar_filings.json` | 17 EDGAR queries, 493 FTS hits, 261 CIKs, 76 Form D filings parsed; 612 related persons and 687 roles extracted (Director 437, Executive Officer 248, Promoter 2); all 76 first-sale dates and federal-exemption lists populated; **0 Form D filings by General Medicine or Path Healthcare Systems Corp.**; 4 context filings totaling **$90,729,961** | | `x_posts.json` | 51 X posts and 12 profiles across 10 queries (27 high-relevance posts) | | `linkedin_team_and_posts.json` | 87 public LinkedIn people (33 high-relevance), 10 company pages, 31 leadership posts | | `news_and_quotes.json` | 186 news/RSS articles, 20 full articles scraped, 148 verbatim quotes | | `apify_runs.json` | Verified Apify account, actor run ID/status/spend, 71 flattened SERP results, all provider status | | `infra_npi_catalog.json` | 55 unique subdomains, 38 HTTP fingerprints, 23 relevant NPIs, 329 live SKUs across 9 categories | | `live_sitemap_skus.json` | 3,290 unique URLs from 4 sitemaps, **3,184 SKU URLs** across 23 numeric series, **448 surfaced by the 108-query sample (326 top-level priced; 122 null top-level, 8 with option-level fees; 2,736 sample-unsurfaced)**, 20 bios, 5 policies | | `internal_portals_recon.json` | **4 MedicineOS portals, 99 chunks, 238 RTK operations, 183 API paths** (166 `/api/internal*`-prefixed; 142 unique after dedup) | ### Notable signals captured - **Brand residue.** `navhealth.co` still serves the banner **“Nav Health is now General Medicine”**, and **`support@navhealth.co`** is still printed on `generalmedicine.co/refund-policy-labs` — a retired-brand support channel on a live policy page. - **No SEC Form D exists for General Medicine or Path Healthcare Systems Corp.** The nearest name matches are a Solari Capital fund and **NavHealth, Inc. (CIK 0001717158)**, an unrelated Arlington, VA company (Aneesh Chopra, later CareJourney). The script labels both as `name_collision` rather than asserting affiliation. - **Friendly PC NPI cluster.** Emerald Medical Practice PC (Park City, UT), Centennial Medical Practice PC (Tallahassee, FL), and Ruby Medical Practice (Ewing, NJ) were all enumerated in 2024–2025 and share telephone **307-840-9834**, a strong registration cluster consistent with the three Friendly PCs named in the privacy policy. Emerald's two NPIs (`1447011267`, `1750195483`) list non-physician **Ashwin Muralidharan** as President; Centennial (`1174333975`) and Ruby (`1346050150`) list **Dr. Pallabi Sanyal-Dey** as President. - **Internal infrastructure.** `analytics.staging-nile.com` returns a public **Metabase** dashboard (HTTP 200); `internal.generalmedicine.co` returns **Provider Chat**; `visitron.internal.generalmedicine.co` and `visitron.staging-nile.com` return the **General Medicine Visitron** clinician portal; `catalog.internal.generalmedicine.co` and `referrals.internal.generalmedicine.co` redirect to `/login`, while their `*.staging-nile.com` counterparts were reconstructed from served JS bundles; `wmt.staging-nile.com` and `mcy.staging-nile.com` are auth-gated Walmart and Mercy tenant hosts; DNS also exposes `waystar-connector.staging-nile.com` and `waystar-bridge.staging-nile.com` (Waystar clearinghouse integration). - **Route estate.** Consumer: **194 routes / 119 verified RTK ops** (137 total). Internal portals: **183 routes / 238 RTK ops**. Reconciled: **377 routes / 357 RTK operations**. - **Catalog.** The public search API returns 329 unique SKUs across 9 live category endpoints; the 108-query sample surfaces **448 SKUs**, of which **326 have top-level cash/insurance price fields** and **122 have null top-level fields** (**8** of the 122 carry option-level fees). The sample is non-exhaustive: **2,736** sitemap SKUs were not surfaced by it, but `400285` is in `sitemap_only_skus` and still returns for `query=chronic pain`. Null top-level price is not proof of unpurchasability: `300603` is one of **8** null-top-level SKUs with option-level `checkout_fee: 4500`. The sitemaps enumerate **3,184 SKU URLs**: 1,362 `700xxx` pharmacy products, 909 `200xxx` medication products, 511 `300xxx` services/conditions, 280 `500xxx` labs, 101 `400xxx` in-person visits, and 20 `100xxx` items. `sku-refresh.sitemap.xml` alone lists 3,099 URLs. - **Lab fee resolution.** `LabPanelPricing.tsx:59–69` reads `clinical_fee` from `/api/external/lab_skus/:id` and uses `STANDARD_CLINICAL_FEE = 30` (`types/enums/lab-pricing-constants.ts:8`) only as a fallback when `clinical_fee` is omitted. Live responses returned `clinical_fee: 15.0` across all seven sampled SKUs (`total_cash_price = test_price + clinical_fee`), along with unrendered JSON fields `platform_fee` ($15.00–$40.00), `collection_fee` ($3.00–$9.00), and `order_fee` ($6.00). - **Coverage caveats.** crt.sh returned HTTP 5xx throughout the run; Cert Spotter, HackerTarget, RapidDNS, and brute-force DNS supplied the certificate/subdomain data. Exa returned `HTTP 402` (no credits) and Perplexity `HTTP 401` (quota exhausted); both failures are preserved in `provider_status` and did not block the other providers. ================================================================================ # DOCUMENT: Clinician Recruiting: Deep-Dive Briefing (raw/reports/deep-dive-clinician-recruiting.md) ================================================================================ # Clinician Recruiting: Deep-Dive Briefing **As of:** 2026-10-19 · **Deck:** [HTML](../deep-dives/clinician-recruiting.html) · [PDF](../deep-dives/clinician-recruiting.pdf) General Medicine (GM) recruits clinicians through a five-step funnel that ends in a licensed, credentialed 1099 panel and a small full-time clinical core. The live Ashby board lists 16 roles on 2026-10-19, four of them in the Clinical department and one, the Clinical Recruiter, in Ops. Pay is per completed visit for contractors ($50 video and $12 chat for physicians, $35 and $8 for nurse practitioners) and salaried for the full-time primary care physician ($180,000–$200,000). Reach is set by how much of the U.S. population each clinician's license covers, not by headcount: 20–30% for a physician, at least 30% for a nurse practitioner. ## Key findings 1. **The funnel has five steps joined by handoffs.** The hiring page and job boards generate interest, the apply flow routes candidates to the right Ashby posting, a recruiter screens and owns the requisition from intake through offer, and the licensure manager runs a pre-hire NP license review. Credentialing and training are separate gates before the first patient, and the booking service applies the state filter at the point of care. 2. **Four clinical requisitions are open, and the recruiter seat is in Ops.** The Clinical department lists a full-time physician, a part-time 1099 physician, a 1099 nurse practitioner and a Manager of NP Licensure and Collaborative Practice. The Clinical Recruiter, Physicians sits in Ops, which separates pipeline generation from clinical management. 3. **Video pays the physician $50 and the NP $35; chat pays $12 and $8.** The contractor model prices each completed visit, with no hourly rate. At the full-time posting's cap of nine video visits per four-hour block, the fees imply ceilings of $112.50 an hour for a physician and $78.75 for an NP if every slot fills. 4. **Licensure coverage, not headcount, sets which states GM can serve.** Each 1099 physician must hold licenses covering 20–30% of the U.S. population, and each NP at least 30%, with California, Texas, Florida and New York preferred. The booking flow filters the clinician pool by the patient's state on the server, and an uncovered state returns no availability. 5. **One sourcing-heavy recruiter and public job boards feed the pipeline.** The recruiter posting asks for full-cycle, sourcing-heavy work with high call volume, Ashby tracking and AI-enabled sourcing tools. GM also lists the part-time physician role on MDLinx and Health eCareers, and the CPO posts the same practice-model copy on LinkedIn. 6. **The hiring page and the postings disagree on hours, scope and pay.** The page says this is not telehealth as a side hustle while the 1099 roles are 10–15 hours a week. It offers "pick your own hours" while shifts run in 4–6 hour blocks inside one time zone. An earlier "Competitive pay" card is gone, replaced by a per-visit fee schedule that appears only in the postings. ## The funnel has five steps joined by handoffs The hiring page, the job board and the applicant tracking system describe one path from interest to first shift. Each step hands the candidate to a different function, and the requisition closes at offer. | Step | What happens | Function | Evidence | |---|---|---|---| | 1. Attract | The clinician hiring page runs a two-minute overview video, four health-system logos, five named clinician testimonials and a practice-model pitch. GM also posts roles on MDLinx and Health eCareers, and the CPO reposts the copy on LinkedIn. | Hiring page, job boards and LinkedIn | [2], [6], [8], [9], [10] | | 2. Apply | A modal asks "Which role are you interested in?" with two choices, Physician or Advanced Nurse Practitioner, and opens the matching Ashby posting. Each click is logged with the role and the attribution cookies, and the same 11 fields are appended to the Ashby URL. | Role picker and Ashby apply flow | [6], [7] | | 3. Screen | The recruiter runs high-volume phone screens that test role fit, motivation and baseline clinical qualifications. For NP candidates, the licensure manager adds a pre-hire licensure review and returns feedback through Ashby. | Recruiter screens and NP license review | [1], [5] | | 4. Credential and train | Credentialing covers multistate licenses and, for the full-time role, a DEA license and Medicare and Medicaid enrollment. The posting promises renewals and expedited credentialing at company cost. Sam Schisler leads training so a new clinician knows how GM works before the first patient. | Credentialing and clinical training | [1], [5] | | 5. Practice | Clinicians work booked shifts in Visitron, with 20-minute video appointments, a maximum of nine per four-hour block and a three-hour chat response window. The booking flow filters the clinician pool by the patient's state. | Booking, shifts and the state gate | [1], [2] | The handoffs are where candidates stall. A candidate who clears the recruiter can still fail the NP license review, and a clinician who clears licensure still needs credentialing and training before taking a visit. The licensure manager's work spans pre-hire review, credentialing and live escalations, so the steps cannot be treated as independent. ## The pitch sells supported, specialist-backed medicine The live page leads with "Work with General Medicine" and "Serious medicine, without compromise." It describes a care system rather than a standalone telehealth product: video visits, asynchronous chat, labs and imaging, specialist e-consults, and referrals to in-person care. It lists five modalities and four health-system logos, then five clinician testimonials. | Clinician | Quoted phrase on the page | |---|---| | Lauralee Yalden, MD, FAAFP | "The tools from General Medicine have been transformative to my medical practice." | | Johnny Guzman, DO | "Unlike telemedicine platforms I have worked on, the General Medicine technology allows me to spend more time relating and connecting with my patients" | | Karla Noel, MD, FAAFP | "I love working with General Medicine as a part of a collaborative and supportive team." | | Daniel McConnell, MD | "The ability to reach patients wherever they are, using powerful physician-created clinical tools" | | Sam Schisler, AGACNP, FNP | "Working as a nurse practitioner with General Medicine has reminded me why I went into healthcare in the first place." | The offer block has four cards: 1099 flexibility, white-glove onboarding ("Expedited, compensated process for referred clinicians"), interesting cases and clinician community. The recovered page content also contains a fifth card, "Competitive pay: Above-market compensation for telehealth work," commented out. It does not render on the live page. The four logo slots are Mass General Brigham, UCSF Health, Stanford Medicine and Kaiser Permanente in the page markup. In the rendered page, the third slot displays the Intermountain Health wordmark: the image file served under the Stanford name is an Intermountain asset. The image alternative text still reads Stanford Medicine. That is a live page defect, and it changes what the logo band actually claims. The page also promises that referred clinicians receive expedited review and that an "extended, compensated trial period" lets a candidate shadow visits. Neither the length of that period nor its pay is stated. ## Four clinical requisitions are open The Ashby board returns 16 listed jobs on 2026-10-19. The distribution is Clinical 4, Ops 2, Finance 3, Engineering 4 and Product 3. The careers page lists the same 16 roles in the same order. | Role | Type | Posted | Hours per week | Pay | Licensure bar | Other requirements | |---|---|---|---|---|---|---| | Virtual Advanced Nurse Practitioners - 1099 | Contract | 2026-07-23 | About 12–15 | $35 per video visit, $8 per chat visit | Active, unrestricted NP license covering at least 30% of the U.S. population; California, Texas, Florida and New York preferred | Family or internal medicine; 3+ years of full-time primary care; U.S. resident; independent clinical judgment | | Full Time Physician - Primary Care | Full-time | 2026-03-04 | 36 clinical | $180,000–$200,000 plus equity | Active, unrestricted U.S. license, multi-state required; credentialing support provided | MD or DO, board-certified in internal medicine or family medicine; 2+ years in primary care; DEA license; Medicare and Medicaid enrollment | | Virtual Physician (Part-Time - 1099) | Contract | 2026-09-17 | About 10–12 | $50 per video visit, $12 per chat visit | Active, unrestricted license covering 20–30% of the U.S. population; California, Texas, Florida and New York preferred | MD or DO, board-certified in family medicine or internal medicine; U.S. resident; telehealth experience a plus | | Manager, NP Licensure & Collaborative Practice | Full-time | 2026-10-12 | Not posted | Not posted | NP or APRN licensure, credentialing or collaborative practice experience; state board processes | Collaborative practice agreement templates, collaborating-physician bench, primary-source verification, state filings, pharmacy escalations | Three patterns sit in that table. The full-time physician is the only clinical role with a salary, benefits narrative and equity. The posting also carries the most detailed operating description on the board: platforms, visit types, shift blocks, scope and the Medicare and Medicaid enrollment requirement. The two 1099 roles are the volume model, and they pay only for completed visits. Neither posting states a minimum shift count beyond the weekly hour range. The licensure manager is a compliance and operations role, not a clinical one. It is the only posting that names primary-source verification, state paperwork and pharmacy refusals, and the only one that describes pre-hire review as an input to recruiting. ## Pay is per completed visit, priced off the salaried model The fee schedule appears in the two 1099 postings. Patient prices come from the storefront: $100 for a cash video visit, $30 for a cash chat visit and a $25 copay on the insured path. | Visit type | Patient pays | Physician fee | NP fee | Physician margin | NP margin | |---|---|---|---|---|---| | Video, cash | $100 | $50 | $35 | 50% | 65% | | Chat, cash | $30 | $12 | $8 | 60% | 73% | | Video, insured | $25 copay | $50 | $35 | -$25 | -$10 | | Chat, insured | $25 copay | $12 | $8 | +$13 | +$17 | Margins subtract the clinician fee from the patient price and exclude platform, pharmacy, lab and overhead costs. The insured rows exclude payer reimbursement, which is the whole point of the negative figures: a $25 copay does not cover a $50 physician fee, so the insured video path only works if the claim pays. Three derived figures follow from the posted terms. The full-time posting caps video at nine visits per four-hour block, or 2.25 visits an hour, which gives a contractor ceiling of $112.50 an hour for a physician and $78.75 for an NP if every slot fills. The same cap applied to a salaried physician gives 81 visits a week and, at 36 clinical hours over 48 working weeks, 3,888 visits a year. A $180,000–$200,000 salary therefore implies roughly $46 to $51 of physician labor per visit before malpractice, credentialing, benefits or no-show slack. The $50 contractor video fee sits almost exactly on that salaried per-visit cost. That is what pricing a 1099 rate off an employed model looks like. One external listing goes further. Health eCareers advertises the part-time physician role at "$100 - $190 Hourly" on a pay-per-visit model, a range that only makes sense as an earnings range at high visit volume, not as an hourly wage. The Ashby posting itself states no hourly rate. ## Licensure coverage, not headcount, sets national reach GM does not hire one clinician per state. It hires clinicians whose licenses overlap enough to cover the country. The postings state the bar directly: | Role | Population coverage required per clinician | Preferred states | |---|---|---| | 1099 physician | 20–30% of the U.S. population | California, Texas, Florida, New York | | 1099 nurse practitioner | At least 30% of the U.S. population | California, Texas, Florida, New York | | Full-time physician | Active, unrestricted U.S. license; multi-state required | Not stated | The public claim on the FAQ is that GM has clinicians licensed in all 50 states, including DC, and that care is for adults 18 and older. Coverage of that claim is a network property: enough overlapping licenses to reach every state, not a licensed clinician resident in each one. The Manager, NP Licensure & Collaborative Practice exists to make the NP layer legal state by state. The posting lists the work: - Manage the bench of collaborating physicians: track capacity, match agreements to NPs, onboard new collaborators. - Build and maintain state-specific and provider-specific collaborative practice agreement templates and their collateral paperwork. - Review completed agreements, file them internally, submit required state paperwork and update licensure records. - Run primary-source verification and license viability review for new and existing NPs, and communicate findings to providers and internal stakeholders. - Track licensure and agreement status across states and drive licenses to viability. - Handle licensure escalations, such as a pharmacy declining to fill a prescription written by an NP in a given state. - Provide pre-hire licensure review for NP candidates and feedback to the recruiting team through Ashby. - Support NP offboarding as it relates to collaborative relationships. The booking flow is the other half of the gate. The patient's state is collected per booking, and the clinician pool is filtered on the server, so the browser never receives the licensed set. When no clinician is licensed in the patient's state, the patient sees no availability rather than an unlicensed clinician. ## Academic logos describe the leaders, not the 1099 panel The logo band reads as a statement about the clinician panel. It is more accurately a statement about where five named leaders trained and worked. | Displayed institution | Named person | Role at GM | Affiliation evidence | |---|---|---|---| | UCSF Health | Dr. Pallabi Sanyal-Dey, MD | Medical Director | Associate clinical professor at Zuckerberg San Francisco General Hospital; directed clinical operations for the Division of Hospital Medicine; Physician Advisor for Clinical Documentation and Integrity | | Mass General Brigham | Dr. Marjory Bravard, MD; Dr. Poushali Bhattacharjee, MD, MS, FACP | Director of Clinical Partnerships; leads clinical operations | Bravard was Director of Operations and Director of Inpatient Medicine at Massachusetts General Hospital; Bhattacharjee was a hospitalist and instructor in medicine there | | Kaiser Permanente | Dr. Adam Carewe, MD | Physician, clinical informatics | 13 years at Kaiser Permanente Colorado; rose from Physician Optimization Lead to Director of Medical Informatics to Chief Medical Informatics Officer | | Stanford Medicine (label), Intermountain Health (rendered image) | No named leader on the 20 bio pages | Specialist e-consult network, per the earlier briefing | The image served in that slot is the Intermountain Health wordmark; Dr. Bravard lists Intermountain Healthcare among prior employers | The 20 public bio pages break down into three groups: - **Five operating clinical leaders:** Pallabi Sanyal-Dey, Marjory Bravard, Poushali Bhattacharjee, Adam Carewe and Samantha Schisler. - **Three founders and executives:** Ashwin Muralidharan, Elliot Cohen and TJ Parker. - **Twelve content clinicians, physician assistants and health writers:** Ashley Allen, Devon Pace, Ellen Britt, G. Michael Dileo, Kaitlyn Alemida, Karen Shackelford, Robert Stevens, Sean Dupont and Young Bo Sim, plus writers Jaime Osnato, Jennifer Chesak and Kathleen Ferraro. A bio page is not proof of employment, ownership or panel size, and a logo is not a roster. The academic names describe a leadership pedigree. The 1099 panel that delivers most visits appears only as an aggregate licensure requirement. ## One recruiter seat and job boards feed the pipeline The Clinical Recruiter, Physicians posting is the clearest statement of how GM intends to fill physician requisitions. | Attribute | Posting detail | |---|---| | Department | Ops | | Type and location | Full-time, remote | | Posted | 2026-09-22 | | Shape of the role | Full-cycle and sourcing-heavy; owns requisitions from intake through offer | | Daily work | Cold outreach, phone screens, candidate check-ins, hiring manager syncs | | Load | Multiple open physician requisitions at once; high-volume phone screens | | Systems | Ashby for pipeline tracking; AI-enabled tools for sourcing and screening | | Experience | 2–5 years of full-cycle clinical recruiting, physician recruiting required; telehealth recruiting strongly preferred | The phrase "building pipeline from scratch, not just managing what comes through the door" is the operating thesis. GM is not relying on inbound applications. The off-board channels match that thesis. MDLinx carries a "Virtual Physician (Part-Time, 1099)" listing with a Texas location and the contact address allison@nile.health. Health eCareers carries the same role with "$100 - $190 Hourly", "Pay per visit model" and the same contact. The CPO posts the hiring message on LinkedIn with the practice-model copy. Attribution is instrumented end to end. The role picker offers Physician or Advanced Nurse Practitioner. Each apply click is logged with the role and the attribution cookies, then 11 fields are appended to the Ashby URL: `utm_source`, `utm_medium`, `utm_campaign`, `utm_content`, `gclid`, `gbraid`, `wbraid`, `fbclid`, `msclkid`, `kad_cid`, `oppref`. That is standard consumer-marketing instrumentation applied to clinician recruiting, and it implies GM expects to buy or earn traffic to the hiring page, not only to receive referrals. ## Clinicians join a capped, shift-based production model The full-time physician posting is the most detailed operating document in the public record. | Dimension | Posted term | |---|---| | Shifts | 4–6 hour blocks, Monday to Friday, 7 a.m. to 7 p.m. MT; weekend and evening expansion underway | | Video visits | 20-minute appointments, maximum 9 per 4-hour block | | Chat | Asynchronous triage and chat with a 3-hour response window | | Clinical hours | 36 per week for the full-time role | | Platforms | Athena (records), Zoom (video), Zendesk (chat), Slack (team), Nabla (scribe AI) | | Scope | Adult medicine only; no pediatrics, advanced psychiatry or controlled substances | | Non-clinical work | Handled by operations | The nine-visit cap is a 75% ceiling on the 12 possible 20-minute slots in a four-hour block. The slack absorbs charting, the chat window and visit overruns. It also caps contractor earnings: at nine visits and a $50 fee, a four-hour block pays $450 before any unfilled slot. The 1099 postings describe the same model at lower hours. The physician role is built to fit alongside an existing hospital, emergency department or outpatient practice at roughly 10–12 hours a week. The NP role is roughly 12–15 hours a week. Both are secondary-income roles by design. ## Where the pitch and the postings diverge | Claim | Postings and operating terms | Implication | |---|---|---| | "This is not telehealth as a side hustle." | The 1099 roles are 10–12 hours a week for physicians and 12–15 for NPs, built to fit alongside an existing practice. | The page sells depth of practice; the contract is part-time. | | "Pick your own hours." | Shifts run in 4–6 hour blocks, Monday to Friday, 7 a.m. to 7 p.m. MT. Weekend and evening coverage is described as underway. | Scheduling is block-based inside one time zone. | | No insurance paperwork, per the Executive Briefing. | The full-time posting requires enrollment, or willingness to enroll, as a Medicare and Medicaid participating provider; the NP posting states that GM accepts insurance including Medicare and Medicaid. | Operations absorbs scheduling and coordination, not payer enrollment. | | "Selective by design: peer referrals prioritized, fit matters." | A sourcing-heavy recruiter, MDLinx and Health eCareers listings, and a posted "$100 - $190 Hourly" range. | Outbound and job-board channels run alongside referrals. | | 82% of U.S. counties, per AlphaSense. | Each physician license covers 20–30% of the population; each NP covers 30%. Booking filters by patient state. | County reach is a network claim, not a per-clinician one. | | An earlier "Competitive pay" card is no longer displayed. | $50 and $35 per completed video visit; $12 and $8 per chat visit. No hourly rate appears on the hiring page. | A specific per-visit fee replaced an above-market claim. | The page promises that operations handles administrative work and care coordination. The postings still put payer enrollment on the physician and state that GM accepts insurance including Medicare and Medicaid. Operations absorbs scheduling, referrals and coordination, not credentialing with payers. The posting says weekend and evening expansion is underway, while the FAQ already tells patients that visits are often available after hours or on weekends depending on clinician availability. The patient-facing promise runs ahead of the posted shift window. ## Changes since the Executive Briefing - **82% of counties is a third-party figure.** Slide 9 states 82% of U.S. counties as a company claim. The figure comes from the AlphaSense primer; the hiring page makes no geographic claim, and the postings define reach through licensure coverage instead. - **The Stanford logo slot renders another company.** The live page's third logo slot carries the Stanford Medicine image label but displays the Intermountain Health wordmark, and the served image is an Intermountain asset. Slide 9 maps Stanford to a specialist e-consult network. The deck records the label and the rendered image separately. - **"No insurance paperwork" is not on the live page.** Slide 9 promises "no insurance paperwork". The live page promises an operations team for administrative work, while the postings require Medicare and Medicaid enrollment for the full-time role and state that GM accepts insurance including Medicare and Medicaid. - **"Competitive pay" was removed, and pay moved to the postings.** The recovered page content still contains the card, commented out. The live page shows four offer cards and no pay claim; the fee schedule appears only in the 1099 postings: $50 and $35 per completed video visit, $12 and $8 per chat visit. - **Hours: 10–12 for physicians, 12–15 for NPs.** That is the posted split for the two 1099 roles. - **Salary: $180,000–$200,000.** The posting pairs it with equity, malpractice with indefinite tail coverage, and covered licensure and credentialing. The derived labor cost of about $46–$51 per visit follows from that range. - **Correction: the recruiter sits in Ops.** The live board places Clinical Recruiter, Physicians in Ops, so the Clinical department lists four requisitions and the recruiter is a fifth clinical-adjacent seat. - **The count is still 16.** The Manager, NP Licensure & Collaborative Practice was published 2026-10-12, after the Series B batch of 2026-10-07, and is the newest clinical-adjacent requisition. - **The trial-period language is confirmed.** The process section states an "extended, compensated trial period" that lets a candidate shadow visits. The deck uses the shorter card text ("Expedited, compensated process for referred clinicians"). ## Open questions 1. **How large is the active 1099 panel?** GM publishes requisitions, not filled seats. No count of active physicians or NPs appears on the site, in the postings or in the press coverage reviewed. 2. **What share of the nine-visit block is actually filled?** The cap is a ceiling. Utilization determines whether the $112.50 and $78.75 hourly ceilings are real or theoretical. 3. **Who performs credentialing?** The postings promise expedited credentialing and covered renewals but name no vendor and no internal team. The licensure manager covers NP licenses and collaborative agreements, not payer enrollment. 4. **What is 12-month retention for 1099 clinicians?** These are secondary-income roles that compete with the primary practice supplying the clinician. No cohort or attrition figure is public. 5. **How long is the compensated trial period, and what does it pay?** The page promises an extended, compensated period with visit shadowing. Neither duration nor compensation is stated. 6. **When do weekend and evening shifts open?** The full-time posting says expansion is underway, and the FAQ already promises some after-hours availability. The posted schedule remains Monday to Friday, 7 a.m. to 7 p.m. MT. 7. **Does any single clinician hold enough licenses to cover 30% of the population alone, or is coverage assembled from several part-time clinicians?** The postings set a per-clinician floor but do not describe how the licenses overlap. 8. **How does the recruiter's sourcing target interact with the licensure bar?** A sourcing-heavy recruiter can fill a screen quickly; a candidate who cannot cover 20–30% of the population cannot be deployed regardless of fit. ## Sources 1. Ashby job board API, `general-medicine`, 16 listed roles with descriptions, departments, types and publish dates. Retrieved 2026-10-19. Snapshot: `rea/osint/deep-dives/ashby_job_board_2026-10-19.json`. https://api.ashbyhq.com/posting-api/job-board/general-medicine?includeCompensation=true 2. General Medicine clinician hiring page, page text and HTML. Retrieved 2026-10-19. Snapshot: `rea/osint/deep-dives/gm_public_pages_2026-10-19.json`, key `/clinician-hiring`. https://generalmedicine.co/clinician-hiring 3. General Medicine careers page, role list and locations. Retrieved 2026-10-19. Snapshot: `rea/osint/deep-dives/gm_public_pages_2026-10-19.json`, key `/company/careers`. https://generalmedicine.co/company/careers 4. General Medicine FAQ, 50 states plus DC, adults 18 and older, support hours. Retrieved 2026-10-19. Snapshot: `rea/osint/deep-dives/gm_public_pages_2026-10-19.json`, key `/faq`. https://generalmedicine.co/faq 5. General Medicine clinician bios: Dr. Pallabi Sanyal-Dey, Dr. Marjory Bravard, Dr. Poushali Bhattacharjee, Dr. Adam Carewe, Samantha Schisler. Retrieved 2026-10-19. Snapshot: `rea/osint/deep-dives/gm_public_pages_2026-10-19.json`, keys `/bio/*`. 6. Recovered clinician hiring content module: testimonial text, logo imports, offer cards (Competitive pay commented out), process steps. `lib/hardcoded-data/ClinicianHiring/clinician-hiring-content.tsx`. 7. Recovered apply modal and attribution hook: role picker URLs, apply-click logging, 11 attribution fields. `components/Refresh/Modals/JobModal/JobModalContent.tsx`; `hooks/useAttributionTracking.tsx`. 8. MDLinx listing, Virtual Physician (Part-Time, 1099), Texas, contact allison@nile.health. Retrieved 2026-10-19. https://career.mdlinx.com/family-medicine/career/job-listing.cfm/1485628/Virtual-Physician-Part-Time-1099--job-in-TX 9. Health eCareers listing, same role, "$100 - $190 Hourly", pay-per-visit model. Retrieved 2026-10-19. https://www.healthecareers.com/job/virtual-physician-part-time-1099/13635774 10. LinkedIn post by Ashwin Muralidharan, "General Medicine is hiring clinicians", carrying the practice-model copy. Snapshot: `raw/osint/linkedin_team_and_posts.json`. https://www.linkedin.com/posts/ashwinmuralidharan_general-medicine-is-hiring-clinicians-working-activity-7439710739847786497-CLOY 11. AlphaSense Company Primer, 2026-10-19: 82% of U.S. counties; dual pricing and per-visit billing quotes. `wiki/raw/alphasense/alphasense-company-primer-2026-10-19.md`. 12. Executive Briefing, slide 9 (clinician recruiting) and Appendix C.09 (hiring subsystem index). `deck/index.html`. ================================================================================ # DOCUMENT: Hiring Signals: Revenue Cycle, Product and Care Ops (raw/reports/deep-dive-hiring-rcm-product-care-ops.md) ================================================================================ # Hiring Signals: Revenue Cycle, Product and Care Ops **As of:** 2026-10-19 · **Deck:** [HTML](../deep-dives/hiring-rcm-product-care-ops.html) · [PDF](../deep-dives/hiring-rcm-product-care-ops.pdf) ## Key findings 1. **Sixteen roles; seven published on Oct 7, the day after the Series B.** The board lists 16 jobs across five departments. Four engineering roles and three product roles all carry a 2026-10-07 publish date, one day after the $120M Series B announcement on 2026-10-06. 2. **Two RCM leadership postings share one body of text.** The Revenue Cycle Management, Director and VP postings were published four minutes apart on 2026-08-12 with the same 15 job essentials and 10 qualifications. The VP version opens with a stray Strategic Finance Manager header and misspells its own title. 3. **Eligibility and coding rails appear in the platform; claim and denial records were not found.** The recovered platform runs real-time eligibility checks, card-photo eligibility, a Waystar clearinghouse bridge, Athena encounter sync and CPT/ICD-10 mapping. No claim status, denial queue, prior-authorization case, superbill or good-faith estimate was found in the recovered route inventories; an unrecovered service or external vendor claims system is not ruled out. 4. **A $25 insured video visit loses $25 on an MD and $10 on an NP until the claim pays.** The 1099 postings pay $50 per video visit to a physician and $35 to a nurse practitioner. The insured video copay is $25, so the visit is cash-negative before any payer reimbursement. 5. **Two of three product hires point at payer, employer and pricing plumbing.** The Growth PM builds integrations with payers, employer partners and healthcare networks as the first Growth PM, reporting to the CEO. The VP Product owns a roadmap that includes pricing and payer infrastructure. 6. **Care ops is a $22/hr phone and referral desk.** The Care Coordinator answers and places calls with patients, provider offices, insurers and labs, works the Referrals queue, and reports to the Operations Manager. Athena and medical billing experience are preferred, not required. ## The board: 16 roles, five departments The Ashby board lists 16 jobs on 2026-10-19. Department counts are Clinical 4, Engineering 4, Finance 3, Product 3 and Ops 2. The careers page lists the same 16 titles. | Department | Role | Location | Published | Posted pay | | :--- | :--- | :--- | :--- | :--- | | Clinical | Virtual Advanced Nurse Practitioners - 1099 | Remote | 2026-07-23 | $35 video / $8 chat; 12–15 hrs per week | | Clinical | Full Time Physician - Primary Care | Remote | 2026-03-04 | $180,000–$200,000 + equity | | Clinical | Virtual Physician (Part-Time - 1099) | Remote | 2026-09-17 | $50 video / $12 chat; 10–12 hrs per week | | Clinical | Manager, NP Licensure & Collaborative Practice | Remote | 2026-10-12 | Not posted | | Engineering | Frontend Engineer (Boston) | Boston | 2026-10-07 | $150,000–$225,000 base | | Engineering | Frontend Engineer (SF) | San Francisco | 2026-10-07 | $150,000–$225,000 base | | Engineering | Full-Stack Engineer (Boston) | Boston | 2026-10-07 | $150,000–$225,000 base | | Engineering | Full-Stack Engineer (SF) | San Francisco / Boston | 2026-10-07 | $150,000–$225,000 base | | Finance | Revenue Cycle Management, Director | Remote | 2026-08-12 | Not posted | | Finance | Revenue Cycle Management, VP | Remote | 2026-08-12 | Not posted | | Finance | Strategic Finance Manager | Remote / Boston / SF | 2026-05-06 | Not posted | | Product | Product Manager - Growth | San Francisco | 2026-10-07 | $175,000–$225,000 base + equity | | Product | Product Manager, Consumer | San Francisco | 2026-10-07 | $175,000–$225,000 base + equity | | Product | VP Product | San Francisco | 2026-10-07 | Not posted | | Ops | Care Coordinator | Remote | 2026-09-18 | $22/hr | | Ops | Clinical Recruiter, Physicians | Remote | 2026-09-22 | Not posted | The board's structured compensation object is empty even when the request asks for compensation. Every pay figure above is read from the posting text. Six of the 16 postings list no pay: both RCM roles, Strategic Finance Manager, VP Product, Clinical Recruiter and Manager NP Licensure. The four engineering roles do post a $150,000–$225,000 base band. The VP Product does not post one. Two postings name a second site: Full-Stack Engineer (SF) also lists Boston, and Strategic Finance Manager lists Boston and San Francisco alongside remote work. The Oct 7 cohort is the signal. Four frontend and full-stack roles, two PM roles and a VP Product went up together, the day after the funding announcement. The engineering postings describe hybrid work three days a week in Boston's Central Square or San Francisco's Spear Street office. The Growth PM posting asks for three days a week near Market and Spear; the Consumer PM posting says hybrid in San Francisco. ## Revenue cycle: two postings, one body Both RCM postings are in Finance, both are remote, and both were published 2026-08-12: the VP at 18:19 UTC and the Director at 18:23 UTC. | Attribute | Director | VP | | :--- | :--- | :--- | | Department | Finance | Finance | | Published | 2026-08-12 | 2026-08-12, four minutes earlier | | Location | Remote | Remote | | Experience | 12+ years in revenue cycle; 5+ years at director or executive level | Same | | Scope | Patient access, authorization, coding, billing, denials, collections, reporting | Same seven functions | | Payer work | Contracting support, reimbursement, dispute resolution | Same | | Body | 15 job essentials and 10 qualifications | Same 25 bullets | The two documents differ in three places. The Director posting opens with its own title block. The VP posting opens with a stray "STRATEGIC FINANCE MANAGER / REMOTE OR HYBRID (BOSTON OR SAN FRANCISCO)" header, then spells the title "Revenue Cycle Mnagement, VP" in the body. The first sentence of the VP version says "VP of Revenue Cycle Management" where the Director version says "Revenue Cycle Management, Director". Everything after that matches exactly, including the bullet about serving as "the executive sponsor for audit readiness." Two readings are possible. The company may intend two seats, a VP over strategy and a Director over execution, and reused one document to post both. Or one seat is being posted twice to widen the funnel. The board cannot distinguish them. The description, the qualifications and the reporting language are identical. The third Finance role is context, not scope. Strategic Finance Manager was published 2026-05-06, five months before the Series B. It is described as the CFO's first finance hire, working directly with the CFO on models, unit economics and board materials, and asks for 2–6 years in investment banking, private equity, venture capital, management consulting or strategic finance. ## What the RCM seat owns The scope is written wider than billing. The 15 job essentials cover four areas. **Patient access and authorization.** The postings put "patient access" and "authorization" inside the executive oversight line, and the company description names "eligibility systems" and "reconciliation workflows" as the infrastructure behind the storefront. The qualifications ask for depth in "multi-state and telehealth environments." **Coding and billing.** The posting asks for "Strong knowledge of medical coding standards (CPT, ICD-10), E/M guidelines, and complex payer structures." Coding and billing also appear as functions under executive oversight, and the qualifications ask for "Experience with EMR and RCM systems." Video and chat are separate visit products, so the billing model has to span both. **Denials and reporting.** The postings name "denials management, collections, and reporting" in the same oversight line, and ask the seat to "Establish enterprise-level KPIs, benchmarks, and performance frameworks." Reporting runs "to the executive team and board." **Payer strategy and compliance.** Contract negotiation support, reimbursement optimization, dispute resolution, third-party billing vendors, clearinghouses, HIPAA, CMS and commercial payer policy all appear. So does "executive sponsor for audit readiness, risk management, and regulatory response initiatives." The scope implies a team. The postings call for "organizational design and workforce strategy for the revenue cycle team, including leadership development, succession planning, and vendor management," and for "Demonstrated success leading large, distributed teams." No such team is visible in the board: there is no analyst, coder, billing specialist or prior-authorization requisition. The two RCM leaders would be the first hired members of a function described as already large. ## The rails RCM inherits The recovered platform has billing-adjacent infrastructure, but it stops before claims management. | Observed | Where it appears | | :--- | :--- | | Real-time eligibility checks | Insurance endpoints, including a trigger that returns eligible status and copay | | Card-photo eligibility | OCR on front and back images of an insurance card | | Waystar clearinghouse bridge | Staging hosts for a connector and a bridge; the connector timed out and the bridge host did not resolve | | Athena encounter sync | Visitron writes encounters, summaries and care plans into Athena | | CPT and ICD-10 mapping | Catalog procedure-code mappings and ICD-10 search, used for billing and referrals | | Three billing types | Cash, insurance and pharmacy delegation on the same pharmacy order | | GM pharmacy card | A digital card with BIN, PCN, group and member ID, presented at the counter | | DoseSpot benefit inquiries | Real-time benefit checks, formulary lookups and insurance sync | | Mercy billing gateway | Trust Commerce routes for Mercy hospital billing | | Assignment of benefits | The patient assigns payment to Emerald Medical Practice P.C. | | Not found in the recovered portals | Consequence | | :--- | :--- | | Claim status | No tracker or per-claim state; a submitted claim has no product surface | | Denial queue | No workqueue, appeal object or denial reason record | | Prior-authorization case | No submission, status or appeal object; benefit checks only flag that a PA may be required | | Superbill | No generator for a patient-facing itemized bill | | Good-faith estimate | No estimate artifact tied to a scheduled service | Absence here means absence from the route and operation inventories of the recovered platform; an unrecovered internal service or external vendor/clearinghouse system is not ruled out. Within the recovered portals, the new RCM leaders inherit front-end eligibility and coding integrations rather than an in-app claims and denials workflow. ## The arithmetic of an insured video visit The 1099 postings pay per completed visit: $50 per video visit and $12 per chat visit for a physician, $35 and $8 for a nurse practitioner. The storefront's insured video copay is $25. | Visit | Patient pays | MD fee | NP fee | Margin before the payer | | :--- | :--- | :--- | :--- | :--- | | Video, cash | $100 | $50 | $35 | $50 MD / $65 NP | | Video, insured | $25 copay | $50 | $35 | -$25 MD / -$10 NP | | Chat, cash | $30 | $12 | $8 | $18 MD / $22 NP | | Chat, insured | $25 copay | $12 | $8 | $13 MD / $17 NP | The margins are arithmetic on posted terms, not company disclosure. They exclude platform cost, malpractice, no-show slack and payment delays. Two facts make the insured row matter. First, the clinical postings sell insurance in their own copy: "We accept insurance (including Medicare/Medicaid) and self pay," with "a full operational backbone for referrals, labs, and scheduling." Second, the full-time physician must be "enrolled or willing to enroll" as a Medicare and Medicaid participating provider, and a DEA license is required for credentialing. Insured volume is not an edge case; it is in the job requirements. AlphaSense describes the same model from the outside. The primer says the platform "is designed to accept most major health insurance plans" and shows "real-time insurance-adjusted rates alongside flat cash prices side-by-side." Its risk list names "Complex Billing and Insurance Friction," and specifically "transactional per-visit payments across a highly fragmented network of major insurance payers." That is the work the RCM postings describe. ### Prior authorization has three answers - The medications page says: "We even take care of prior authorizations." - The Assignment of Benefits says obtaining necessary pre-authorization is "the responsibility of the patient, financially responsible party, and /or the referring physician." - The recovered software has no prior-authorization case object, queue or submit operation. The only PA-adjacent software is the real-time benefit layer, which can flag that a PA may be required. The new RCM scope names authorization as an owned function. The patient form assigns it to the patient. The software has no record of it. Whoever files prior authorizations today, the function is being formalized by these hires. ## Product: a founding VP seat The VP Product posting was published 2026-10-07. It reports to the CPO, sits on the senior leadership team, and calls itself "the founding product leadership seat." The role owns a roadmap across three areas: 1. **Consumer experience.** Onboarding, search, booking, pricing and visit follow-up across virtual and in-person care. 2. **Clinical and provider tooling.** The care-team workflow: encounters, prescribing, care journeys and referrals. 3. **Pricing and payer infrastructure.** Eligibility, reconciliation and payer integrations, named as a roadmap rather than plumbing. The posting asks the hire to build the function, not inherit it: hiring, processes, review cadences, how specs are written, how success metrics are defined, how experiments run, and how product and engineering work together, "before writing most of that playbook yourself." It also asks the hire to allocate engineering capacity across the three areas and to pitch business cases to the CPO, Medical Director, CFO and VP Engineering. The VP Engineering reference is a hiring signal by itself. The posting treats that seat as a peer on the senior team, but no VP Engineering role appears on the board. The engineering requisitions are four individual contributor roles. ## Three product hires compared | Attribute | VP Product | Product Manager - Growth | Product Manager, Consumer | | :--- | :--- | :--- | :--- | | Reports to | CPO; senior leadership team | CEO, directly | Not stated | | Core scope | Three roadmaps: consumer, clinical tooling, pricing and payer infrastructure | Integrations with payers, employer partners and healthcare networks; the enterprise layer | Onboarding, search, booking, pricing, visit follow-up | | Experience | Founder or early product leadership; shipped 0 to 1 | 4–8 years, B2B or integration-heavy | 5–10+ years, consumer web | | Posted pay | Not posted | $175,000–$225,000 base + equity | $175,000–$225,000 base + equity | | Location | San Francisco, hybrid | San Francisco, three days a week | San Francisco, hybrid | | Published | 2026-10-07 | 2026-10-07 | 2026-10-07 | The Growth PM posting is explicit about direction: "You will build the systems that connect our platform to payers, employer partners, and healthcare networks." It calls the work foundational, not maintenance, and asks for someone who can turn "regulatory, contractual, and operational requirements into clear, testable product specifications." The role is the "first Growth PM," reports to the CEO, and works from the office at least three days a week. The Consumer PM posting is the only one that stays on the patient surface. It covers onboarding, conversion, booking and retention, and says healthcare experience is not required. The distribution matters: two of three product hires build or own the payer-facing layer, and the third owns the consumer surface the storefront already has. ## Care ops: the $22/hr coordinator The Care Coordinator posting was published 2026-09-18, sits in Ops, is remote and pays $22/hr. It reports to the Operations Manager and works with the Director of Operations, the Medical Director and clinicians. The work is phones and records: - Inbound and outbound calls with patients, provider offices, insurance companies, labs and "other individuals involved in our patients care." - Appointment scheduling, notifications, reminders and troubleshooting. - Care documentation in electronic medical records and internal tools. - Support for the clinical team, with follow-up and follow-through. The preferred list is where the operating model shows. It asks for Athena experience, "medical billing submission, clarification and troubleshooting to optimize reimbursement," and "specialist referral processes, including insurance authorization and documentation requirements." Those are the three systems a referral actually crosses: the EHR, the claim and the payer's authorization desk. The Referrals portal matches the job. It is a concierge queue where a coordinator claims an unbooked referral, phones specialist offices, records outreach, logs an outcome and ends the shift. The queue can be disabled per environment, and work claiming is atomic so two coordinators cannot take the same referral. That is a phone operation with software around it, not an automated routing engine. Two other roles sit on the edge of this function. The Clinical Recruiter, Physicians is in Ops and published 2026-09-22; it is covered in the clinician recruiting deck. The Manager, NP Licensure & Collaborative Practice is in Clinical and published 2026-10-12; it owns collaborative practice agreements, the collaborating-physician bench, primary-source license verification, and pre-hire licensure review passed back to the recruiting team. ## Who is already in these functions | Name | Role | Function | Source | Confidence | | :--- | :--- | :--- | :--- | :--- | | Ashwin Muralidharan | Co-founder and Chief Product Officer | Product, engineering, design, clinical, operations | GM bio page | High | | Ed Cao | Chief Financial Officer | Finance; CFO since February 2025 | LinkedIn; market report | High | | Steph Croteau | Director of Operations | Care operations | LinkedIn; market report | High | | Jeff Vlahos | Head of Design, founding designer | Design and brand | LinkedIn; market report | High | | Thomas S. | RCM Specialist, Path Healthcare Systems, since March 2026 | Revenue cycle | LinkedIn search result | Medium | | Dr. Pallabi Sanyal-Dey | Medical Director | Clinical oversight and sign-off | GM bio page | High | Confidence levels: High means a first-party bio or a named LinkedIn profile. Medium means a search-result snippet only; the profile page itself was not retrieved. The shape is thin at the top and empty below it. The CPO already runs product, engineering, design, clinical and operations. The CFO has been in seat since February 2025. The Director of Operations is the named operations leader, and the Care Coordinator posting refers to an Operations Manager who is not named publicly. One revenue cycle specialist appears in the LinkedIn record set, with a start date of March 2026. Brijesh Bhagat appears in the same record set with prior-authorization language, but the record does not tie him to Path Healthcare Systems or General Medicine, so he is excluded from this table. ## What the listings say together Five themes run across the postings: 1. **Insured care at scale.** Eligibility, billing, payer contracting and board reporting become executive work. The RCM postings name commercial payer policies, CMS, clearinghouses and contract negotiation in the same document. 2. **Founder-led to institutional product.** A VP Product is hired to write the playbook the founders have been running, including how ideas are pitched and greenlit. 3. **A payer and employer integration layer.** The Growth PM builds the enterprise edge. AlphaSense's partner research says health plans resist point solutions until the vendor aligns on IT integration, cost-sharing and employer economics. 4. **Human, phone-heavy care ops.** The Care Coordinator is a $22/hr phone job with a referral queue, and the preferred qualifications are Athena, billing submission and referral authorization. 5. **A leadership-first RCM build.** Two executive seats are posted before any analyst, coder or prior-authorization specialist. Five things are missing from the board: 1. **No billing or coding specialist.** CPT, ICD-10 and E/M work is named in the RCM scope but not staffed by a requisition. 2. **No prior-authorization specialist.** No PA role exists, and no PA case record exists in the recovered software. 3. **No payer enrollment or credentialing specialist.** Credentialing is offered to physicians as a benefit, not hired as a team. 4. **No VP Engineering.** The VP Product posting names the seat as a peer, but only individual contributor engineering roles are open. 5. **No data or analytics role.** RCM reporting and board KPIs have no dedicated hire, though Metabase and Databricks sit behind the BI layer. ## Changes since the Executive Briefing - **Publish dates differ from the working notes.** The live board shows Strategic Finance Manager on 2026-05-06, Care Coordinator on 2026-09-18, Clinical Recruiter on 2026-09-22 and Manager, NP Licensure on 2026-10-12. Earlier notes carried 2026-09-10, 2026-09-25 and 2026-10-06 for the finance, care ops and licensure roles. The licensure manager is the newest posting, published six days after the Series B, not before it. Source: Ashby board, 2026-10-19. - **Department labels in Executive Briefing slide 8 are editorial.** Slide 8 groups the roles as "Clinical & Licensure (5 Roles)" and "Product & Care Ops (4 Roles)." The live board labels them Clinical 4, Engineering 4, Finance 3, Product 3 and Ops 2. The licensure manager is in Clinical and the physician recruiter is in Ops, so Ops has two roles, not one. The total of 16 and the four product-and-care-ops titles still match. Source: Ashby board and GM careers page. - **The RCM experience bar is higher than earlier notes.** Slide 8 and the prior role table did not state a bar; earlier working notes used 8+ years with 3+ years at director or VP level. Both live postings ask 12+ years in revenue cycle and 5+ years at director or executive level. Source: both RCM postings. - **The RCM postings share one body of text.** Slide 8 presents a VP of RCM and a Director of RCM as two seats. The live text is the same 25 bullets with a title swap, plus a stray Strategic Finance Manager header and the misspelling "Revenue Cycle Mnagement, VP" on the VP version. Whether the company intends two seats or one is now an open question, not a finding. - **Pay is now posted for ten roles.** The prior role table recorded no pay. Live text posts $150,000–$225,000 base for the four engineering roles, $175,000–$225,000 base plus equity for both PM roles, $180,000–$200,000 for the full-time physician, per-visit fees for the two 1099 clinician roles, and $22/hr for the Care Coordinator. Six roles post no pay at all, including VP Product and both RCM roles. Source: posting text; the board's structured compensation fields are empty. - **Slide 9 is unchanged on clinical supply.** Four clinical requisitions remain listed, and the 1099 pay figures ($50/$12 for physicians, $35/$8 for NPs) and the 10–12 and 12–15 hour expectations still match. The only date change is the NP licensure manager, which moved from a pre-Series B assumption to 2026-10-12. Source: Ashby board. ## Open questions - **Two RCM seats or one?** The postings are identical in substance. The answer changes whether the company is building a two-layer revenue organization or widening one funnel. - **Who files prior authorizations today?** The marketing page says the company does; the Assignment of Benefits says the patient or referring physician does; the software has no PA object. The new RCM scope claims the function without describing the current process. - **Is the Waystar bridge live?** Only staging hosts were observed, the connector timed out and the bridge host did not resolve. Claim movement through Waystar is not established. - **Where does the Growth PM sit after the VP Product starts?** The Growth PM reports to the CEO today. The VP Product is hired to run the product org. Which reporting line survives is not stated in either posting. - **How large is the care coordinator team?** There is one open requisition, no published team size, and no queue volume data. The Referrals portal shows the workflow, not the headcount. - **What do the RCM roles pay?** Neither posting lists a band, and the board's structured compensation field is empty. - **Is a VP Engineering being recruited off-board?** The VP Product posting names the seat as a peer, but no requisition exists. - **Does the RCM scope include the physician-owned PCs?** The Assignment of Benefits names Emerald Medical Practice as the billing party. Whether the new RCM leaders set policy for the PCs, the MSO, or both is not stated. ## Sources 1. Ashby job board, general-medicine, API with compensation flag: https://api.ashbyhq.com/posting-api/job-board/general-medicine?includeCompensation=true. Snapshot: `rea/osint/deep-dives/ashby_job_board_2026-10-19.json`. Retrieved 2026-10-19. 2. General Medicine careers page: https://generalmedicine.co/company/careers. Snapshot entry `/company/careers` in `rea/osint/deep-dives/gm_public_pages_2026-10-19.json`. Retrieved 2026-10-19. 3. General Medicine Assignment of Benefits: https://generalmedicine.co/assignment-of-benefits. Snapshot entry `/assignment-of-benefits` in the same file. Retrieved 2026-10-19. 4. Platform architecture: vendor table, billing types, Athena sync and Referrals queue: `raw/reports/architecture.md`. 5. API route inventory: eligibility endpoints and DoseSpot benefit inquiries: `raw/reports/api-spec.md`. 6. GLP-1 journey dossier (clinical operations & unit economics): per-visit fees, insured video arithmetic and staffing gaps: `raw/reports/glp1-tirzepatide-journey.md`. 7. GLP-1 journey dossier (insurance & prior authorization): prior authorization has no case object: `raw/reports/glp1-tirzepatide-journey.md`. 8. Medications category page copy: "We even take care of prior authorizations": `lib/hardcoded-data/CategoryPages/medications.ts:43`. 9. AlphaSense Company Primer, 2026-10-19: dual cash and insurance pricing, payer acceptance: `wiki/raw/alphasense/alphasense-company-primer-2026-10-19.md`. 10. AlphaSense Operational and Financial Analysis, 2026-10-18: payer and PBM partnership economics: `wiki/raw/alphasense/alphasense-operational-financial-analysis-2026-10-18.md`. 11. Market report: executives and the prior 16-role table, sections 2.3 and 2.8. 12. LinkedIn people records: Thomas S., RCM specialist at Path Healthcare Systems: `raw/osint/linkedin_team_and_posts.json`. 13. General Medicine bio, Ashwin Muralidharan: https://generalmedicine.co/bio/ashwin-muralidharan. Snapshot entry in the 2026-10-19 file. Retrieved 2026-10-19. 14. General Medicine bio, Dr. Pallabi Sanyal-Dey: https://generalmedicine.co/bio/dr-pallabi-sanyal-dey. Snapshot entry in the 2026-10-19 file. Retrieved 2026-10-19. ================================================================================ # DOCUMENT: Physician-Owned PCs: How the Clinical Entity Structure Works (raw/reports/deep-dive-physician-owned-pcs.md) ================================================================================ # Physician-Owned PCs: How the Clinical Entity Structure Works **As of:** 2026-10-19 · **Deck:** [HTML](../deep-dives/physician-owned-pcs.html) · [PDF](../deep-dives/physician-owned-pcs.pdf) ## Key findings 1. **Three PC groups hold four NPI records.** CMS NPPES returns Emerald Medical Practice PC twice, `1447011267` and `1750195483`, with the same name, President and phone number. Centennial Medical Practice PC (`1174333975`) and Ruby Medical Practice (`1346050150`) each have one record. No separate organization record appears for the Arizona, California or Kansas Emerald names used in the consent pages; the Idaho Centennial name is the same record as the Florida-registered Idaho corporation. 2. **The PCs furnish care and take the insurance assignment; Path runs the business.** The Terms of Service say Path provides administrative and management services to independent, physician-owned practices and does not provide care. The Assignment of Benefits names Emerald Medical Practice P.C. as "the Practice" and assigns insurance payment to it. The platform-level RCM, product and finance hires sit on the Path side of that line. 3. **A non-physician co-founder is President of both Emerald records.** Ashwin Muralidharan, cofounder and Chief Product Officer, is the authorized official and President on `1447011267` and `1750195483`. His bio lists no clinical credential, and NPPES returns no individual record for his name. Utah Code 16-11-8 allows a non-licensed person to serve only as secretary or treasurer, so the title is an open question rather than a settled permission. 4. **One phone number and one Park City address cover the four records.** All four PC NPIs list `(307) 840-9834`, a Wyoming area code, on the Utah, Florida and New Jersey entities. Three records use 1743 S Sidewinder Dr Unit 114, Park City, UT 84060 as the mailing address; the fourth mails from 1441 Ute Blvd Ste 370 in the same city. 5. **Utah's Professional Corporation Act limits unlicensed officers.** Section 16-11-8 requires officers, directors and shareholders to be licensed to render the same professional service, or qualified under the applicable licensing act, and permits a non-licensed person to serve only as secretary or treasurer. Section 16-11-7 voids shares issued to anyone else, and 16-11-9 requires services to run through licensed officers, employees and agents. The retrieved sections show amendments from 1963 through 2019, not a 2025 or 2026 change. 6. **California SB 351 targets private equity and hedge funds; Oregon SB 951 phases in through 2029.** California bars covered investors from controlling payer contract parameters and coding and billing decisions, with Attorney General enforcement and an effective date of January 1, 2026 under the state's default rule. Oregon's Section 1 applies January 1, 2026 to entities organized on or after the effective date and January 1, 2029 to entities that existed before it, with a telemedicine carve-out that covers the ownership and officer bars but not de facto control. ## One MSO, three PC groups and a delegated network Path Healthcare Systems Corp. is a Delaware corporation with a Florida foreign registration (`F24000004983`) and EIN `93-2571245`. It is the contracting party behind the General Medicine brand and the operator of the storefront, platform, payments and hiring. The clinical work is furnished by three professional corporation groups, and a fourth network of delegated entities handles lab requisitions. The consent pages name the clinical entities with state suffixes: - Emerald Medical Practice P.C. (AZ) - Emerald Medical Practice P.C. (CA) - Emerald Medical Practice P.A. (KS) - Centennial Medical Practice P.C. (ID) - Ruby Medical Practice P.C. (NJ) CMS NPPES maps those names to four organization records. Emerald is enumerated twice in Utah. Centennial carries a Florida location address that matches its registered agent, while its state of incorporation is Idaho. Ruby is the New Jersey record. The delegated layer is disclosed on a separate Vital consent page. It names three network families and their state variants, 15 entities in total. The page describes Vital as an affiliate of Openloop Healthcare Partners, PC. Edges in the diagram: | Edge | What it represents | Status | | :--- | :--- | :--- | | Path to each PC | Management services agreement | Terms not public | | Path to each PC | Business associate agreement | Referenced in the Privacy Notice | | Patient to Emerald | Assignment of benefits | Published form | | Patient to the PCs | Telehealth consent | Published consent | | Path to Vital | Vendor contract | Not public | Nothing in the public record shows the fee Path charges each PC, the money flow between them, or the shareholder list of any PC. The diagram marks those as unobserved. ## Entity ledger The table reports the records as returned on 2026-10-19. NPPES renders organization names in uppercase without punctuation, so the table uses the consent form where one exists. "Authorized official" is the NPPES field, not an ownership field. Dates are enumeration and last-update dates. | Legal / consent name | State(s) | NPI | Enumerated / updated | Authorized official | Location address | Mailing address and phone | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Emerald Medical Practice, P.C. | UT | `1447011267` | 2024-01-18 / 2026-06-09 | Ashwin Muralidharan, President | 1743 S Sidewinder Dr Unit 114, Park City, UT 84060 | 1441 Ute Blvd Ste 370, Park City, UT 84098 · (307) 840-9834 | | Emerald Medical Practice, P.C. (second record) | UT | `1750195483` | 2025-02-04 / 2025-02-04 | Ashwin Muralidharan, President | 1743 S Sidewinder Dr Unit 114, Park City, UT 84060 | 1743 S Sidewinder Dr Unit 114, Park City, UT 84060 · (307) 840-9834 | | Centennial Medical Practice, P.C. | ID; Florida foreign registration | `1174333975` | 2025-01-13 / 2026-09-22 | Pallabi Sanyal-Dey, MD, President | 1201 Hays St, Tallahassee, FL 32301 (registered agent) | 1743 S Sidewinder Dr Unit 114, Park City, UT 84060 · (307) 840-9834 | | Ruby Medical Practice, P.C. | NJ | `1346050150` | 2025-01-13 / 2026-09-23 | Pallabi Sanyal-Dey, MD, President | 100 Charles Ewing Blvd Ste 160, Ewing, NJ 08628 | 1743 S Sidewinder Dr Unit 114, Park City, UT 84060 · (307) 840-9834 | | Path Healthcare Systems Corp. | DE; Florida foreign registration | None | DE file `7571245`; FL filed 2024-09-19 | Elliot Cohen, President and director (FL record) | 50 W Broadway Ste 333 PMB 518579, Salt Lake City, UT 84101-2027 | Same address · (801) 251-6055 | | Consent-only names: Emerald P.C. (AZ), Emerald P.C. (CA), Emerald P.A. (KS) | AZ, CA, KS | None in the name search | Named in the consent and terms only | Not disclosed | No separate registry record retrieved | Not disclosed | Additional identifiers: - Path: EIN `93-2571245`; Florida document `F24000004983`; Delaware file `7571245`. - Centennial: Florida document `F24000005250`; FEI/EIN `33-1746145`; state of incorporation Idaho. - Emerald records: both classified under taxonomy `174400000X` (Specialist). - Centennial and Ruby: classified under `207Q00000X` (Family Medicine). Practice locations in NPPES add states that do not appear in the consent: Emerald `1447011267` lists Phoenix AZ, Boulder CO, Columbus OH and Springfield IL; Centennial lists Richmond VA and Madison WI; Emerald `1750195483` and Ruby list none. These are self-reported practice-location fields, not registrations or consent-named entities. Two NPPES details are easy to misread. First, the "location" for Centennial is the Tallahassee address of Corporation Service Company, the registered agent named on Sunbiz, not a clinic. Second, the two Emerald records differ in mailing address and update date, which is a registration-maintenance pattern rather than evidence of two practices. ## The MSO runs the business; the PCs furnish care The public documents draw a consistent line. Path sells, operates and employs the platform. The PCs are the provider and the billing entity. The split is typical of a Friendly PC model, but only some rows are observed in public records. "Observed" below means the statement appears in a public document, not that it was independently confirmed. | Function | Responsible party | Basis | Where it shows | | :--- | :--- | :--- | :--- | | Brand and storefront | Path Healthcare Systems Corp. | Observed | The Terms of Service define "General Medicine" as Path; the site and the copyright line are Path's. | | Marketing and patient acquisition | Path, at brand level | Model; brand assets are Path's | The public site and social accounts carry the General Medicine brand. No marketing services agreement, agency contract or spend record is public. | | Platform, data and card payments | Path | Observed | The Privacy Notice calls Path a service provider to the PC providers and names business associate agreements with them; Stripe stores cards. | | Clinician recruiting, training and RCM hiring | Path, at brand level | Observed; legal employer not named | The careers page and Ashby postings carry the General Medicine brand, including the RCM Director and VP roles. | | Non-clinical staff employment (support, care ops) | Not disclosed | Model | The Ashby postings do not name the legal employer. A Friendly PC model usually places support and care-ops staff with the MSO, but no record confirms it here. | | Clinical services and prescribing | The PCs | Observed | The telehealth consent says services are offered by the named PCs and their providers, and that Path does not provide the Services. | | Claim billing and insurance assignment | Emerald | Observed | The Assignment of Benefits names Emerald Medical Practice P.C. as "the Practice" and assigns payment to it. | | Clinical oversight and sign-off | Medical Director | Observed | Dr. Sanyal-Dey's bio says she leads clinical oversight and sign-off; the Terms say the PC providers are owned and operated by a licensed physician. | | Lab requisitions | Vital network entities | Observed | The Vital consent names 15 delegated entities. | | MSA fee and PC stock ownership | Not disclosed | Model or unknown | No management services agreement, fee schedule, transfer record or shareholder list is public. | Three rows carry the most uncertainty. The Assignment of Benefits names only Emerald, so the public form does not show how Centennial or Ruby bill. The employment entity behind the clinician, RCM and care-ops postings is not named, so "Path hires" is an inference from the brand and the management-services description, not a disclosed fact. Marketing and non-clinical staff employment are model assumptions: the brand assets are Path's, but no agreement or employment record is public. ## A visit passes through four legal parties A General Medicine visit crosses four parties: the patient, the PC that furnishes care, the payer, and Path as the management company. 1. **Consent.** The patient accepts the telehealth consent, which names the PCs as the providers. The consent states: "Path Healthcare Systems Corp. does not provide the Services." It also names the five state-tagged PC entities collectively as "Emerald". 2. **State check.** The patient's state is captured during booking. The clinician pool is filtered on the server by licensure, so the client never sees the licensed set. If no clinician is licensed in that state, the booking flow returns no availability. 3. **Care.** A clinician licensed in the patient's state delivers video or asynchronous care. If a lab is ordered, the requisition can route to a Vital entity under a separate consent. 4. **Billing.** Emerald submits the insurance claim under the assignment of benefits. Cash visits charge on the General Medicine platform. The assignment form puts pre-authorization responsibility on the patient, the financially responsible party or the referring physician. What the record does not show: - The management services agreement between Path and any PC. - The fee Path charges, its base, or any per-visit transfer. - The money flow from Emerald to Path. - Which PC entity bills a given state when the consent names five and NPPES carries four records. The deck marks the MSO fee as an unobserved hop. It is the largest gap in the structure: the public forms establish who provides care and who takes the assignment, but not how the management company is paid. ## Lab orders route through Vital's 15-entity network The Vital telehealth consent names three network families and their variants, 15 distinct legal names in all. The list below reproduces the names as written on the page. **OpenLoop** - Openloop Healthcare Partners, PC - Openloop Healthcare Partners California, PC - Openloop Healthcare Partners Colorado, PC - Openloop Healthcare Partners New Jersey, PC - Openloop Healthcare Partners Wisconsin SC **Reliant.MD** - Reliant.MD Medical Associates, PLLC - Reliant.MD Medical Associates California, PC - Reliant.MD Medical Associates Colorado, PC - Reliant.MD Medical Associates New Jersey, PC - Reliant.MD Medical Associates Wisconsin, SC **MECNB** - MECNB Physician Services, PC - MECNB Physician Services California, PC - MECNB Physician Services Colorado, PC - MECNB Physician Services New Jersey, PC - MECNB Physician Services, SC The page opens by describing Vital as "an affiliate of Openloop Healthcare Partners, PC" and lists Openloop Healthcare Partners, PC twice in the enumeration. Counting unique names gives 15 entities: five in each family. **What the consent establishes.** A lab requisition has to come from a clinician licensed where the patient is. The consent names a family of professional entities as the providers for the states it lists, without naming a General Medicine PC for every state. The page does not list the states each entity covers, and no routing rule, contract, fee or volume figure appears in the record. **What is not shown.** Which orders go to Vital rather than to an Emerald clinician is not disclosed. No code path recovered from the storefront routes lab orders to a named Vital entity. ## Two officers sign for the PCs; one is not a physician **Dr. Pallabi Sanyal-Dey, MD** is the Medical Director and the physician officer for two PC groups. NPPES lists her as President and authorized official for Centennial (`1174333975`) and Ruby (`1346050150`). The Florida Sunbiz record for Centennial lists her as President, Secretary, Treasurer and Director. Her individual NPI record, `1245562594`, is the only NPPES record under the name and carries a California internal medicine license (`A110871`) and a Colorado hospitalist license (`DR.0071496`). Her bio describes clinical oversight and sign-off, not state-by-state licensure. **Ashwin Muralidharan** is a cofounder and the Chief Product Officer, and he is listed as President and authorized official on both Emerald records, `1447011267` and `1750195483`. The Florida Sunbiz record for Path lists him as Director, Secretary and Treasurer. His bio says he led the company as founding CEO before becoming CPO and lists no clinical credential. NPPES returns no individual record for his name. That combination makes him the only non-physician officer in the PC records retrieved and the reason the Utah officer rule matters. **Dr. Sunita Mishra** appears in the record only through press reporting. STAT News, as summarized in the AlphaSense primer, reports that the Chief Medical Officer of Amazon Health Services advised in stealth and was the initial physician owner of one clinical entity. The primer says ownership moved to Dr. Sanyal-Dey before launch. No current role for her is disclosed in the documents retrieved. **The clinical bench named on the site:** | Name | Credential | Role on the site | | :--- | :--- | :--- | | Dr. Marjory Bravard | MD | Founding physician; Director of Clinical Partnerships | | Dr. Poushali Bhattacharjee | MD, MS, FACP | Physician; leads clinical operations | | Dr. Adam Carewe | MD | Physician; family medicine and clinical informatics | | Samantha Schisler | FNP | Leads training for new clinicians | **The ownership caveat.** The NPPES field names the person authorized to act for the organization. It is not a shareholder field. A title in NPPES can name an officer without describing who owns the shares, and no PC shareholder list is public. The AlphaSense statement that ownership moved to Dr. Sanyal-Dey and the NPPES title naming Muralidharan as President are not necessarily in conflict: one is about stock, the other about who signs for the entity. ## Registration records point to central management Six registration findings stand out. 1. **One phone number on four records.** `(307) 840-9834`, a Wyoming area code, appears on the Utah, Florida and New Jersey entities. Centennial and Ruby list the Medical Director's own number, `(617) 256-3472`, as the official's contact, while the entity phone stays on the shared line. 2. **Two Park City addresses.** 1743 S Sidewinder Dr Unit 114 is the location on both Emerald records and the mailing address on Centennial, Ruby and Emerald `1750195483`. Emerald `1447011267` mails from 1441 Ute Blvd Ste 370, Park City, UT 84098. 3. **Emerald enumerated twice.** The records are dated 2024-01-18 and 2025-02-04, about 12.5 months apart. They share a name, President and phone but differ in mailing address and update history. 4. **Consent-only state names.** The Arizona, California and Kansas Emerald names appear in the consent and terms. An NPPES organization-name search returns no separate record for them. The Idaho Centennial name maps to the same record as the Florida-registered Idaho corporation. 5. **Florida filings.** Path `F24000004983`, a Delaware corporation, filed 2024-09-19 and was reinstated 2026-05-18, with the 2025 and 2026 annual reports filed the same day. Centennial `F24000005250`, an Idaho corporation, filed 2024-09-18 and was reinstated 2025-10-11. Both use 50 W Broadway Ste 333 as the principal address. 6. **Sunbiz officers.** Path lists Elliot Cohen (President and director), Ashwin Muralidharan (Director, Secretary, Treasurer), TJ Parker (Director) and Orin Hoffman (Director). Centennial lists Pallabi Sanyal-Dey as President, Secretary, Treasurer and Director. The pattern is consistent with centralized management. It is also common in Friendly PC arrangements, so it is evidence of a shared service center rather than proof of control. The two registrations that would settle more are the Utah corporate filings for Emerald, which were not retrieved, and the shareholder records for each PC, which are not public. ## What the 2026 laws actually say ### California SB 351 Chapter 409, approved 2025-10-06, adds Division 1.7 (Sections 1190 to 1192) to the Health and Safety Code. - **Scope.** A "private equity group" is an investor or group of investors who primarily engage in raising or returning capital and who invests, develops or disposes of specified assets. A "hedge fund" is a pool of funds managed for a return. Both definitions exclude passive contributors, hospital systems and public agencies. The hedge fund definition also excludes entities that solely provide or manage debt financing. - **Conduct barred.** A covered investor involved with a physician practice may not interfere with clinical judgment, including tests, referrals, ultimate care, and patient volume or hours. It may not own or set the content of patient medical records, select, hire or fire clinical staff based on clinical competency, set payer contract parameters (1191(a)(2)(C)), set clinical competency parameters for physician-to-physician contracts, make coding and billing decisions (1191(a)(2)(E)), or approve the selection of medical equipment and supplies. - **Contracts.** A contract that enables a prohibited act is void and unenforceable. Contracts may not bar providers from competing after termination or from commenting on quality, utilization, ethics or revenue strategy. - **Enforcement.** The Attorney General may seek injunctive relief, other equitable remedies, and attorney fees and costs. - **Carve-out.** Section 1191(h) allows an unlicensed person or entity to assist or consult on the listed decisions if the physician or dentist retains ultimate responsibility or approval. - **Date.** The chaptered text has no operative-date clause. A 2025 non-urgency statute takes effect January 1, 2026 under California's default rule. The statute does not regulate management services organizations as a class. It regulates private equity groups and hedge funds, which is why investor status is the threshold question for General Medicine. ### Oregon SB 951 The 2025 enrolled bill declares an emergency and takes effect on passage. It applies to management services organizations and professional medical entities, without a private equity definition. - **Section 1 conduct bars.** An MSO, or its shareholder, director, member, manager, officer or employee, may not own or control a majority of shares in a contracted practice, serve as its director or officer, exercise proxies, control share transfers, issue shares, pay dividends, acquire a majority, or exercise de facto control over administrative, business or clinical operations in a way that affects clinical decisions or care quality. The de facto list includes hiring and compensation of clinicians, staffing levels and visit length, diagnostic coding, clinical standards, billing and collection policies, advertising under a non-PC name, prices, and negotiating or enforcing third-party payer contracts. - **Telemedicine carve-out.** Section 1(4)(a) exempts an entity engaged in telemedicine with no Oregon clinical location, other than one needed for federal controlled-substance rules, from subsections (2)(a)(A) to (C): majority ownership, officer roles and proxies. The exemption does not reach (D) to (H), which include share-transfer control, share issuance, dividends, acquisition and de facto control over billing and payer contracts. - **Enforcement.** A provision that violates Section 1 is void. A medical licensee or professional entity that suffers an ascertainable loss may sue for actual damages, an injunction, other equitable relief, punitive damages and attorney fees. - **Dates.** Section 9 applies Section 1 on January 1, 2026 to entities organized in Oregon on or after the effective date, and on January 1, 2029 to entities that existed before it. The amendments to ORS 58.375 and 58.376 apply to contracts entered into or renewed on or after the effective date. - **Clinician contracts.** Sections 7 and 8 void noncompetition agreements between a medical licensee and an MSO, subject to limited exceptions, and restrict nondisclosure and nondisparagement agreements. Retaliation against a clinician for reporting a violation is barred. - **Corporate form.** Amended ORS 58.375 requires Oregon-licensed physicians to hold a majority of voting shares, a majority of directors, and all officers except secretary and treasurer. For a telehealth-only management company, the carve-out reduces the ownership and officer exposure but leaves the billing, payer-contract and de facto control bars in place. ### Utah Professional Corporation Act Utah Code Title 16, Chapter 11, as retrieved: - **Section 16-11-6.** A professional corporation may be organized for one specific professional service and ancillary services only. - **Section 16-11-7.** Shares may be issued or transferred only to persons licensed to render the same professional service, or to others to the extent the applicable licensing act allows. Shares issued in violation are void. - **Section 16-11-8.** An officer, director or shareholder must be licensed to render the same professional service, or qualified under the applicable licensing act. A non-licensed person may serve as secretary or treasurer. - **Section 16-11-9.** A professional corporation may render services only through licensed officers, employees and agents. - **Section 16-11-10.** The Act does not alter the law governing the professional relationship or liability. The operative text of Section 16-11-8(1) reads: > 16-11-8. Officer, director, or shareholder shall be licensed professional -- Nonlicensed person as secretary or treasurer. > > (1) > (a) Except as provided in Subsection (1)(b), a person may not be an officer, director, or shareholder of a professional corporation unless that person is: > (i) an individual licensed to render the same specific professional services as those for which the corporation is organized; or > (ii) qualified to be an officer, director, or shareholder under the applicable licensing act for the profession for which the corporation is organized. > (b) Notwithstanding Subsection (1)(a), a nonlicensed person may serve as secretary or treasurer of the professional corporation. The retrieved sections state no separate penalty or enforcement provision. The sections show amendments from 1963 through 2019. No 2025 or 2026 amendment appears in the retrieved text. The earlier briefing's statement that Utah permits a non-MD officer is broader than the statute: the only non-licensed office the text allows is secretary or treasurer. ## Exposure map | Issue | Observed evidence | Why it matters | Status | | :--- | :--- | :--- | :--- | | Non-physician President of a Utah PC | NPPES lists Ashwin Muralidharan as President on Emerald `1447011267` and `1750195483`. His bio lists no clinical credential and NPPES returns no individual record for his name. | Utah Code 16-11-8 allows a non-licensed person to serve only as secretary or treasurer, not as President. | Open. The NPPES title is self-reported and no Utah corporate filing was retrieved. | | MSO-level billing and payer control | The RCM Director and VP postings own payer contracting, coding, denials and collections for the virtual practice. | California SB 351 voids control over payer contract parameters and coding and billing if an investor is a private equity group or hedge fund. | Conditional on investor status, which is not public. | | Oregon coverage | No General Medicine entity is named for Oregon in the consent, terms, privacy notice or NPPES records retrieved. | Oregon SB 951 applies to an MSO and an Oregon professional entity, with a 2029 transition for pre-existing pairs. The telemedicine carve-out does not reach the billing or payer-contract bars. | Open. Which entity serves Oregon is not disclosed. | | Leadership concentration | Dr. Sanyal-Dey is Medical Director and President of Centennial and Ruby. No other physician officer appears in the records retrieved. | One license, departure or discipline reaches two PC groups and clinical oversight at once. | Observed. | | Payer clawback | The AlphaSense primer says insurers can demand repayment of disbursed funds with triple damages if an MSO exercises de facto control. | Revenue already paid on claims could be reclaimed if a payer treats the MSO as the de facto practice. | Attributed claim. No retrieved statute states a triple-damages remedy. | The map separates what the records show from what the law would do about it. The records establish titles, addresses, dates and a shared service center. They do not establish stock ownership, the MSA terms, payer enrollment, or whether any investor is a private equity group. ## Changes since the Executive Briefing - **Slide 7, PC count.** The slide says "four Friendly PCs (Emerald, Centennial, Ruby)." NPPES returns three names and four organization records, because Emerald is enumerated twice in Utah. This briefing uses "three PC groups, four NPI records." - **Slide 7, Emerald states.** The slide lists "AZ · CA · CO · KS (P.A.) · UT." The live consent names Emerald P.C. (AZ), P.C. (CA) and P.A. (KS). NPPES records the entity in Utah, lists Arizona, Colorado, Ohio and Illinois as Emerald practice locations, and lists Virginia and Wisconsin for Centennial. Colorado is a practice location, not a consent-named entity; Ohio, Illinois, Virginia and Wisconsin appear only in NPPES; California has no practice location in the record. - **Slide 7 and Appendix F.04, Utah officer rule.** The appendix says "non-MD officer permitted under Utah CPOM reform." Utah Code 16-11-8 says an officer, director or shareholder must be licensed, and only the secretary or treasurer may be non-licensed. No 2025 or 2026 amendment appears in the retrieved sections. The deck treats the Emerald title as an open question, not a permission. - **Slide 7, statute dates.** The slide says both statutes "tighten limits on MSO influence" from January 1, 2026. California SB 351 reaches private equity groups, hedge funds and entities they control, not management companies as a class, and its chaptered text has no operative date, so January 1, 2026 comes from California's default rule. Oregon SB 951 takes effect on passage, applies Section 1 on January 1, 2026 to entities organized on or after that date, and on January 1, 2029 to entities that existed before it. - **Slide 7, Vital network names.** The slide shortens the network to "Openloop Healthcare PC" and "Reliant.MD & MECNB PC." The live page names 15 entities: five OpenLoop, five Reliant.MD and five MECNB, with California, Colorado, New Jersey and Wisconsin variants and a fifth MECNB name that carries no state label. There is no Pennsylvania or Kansas entity on the page. - **Slide 7, medical director licensure.** The slide labels Dr. Sanyal-Dey "50-State Licensed." Her live bio does not state a license count. The FAQ says the company's clinicians are licensed in all 50 states including DC, and her individual NPI record carries California and Colorado licenses. The deck states the licenses that appear in the record. - **Slide 7 and Appendix F.04, NPPES titles.** Both read the "President" field as a governance fact. NPPES calls it an authorized official, an administrative attestation. This briefing separates the title from stock ownership and flags that no shareholder list is public. - **New Sunbiz detail.** Centennial is an Idaho corporation with a Florida foreign registration filed 2024-09-18 and reinstated 2025-10-11. Path was reinstated 2026-05-18 with both annual reports filed that day. Neither date appears in the Executive Briefing. - **Revised legal pages.** The Terms of Service were revised 2026-09-16, the Privacy Notice 2026-09-02, and the HIPAA Notice 2025-11-03. The telehealth consent carries a 2025 date. The Executive Briefing does not distinguish those revisions. ## Open questions 1. **Who owns the PC shares?** NPPES names authorized officials, not shareholders. AlphaSense says ownership moved to Dr. Sanyal-Dey before launch. No shareholder list for Emerald, Centennial or Ruby is public. 2. **What does the MSA pay Path?** No management services agreement, fee schedule, fair-market-value opinion or transfer record was retrieved. The fee base and the per-visit rate are unknown. 3. **Which entity is qualified in each state?** No Oregon name appears in the consent or terms. Foreign-qualification records for Oregon, Arizona, Kansas, Idaho and California were not retrieved, so the operating entity in each state is unknown. Oregon SB 951's 2026 and 2029 dates make the Oregon entity's organization date material. 4. **Which NPI is enrolled with payers?** One assignment form names Emerald Medical Practice P.C. The consent lists five state-tagged names. Which NPI holds Medicare, Medicaid and commercial contracts is not disclosed. 5. **Is any investor a private equity group under SB 351?** California SB 351 turns on the 1190 definitions. The statute excludes hospital systems, public agencies and passive contributors, and it does not name management companies. Whether any General Medicine investor meets the definition is a legal question, not a disclosed fact. 6. **Why was Emerald enumerated twice?** Two Utah records share a name, officer and phone but differ in mailing address and update history. Which record payers use, and whether one is a duplicate, is unknown. ## Sources 1. **CMS NPPES API.** Registry queries for `1447011267`, `1750195483`, `1174333975`, `1346050150`, the three organization-name wildcards, and the individual name query. Snapshot: `rea/osint/deep-dives/nppes_pcs_2026-10-19.json`. Retrieved 2026-10-19. https://npiregistry.cms.hhs.gov/api/?version=2.1 2. **General Medicine telehealth informed consent.** Last revision 2025-05-21. Names the five state-tagged PC entities and states that Path does not provide the Services. Snapshot: `rea/osint/deep-dives/gm_public_pages_2026-10-19.json`. https://generalmedicine.co/telehealth-informed-consent 3. **General Medicine Terms of Service.** Last revision 2026-09-16. Defines Path as "General Medicine," describes administrative and management services to physician-owned practices, and gives the notice address. Same snapshot. https://generalmedicine.co/terms-of-service 4. **General Medicine Assignment of Benefits.** Names Emerald Medical Practice P.C. as "the Practice" and assigns insurance payment to it. Same snapshot. https://generalmedicine.co/assignment-of-benefits 5. **General Medicine Privacy Notice.** Last updated 2026-09-02. Refers to business associate agreements with the Emerald Providers. Same snapshot. https://generalmedicine.co/privacy-policy 6. **General Medicine HIPAA Notice of Privacy Practices.** Last updated 2025-11-03. Issued by the five PC entities collectively as Emerald. Same snapshot. https://generalmedicine.co/hipaa-privacy-practices 7. **General Medicine Vital informed consent.** Names the 15 delegated entities across OpenLoop, Reliant.MD and MECNB. Same snapshot. https://generalmedicine.co/vital-informed-consent 8. **General Medicine clinician bios.** Pages for Dr. Pallabi Sanyal-Dey, Ashwin Muralidharan, Dr. Marjory Bravard, Dr. Poushali Bhattacharjee, Dr. Adam Carewe and Samantha Schisler. Same snapshot. https://generalmedicine.co/bio/dr-pallabi-sanyal-dey 9. **General Medicine FAQ.** States that clinicians are licensed in all 50 U.S. states including DC. Same snapshot. https://generalmedicine.co/faq 10. **Florida Sunbiz, Centennial Medical Practice P.C. Corporation.** Document `F24000005250`; Idaho corporation; filed 2024-09-18; reinstated 2025-10-11; officer Pallabi Sanyal-Dey. Snapshot: `rea/osint/deep-dives/law_and_registry_2026-10-19.json`. https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?inquiryType=EntityName&searchTerm=CENTENNIAL%20MEDICAL%20PRACTICE 11. **Florida Sunbiz, Path Healthcare Systems Corp.** Document `F24000004983`; Delaware corporation; filed 2024-09-19; reinstated 2026-05-18; officers Elliot Cohen, Ashwin Muralidharan, TJ Parker and Orin Hoffman. Same snapshot. https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?inquiryType=EntityName&searchTerm=PATH%20HEALTHCARE%20SYSTEMS 12. **California SB 351, Chapter 409.** Approved 2025-10-06; adds Health and Safety Code Sections 1190 to 1192. Same snapshot. https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202520260SB351 13. **Oregon SB 951, 2025 enrolled.** Sections 1 to 10, including the Section 9 operative dates and the Section 10 emergency clause. Same snapshot and `rea/osint/deep-dives/or-sb951-enrolled.pdf`. https://olis.oregonlegislature.gov/liz/2025R1/Downloads/MeasureDocument/SB951/Enrolled 14. **Utah Code Title 16, Chapter 11, Professional Corporation Act.** Sections 16-11-2 and 16-11-6 through 16-11-10. Same snapshot. https://le.utah.gov/xcode/Title16/Chapter11/16-11.html 15. **STAT News via the AlphaSense company primer, 2026-10-19.** Reports Dr. Sunita Mishra as an early advisor and initial physician owner, the transfer to Dr. Sanyal-Dey, and the clawback claim. `wiki/raw/alphasense/alphasense-company-primer-2026-10-19.md`. 16. **Ashby job board.** Live board for General Medicine, including the RCM Director and VP postings. Snapshot: `rea/osint/deep-dives/ashby_job_board_2026-10-19.json`. https://api.ashbyhq.com/posting-api/job-board/general-medicine?includeCompensation=true 17. **Recovered booking code.** `lib/routes/skuBooking.ts` (`practiceId`) and `lib/api/endpoints.ts` (patient-state filter). 18. **Market & Leadership Dossier, sections 1.3 and 1.4.** Delaware file `7571245` and the prior Friendly PC entity table.